Latest Citrini's macro & equity research reports. My own summary + their long/short tickers, with PnL performance if you followed their call. The Mentions column flags who else is in each name — Big Investors (I), Serenity (S), Activists (A), Politicians (P), Trump (T).
#127
Thematic Update
Jul 20, 2026
All Along the AI Watchtower
A violent, leverage-driven unwind of the most crowded AI expressions — not open-source competition, Kimi3, or the Iranian conflict — is what explains the recent selloff, and the unwind has mispriced stocks by category rather than by fundamentals. The market has been willing to pay for infrastructure software but has indiscriminately clobbered application software, data businesses, and anything wearing an old label. Citrini therefore hunts for AI upside in names filed under the wrong category: Qualcomm as a data-center architecture play rather than a handset laggard, developer and context tooling that gets called more even as seats shrink, database and search vendors that meter agentic context maintenance, and the enterprise hardware and security complex that IBM's miss revealed is absorbing redirected capex. The unifying causal chain is that agentic AI shifts retrieval from an occasional preprocessing step to continuous execution-loop context maintenance, and pushes enterprises toward owning their stack — which routes spend to servers, storage, memory, and cybersecurity. Meta is the capstone: it is the only hyperscaler whose compute converts directly to P&L through advertising, so the bears subtracting capex first are getting the order of operations wrong.
aineocloudaisemicybersecuritymag5saas
Positions & performance
-0.8%avg return31% win · 16 tracked · L -0.8%
Full summary 601 words
Citrini opens with a Dylan lyric to frame the AI value-accrual debate: everyone along the chain can price the piece in front of them, but nobody agrees what the whole is worth. Against a historic momentum correction, the firm argues the popular explanations for the selloff — open-source alternatives, cost competition, Kimi3, even the renewed Iranian conflict — do not hold up. Aggregate token spend is still growing rapidly and Kimi's K3 is itself compute-constrained. The likelier culprit is that a leverage-fueled breakout in the most crowded thematic expressions created its own fragility, with the unwind mirroring the vigor of the ascent. The report is explicitly a hunt for names sitting in the wrong category.
The first case is Qualcomm. Citrini killed an earlier piece after sources close to both Anthropic and Qualcomm denied a partnership implied by hidden HTML on QCOM's site, but publishes on the company anyway. The June 24 Investor Day nearly doubled FY29 non-handset guidance from $22bn to $40bn, driven by data center. The differentiator is architectural: High Bandwidth Compute stacks the accelerator directly beneath an LPDDR stack via through-silicon vias, routing bandwidth vertically rather than out the edges like HBM, eliminating the interposer and CoWoS constraints. EVP Tony Pialis claims 6x bandwidth per watt versus HBM. The broader implication — a theme Citrini has run since December — is that rising DRAM prices strengthen near-term memory revenue while strengthening the case for architectures that use fewer HBM bytes per token. Credibility comes from Alphawave SerDes, two hyperscaler custom-silicon programs contributing in FY27, a multi-generation Meta CPU agreement, and the pending Modular acquisition.
Section two argues the market has underwritten value accrual beyond the data center only for "hard software" — the FROGs and DDOGs — while application software and data businesses were clobbered by categorical classification rather than idiosyncratic factors. Citrini's April 2025 "Phase 2" basket beat both IGV and the SPX through the SaaSpocalypse. Rather than a blanket cheap-software call, they favor direct AI tailwinds: GitLab, whose Orbit platform turns the repository into a runtime context graph with a potential credit toll on Claude Code, Codex and Cursor via MCP/REST, though Orbit Remote is still beta and Duo queries are zero-rated; MongoDB, whose Atlas meters hot working-set capacity that agents touch compulsively; Elastic, which sells the queryable permission-aware copy of everything and is priced as ex-growth; and Figma, where 46% growth and 139% NRR argue hybrid human-machine design systems endure.
Section three reads IBM's July 14 pre-announcement as the key signal — clients redirected quarterly capex toward servers, storage, and memory ahead of price increases, and were distracted by cybersecurity concerns, with Arvind Krishna citing Mythos on CNBC. Since Mythos Preview, thousands of zero-days surfaced, including a 27-year-old OpenBSD bug. With software cyber already re-rated, Citrini pivots to physical and data security — Fortinet's FortiASIC moat and OT push, Yubico's YubiKey and OpenAI Trusted Access partnership, and the last listed DSPM pure-play Varonis — plus the sovereignty leg: Palantir/Nvidia's June 29 on-prem reference architecture and 88% CIO repatriation intent, expressed via Dell, HPE, Lenovo, Fujitsu, NetApp, Everpure, F5 and Nutanix in a new Enterprise Security and Sovereignty Basket.
The closer, PEMDAS, argues Meta is the Google setup of a year ago. Meta is the fastest-growing hyperscaler without external cloud revenue, so compute converts directly to P&L; MSL is treated as a free option; Muse is the cheapest quality US model; and Andromeda, GEM and Advantage+ already monetize GPUs at high margin. The unappreciated kicker is Meta's move on third-party CTV and programmatic inventory — a $40-50bn US pool — making the cloud-platform requirement a smokescreen.
Key metrics
- QCOM FY29 non-handset revenue guidance nearly doubled from $22bn to $40bn at the June 24 Investor Day
- Qualcomm High Bandwidth Compute (HBC) claims 6x bandwidth per watt vs HBM, 200x capacity per watt vs SRAM, 4-8x better decode performance per watt; arrives 2027
- QCOM automotive did $1.33bn in the March quarter, +38%; $65bn cumulative design pipeline; IoT target held at ~$14bn; robotics guidance embeds ~$700m
- MongoDB Atlas growth re-accelerated from ~26% to over 29% through fiscal 2026, crossing a $2bn annualized run rate; Atlas list pricing unchanged since at least 2020
- Elastic FY26 revenue +17%, Q4 +16%, FY27 guided ~14%; cRPO +20%, total RPO +28%; over a third of $100k+ customers using AI capabilities; SMB cloud +3%; ~19% operating margins
- Figma revenue growth 46% YoY with 139% net dollar retention, accelerating sequentially each quarter
- Fortinet: 900,000+ customers; product now low-to-mid 30s % of sales vs 40%+ a decade ago; consensus $763m Q4 2026 product sales; 70% OT billings growth in Q1
- Barclays survey: 88% of enterprise CIOs intend to move at least some public cloud workloads back to private cloud or on-prem
- Meta Andromeda co-design: 10,000x model capacity, 10x inference efficiency, 3x+ query throughput, 6% retrieval-recall gain, 8% ads quality gain; Advantage+ shopping +22% ROAS
- US CTV/online video sized at $45.2bn in 2025 (IAB); open-web programmatic display to $42.5bn by 2027 (EMARKETER); Meta planning ~14GW over three years
Key insights
- Citrini's diagnosis of the selloff is positioning, not fundamentals: a leverage-fueled breakout in crowded thematic trades created its own fragility, and performance since has been driven almost entirely by categorical classification rather than idiosyncratic factors — which makes the dispersion a mispricing opportunity.
- The HBM trade contains its own antidote: every increase in HBM pricing strengthens near-term memory revenue while strengthening the case for near-memory architectures that use fewer HBM bytes per token. Qualcomm's HBC (2027) claims 6x bandwidth per watt vs HBM and removes the CoWoS packaging constraint.
- Citrini is more bullish on Qualcomm's automotive and IoT than management is: auto did $1.33bn in the March quarter (+38%) with content per vehicle rising eightfold between third- and fifth-generation platforms, while the IoT target was left unchanged at ~$14bn.
- GitLab's Orbit could become a toll on external coding agents — queries via MCP or REST consume GitLab Credits — but the economics are not yet real: Orbit Remote is beta, Duo Agent Platform queries are zero-rated, Orbit Local is free, and no per-query multiplier is published.
- MongoDB's edge is that Atlas list pricing hasn't moved since at least 2020 while new hot-capacity meters were bolted onto the same base curve — the toll booth was already built. Atlas re-accelerated from ~26% to 29%+ past a $2bn run rate.
- Elastic's numbers point in two directions: revenue decelerating to ~14% FY27 guidance while cRPO +20% and RPO +28% and SMB cloud grows just 3% — either enterprises are standardizing ahead of consumption (bullish) or contract duration is simply stretching (cosmetic).
- IBM's miss is the cleanest read on enterprise budget rotation: capex shifted to servers, storage, memory, and cybersecurity in the last few weeks of June, ahead of expected price increases — the empirical basis for the Enterprise Security and Sovereignty Basket.
- The Meta bull case is sequencing: it is the only hyperscaler growing fast without external cloud revenue, so compute hits the P&L directly — and the unmodeled leg is third-party CTV/programmatic inventory against a $40-50bn US pool where Meta owns the demand rather than the media.
#126
Small Themes
Jun 24, 2026
Small Themes: June 2026
With virtually all analyst attention crowded into the AI trade, Citrini argues attention itself is the scarcest input -- so under-owned, under-modeled names outside AI are where thematic money gets made as 'AI exhaustion' rotation risk rises. The June 2026 Small Themes lays out five trades that need no view on AGI: US mainline airlines (DAL, UAL) finally getting their supply-constrained cycle as exogenous shocks fade; senior housing riding an unstoppable Boomer demographic wave into collapsed supply (WELL, JAN, BKD); live events and scarce sports assets where economics migrate from resellers to owners (long LYV/SPHR/MSGS/FWONK-type names, short SEAT/STUB); the end of CME's futures monopoly as 24/7 perps go legal (short incumbents, long HOOD/COIN/SPGI, with MIAX the exception); plus retail broker consolidation and a misunderstood, inflecting BNPL sector (AFRM, KLAR, SEZL).
aineocloudconsumertravelfinancecryptofinancefintechhealthhealthsenior-home
Positions & performance
+1.8%avg return55% win · 40 tracked · L +2.4% · S -2.7%
| Position | Mentions | Entry | Last | Return |
|---|
| SSTUB:NYSE consumertravel StubHub | I | 11.27Jun 24 '26 | 8.25 | +26.8% |
| LMIAX:NYSE financefintech Miami International Holdings | AP | 36.49Jun 24 '26 | 43.42 ● | +19.0% |
| LVTR:NYSE healthsenior-home Ventas | IPT | 86.57Jun 24 '26 | 100.11 ● | +15.6% |
| LAHR:NYSE healthsenior-home American Healthcare REIT | — | 50.1Jun 24 '26 | 57.44 | +14.7% |
| LBULL:NASDAQ financefintech Webull | S | 6.71Jun 24 '26 | 7.54 ● | +12.4% |
| LWELL:NYSE healthsenior-home Welltower | PT | 221.43Jun 24 '26 | 248.34 ● | +12.2% |
| LSNDA:NYSE healthsenior-home Sonida Senior Living | IAP | 38.58Jun 24 '26 | 42.82 ● | +11.0% |
| LJAN:NYSE healthsenior-home Janus Living | A | 28.58Jun 24 '26 | 31.6 ● | +10.6% |
| LLTC:NYSE financecrypto LTC Properties | SA | 38.07Jun 24 '26 | 41.94 ● | +10.2% |
| LMANU:NYSE consumertravel Manchester United | A | 21.11Jun 24 '26 | 22.99 ● | +8.9% |
| LMSGS:NYSE consumertravel MSG Sports | IA | 366.05Jun 24 '26 | 396.4 | +8.3% |
| LFWONK:NASDAQ consumertravel Formula One (Liberty Media) | P | 90.03Jun 24 '26 | 97.05 | +7.8% |
| LNHI:NYSE healthsenior-home National Health Investors | P | 75.21Jun 24 '26 | 80.54 | +7.1% |
| LSPGI:NYSE financefintech S&P Global | IAPT | 402.35Jun 24 '26 | 426.4 | +6.0% |
| LCOIN:NASDAQ financecrypto Coinbase | ISPT | 150.11Jun 24 '26 | 158.29 | +5.4% |
| LBKD:NYSE healthsenior-home Brookdale | — | 14.69Jun 24 '26 | 15.47 ● | +5.3% |
| LLYV:NYSE consumertravel Live Nation | IPT | 171.47Jun 24 '26 | 179.4 ● | +4.6% |
| LCHDN:NASDAQ consumertravel Churchill Downs | T | 84.61Jun 24 '26 | 88.17 ● | +4.2% |
| LETOR:NASDAQ financefintech eToro | SAP | 36.53Jun 24 '26 | 37.81 ● | +3.5% |
| LSBRA:NASDAQ healthsenior-home Sabra Health Care | — | 19.09Jun 24 '26 | 19.54 | +2.4% |
| LCNK:NYSE consumertravel Cinemark | T | 33.16Jun 24 '26 | 33.66 ● | +1.5% |
| LMSGE:NYSE consumertravel MSG Entertainment | A | 76.51Jun 24 '26 | 77.32 ● | +1.1% |
| LIBKR:NASDAQ financefintech Interactive Brokers | IST | 92.79Jun 24 '26 | 92.27 ● | -0.6% |
| LLLYVA:NASDAQ consumertravel Liberty Live Holdings | PT | 96.34Jun 24 '26 | 95.65 | -0.7% |
| LBATRA:NASDAQ consumertravel Atlanta Braves Holdings | A | 56.16Jun 24 '26 | 55.05 ● | -2.0% |
| LHOOD:NASDAQ financefintech Robinhood | ISPT | 97.19Jun 24 '26 | 94.91 | -2.3% |
| LSEZL:NASDAQ financefintech Sezzle | AT | 159.27Jun 24 '26 | 153.89 | -3.4% |
| SSEAT:NASDAQ consumertravel Vivid Seats | — | 7.42Jun 24 '26 | 7.72 ● | -4.0% |
| LVIRT:NYSE financefintech Virtu Financial | ST | 62.35Jun 24 '26 | 59.74 | -4.2% |
| LDAL:NYSE consumertravel Delta Air Lines | IT | 90.65Jun 24 '26 | 86.67 ● | -4.4% |
| LKLAR:NYSE financefintech Klarna | I | 18.39Jun 24 '26 | 17.36 | -5.6% |
| LAFRM:NASDAQ financefintech Affirm | IT | 77.66Jun 24 '26 | 73.05 ● | -5.9% |
| LIMAX:NYSE consumertravel IMAX | A | 43.92Jun 24 '26 | 41.08 | -6.5% |
| LUAL:NASDAQ consumertravel United Airlines | IPT | 130.54Jun 24 '26 | 118.27 | -9.4% |
| LSPHR:NYSE consumertravel Sphere Entertainment | APT | 155.12Jun 24 '26 | 139.95 ● | -9.8% |
| SCME:NASDAQ financefintech CME Group | IAPT | 231.68Jun 24 '26 | 255.31 | -10.2% |
| LTKO:NYSE consumertravel TKO Group Holdings | IA | 203.51Jun 24 '26 | 180.62 | -11.2% |
| SICE:NYSE financefintech Intercontinental Exchange | IPT | 130.02Jun 24 '26 | 145.79 | -12.1% |
| SCBOE:NASDAQ financefintech Cboe Global Markets | IPT | 249.59Jun 24 '26 | 285.07 | -14.2% |
| LGLXY:NASDAQ aineocloud Galaxy Digital | ISA | 28.58Jun 24 '26 | 22.68 | -20.6% |
Non-US / no priceSIA:TSX healthsenior-home
Full summary 542 words
This June 24, 2026 'Small Themes' piece opens with the observation that AI has created a shortage of attention: capital crowding into one theme leaves everything else under-owned and under-modeled, and with Citrini trimming its AI allocation amid crowding, it goes hunting in 'AI's blind spot' with five themes that require no view on AGI timelines or token economics.
Airlines: the November 2024 structural-reset thesis (aircraft shortage as a capacity governor, premium-heavy legacies winning) was right but interrupted by two exogenous shocks -- 2025's tariff/border-detention tourism collapse (international arrivals fell 5.5% to 68 million; the US was the only country of 184 where inbound spending declined) and 2026's Iran war spiking Brent from $75 to over $120. Yet earnings held: Delta posted a record March quarter ($14.2B revenue, premium +14%) and United grew revenue almost 11%. Supply got tighter still -- Spirit ceased operations in May (removing 3.5 points of domestic capacity) -- and World Cup virality is flipping inbound sentiment (1.24 million visitors expected, ~$4,000 average spend). DAL and UAL remain the picks. Senior living: the oldest Boomers turn 80 this year, the 80+ population grows 56% over the next decade, occupancy hit 89.5% (nineteenth straight quarterly increase) while construction starts are down 77% and inventory growth is 0.4% -- a 'Post-Traumatic Supply Disorder' setup where rents must rise ~30% for new development to pencil. Operating leverage on filling built units is enormous (margins back above 25%); picks are Welltower ($10B deployed YTD while de-levering from 3.3x to 2.7x), the freshly spun Janus, and turnaround Brookdale, and Citrini pushes back hard on the 'it's just a rates trade' framing.
Live events: physical presence became a luxury good (Dallas Cowboys from $238M in 1995 to ~$13B; league media rights from $5.3B in 2006 to $21.9B in 2026). Live Nation sold 107M+ tickets through April (+11%), TKO posted Q1 revenue +26% on ~$12.9B of Netflix/Paramount deals, Sphere segment revenue grew 69%, and World Cup get-in prices hit ~$1,000 (+80% in 30 days). The twist: own the creators/owners and short the resellers being squeezed by the FTC's all-in pricing rule and anti-scalping laws -- Vivid Seats' EBITDA collapsed under $10M and StubHub trades at ~$11 vs a $23.50 IPO. Scarce sports assets (Braves, MSGS with 30-40% SOTP upside and a potential spin, Manchester United, Formula One/MotoGP, Churchill Downs) form the second long basket. Exchanges: legalized 24/7 perpetual futures end CME's twenty-year toll road -- S&P DJI licensed the S&P 500 to trade.xyz, weekend crude perp volume hit $1.7B in a day during the Iran war, and the CFTC cleared onshore Bitcoin perps; short CME/CBOE/ICE, long adopters Robinhood (prediction revenue $3M to $104M in a year) and Coinbase, long licensor S&P Global, with MIAX the exception via its retained 10% of MIAXdx and 17%+ options share. Finally, retail-trading consolidation (PDT minimum cut from $25,000 to $2,000; targets BULL, ETOR, GLXY; plus VIRT) and a BNPL defense: the 'subprime time bomb' framing misreads CECL accounting, as Klarna posted its first GAAP profit in five years, Affirm reached GAAP profitability on $37B volume with 30+ delinquencies in the high-2% range and a path to $100B GMV, and Sezzle's EBITDA margins are heading to ~38% -- all supported by an institutional bid for their paper and bank-charter ambitions.
Key metrics
- International arrivals to the US fell 5.5% to 68 million in 2025; Brent ran from $75 to north of $120 in 2026
- Delta record March quarter: $14.2B revenue (+9%), premium revenue +14%; Spirit shutdown removed 3.5 points of domestic capacity
- US 80+ population to grow >56% over the next decade vs ~5% total population growth
- Senior housing occupancy 89.5% (19th consecutive quarterly increase); construction starts -77% from peak; inventory growth 0.4%
- Welltower: $10B invested YTD while net leverage fell from 3.3x to 2.7x
- Dallas Cowboys valuation: $238M (1995) to ~$13B; league media rights run-rate $5.3B (2006) to $21.9B (2026)
- Live Nation: 107M+ concert tickets sold through April 2026, +11%; Sphere Q1 segment revenue $266M (+69%)
- World Cup: ~1.24M visitors expected at ~$4,000 average spend; average get-in resale price ~$1,000 (+80% in 30 days)
- Robinhood prediction-market revenue: $3M to $104M in one year; weekend crude perp volume spiked to $1.7B in a single day
- Affirm: $46B GMV in 12 months through March 2026 (~$50B pace, +35% YoY), 30+ day delinquencies high-2%; Sezzle EBITDA margins low-30s to ~38%; Klarna quarterly GMV $33.7B
Key insights
- Attention is AI's scarcest byproduct: crowding leaves non-AI names under-owned and under-modeled, and with 'AI exhaustion' rotation risk high, Citrini has been trimming AI exposure and buying what the 'AI Dutch disease' left behind.
- Airlines earned through two exogenous shocks (2025 tourism collapse: arrivals -5.5% to 68M; 2026 Brent spike $75 to $120+): Delta posted a record March quarter and Spirit's May shutdown removed 3.5 points of domestic capacity -- DAL and UAL are set up for the cycle they deserve, helped by World Cup-driven sentiment reversal.
- Senior housing is a demographic certainty meeting collapsed supply: 80+ population grows 56% in a decade, occupancy at 89.5% (19th straight quarterly gain), construction starts -77%, inventory growth 0.4%, and rents must rise ~30% for new builds to pencil; WELL, JAN and BKD are the picks, and it is not merely a rates trade.
- In live events, own the creator and fade the reseller: FTC all-in pricing and anti-scalping laws are crushing middlemen (Vivid Seats EBITDA under $10M from $21.7M; StubHub ~$11 vs $23.50 IPO after a $10M FTC refund order), while Live Nation (107M+ tickets through April, +11%) and Sphere (revenue +69%) capture the economics.
- Scarce sports assets compound on fixed supply: Cowboys $238M (1995) to ~$13B; MSGS trades ~30-40% below Forbes-implied Knicks+Rangers value with a spin-off catalyst; MANU rumored to clear above 5 billion pounds vs ~3.5 billion market value; CHDN guided record Derby Week EBITDA on premium hospitality.
- CME's monopoly is ending as perps go legal: S&P 500 licensed to trade.xyz for 24/7 perps, weekend crude perp volume hit $1.7B/day during the Iran war, and CME is suing the CFTC -- short CME/CBOE/ICE, long Robinhood (prediction revenue $3M to $104M in one year), Coinbase, and S&P Global as the venue-agnostic licensor.
- MIAX is the exchange exception: it kept 10% of MIAXdx (the venue Robinhood/Susquehanna bought), has taken 17%+ of US options volume with Q1 revenue +40% and EBITDA +66%, and holds a decade-long exclusive Bloomberg index license -- the 10% stake could be worth more than the current market cap.
- BNPL's 'next domino' framing misreads upfront CECL loss provisioning against ratable revenue: Klarna printed its first GAAP profit in ~5 years ($33.7B quarterly GMV), Affirm hit FY25 GAAP profitability with 30+ delinquencies in the high-2% range and a path to $100B GMV, and Sezzle's adjusted EBITDA margins are expanding toward 38%.
#125
Macro Memo
Jun 14, 2026
Macro Memo: Spin Cycle
Citrini stays medium-term bullish on the US economy and equities despite a fresh inflation-and-rate-hike scare: the Iran/Hormuz energy shock created an 'Echo Shock' where measured inflation peaks just as source pricing pressure reverses, core inflation and wages show no spiral, and strong payroll prints overstate labor market heat. New Fed chair Kevin Warsh -- feared as a hawk and priced 70% for a December hike -- will do nothing, because no wage-price spiral exists and his own framework points dovish. The melt-up therefore continues (S&P 500 seen trading 8000 before real trouble) amid more frequent 10-15% drawdowns; trades are long SFRH7 to fade the priced hike and long gold as the credibility hedge.
Positions & performance
No single-stock positions tracked in this report.
Full summary 547 words
This June 14, 2026 Macro Memo addresses the market's swing from an AI-driven melt-up to an inflation and rate-hike scare. Since the war with Iran began February 28, short-term rate expectations jumped more than 100bps, and in May SOFR futures priced near-term hikes for the first time this cycle. The April FOMC held rates in an unusual 8-4 split, the ECB hiked 25bps citing energy costs, CPI printed its highest headline since 2023, and the May jobs report (172,000 vs 88,000 consensus) sent yields up and momentum names down after a seven-week straight rally. Citrini frames this as the perpetual 'thematic momentum vs. macro conditions' oscillation and calls the sell-off an overdue flush of leverage rather than a top.
The case against the inflation scare rests on three legs. First, Iran resolution looks more tangible than at any point in the war; spot energy has rolled over and some at-risk commodities (fertilizer, corn, wheat) are cheaper than pre-war. The report coins the 'Echo Shock': measured inflation peaking just as actual pricing pressure at the source reverses -- June and July prints may run hot on pre-Memorial Day dynamics, but a deal makes it easy for the Fed to look through them. Second, core stays calm: the April shelter pop (0.6% m/m) was payback for the October government shutdown's zero-rent assumption in BLS data, core goods inflation turned negative as tariff effects lap, and crucially there is no wage pressure -- real wage growth turned sharply negative, so the shock is supply-driven and unlikely to have legs. Third, the labor market has slack: jobless claims are low but hire and quit rates have not inflected, layoffs ticked up, Indeed's job-openings gauge is muted, and hiring remains below 2019 levels; NFP is likely overstating strength now just as it overstated weakness in fall 2025.
On the new Fed chair: Kevin Warsh took office May 22, and markets read him through G. William Miller -- the 1978 chair who jawboned through the Iranian oil shock and was replaced by Volcker -- which is partly why a December hike is 70% priced. Citrini argues 2026 is not 1979: COLA contracts no longer transmit oil into wages, the US uses less than half the oil per real GDP dollar and is a net petroleum exporter. Warsh spent confirmation praising trimmed-mean inflation and calling AI productivity disinflationary; Loretta Mester expects him to build consensus for lower rates. The call: Warsh does absolutely nothing -- no hike, no balance-sheet push. Watch the June 16-17 FOMC presser (listen for 'trimmed') and July 2 payrolls (May's strength was ~60% restaurants and local government). Equities: the melt-up has not topped; fundamentals support a run into late summer with more frequent 10-15% drawdowns, a potential scenario of the S&P jumping another 10-15% with AI names doubling, and S&P 500 trading 8000 before worries meaningfully materialize. Trades: (1) Fade the Warsh Hike -- long SFRH7 (March 2027 SOFR), worth ~30bps repricing in the base case and double if cuts return, while closing the 2s30s flattener from 26 Trades that has now fully paid; (2) The Credibility Hedge -- long gold, which has 'paid the hawk tax twice' (an 11% single-session drop on Warsh's nomination, then the Iran inflation angle) and can pop as rates decline and risk sentiment improves.
Key metrics
- Short-term rate expectations up over 100bps since the war began February 28
- May payrolls: 172,000 jobs vs 88,000 consensus
- April FOMC vote split 8-4; ECB hiked 25bps
- December Fed hike ~70% priced into markets
- April shelter CPI +0.6% m/m, double its trend contribution (shutdown payback)
- ~60% of May payroll gains from restaurants and local government
- S&P 500 target: trades 8000 before worries meaningfully materialize; potential 10-15% further melt-up
- Effective Fed Funds ~3.6%; SFRH7 trade worth ~30bps of repricing in base case
- Gold fell 11% in a single session on Warsh's nomination
- Expect higher incidence of 10-15% drawdowns over the next 3-4 months
Key insights
- Since the Iran war began February 28, short-term rate expectations jumped over 100bps and SOFR futures priced near-term hikes for the first time this cycle -- a repricing Citrini thinks is wrong and fadeable.
- The 'Echo Shock' concept: measured inflation peaks just as actual source pricing pressure reverses; spot energy has already rolled over and fertilizer, corn and wheat are cheaper than before the war started.
- Core inflation is calmer than it looks: April's 0.6% shelter jump was mechanical payback for the October government shutdown's zero-rent BLS assumption, core goods inflation turned negative, and real wage growth is sharply negative -- no wage-price spiral conditions exist.
- The May payrolls beat (172,000 vs 88,000 consensus) overstates labor strength: hire and quit rates haven't inflected, layoffs ticked up, hiring is below 2019 levels, and ~60% of May's gains came from restaurants and local government.
- The market has Warsh backwards: despite a 70%-priced December hike and G. William Miller comparisons, Warsh praised trimmed-mean inflation and AI-driven disinflation in confirmation; Citrini's call is he does absolutely nothing -- no hike, no balance sheet shrink.
- 2026 is not 1979: COLA contracts no longer transmit oil into wages, the US uses less than half the oil per real dollar of GDP, and is a net petroleum exporter -- tightening would stack a demand shock on an existing one.
- Equity view: the sell-off was a leverage flush, not a top; melt-up continues into late summer with more frequent 10-15% drawdowns, and the S&P 500 trades 8000 before worries meaningfully threaten the cycle.
- Trades: long SFRH7 (fade the priced hike, ~30bps base-case repricing, double if cuts return; closing the completed 2s30s flattener) and long gold as the credibility hedge after it paid the 'hawk tax' twice.
#124
State of the Themes
Jun 01, 2026
State of the Themes: June 2026
Citrini's June 2026 State of the Themes takes stock after a blistering AI-led rally: the dominant new narrative is 'Token Panic' -- exploding agentic token consumption colliding with labs' shift to usage-based pricing, so enterprise AI bills are blowing up budgets (Anthropic ARR hit $45B, up 5x YTD) and cost/efficiency themes now matter most. That favors edge AI and on-device inference, flash-based workarounds to the DRAM tax, agentic utilities that win on usage regardless of token cost, and selective 'AI loser' rebounds, while robotics custom silicon, EU Chips Act 2.0 beneficiaries, Colombia's rightward election, a tightening oil capex cycle, and new ideas (Shopify, Hyperliquid, healthcare's cyclical inflection) round out the thematic map. The unifying view: the AI trade broadens and rotates rather than ends.
aimemoryaiopticalairobotaisemiconsumershoppingcybersecurityenergyaienergywarfinancecryptofinancefintechhealthindexarindexcomag5saas
Positions & performance
-6.5%avg return30% win · 27 tracked · L -6.9% · S +1.8%
| Position | Mentions | Entry | Last | Return |
|---|
| LCIB:NYSE financefintech Grupo Cibest | — | 73.37Jun 01 '26 | 87.93 ● | +19.8% |
| LTMO:NYSE health Thermo Fisher | IPT | 494.04Jun 01 '26 | 568.26 | +15.0% |
| LRVMD:NASDAQ health Revolution Medicines | T | 163.68Jun 01 '26 | 188.07 ● | +14.9% |
| LDHR:NYSE health Danaher | IPT | 179.87Jun 01 '26 | 196.5 ● | +9.2% |
| LMOH:NYSE health Molina Healthcare | IT | 183.25Jun 01 '26 | 197.55 | +7.8% |
| LRGEN:NASDAQ health Repligen | IT | 123.1Jun 01 '26 | 131.96 | +7.2% |
| LFSLY:NASDAQ saas Fastly | — | 19.08Jun 01 '26 | 20.24 | +6.1% |
| SFDS:NYSE saas FactSet | IPT | 270.85Jun 01 '26 | 265.9 ● | +1.8% |
| LFROG:NASDAQ saas JFrog | — | 88.31Jun 01 '26 | 87.58 | -0.8% |
| LEC:NYSE energywar Ecopetrol | — | 16.25Jun 01 '26 | 16.01 | -1.5% |
| LNET:NYSE saas Cloudflare | ISPT | 270.82Jun 01 '26 | 262.15 | -3.2% |
| LDT:NYSE saas Dynatrace | IAT | 44.47Jun 01 '26 | 41.62 | -6.4% |
| LOIH:NYSE energywar VanEck Oil Services ETF | — | 420.59Jun 01 '26 | 385.68 ● | -8.3% |
| LSHOP:NASDAQ saas Shopify | ISP | 124.12Jun 01 '26 | 113.75 | -8.4% |
| LSIMO:NASDAQ aimemory Silicon Motion | S | 268.05Jun 01 '26 | 244.45 ● | -8.8% |
| LAMBA:NASDAQ aisemi Ambarella | — | 75.67Jun 01 '26 | 68.23 ● | -9.8% |
| LHP:NYSE energywar Helmerich & Payne | — | 39.23Jun 01 '26 | 35.34 | -9.9% |
| LDDOG:NASDAQ saas Datadog | IPT | 277.49Jun 01 '26 | 246.86 | -11.0% |
| LPDS:NYSE energywar Precision Drilling | — | 92.31Jun 01 '26 | 80.24 ● | -13.1% |
| LNBR:NYSE energywar Nabors | A | 92.45Jun 01 '26 | 78.65 ● | -14.9% |
| LPTEN:NASDAQ energywar Patterson-UTI | T | 11.53Jun 01 '26 | 9.59 | -16.8% |
| LRES:NYSE energywar RPC | — | 6.8Jun 01 '26 | 5.47 ● | -19.6% |
| LSAIL:NASDAQ cybersecurity SailPoint | IT | 19.25Jun 01 '26 | 14.95 | -22.3% |
| LOUST:NASDAQ airobot Ouster | IS | 44.93Jun 01 '26 | 34.04 | -24.2% |
| LAKAM:NASDAQ saas Akamai | IPT | 154.01Jun 01 '26 | 115.37 | -25.1% |
| LHSAI:NASDAQ airobot Hesai | — | 20.03Jun 01 '26 | 14.6 | -27.1% |
| LSNDK:NASDAQ aimemory Sandisk | ISPT | 1761.43Jun 01 '26 | 1278.23 ● | -27.4% |
Full summary 597 words
This flagship June 2026 review updates Citrini's whole thematic universe, opening with a victory lap on the August 2025 edition (Google doubled, KOSPI tripled, Taiwan beat QQQ by 60%+) before turning to the narrative that will shape flows: Token Panic. In weeks the market went from tokenmaxxing to cost shock -- Uber reportedly burned its entire AI budget in four months, Anthropic's ARR reached $45B in May (5x since January per The Economist), Sam Altman admitted 'my company spent my entire 2026 budget in Q1' has become a meme, and Microsoft's AI chief called Anthropic 'extremely expensive' after cancelling Claude Code licenses. Labs are all flipping to usage pricing (OpenAI Codex April 2, Google Gemini May 19, GitHub Copilot June 1), while Claude's new tokenizer can consume up to 35% more tokens for the same text. Chinese models (Qwen 3.7, DeepSeek V4) are 10-25x cheaper and DeepSeek passed Anthropic on OpenRouter tokens. Citrini's conclusion: revenue still grows, but cost, efficiency, routing, observability and 'good enough' models become the investable themes.
That leads to Edge AI and inference-on-device (a thesis first published July 2024, 'regrettably way too early'): Nvidia's Spark AI PC (1 petaflop FP4, 128GB unified memory), OpenAI's io/device roadmap, Google glasses and Apple's hardware-focused CEO transition validate a hybrid local-plus-cloud model. 'Flash Point' explores ways past the DRAM tax -- HBM eats ~a quarter of DRAM wafer capacity and contract prices rose ~90% in a quarter -- via controller optimization, NAND stacking, and the Sandisk/SK Hynix High Bandwidth Flash standard (8-16x HBM4 capacity), with flash ~55x cheaper per bit; SIMO and Phison are the plays, and HBF could eventually dent HBM's scarcity premium. The Agentic Utilities update tallies wins: Bandwidth +300% since the primer (Salesforce Agentforce contract), Twilio's Conversation Memory, SailPoint (11% of governed SaaS identities already non-human), Palo Alto's Idira, observability beats at Datadog/Dynatrace, JFrog, and the CDN triad where Fastly RPO exploded 63% and Akamai landed a 7-year $1.8B compute commitment from a frontier lab. Agentic payments disappoint so far; on AI Losers, the rally is an undiscerning short squeeze, but FactSet (MCP-driven seats could drive shares 50-70% higher), FICO, Equifax, Shopify and Guidewire are selectively buyable.
Robotics focuses on custom silicon: Hesai's Picasso and Ouster's Rev8 SPAD-based color LiDAR collapse the camera-vs-LiDAR debate (Ouster L4: 42.9 GMACs, 10.4M points/sec; Hesai: >40% photon detection efficiency, 600m range), with Ambarella watched; Amazon is investing EUR 10B in European robotics and Figure AI began production at 12,000 units/year peak. Fiscal Primacy covers the EU Chips Act 2.0 (June 3 proposal pivoting from the failed 20%-share supply push to demand-side measures, EUR 15-30B for European memory), with picks Huber+Suhner (optical circuit switches, CHF 432M record backlog), BESI, Canatu (only listed CNT pellicle pure-play), ams-OSRAM and Nordic Semiconductor; plus Colombia, where a likely De la Espriella win could trigger a Milei-style re-rate (Ecopetrol, COLO, Cibest). NatGas & Energy argues the four-month Hormuz closure is draining OECD inventories to decade lows, favoring contract drillers (NBR, PTEN, HP, PDS), RES and OIH. Updates cover the Girlfriend Index (Korean luxury: Shinsegae jewelry +147%; APR/Medicube), GOP losing the House (Molina: normalized EPS >$28, >$30 by 2028), and RVMD's RAS(ON) platform. New ideas: Shopify (14%+ of US e-commerce, ~$380B GMV +30%, Shop Pay $160B annualized, UCP protocol with Google, Thrive Capital's $100M stake), Hyperliquid (HYPE: $40-50B weekly perp volume, $2B+ cumulative buybacks, ~7% annual buyback yield, $1B token burn, HIP-3 tokenized equities/HIP-4 outcome contracts), and healthcare's cyclical inflection finally arriving (Cytiva orders +30% YoY, 173 AI-originated drug programs vs ~24 in 2023, McKinsey's $60-110B annual savings estimate) -- with picks-and-shovels preferred over TechBio.
Key metrics
- Anthropic ARR $45 billion in May 2026, up 5x since start of year
- Claude Opus 4.7/4.8 new tokenizer can use up to 35% more tokens for the same text; Chinese models 10-25x cheaper
- Prior calls: GOOG doubled in 9 months, KOSPI tripled, Taiwan outperformed QQQ by >60%
- DRAM contract prices up ~90% in a single quarter; flash ~55x cheaper per bit; HBF offers 8-16x HBM4 capacity
- Bandwidth up nearly 300% since Agentic Utilities; Fastly RPO +63%; Akamai $1.8B 7-year frontier-lab compute deal
- Amazon investing EUR 10 billion in European robotics; Figure AI initial peak capacity 12,000 robots/year
- Chips Act 2.0 includes EUR 15-30 billion to establish European memory production; Huber+Suhner backlog record CHF 432M
- Shopify: >14% of US e-commerce, ~$380B volume (+30% YoY), Shop Pay >$160B annualized GMV, Thrive Capital $100M investment
- Hyperliquid: $40-50B weekly perp volume, >$2B cumulative HYPE buybacks (~7% of market cap annually), $1B token burn, HIP-3 OI >$3B
- Molina normalized EPS seen >$28 (> $30 by 2028); Shinsegae luxury jewelry sales +147% YoY; Danaher Cytiva bioprocessing orders +30% YoY
Key insights
- Token Panic is the new market narrative: Anthropic ARR hit $45B in May (5x YTD), Uber reportedly burned its full-year AI budget in four months, and OpenAI, Google and Microsoft all shifted to usage-based pricing between April 2 and June 1, 2026 -- making cost, routing, and observability the investable themes.
- Chinese and open-source price pressure is real: Qwen 3.7 and DeepSeek V4 are 10-25x cheaper than frontier US models, DeepSeek passed Anthropic on OpenRouter token volume, and Cursor's Moonshot-based model matches frontier quality at 10x lower cost per task.
- Edge AI is inflecting after being 'way too early' in July 2024: Nvidia's Spark AI PC (1 petaflop FP4, 128GB unified memory), OpenAI's io device roadmap, and Google eyewear point to a hybrid local/cloud model; the Edge basket has begun outperforming SMH.
- Flash is the way past the DRAM tax: DRAM contract prices rose ~90% in a quarter and HBM eats ~25% of DRAM wafer capacity, while flash runs ~55x cheaper per bit; Sandisk/SK Hynix's High Bandwidth Flash offers 8-16x HBM4 capacity -- bullish SIMO and Phison, medium-term negative for HBM scarcity premiums.
- Agentic Utilities validated: Bandwidth +~300% since the primer with a Salesforce Agentforce win, Fastly RPO +63%, Akamai signed a 7-year $1.8B frontier-lab compute deal, and SailPoint reports 11% of governed SaaS identities are already non-human.
- The AI Losers rally is mostly an undiscerning short squeeze (Chegg, Upwork, call centers bouncing despite impaired models), but FactSet could trade 50-70% higher on MCP-driven seats; FICO, EFX, Shopify and Guidewire are the selective buys.
- SPAD-based color LiDAR (Hesai Picasso, Ouster Rev8/L4) collapses the camera-vs-LiDAR debate and cuts robotics compute costs; Amazon is putting EUR 10B into European robotics and Figure AI began production with 12,000/year peak capacity.
- EU Chips Act 2.0 (June 3, 2026) abandons the 20% production-share goal for demand-side measures including EUR 15-30B for European memory; under-owned beneficiaries include Huber+Suhner (OCS, CHF 432M backlog), Canatu, BESI, ams-OSRAM and Nordic Semiconductor.
- New ideas: Shopify (14%+ of US e-commerce, ~$380B volume +30% YoY, Thrive's $100M stake), Hyperliquid's HYPE ($2B+ buybacks, ~7% annual buyback rate, HIP-3 open interest >$3B), and healthcare's cyclical inflection (Cytiva orders +30%, 173 AI-originated drug programs in the clinic vs ~24 in late 2023).
#123
Semis Memo
May 01, 2026
Semis Memo: Supply Chain Inheritance
The AI infrastructure trade has matured past first-order picks, so Citrini's third Semis Memo hunts mispriced second-order bottlenecks. The core idea is 'Supply Chain Inheritance': Nvidia's 800V DC rack architecture inherits the silicon carbide/GaN supply chain built for EVs and solar, so power semis still valued on a weak EV cycle (STM, ON, Infineon, and above all post-bankruptcy Wolfspeed) get a second demand cohort just as the first wobbles. Around that anchor, the memo argues CPUs and the orchestration plane become strategic in the agentic era (ASPEED, LOTES, Qualcomm), an inference shortage re-rates neoclouds (CoreWeave, Hut 8), AI materials bottlenecks keep worsening (Ibiden, WF6 gases via Kanto Denka), and Samsung Foundry's re-rating as TSMC's realistic second source unlocks Korean beneficiaries (Doosan Tesna, Wonik IPS, Samsung Electro-Mechanics, LG Innotek).
aimemoryaineocloudaisemienergyai
Positions & performance
-5.7%avg return31% win · 13 tracked · L -5.7%
| Position | Mentions | Entry | Last | Return |
|---|
| LHUT:NASDAQ aineocloud Hut 8 | IS | 76.98May 01 '26 | 109.99 | +42.9% |
| LWYFI:NASDAQ aineocloud WhiteFiber | S | 16.65May 01 '26 | 23.15 ● | +39.0% |
| LHIMX:NASDAQ aisemi Himax | S | 12.31May 01 '26 | 12.62 | +2.5% |
| LDGXX:NASDAQ aineocloud Digi Power X | S | 3.76May 01 '26 | 3.84 ● | +2.1% |
| LQCOM:NASDAQ aisemi Qualcomm | ISPT | 177.01May 01 '26 | 170.04 ● | -3.9% |
| LSTM:NYSE aisemi STMicroelectronics | SP | 55.75May 01 '26 | 53.45 ● | -4.1% |
| LACLS:NASDAQ aimemory Axcelis Technologies | IST | 139.99May 01 '26 | 128.11 ● | -8.5% |
| LON:NASDAQ aisemi ONSemi | IT | 103.03May 01 '26 | 89.04 ● | -13.6% |
| LMPWR:NASDAQ aisemi Monolithic Power Systems | ISPT | 1583.48May 01 '26 | 1339.08 ● | -15.4% |
| LAEHR:NASDAQ aisemi Aehr Test Systems | S | 93.07May 01 '26 | 77.48 ● | -16.8% |
| LVICR:NASDAQ energyai Vicor | IST | 268.36May 01 '26 | 211.01 | -21.4% |
| LWOLF:NYSE energyai Wolfspeed | IS | 36.76May 01 '26 | 23.09 | -37.2% |
| LCRWV:NASDAQ aineocloud CoreWeave | IST | 119.01May 01 '26 | 71.88 | -39.6% |
Full summary 597 words
The May 2026 Semis Memo (third in the series, by semis analysts Zephyr and Jukan) opens by noting the easy phase of the AI infrastructure trade is over: valuations no longer forgive, so outperformance requires finding areas where forecasts still reflect non-AI overhangs that AI demand will overwhelm. The anchor thesis is 'Supply Chain Inheritance.' Nvidia's own May 2025 blog on 800V DC racks credits the underlying technology to the EV and solar industries: the transition to 800V -- the only path to 600kW racks -- requires SiC and GaN at every conversion stage, and that wide-bandgap supply chain was already scaled and cost-reduced by Porsche, BYD and solar inverter makers. SiC grew from a $300M niche in 2018 to $3.5B by 2024 on EVs; AI is estimated to reach half of total SiC demand by 2030, on the same wafers. Rack power BOM grows ~16% in the transition while wide-bandgap silicon plus high-voltage connectors go from 0% to ~64% of rack power BOM. Names like STM, ON and Infineon are still valued on the anemic EV cohort. The memo also maps solid-state transformers (Eaton, ABB, Siemens; Heron Power's $140M Series B) and the VRM 'thousand-amp problem' (Rubin Ultra GPUs drawing ~2,500W imply ~3,500 amps at 0.7V; MPWR, Vicor, Renesas). The single-stock highlight is Wolfspeed: it spent $6.5B on SiC capacity, went bankrupt in June 2025 when EVs didn't show up, and emerged debt-light owning the world's only commercial-scale 200mm SiC fab -- plus a 300mm SiC crystal demonstrated in January 2026 (matched only by Coherent), with a thermal/packaging kicker as SiC cold plates move toward the chip.
Section two argues agents move value to the CPU/orchestration plane: agents use 10-30x more tokens than chatbots and their loops (tool calls, RL environments, scheduling) run on CPUs. Highlights: ASPEED (80% BMC share overall, 100% in Nvidia Hopper/Blackwell; 87 BMCs per NVL72; TAM revised from 46.5M to 65M chips by 2030; Q1 revenue beat guidance by 17-21%), LOTES (~35% CPU socket share, sockets going from ~5,000 to 7,000+ pins), FIT Hon Teng, Montage Technology (36.8% memory-interface share), and pet-favorite Qualcomm (unpriced data center CPU and on-device inference optionality). Section three documents the inference shortage: OpenAI compute rose from 0.2 GW to 1.9 GW as ARR went from $2B to $20B+ (later $2-3B/month revenue, 15B tokens/minute); Anthropic's run-rate hit $45B by May 2026, up ~400% from ~$9B at end-2025, and it is grabbing capacity via Amazon (up to 5 GW), Google/Broadcom TPUs ($200B over five years), SpaceX (300+ MW, 220,000+ GPUs) and a $1.8B, 7-year Akamai deal. CoreWeave's RPO grew to $99.4B by Q1 2026, plus a $21B Meta expansion; Hut 8 signed a $9.8B, 15-year take-or-pay lease.
Remaining sections update AI materials (all severe bottlenecks worsened: T-glass relief pushed to 2027+, Korean CCL import prices +74.5% YoY; Ibiden is the top pick, WF6 specialty gas via Kanto Denka an emerging bottleneck) and 'Korea Unlocked': Samsung Foundry as the realistic second source to TSMC (per C.C. Wei, supply remains 'very tight'), benefiting Doosan Tesna (KRW 171.4B + 190.9B equipment buys tied to Apple CIS and Nvidia's Groq-derived LPU), Wonik IPS (Taylor fab tooling; Tesla's $16.5B deal anchors Taylor 1), Samsung Electro-Mechanics (FC-BGA plus MLCC shortage -- Rubin Ultra needs ~1.8M MLCCs, ~90x H100, with 24-week lead times), and LG Innotek (SiP substrate squeeze). Prior picks AEHR (+300%, $41M Google TPU burn-in order) and Himax (+125%) stay longs. The memo closes noting even Citrini's most bullish estimates proved conservative -- 2027 AI spending is now estimated above $3 trillion -- and that the cycle will end via macro/Fed tightening, not technology.
Key metrics
- SiC market: $300M (2018) to $3.5B (2024), ~12x; AI estimated at half of SiC demand by 2030
- Rack power BOM +16% in 800V transition; wide-bandgap + HV connectors from 0% to ~64% of rack power BOM
- Rubin Ultra GPU projected >2,500W, implying ~3,500 amps at 0.7V core voltage
- Wolfspeed spent $6.5B on SiC capacity before June 2025 Chapter 11; demonstrated 300mm SiC crystal in January 2026
- ASPEED: 80% BMC share (100% in Nvidia Hopper/Blackwell), 87 BMCs per NVL72, TAM revised to 65M chips by 2030
- OpenAI: compute 0.2 GW to 1.9 GW (2023-2025), $2B/month revenue by March 2026, 15B+ tokens/minute
- Anthropic run-rate revenue $45B by May 2026, up ~400% from ~$9B at end-2025
- CoreWeave RPO $99.4B in Q1 2026; $21B Meta expansion; Hut 8 $9.8B 15-year lease (352 MW)
- Korean CCL import prices +74.5% YoY; MLCC lead times 24 weeks (~3x production cycle); Rubin Ultra ~1.8M MLCCs (~90x H100)
- AEHR +300% with $41M Google TPU order; Himax +125%; 2027 AI spending now estimated above $3 trillion
Key insights
- Supply Chain Inheritance: Nvidia's 800V DC architecture inherits the EV/solar SiC-GaN supply chain -- SiC grew 12x from $300M (2018) to $3.5B (2024) on EVs, and AI is estimated to reach half of total SiC demand by 2030 on the same wafers, while SiC names are still valued on the weak EV cohort.
- The 800V transition grows rack power BOM ~16% but shifts mix dramatically: wide-bandgap silicon plus high-voltage connectors go from 0% to roughly 64% of rack power BOM; VRM content compounds as Rubin Ultra GPUs (~2,500W) require ~3,500 amps at 0.7V core voltage.
- Wolfspeed is the 'crouching tiger' pick: $6.5B of capex bankrupted it in June 2025, but post-restructuring equity owns the world's only commercial-scale 200mm SiC fab and one of only two demonstrated 300mm SiC crystals (Coherent the other), with New York State billions sunk and not expecting repayment.
- Agents shift value to the CPU/orchestration plane (agents use 10-30x more tokens than chatbots); ASPEED has 80% BMC market share overall and 100% in Nvidia Hopper/Blackwell servers (87 BMCs per NVL72), and revised its 2030 BMC TAM from 46.5M to 65M chips.
- The inference shortage is visible in deals: Anthropic's run-rate revenue hit $45B by May 2026 (up ~400% from ~$9B at end-2025) and it signed Amazon (up to 5 GW), Google/Broadcom ($200B over 5 years), SpaceX (300+ MW, 220,000+ GPUs) and Akamai ($1.8B/7yr); CoreWeave RPO reached $99.4B in Q1 2026.
- AI materials bottlenecks all worsened: T-glass relief pushed to 2027+, Korean CCL import prices +74.5% YoY, Nvidia substrate area going from 3,190mm2 (Hopper) to ~8,000mm2 (Rubin); Ibiden is the top materials pick and WF6 specialty gas (Kanto Denka) the emerging bottleneck.
- Samsung Foundry is the realistic second source to a maxed-out TSMC, unlocking Korean beneficiaries: Doosan Tesna (Apple CIS + Nvidia LPU test capex of KRW 362B+), Wonik IPS (Taylor fab tooling, anchored by Tesla's $16.5B deal), Samsung Electro-Mechanics (FC-BGA + MLCC: Rubin Ultra uses ~1.8M MLCCs, ~90x H100), and LG Innotek (SiP substrate survivor economics).
- Prior memo picks validated and held: AEHR +300% (with a $41M Google TPU burn-in follow-on order and 2H bookings above $92M) and Himax +125%; Citrini's meta-lesson is that even 5x-consensus AI estimates proved conservative -- 2027 AI spend now estimated above $3 trillion -- and the cycle ends on macro, not technology.
#122
Flash Note
Apr 27, 2026
Flash Note: Defense Production Act
On April 20, 2026 the President signed Presidential Determination 2026-10, a Defense Production Act Section 303 determination classifying grid infrastructure -- transformers, transmission, conductors, substations, breakers, relays and electrical core steel -- as essential to national defense. This converts Citrini's long-running Fiscal Primacy x AI power thesis into an actual federal priority regime: priority ratings compress lead times for grid customers, federal capital crowds in private investment, and a national-security frame replaces climate policy, making the spending durable across administrations. Winners are the already-known grid supply chain plus overlooked names, above all Cleveland-Cliffs, whose GOES electrical steel monopoly maps one-for-one onto the DPA designation, along with Quanta, Worthington Steel and Hammond Power.
energygrid
Positions & performance
-2.2%avg return20% win · 5 tracked · L -2.2%
| Position | Mentions | Entry | Last | Return |
|---|
| LCLF Cleveland-Cliffs | IS | 10.61Apr 27 '26 | 12.25 ● | +15.5% |
| LPWR:NYSE energygrid Quanta Services | PT | 637.28Apr 27 '26 | 625.84 | -1.8% |
| LWS:NYSE energygrid Worthington Steel | A | 37.71Apr 27 '26 | 35.98 | -4.6% |
| LGEV:NYSE energygrid GE Vernova | IPT | 1120.23Apr 27 '26 | 1014.75 | -9.4% |
| LPOWL:NASDAQ energygrid Powell Industries | ST | 260.52Apr 27 '26 | 232.21 | -10.9% |
Full summary 455 words
This short flash note (April 27, 2026) updates Citrini's longest-running intersection trade -- power as the meeting point of its two decade themes, Fiscal Primacy and AI. On April 20 the President signed Presidential Determination 2026-10, a Defense Production Act Section 303 determination for grid infrastructure, building on the January 2025 National Energy Emergency executive order. The text formally classifies transformers, transmission lines, conductors, substations, high-voltage circuit breakers, power control electronics, protective relays, capacitor banks and electrical core steel as essential to national defense. Citrini has been long this supply chain since 2023 (expanded in June 2024's 'The Utility of Bubbles'), and notes the backlog keeps growing despite years of upward revisions: in 1Q26 the net addition to GE Vernova's electrification backlog was nearly as large as the annual additions from 2022-2025.
The note explains what the DPA actually does: (1) priority ratings route grid orders ahead of other industrial uses, compressing lead times for grid customers (large power transformer lead times run three to four years, distribution transformer backlogs near a year); (2) federal capital crowds in private investment and protects US manufacturers from Chinese undercutting; (3) a national-security frame replaces climate policy, and that framing survives administration transitions. Only ~$323 million of FY26 DPA Title III money remains, so the immediate firehose is small -- scale comes via the much larger DOE Loan Programs Office, forward purchase commitments, and the priority rating system itself. The transformer bottleneck is acute: the marginal supplier is Korean, with Hyosung's Memphis plant the only US facility making 765 kV ultra-high-voltage transformers, HD Hyundai Electric expanding Montgomery, AL to 150 units/year by 2027, LS Electric opening in Bastrop, TX, and Iljin winning a record $333M US order; the Korean Big Four backlog is $23.9B (five to six years of work).
Positioning: most AI-power names (e.g., POWL, nearly tripled since the Stargate Field Trip) have already re-rated, so asymmetry sits in laggards. Cleveland-Cliffs is the standout -- the sole domestic GOES (grain-oriented electrical steel) producer via Butler, PA and Zanesville, OH, restarting Weirton, WV as a $150 million transformer plant, protected by tariffs reaching 50% on derivative foreign GOES; Citrini says it knows of no other public security where a single national-security determination so directly maps to one company's monopoly. Other names: Quanta Services (record transmission backlog; the DPA can fund factories but not the multi-year linemen pipeline, so EPC contractors should outperform OEMs on a 24-month view), Worthington Steel (ignored toll-processor one step downstream from Cliffs), and Hammond Power Solutions (North America's largest dry-type transformer maker, the fast-deploy default for data centers, with a Monterrey nearshoring angle). The caveat: if the DPA succeeds in adding supply, margins eventually compress -- but likely not for a couple of years.
Key metrics
- ~$323 million of FY26 DPA Title III funding remaining at announcement
- Korean Big Four transformer order backlog: $23.9B as of Q3 2025 (5-6 years of work)
- Large power transformer lead times: 3-4 years; distribution transformer backlogs ~1 year
- HD Hyundai Electric expanding Montgomery, AL to 150 transformer units/year by 2027
- Iljin Electric won a record $333M order from a US energy company
- GEV 1Q26 electrification backlog net addition nearly equal to annual additions from 2022-2025
- Cleveland-Cliffs restarting Weirton, WV as a $150M transformer plant
- Foreign GOES faces tariff stack reaching 50% on derivative products
- POWL nearly tripled since Citrini's Stargate Field Trip pick
Key insights
- Presidential Determination 2026-10 (April 20, 2026) invokes DPA Section 303 for grid infrastructure, formally naming transformers, transmission, substations, breakers, relays, capacitor banks and electrical core steel as essential to national defense.
- The DPA's real power is not money (~$323M of FY26 Title III funds remain) but priority ratings that reroute supply to grid uses, crowded-in private capital, DOE Loan Programs Office access, and a national-security framing that survives administration changes.
- The grid backlog keeps accelerating: GE Vernova's 1Q26 electrification backlog net addition was nearly as large as the annual additions from 2022-2025; large power transformer lead times run 3-4 years.
- The marginal US transformer supplier is Korean: the Big Four (Hyosung, HD Hyundai Electric, LS Electric, Iljin) hold a combined $23.9B backlog -- five to six years of work -- and are building US plants.
- Cleveland-Cliffs is effectively the sole domestic GOES producer (Butler PA / Zanesville OH, only domestic high-permeability TRAN-COR), is converting Weirton WV into a $150M transformer plant, and is shielded by tariffs up to 50% -- a rare one-company map to a national-security determination.
- EPC contractors like Quanta Services should outperform equipment OEMs on a 24-month view: the DPA can fund factories but cannot quickly fund the human-capital pipeline of high-voltage linemen.
- Overlooked downstream/adjacent picks: Worthington Steel (toll-processing GOES into slit coils and lamination blanks, un-rerated) and Hammond Power Solutions (largest North American dry-type transformer maker, faster to deploy for data centers).
- Self-aware risk flag: success in adding capacity via the DPA eventually means lower margins for the complex, but likely not for another couple of years.
#121
Field Trip
Apr 05, 2026
Strait of Hormuz: A Citrini Field Trip
Citrini sent a field analyst to the Strait of Hormuz during the live US-Iran conflict and concluded the market's binary 'open vs. closed' framing is wrong: Iran is running the strait as a toll road, not a blockade, approving vessels through a Qeshm-Larak checkpoint while the ground conflict continues. Hot war and commercial diplomacy are happening simultaneously -- US allies like France, India and Japan are negotiating passage with Tehran, mostly via underreported diplomatic workarounds rather than yuan or crypto payments. Traffic should keep rising (Citrini expects ~50% of pre-conflict volume within 4-6 weeks) even as the conflict escalates, so the trades are ones that win regardless of resolution: tankers (BWET), US petrochemicals (DOW, WLK), long SFRH7 rates, long December 2026 WTI versus front month, relative country pairs, and EU/Japan energy-independence and defense names (EUAD).
commoditiesdefenseenergywar
Positions & performance
-18.6%avg return25% win · 4 tracked · L -18.6%
| Position | Mentions | Entry | Last | Return |
|---|
| LEUAD:NASDAQ defense Europe Aerospace & Defense ETF | — | 42.75Apr 06 '26 | 42.97 | +0.5% |
| LBWET:NYSE energywar Breakwave Tanker Shipping ETF | — | 140.66Apr 06 '26 | 128.0 | -9.0% |
| LDOW:NYSE commodities Dow | PT | 40.56Apr 06 '26 | 29.84 | -26.4% |
| LWLK:NYSE commodities Westlake | — | 119.53Apr 06 '26 | 72.33 ● | -39.5% |
Full summary 520 words
This April 2026 piece is field reporting: Citrini dispatched 'Analyst #3' -- fluent in Arabic, carrying $15,000 in cash and hidden recording gear -- to Dubai, Fujairah, and Oman's Musandam province to observe the Strait of Hormuz first-hand during the US-Iran war, after concluding that nobody (analysts, correspondents, retired generals) actually knew what was happening and that AIS data was missing roughly half of actual transits. The narrative covers a Dubai poker game with connected Gulf contacts (who correctly predicted strikes on Qeshm), interrogation by Omani CID agents who ordered him to cancel his boat trip, an illicit speedboat run to Kumzar and the open strait with smuggler Hamid, direct observation of Shahed drones and AIS-dark tankers, detention by the Coast Guard, and eventual exit under surveillance.
The findings overturn consensus. Iran has built a functioning 'toll booth': approved traffic routes through the Qeshm-Larak channel after brokers submit ownership, flag, cargo and crew details; payment is made in cash, crypto, or -- far more commonly than reported -- diplomatic workarounds like unfreezing Iranian assets (often settled via Bank of Kunlun), which sidestep OFAC fears. Enforcement is selective but real: no ship with IRGC clearance has been struck, while drones hit non-compliant vessels. Analyst #3 confirmed 15 ships crossing on April 2 (versus 2-5/day two weeks earlier, but far below the >100/day pre-conflict), with contacts reporting 15-18 more on April 4, and saw a Greek Dynacom tanker running full-speed through the center of the strait -- evidence the strait is not mined and that bespoke deals exist. On March 26 Iran granted passage to China, Russia, India, Iraq and Pakistan; within a week Malaysia, Thailand, the Philippines, France and Japan secured access. The Houthis are being deliberately restrained by a still-centralized Iranian command, holding the Bab al-Mandab card in reserve. An Omani official compared Iran's endgame to Turkey's Montreux Convention management of the Bosphorus -- sovereignty and tolls, not blockade. The report estimates the net hit to global commercial oil stocks at 10.6 million barrels/day and warns that if traffic stays at only ~15 ships/day through end-April the situation turns disastrous; if the strait stays effectively closed, global equities could fall ~15-20%.
Positioning follows the 'wins either way' logic. Tankers, via the BWET ETF (up more than 4x since the January call), have not topped; the Iran Conflict Beta basket is +17% since inception. The most asymmetric leg is US petrochemicals -- Dow and Westlake -- because Gulf capacity destruction is underreported, up to 50% of polyethylene supply is offline or constrained per Dow's CEO, who sees 250-275 days to normalize even after reopening, and Dow followed a $0.10 March polyethylene hike with $0.30 in April. Macro trades include long SFRH7 (playing rate cuts being priced back in), long December 2026 WTI (at $71 versus $110 front month, the market wrongly prices a short sharp disruption) with an eventual long CLZ6/short front-month spread, country pairs (long Norway/short Australia, long Japan/short Korea, etc. scored on energy security and willingness to deal with Tehran), and buying dips in EU/Japan energy independence and defense (EUAD), a permanent multipolar-world shift regardless of how Hormuz resolves.
Key metrics
- 15 ships confirmed crossing the strait on April 2; 15-18 on April 4, vs 2-5/day two weeks prior and >100/day pre-conflict
- Net hit to global commercial oil stocks estimated at 10.6 million barrels per day
- Front-month WTI ~$110 vs December 2026 WTI ~$71
- BWET has more than quadrupled since the January tanker call; Iran Conflict Beta basket +17% since inception
- Up to 50% of global polyethylene supply offline, constrained or impacted (Dow CEO); 250-275 days to normalize supply post-reopening
- Dow polyethylene price hikes: $0.10 in March, $0.30 in April (double the announced $0.15)
- SFRH7 fell to 96.05 on rate overreaction, recovered to ~96.40
- March 26: Iran granted passage to China, Russia, India, Iraq, Pakistan; Malaysia, Thailand, Philippines, France, Japan added within a week
- If the strait stays effectively closed, global equities seen falling ~15-20%
- Expectation of up to ~50% of pre-conflict strait traffic within 4-6 weeks
Key insights
- Iran is running a toll road, not a blockade: vessels submit ownership/flag/cargo/crew details through brokers, pay via cash, crypto or -- most commonly and underreported -- diplomatic workarounds like unfreezing Iranian assets settled through Bank of Kunlun, then transit the Qeshm-Larak channel with a confirmation code.
- Hot war and commercial diplomacy coexist: traffic rose from 2-5 ships/day to a confirmed 15 on April 2 and 15-18 on April 4 even as a US F-15 and A-10 were shot down over Qeshm -- though this remains far below >100 ships/day pre-conflict, and mostly smaller than Aframax vessels.
- No ship with IRGC clearance has been struck, and the Houthis are being deliberately restrained from closing the Bab al-Mandab -- evidence of a centralized Iranian command holding escalation cards in reserve.
- The 'insurance is the bottleneck' narrative is wrong; per a vessel captain, the bottleneck is not wanting to die and not wanting to lose an irreplaceable ship in the hottest rate environment ever -- while idle ships print money as floating storage.
- Iran's endgame is a Montreux Convention-style sovereignty regime (like Turkey's Bosphorus management since 1936): tolls and rules under Tehran's control with commercial traffic flowing, positioning the US as the disruptive actor.
- US petrochemicals is the most asymmetric trade: up to 50% of global polyethylene supply is offline/constrained per Dow's CEO, who sees 250-275 days to normalize even post-reopening; Dow hiked polyethylene $0.10 in March and $0.30 in April; longs are DOW and WLK, still in ~50% drawdowns.
- Tankers (BWET, up more than 4x) haven't topped -- rates stay elevated in nearly every scenario -- and the Iran Conflict Beta basket is +17% since inception.
- The oil curve misprices duration: front-month WTI at $110 vs December 2026 at $71 implies a short sharp shock, but Citrini sees a longer disruption with a permanent risk premium, expecting ~50% of pre-conflict traffic within 4-6 weeks; the crisis reads as a symptom of a multipolar world (upcoming 'Age of Empires' primer).
#120
Thematic Primer
Mar 25, 2026
Agentic Utilities: Always On, Never Prompted
AI agents reached an inflection point with the viral adoption of OpenClaw in late 2025, converting theoretical agentic AI into a real workload that consumes tokens around the clock. Because agents generate up to 25x the network traffic of chatbots, run always-on persistent sessions, and route traffic 'east-west' between servers rather than 'north-south' to humans, the structure of the internet itself must be rebuilt. The winners are 'Agentic Utilities' -- infrastructure names (CDNs, optical, DNS, data centers), business-to-agent ecosystem tollbooths (payments, telephony, e-signature), and governance vendors (observability, identity, security) -- many of which are legacy stocks left for dead that are already seeing revenue inflections. Citrini is long AKAM, FSLY, CRCL and NET in the Citrindex and publishes a broad Agentic Utilities basket.
aineocloudaiopticalaisemicybersecurityfinancecryptofinancefintechsaas
Positions & performance
+35.2%avg return71% win · 24 tracked · L +40.1% · S -77.3%
| Position | Mentions | Entry | Last | Return |
|---|
| LBAND:NASDAQ saas Bandwidth | I | 17.1Mar 25 '26 | 59.8 | +249.7% |
| LRXT:NASDAQ aineocloud Rackspace | — | 1.3Mar 25 '26 | 3.94 | +203.1% |
| LPANW:NASDAQ cybersecurity Palo Alto Networks | IAPT | 153.22Mar 25 '26 | 323.79 | +111.3% |
| LDDOG:NASDAQ saas Datadog | IPT | 123.29Mar 25 '26 | 246.86 | +100.2% |
| LHPE:NYSE aineocloud Hewlett Packard Enterprise | IPT | 25.78Mar 25 '26 | 47.69 | +85.0% |
| LTWLO:NYSE saas Twilio | IP | 125.43Mar 25 '26 | 194.47 ● | +55.0% |
| LATEN:NYSE saas A10 Networks | — | 23.26Mar 25 '26 | 33.47 ● | +43.9% |
| LCSCO:NASDAQ aisemi Cisco | PT | 81.83Mar 25 '26 | 114.17 | +39.5% |
| LDOCN:NYSE aineocloud DigitalOcean | IAT | 87.0Mar 25 '26 | 120.2 ● | +38.2% |
| LFFIV:NASDAQ saas F5 | PT | 297.86Mar 25 '26 | 394.53 | +32.5% |
| LSAIL:NASDAQ cybersecurity SailPoint | IT | 12.33Mar 25 '26 | 14.95 | +21.2% |
| LNET:NYSE saas Cloudflare | ISPT | 218.0Mar 25 '26 | 262.15 | +20.3% |
| LVRSN:NASDAQ saas VeriSign | IPT | 251.7Mar 25 '26 | 280.0 | +11.2% |
| LDLR:NYSE aineocloud Digital Realty | PT | 176.43Mar 25 '26 | 195.76 ● | +11.0% |
| LDOCU:NASDAQ saas DocuSign | IT | 46.3Mar 25 '26 | 50.44 | +8.9% |
| LEQIX:NASDAQ aineocloud Equinix | IT | 965.95Mar 25 '26 | 1046.79 ● | +8.4% |
| LZS:NASDAQ cybersecurity Zscaler | T | 139.44Mar 25 '26 | 142.32 | +2.1% |
| LAKAM:NASDAQ saas Akamai | IPT | 119.15Mar 25 '26 | 115.37 | -3.2% |
| LCOIN:NASDAQ financecrypto Coinbase | ISPT | 181.1Mar 25 '26 | 158.29 | -12.6% |
| LCIEN:NYSE aioptical Ciena | IPT | 437.7Mar 25 '26 | 377.27 ● | -13.8% |
| LVNET:NASDAQ aineocloud VNET Group | A | 9.11Mar 25 '26 | 7.21 | -20.9% |
| LFSLY:NASDAQ saas Fastly | — | 29.79Mar 25 '26 | 20.24 | -32.1% |
| LCRCL:NYSE financecrypto Circle Internet Group | IS | 103.86Mar 25 '26 | 65.67 ● | -36.8% |
| SOKTA:NASDAQ cybersecurity Okta | IAT | 78.12Mar 25 '26 | 138.5 | -77.3% |
Full summary 506 words
This March 2026 report extends Citrini's three-year AI arc into what it calls the Agentic Era. Back in May 2023, Citrini predicted a three-phase AI adoption process ending in agents that carry out tasks without direct prompting; the report argues that phase has now arrived. The catalyst was the November 2025 release of ClawdBot (renamed OpenClaw after Anthropic's lawyers intervened), an open-sourced, self-hosted agentic library whose GitHub adoption and OpenRouter token consumption went vertical in two months. Agents now run overnight from a Mac Mini via iMessage, and Jensen Huang has floated token-based compensation, saying he would be 'deeply alarmed' if a $500,000 engineer consumed less than $250,000 in tokens. Citrini's existing 'AI Losers' short basket began waterfalling as agents made theoretical disruption tangible, and the firm has been adding agentic-utility longs -- AKAM, FSLY, CRCL and NET -- bought when they were viewed as separate from the AI trade.
The framework splits winners into three categories. Infrastructure: Cisco estimates agentic AI generates up to 25x more network traffic than a chatbot, and Nokia forecasts machine-to-machine agentic traffic growing from 66 EB/month in 2025 to 537 EB/month in 2034. Using Austin's missing east-west highways as a metaphor, the report argues agentic traffic moves laterally between servers, benefiting Cisco (SiliconOne G300, AgenticOps), Ciena (optical backbone, capex up ~2.5x historical average), and HPE (networking up 152% YoY post-Juniper, now 30% of revenue and half of operating profits). Chokepoint legacy names include A10 Networks (carrier-grade NAT amid IPv4 scarcity -- only ~4.3 billion addresses exist) and VeriSign (450 billion DNS queries a day, 67% operating margins, agent workflows multiplying lookups per task). CDNs become 'Compute Delivery Networks': Akamai's API-security revenue is growing 100% YoY and it launched the Akamai Inference Cloud with $250 million of capex; Fastly offers the highest convexity; F5's NGINX gateway sees AI API calls running 'meaningfully ahead' of projections. Data center plays include Equinix (500,000 interconnects, 60% of large new contracts from AI), Digital Realty, VNET, DigitalOcean, and higher-risk Rackspace ($2.75 billion of debt, saved by a Palantir partnership). Cloudflare is dubbed the agentic conglomerate -- Workers, NET Dollar stablecoin, x402 co-founder, Firewall for AI.
Ecosystem: agents need payment rails and human interfaces. The report details the x402 standard (Coinbase/Cloudflare), Circle Nanopayments enabling gas-free USDC transfers as small as $0.000001, PayPal's PYUSD (over $4 billion circulation), and Stripe/Visa-backed Tempo, while cautioning it is too early to invest in payments on agentic upside alone. Bandwidth and Twilio own telephony tollbooths -- Twilio already handles 85% of its own inbound sales calls with AI -- and DocuSign's IAM platform ($350 million+ ARR, ~11% of ARR, expected to nearly double in fiscal 2027) carries regulatory moats and Anthropic/OpenAI integrations.
Governance: observability and security converge into 'Agentic Governance', favoring Datadog, Palo Alto (Chronosphere plus the ~$25 billion CyberArk deal), SailPoint, and Zscaler, with Okta watched but unconvincing. The conclusion: merely saying 'agentic' on a slide deck means nothing, but companies that truly enable the structural shift should see meaningful long-term growth, captured in the Agentic Utilities basket on Citrindex.
Key metrics
- Cisco estimate: agentic AI generates up to 25x more network traffic than a chatbot
- Nokia: agentic M2M traffic to grow from 66 EB/month (2025) to 537 EB/month (2034)
- HPE networking segment +152% YoY, now 30% of total revenue and half of operating profits
- VeriSign: 450 billion DNS queries/day, 67% operating margins
- Akamai API security revenue +100% YoY; $250M capex for Akamai Inference Cloud
- Equinix: 500,000 interconnects; 60% of large new contracts from AI workloads
- US call centers employ 3.6 million people (~2.5% of workforce), >$100 billion annual labor spend
- DocuSign IAM: >$350M ARR (~11% of ARR) in FY2026, expected to nearly double in FY2027
- PayPal PYUSD circulation grew to over $4 billion in 2H25
- Rackspace carries $2.75 billion in long-term debt; Palo Alto's CyberArk deal ~$25 billion
Key insights
- Agentic AI went from buzzword to reality with OpenClaw (formerly ClawdBot) in November 2025; its trick of storing context in a text file and looping AI calls drove astronomical GitHub adoption and token usage in two months.
- Cisco estimates agentic AI generates up to 25x more network traffic than a chatbot, and Nokia projects agentic machine-to-machine traffic rising from 66 EB/month in 2025 to 537 EB/month in 2034 -- traffic shifts from north-south (human-server) to ~80% east-west (server-server).
- Legacy internet plumbing is inflecting: HPE networking grew 152% YoY to 30% of revenue, Ciena raised capex ~2.5x its historical average to meet (not anticipate) demand, and VeriSign (450 billion DNS queries/day, 67% operating margins) flagged agentic AI on its last two earnings calls.
- CDNs become 'Compute Delivery Networks': Akamai's API security revenue is up 100% YoY and it launched an Inference Cloud with $250M capex; Fastly turned FCF-positive on agentic traffic and offers the highest convexity after being left for dead.
- A new B2A (business-to-agent) category is emerging in payments: Coinbase/Cloudflare's x402 standard revives the HTTP '402 Payment Required' code, Circle Nanopayments enables gas-free USDC transfers as small as $0.000001, and Cloudflare launched NET Dollar and pay-per-crawl.
- Telephony is a regulatory tollbooth agents cannot vibecode away: Bandwidth (PSTN interconnects, OpenAI Realtime API integration) and Twilio (Segment data, ConversationRelay, 85% of its own inbound sales calls handled by AI) are the picks.
- DocuSign's IAM platform generated over $350 million ARR (~11% of ARR) in fiscal 2026 and is expected to nearly double in fiscal 2027, with MCP/Claude integrations plus FedRAMP and ESIGN/UETA/eIDAS regulatory moats.
- Governance is the third leg: observability and security converge into 'Agentic Governance', favoring Palo Alto (Chronosphere acquisition plus ~$25 billion CyberArk deal), SailPoint, Zscaler and Datadog; Citrini remains unconvinced on Okta despite cheapness.
#119
Thematic Update
Mar 12, 2026
Let There Be Light: Revisiting the Optics & AI Connectivity Theme
Citrini's contrarian mid-2024 optics calls (Interconnects 101, Can You Hear Me Now?) have tripled the connectivity basket, but the obvious winners (Lumentum, Coherent, AAOI) are now priced for perfection, so the next asymmetry sits deeper in the photonics stack. Both pluggable transceivers and co-packaged optics converge on the same upstream substrates, components and equipment — so regardless of CPO timing, MOCVD tools (Aixtron), bonding equipment (SUSS MicroTec), SOI substrates (Soitec), InP fabs (Nokia) and optical attach hardware (Furukawa, Sumitomo Electric) capture the buildout. The highest-conviction single name is Himax, whose nanoimprint-lithography micro-lens arrays and V-groove baseplates appear (per a Hunterbrook patent investigation) to sit inside TSMC's COUPE fiber-array-unit supply chain for Nvidia CPO, with a second underappreciated kicker in Apple smart-glasses optics.
aimemoryaiopticalaisemimag5
Positions & performance
+31.1%avg return83% win · 6 tracked · L +35.8% · S +7.9%
| Position | Mentions | Entry | Last | Return |
|---|
| LTSEM:NASDAQ aisemi Tower Semiconductor | S | 118.54Mar 12 '26 | 224.21 ● | +89.1% |
| LSTM:NYSE aisemi STMicroelectronics | SP | 33.24Mar 12 '26 | 53.45 ● | +60.8% |
| LHIMX:NASDAQ aisemi Himax | S | 10.13Mar 12 '26 | 12.62 | +24.6% |
| LNOK:NYSE aioptical Nokia | SP | 8.14Mar 12 '26 | 9.1 | +11.8% |
| SAAOI:NASDAQ aioptical Applied Optoelectronics | S | 106.19Mar 12 '26 | 97.82 ● | +7.9% |
| LPOET:NASDAQ aioptical POET Technologies | S | 7.44Mar 12 '26 | 6.89 | -7.4% |
Full summary 598 words
This March 2026 report revisits the optics theme Citrini pioneered in July-August 2024, when 'Interconnects 101' and 'Can You Hear Me Now?' argued — against consensus, with the stocks near 52-week lows — that AI connectivity demand would collide with underinvestment to create an optics shortage. The connectivity basket has since more than tripled and is up 35% YTD led by Lumentum, while hyperscaler capex heads toward an estimated $650-700B in 2026. But with crowd favorites approaching priced-for-perfection, the piece asks where the next asymmetry sits and answers: further down the stack, in photonic components, substrates and capital equipment, especially as CPO becomes a necessity.
A Photonics 101 section explains the physics: compute performance improved 60,000x in two decades while electrical interconnect bandwidth rose only 30x; copper hits a wall, and photonic integrated circuits close the gap. Pluggables still dominate and demand is exploding (the AI-cluster transceiver market should exceed $10B in 2026, roughly doubling from 2024), but power consumption at 6.4Tb/s+ forces co-packaged optics, which cut per-port power from ~30W to as low as 9W — Jensen Huang's math is that a million GPUs at six transceivers each would burn 180 megawatts. Citrini flags AAOI as the crowded, fragile expression: ten customers were 96.6% of 2025 revenue (Microsoft 28.8%), its CPO laser is only at sample stage, and the stock could trade 50% lower — yet AAOI's own call confirms the bottleneck ('a major laser shortage, with lead times of at least one year'). Nvidia's Quantum-X CPO ships in H1 2026, NVIDIA invested $2B each into Lumentum and Coherent, Marvell bought Celestial AI, Ciena bought Nubis — the PIC demand pull is accelerating, and Hock Tan's CPO skepticism doesn't matter because the thesis is architecture-agnostic.
The single-name highlight, produced with Hunterbrook, is Himax (HIMX): a sleepy display-driver company (~50% cyclically depressed automotive sales) whose wafer-level optics arm makes the micro-lens optics block (with 45-degree prisms) and V-groove baseplate inside the fiber array units that partner FOCI assembles for TSMC's COUPE platform. Three patents — two Himax, one TSMC — describe what appears to be the same 22-channel FAU design, and a former Lumentum engineer concluded there is 'a high probability' Himax and FOCI are in the FAU supply chain. Himax's nanoimprint lithography experience dates to iPhone X Face ID dot projectors; management guides 2026 as the first mass-production year with potential $100M+ CPO revenue and acceleration in 2027-28 (Morgan Stanley projects 5,000 Rubin Ultra racks in 2027 and 28,000 in 2028). A second kicker is Apple smart glasses, where Himax's WiseEye sensor and later LCoS microdisplays plus nanoimprint waveguides could rival CPO in size; Citrini sees non-driver sales reaching ~50% of revenue by 2028 and the stock at roughly 3-4x EV/EBITDA on 2028 numbers.
The 'PICs and shovels' basket rounds it out: Aixtron (70-90% MOCVD share; photonics orders guided to more than double, plus 85%+ GaN share ahead of Nvidia's 800V HVDC ramp), SUSS MicroTec (~50% of Samsung/Micron HBM temporary bonding, ~90% of TSMC photomask cleaning, the XBS300 CPO bonding platform, ~6x EBIT on 2030 targets vs BESI at ~40x), Soitec (near-monopoly SOI substrates at ~10x trough EV/EBITDA), Shin-Etsu (licenses Smart Cut rather than competing — proof of the moat), Nokia (the West's only vertically integrated InP fab via Infinera, $1B Nvidia 6G investment, CHIPS-subsidized US buildout), Furukawa (DFB laser capacity +500% by 2028), Sumitomo Electric (info-comm profit +360% YTD; connector capacity up 7x by 2028), STMicro (PIC100 in volume with a multi-billion-dollar AWS contract) and speculative POET. Positioning: overweight Himax, underweight POET, consider shorting AAOI against the basket, and take profits in the original priced-for-perfection winners.
Key metrics
- Hyperscaler AI capex estimated at $650B-$700B for 2026; connectivity basket has more than tripled since publication and is +35% YTD
- Compute performance +60,000x over two decades vs electrical interconnect bandwidth only +30x; CPO cuts per-port power from ~30W to as low as 9W
- AI-cluster optical transceiver market on track to exceed $10B in 2026, roughly doubling from 2024; LightCounting: pluggable optics $15.5B in 2025 growing 17% CAGR to >$34B by 2030, CPO >$9B by 2030
- AAOI: ten customers = 96.6% of 2025 revenue (Microsoft 28.8%); >$1B 2026 revenue guided but supply-constrained; 'major laser shortage' with 1-year lead times; $209M 2025 capex vs $120-150M expected
- NVIDIA invested $2B each into Lumentum and Coherent (March 2026) plus $1B into Nokia for 6G; Lumentum expanded EML production 40% in 2025 with another 40% planned in 2026; Tower Semi investing $650M to triple SiPh shipments
- Himax: CPO revenue could exceed $100M annualized in early mass production (2026 first MP year); Gen-2 FAU targets >6.4T for GPUs in late 2027/early 2028; Morgan Stanley projects 5,000 Rubin Ultra racks in 2027 and 28,000 in 2028; HIMX at ~3-4x EV/EBITDA on 2028 estimates
- Apple smart glasses: est. 3-5M launch-year units; Himax WiseEye ASP ~$10-15, combined AR optics ASP ~$70-90 by ~2028; non-driver segment seen going from <20% to ~50% of Himax sales by 2028
- Aixtron: 70-90% MOCVD share, >85% GaN share; photonics guided to more than double YoY (~€120M optoelectronics in 2025 toward +€250M)
- SUSS MicroTec: ~50% share of Samsung/Micron HBM temporary bonding, ~90% of TSMC photomask cleaning; 2030 targets €750-900M revenue at 20-22% EBIT margin (~6x forward EBIT at midpoint) vs BESI ~40x
- Furukawa DFB laser chip capacity +500% by 2028 vs 2025; Sumitomo Electric info-comm operating profit ¥46.1B vs ¥10.4B (+360%), connector capacity +7x 2023-2028, InP substrate capacity +2.4x by 2028; STMicro photonics revenue 'nicely above' $500M this year and well above $1B next year on a multi-billion AWS contract
Key insights
- The equipment/substrate layer is architecture-agnostic: pluggables and CPO consume the same upstream MOCVD reactors, InP crystals and SOI wafers, so the 'which architecture wins' debate doesn't matter for Aixtron, SUSS, Soitec and peers — Hock Tan's CPO skepticism is irrelevant to the thesis (and Broadcom itself has shipped three CPO generations to Meta).
- Citrini's original optics calls tripled the connectivity basket (+35% YTD, led by Lumentum), but the firm now advises taking profits in the crowd favorites: AAOI — 96.6% of 2025 revenue from ten customers, Microsoft 28.8%, CPO laser only at sample stage, mid-2027 targets requiring 5x capacity on unshipped technology — could trade 50% lower and is a candidate short against the new basket.
- The supply chain is validating the bottleneck: AAOI cites a 'major laser shortage' with 1-year lead times, Lumentum is expanding EML output 40% for a second straight year, Tower is spending $650M to triple SiPh shipments, and Nvidia invested $2B each into Lumentum and Coherent in March 2026.
- Himax is the highest-conviction asymmetric play: patent forensics (two Himax patents and a TSMC inspection patent sharing an unusual 22-channel FAU design) plus a former Lumentum engineer's read suggest Himax stamps the optics blocks and V-groove plates that FOCI assembles into FAUs for TSMC's COUPE and Nvidia's CPO platform; management guides $100M+ CPO revenue in early mass production.
- Himax's second kicker is Apple smart glasses: WiseEye sensors at $10-15 ASP on an expected 3-5M unit launch, then LCoS microdisplays and nanoimprint waveguides at $70-90 combined ASP for ~2028 display-equipped AR glasses — potentially rivaling CPO revenue; non-driver sales could reach ~50% of revenue by 2028, putting HIMX at ~3-4x EV/EBITDA on 2028 numbers.
- Aixtron is 'a photonics equipment monopoly with the GaN ramp for free': 70-90% MOCVD share, photonics orders guided to more than double in 2026 (potentially +€250M, becoming the largest segment), and 85%+ GaN share as Nvidia's 800V HVDC Rubin Ultra architecture forces GaN tool orders from H2 2026.
- SUSS MicroTec is the purest advanced-packaging equipment play: ~50% of Samsung/Micron HBM temporary bonding, ~90% of TSMC photomask cleaning, ~70% of revenue tied to advanced packaging, the XBS300 doing CPO heterogeneous integration — at ~16-18x trough EBIT (~6x on 2030 targets) versus BESI at ~40x forward EBIT.
- Soitec's moat is proven by its would-be competitor — Shin-Etsu, the world's largest silicon wafer maker, licenses Smart Cut rather than replicating it (~10x trough EV/EBITDA for an ~80% share SOI monopoly) — while Nokia is a hidden photonics semi company: the Infinera deal gives it the West's only vertically integrated InP fab, CHIPS-subsidized San Jose and Bethlehem buildouts, and it uniquely both receives a $1B Nvidia 6G investment and benefits from Nvidia's $4B spend across Lumentum and Coherent.
#118
Macro Memo
Feb 22, 2026
The 2028 Global Intelligence Crisis: A Thought Exercise in Financial History, from the Future
Written as a fictional macro memo from June 2028, the piece models what happens if AI bullishness is right and that is precisely what is bearish: agentic AI triggers a self-reinforcing 'intelligence displacement spiral' in which capability improvements drive white-collar layoffs, savings are redeployed into more AI, displaced high earners cut the discretionary spending that anchors the consumer economy, and the loop has no natural brake because AI is OpEx substitution, not cyclical capex. The disruption spreads from SaaS repricing to agent-led disintermediation of payments, insurance and marketplaces, then to systemic risk via private credit (insurer-funded 'permanent capital' holding defaulting software LBO debt) and finally to the $13 trillion prime mortgage market as 780-FICO borrowers' incomes are structurally impaired. It is a scenario, not a prediction — published in February 2026 so investors can audit which portfolio assumptions won't survive the decade.
aisemiconsumershoppingfinancefintech
Positions & performance
Full summary 559 words
This is an explicit thought exercise — 'a scenario, not a prediction,' co-conceived with Alap Shah of LOTUS — framed as the Citrini macro memo of June 30, 2028, reconstructing a 'Global Intelligence Crisis.' In the scenario, unemployment prints 10.2%, the S&P is down 38% from October 2026 highs (having touched ~8000, Nasdaq above 30k), and the memo works backward through the sequence. It begins in late 2025 when agentic coding tools take a step-function jump: developers with Claude Code or Codex can replicate mid-market SaaS in weeks, procurement teams renegotiate (one Fortune 500 renewal at a 30% discount), and ServiceNow's fictional Q3 2026 print — net new ACV growth decelerating from 23% to 14% alongside a 15% workforce reduction — reveals the reflexive mechanism: seat-based vendors' AI-driven customer layoffs mechanically destroy their own revenue, and threatened incumbents become AI's most aggressive adopters because they cannot afford not to.
The second phase is disintermediation. Consumer agents become default (the median American consuming 400,000 tokens/day by March 2027, 10x in a quarter), and the economy's 'rent-extraction layer' built on human friction collapses: passive subscription renewals, insurance renewal books (15-20% of premiums from inertia), travel platforms, real estate commissions compressing from 2.5-3% to under 1%, and DoorDash-style habitual-app moats dissolving as agents check every option. Agents then route around 2-3% card interchange into stablecoins, hitting Mastercard, Amex, Synchrony, Capital One and Discover. The third phase is macro: white-collar workers are 50% of employment but drive ~75% of discretionary spending, and the top 10% of earners account for over 50% of consumption, so concentrated upper-decile job losses produce an outsized demand shock with a savings-buffer lag. The 'jobs always come back' counterargument fails because AI improves at the very tasks workers would redeploy into. India's IT services model ($200B+ of exports) collapses; the rupee falls 18% in four months.
The financial cascade runs through private credit: $2.5 trillion by 2026, stuffed with SaaS LBOs whose ARR assumptions died — the fictional Zendesk default marks a $5B direct-lending facility at 58 cents, the largest private credit software default on record. The 'permanent capital' defense unravels because the capital is annuity money at manager-owned life insurers (Athene/Apollo, Global Atlantic/KKR, American Equity/Brookfield) run through opaque offshore Bermuda reinsurance; regulators tighten RBC treatment, Athene goes on negative outlook and Apollo drops 22% in two sessions. The November 2027 crash — 'a daisy chain of correlated bets on white-collar productivity growth,' per fictional Fed Chair Kevin Warsh — precedes the final question: whether $13 trillion of prime mortgages written to 780-FICO borrowers are still money good when the income assumptions beneath them break (Zillow home values -11% YoY in San Francisco in the scenario; a full crack implies a GFC-rivaling 57% drawdown to S&P ~3500). Policy is structurally hamstrung: federal receipts run 12% below baseline because the tax base is human labor, labor share falls from 56% to 46% of GDP, and proposals like a 'Transition Economy Act' funded by an inference-compute tax stall in partisan gridlock while rate cuts cannot fix a real-economy engine driven by a $200/month Claude agent replacing a $180,000 product manager. The piece closes by snapping back to February 2026: none of this has started, the S&P is near highs, and the point is to audit which portfolio assumptions depend on the scarcity of human intelligence — 'the canary is still alive.'
Key metrics
- Scenario: unemployment 10.2% in June 2028; S&P 500 down 38% cumulatively from October 2026 highs (~8000 peak, Nasdaq above 30k)
- Median American consuming 400,000 tokens per day by March 2027 — 10x the end-2026 level
- White-collar workers: ~50% of employment, ~75% of discretionary consumer spending; top 10% of earners >50% of all consumer spending; a 2% white-collar employment decline = 3-4% discretionary spending hit
- Private credit grew from under $1 trillion in 2015 to over $2.5 trillion by 2026; Zendesk's $5B direct lending facility marked to 58 cents in the scenario
- US residential mortgage market ~$13 trillion; scenario Zillow home values -11% YoY San Francisco, -9% Seattle, -8% Austin
- Scenario 10-year yield falls from 4.3% to 3.2% over four months; initial jobless claims surge to 487,000
- Labor share of GDP: 64% (1974) to 56% (2024) to 46% in the 2028 scenario; federal receipts running 12% below CBO baseline
- India IT services exports >$200 billion annually; rupee -18% vs the dollar in four months in the scenario
- Full mortgage-crack scenario: 57% peak-to-trough S&P drawdown (GFC-scale) to ~3500
- A Claude agent doing a $180,000 product manager's work for $200/month — the unit economics driving the displacement spiral
Key insights
- The core mechanism is a feedback loop with no natural brake: AI capability improves, firms cut white-collar jobs and redeploy savings into AI, displaced workers spend less, margin pressure forces more AI adoption — and because it is OpEx substitution rather than capex, falling demand does not slow the buildout.
- Incumbents don't resist the disruptive technology this time — they cannot afford to: the scenario's ServiceNow cuts 15% of its workforce and funds the very AI disrupting it, while seat-based revenue mechanically shrinks with customers' AI-driven layoffs.
- The consumption math is the crux: white-collar workers are ~50% of employment but ~75% of discretionary spending, and the top 10% of earners drive >50% of all US consumer spending, so a 2% white-collar employment decline maps to a 3-4% discretionary spending hit — with a dangerous savings-buffer lag before the data confirms it.
- Agentic commerce destroys 'habitual intermediation': friction-based moats (subscription inertia, insurance renewals worth 15-20% of premiums, 5-6% real estate commissions, delivery-app home-screen loyalty) dissolve when agents compare everything 24/7, and agents route payments around 2-3% interchange into stablecoins.
- Private credit is the transmission channel to systemic risk: $2.5T by 2026 with heavy SaaS LBO exposure; the fictional Zendesk default ($5B facility marked at 58 cents) exposes that 'permanent capital' is actually annuity policyholder money at manager-owned insurers layered through opaque Bermuda reinsurance.
- The endgame question is whether prime mortgages are money good: $13T of loans underwritten on income durability for 780-FICO borrowers — 'the loans were good on day one; the world changed after they were written' — with a full crack implying a 57% GFC-scale equity drawdown to S&P ~3500.
- Government is structurally unfit for this crisis: the revenue base is a tax on human time, receipts run 12% below baseline as labor share of GDP falls from 56% (2024) to 46%, and automatic stabilizers assume workers will be reabsorbed at prior wages — which they are not.
- The investable asymmetries inside the scenario: pure AI-infrastructure economies (Taiwan, Korea) outperform massively while India's $200B IT services surplus evaporates (rupee -18% in four months); the piece's real-world instruction is to audit portfolio assumptions built on scarce human intelligence before the repricing.
#117
Thematic Update
Feb 18, 2026
Thematic Update: Modern Warfare
Modern warfare is being reshaped by three headline-driven trends — directed energy weapons finally working, cheap subsea drones threatening multi-billion-dollar naval assets, and a great-power scramble for Greenland and the Arctic — and the winners are smaller 'enablers' rather than the big primes. nLIGHT, up nearly 6x since Citrini's May 2025 entry, is the only public pure-play vertically integrated directed-energy company targeting a megawatt laser, and Iron Beam's operational deployment plus Golden Dome funding validate a spending wave barely in consensus estimates. Subsea drone offense and defense (Exail, Kraken, Oceaneering and others) and Arctic exposure (miners like Critical Metals and Energy Transition Minerals, icebreaker supply chains, Iridium's polar satcom moat) round out three new baskets built to capture accelerating defense budgets with structural tailwinds beyond headline beta.
airare-earthairobotconsumertraveldefensecomponentsdefensedefensedirected-energydefensedronedefenseprimeenergynuclearenergywarspace
Positions & performance
+28.9%avg return80% win · 5 tracked · L +28.9%
| Position | Mentions | Entry | Last | Return |
|---|
| LIRDM:NASDAQ space Iridium | IAT | 23.07Feb 18 '26 | 45.96 ● | +99.2% |
| LOII:NYSE defensedrone Oceaneering | — | 33.09Feb 18 '26 | 52.17 ● | +57.7% |
| LLASR:NASDAQ defensedirected-energy nLIGHT | IS | 54.35Feb 18 '26 | 70.02 | +28.8% |
| LESLT:NASDAQ defense Elbit Systems | P | 709.15Feb 18 '26 | 715.72 | +0.9% |
| LAVAV:NASDAQ defensedrone AeroVironment | ISP | 265.46Feb 18 '26 | 154.24 ● | -41.9% |
Full summary 563 words
This thematic defense update builds on Citrini's Drones basket from 25 Trades for 2025 — one of its best trades of that year — and The New WFH (War From Home), organizing recent headlines (El Paso airspace closure, dark-fleet tanker seizures and Maduro's extraction, Ukrainian sea drones destroying Russian submarines, Trump's Greenland demands) into three buckets: directed energy weapons, subsea drones, and Greenland/Arctic investment.
The centerpiece is nLIGHT (LASR), bought in the EW basket in May 2025 at $8.47 and up nearly 6x, which Citrini argues is 'just the start.' A Citrini analyst attended the Riyadh World Defense Show, where the 800-employee Camas, Washington company displayed a fully integrated 70kW laser weapon system (with 30kW and 10kW variants) — the only DEW booth at the conference. The report chronicles the field's inflection: the Navy's Vice Admiral McLane committing to 'a laser on every ship,' the UK's DragonFire deploying on Type 45 destroyers by 2027 (half a decade early), and Israel's Iron Beam formally entering IDF service on December 28, 2025 — the first operational high-power laser air defense system, flipping interception economics from $50,000 Iron Dome missiles against $500 rockets to single-digit-dollar marginal cost. CRS thresholds frame the roadmap: ~100kW kills drones and mortars, 300kW engages cruise missiles, 1MW can threaten ballistic missiles and hypersonics. nLIGHT is the only contractor publicly under contract (the $171M HELSI award, expanded from $86M) to scale to a full megawatt, controls the entire stack from diodes to beam directors (thanks largely to the 2019 $33M Nutronics acquisition), supplies Iron Beam, counts the US government and Raytheon as >10% customers, and just raised ~$200M to build capacity ahead of a program of record. Numbers: Q3 2025 revenue $66.7M (+19%) with A&D up ~50% to a record $46M; Q4 preliminary revenue $78-80M; product gross margin a record 41%. A double requires two of three: sustained 40%+ A&D growth toward $450M FY2027 revenue, a HELSI/Golden Dome validation ($24.4B of Golden Dome funding, $13B in FY2026), and an EBITDA inflection toward $75-100M; the bear case is ~30% downside.
The subsea drone section keys off Ukraine's December 16, 2025 underwater-drone strike on a KILO-class submarine inside Novorossiysk harbor — a step-change proving cheap UUVs can penetrate defended ports (and noting Norfolk's port security barriers have far larger gaps). Plays span XLUUV primes (Boeing/HII Orca, Northrop Manta Ray, Anduril Ghost Shark), with preference for pure-plays: Exail Technologies (the most levered integrator, <$2B cap, rapidly growing backlog), Kraken Robotics (synthetic aperture sonar, KATFISH, SeaPower batteries), Norbit, and favorite Oceaneering (OII) — 60 years of subsea robotics, its largest-ever DoW contract ramping 2026/27, the SIIPS 'guard dog' infrastructure-protection system, at 12x forward P/E. The Greenland/Arctic section frames Trump's pressure as a decade-long US-China contest: rare earth plays Critical Metals (Tanbreez, EXIM-funded), Energy Transition Minerals (Kvanefjeld, cutting Chinese ties and pursuing a Nasdaq listing) and Amaroq, all labeled speculative meme-beta; icebreaker exposure via ABB (Azipod propulsion, minority Aker stake) and Viking Supply Ships as Russia runs 40 icebreakers versus one US heavy polar vessel; Iridium's pole-to-pole LEO constellation (a 25-year DoW relationship, the $738.5M EMSS contract up for rebid, with a December 2025 Space Force modernization award suggesting the risk premium unwinds); MDA Space on Canada's ESCP-P polar satcom program; and Kongsberg for Nordic rearmament. A Greenland & Arctic basket is published with acknowledged headline beta but underlying trends that work regardless of any US-Denmark deal.
Key metrics
- LASR entered at $8.47 in May 2025; stock has nearly 6x'd (from $6 to $51 over the past year), market cap ~$2.9B at ~11x trailing revenue
- HELSI contract: $171M (originally $86M, awarded May 2023) to scale from 300kW to 1MW, scheduled completion 2026
- nLIGHT Q3 2025: revenue $66.7M (+19% YoY), A&D revenue ~+50% to record $46M, defense product sales +70%, record 41% product gross margin; Q4 preliminary revenue $78-80M
- Golden Dome: $24.4B federal funding through OBBBA with $13B allocated for FY2026
- Iron Beam funding: ~$1.2B US Congressional supplemental, >2B shekel (~$500M) Rafael/Elbit contract, plus $200M award to Elbit
- Double case: FY2027 revenue toward $450M and EBITDA of $75-100M; bear case ~30% downside to ~$35 on $320M FY2027 revenue at 6x sales
- Global high-energy laser market projected at roughly $10-15B by 2030; nLIGHT's ~$165M A&D run-rate is <2% of that TAM; 5% share = $500-750M defense revenue
- US Navy ~290 deployable ships; $2-3M laser content per ship on half the fleet = $290-435M revenue opportunity
- Russia operates 40 icebreakers (8 nuclear) vs one US heavy polar icebreaker; NSR cuts transit distance ~40% and 10-15 days
- Iridium's EMSS contract: 7 years, $738.5M; Ukraine's Operation Spiderweb used 117 quadcopter drones to destroy or damage at least 40 Russian aircraft
Key insights
- Directed energy hit its operational inflection in a six-week window: UK DragonFire to deploy on Type 45 destroyers by 2027 (five years early), Israel's Iron Beam entered IDF service December 28, 2025 as the world's first operational laser air defense, and the US Navy's top surface warfare officer committed to 'a laser on every ship.'
- DEW economics solve the cost-asymmetry problem: a $500 rocket forces a $50,000 Iron Dome interceptor, while laser interception costs single-digit dollars per shot with an unlimited magazine; CRS power thresholds — 100kW for drones, 300kW for cruise missiles, 1MW for ballistic/hypersonic threats.
- nLIGHT is the only public pure-play targeting the megawatt: the $171M HELSI contract (expanded from $86M, completion scheduled 2026), full vertical integration from diodes to beam directors via the 2019 Nutronics deal, an Iron Beam supply role, and a ~$200M raise to build capacity ahead of a program of record.
- LASR is up nearly 6x from Citrini's $8.47 entry in May 2025, yet the double case needs only two of three: 40%+ A&D growth toward $450M FY2027 revenue, HELSI/Golden Dome validation, and EBITDA inflecting to $75-100M; bear case ~30% downside to ~$35 — a roughly 3:1 risk/reward.
- Golden Dome carries $24.4B of federal funding through the One Big Beautiful Bill Act ($13B allocated FY2026) with no directed-energy awards made yet — an open catalyst for nLIGHT, which confirmed it is responding to RFPs.
- Ukraine's December 2025 UUV strike on a KILO-class submarine inside the enclosed Novorossiysk base proves stealthy subsea drones can penetrate defended harbors — driving spending on detection, barriers and autonomous 'guard dog' systems; Oceaneering (12x forward P/E, record DoW contract ramping 2026/27, SIIPS) is the favorite cheap play, Exail the most levered integrator.
- The Greenland trade is not about annexation: it is about accelerating Western investment in Arctic minerals (CRML's Tanbreez, ETM's Kvanefjeld after cutting Chinese ties, Amaroq), icebreakers (Russia has 40 including 8 nuclear vs one US heavy polar icebreaker; ABB's Azipod is the design lynchpin), and polar satcom.
- Iridium's risk premium should unwind: the stock lost a third when SpaceX bought Echostar spectrum, but Iridium runs the only true pole-to-pole LEO constellation, is the GMDSS backbone for the Northern Sea Route, equips every UUV Citrini researched, and won a December 2025 Space Force ground-modernization contract ahead of the EMSS airtime rebid.
#116
Thematic Primer
Feb 11, 2026
Atoms vs Bits: What Can't You Prompt Your Way Out Of?
Agentic AI has forced the market to apply an 'AI Disruption Discount' to software, rotating capital from bits into atoms — the physical materials, metals and chemicals that AI, defense, aerospace and electrification all need but that no prompt can conjure. The obvious physical winners (power equipment, copper, nuclear, optics) are crowded, so the next leg is in overlooked upstream materials with oligopoly or monopoly supply, multi-year qualification moats, and converging cyclical-plus-structural demand: uranium conversion (Solstice), beryllium (Materion), titanium sponge (Osaka/Toho), aerospace aluminum, tungsten (Kennametal), superalloys, carbon fiber (Hexcel), grain-oriented electrical steel, mining capex (Komatsu), and AI electronic chemicals (Nittobo, Asahi Kasei, Entegris). These names are still priced as commodity producers even as they become critical enablers, and the re-rating 'won't be gentle.'
airare-earthaisemicommoditiesdefensecomponentsdefenseenergygridenergynuclear
Positions & performance
+4.0%avg return46% win · 13 tracked · L +4.0%
| Position | Mentions | Entry | Last | Return |
|---|
| LMTRN:NYSE airare-earth Materion | IST | 157.11Feb 11 '26 | 241.82 ● | +53.9% |
| LPKE:NYSE defensecomponents Park Aerospace | S | 24.09Feb 11 '26 | 34.24 | +42.1% |
| LATI:NYSE defensecomponents ATI Inc | I | 138.72Feb 11 '26 | 192.64 ● | +38.9% |
| LHXL:NYSE defensecomponents Hexcel | I | 87.85Feb 11 '26 | 110.28 | +25.5% |
| LCSTM:NYSE commodities Constellium | I | 24.7Feb 11 '26 | 29.05 | +17.6% |
| LKALU:NASDAQ commodities Kaiser Aluminum | T | 144.71Feb 11 '26 | 161.89 ● | +11.9% |
| LENTG:NASDAQ aisemi Entegris | ISPT | 137.79Feb 11 '26 | 126.37 ● | -8.3% |
| LOLN:NYSE commodities Olin | I | 26.32Feb 11 '26 | 23.2 | -11.9% |
| LKMT:NYSE defensecomponents Kennametal | — | 40.26Feb 11 '26 | 35.23 | -12.5% |
| LCENX:NASDAQ commodities Century Aluminum | IA | 53.44Feb 11 '26 | 44.87 ● | -16.0% |
| LSOLS:NASDAQ commodities Solstice Advanced Materials | PT | 74.95Feb 11 '26 | 60.54 | -19.2% |
| LAA:NYSE commodities Alcoa | IP | 63.15Feb 11 '26 | 44.08 ● | -30.2% |
| LIPX:NASDAQ defensecomponents IperionX | A | 44.07Feb 11 '26 | 26.5 | -39.9% |
Full summary 590 words
Published February 11, 2026 into the software selloff, 'Atoms vs Bits' argues the market is ruthlessly and correctly repricing anything with an unclear AI-era moat — vertical SaaS, digital ads, fintech — and that investors will converge on a simpler question: 'what can't you prompt your way out of?' The answer is atoms. Every real bottleneck in the AI trade has been physical, and the next evolution is where new demand (a proposed $1.5T US defense budget, NATO and Japanese rearmament, a record aerospace backlog, data center gas turbines sharing input materials with jet engines) collides with the buildout to strain supply chains. The screen: companies with pricing power across a capital cycle, concentrated qualified supply, 2-5 year qualification moats, and protection from Chinese flooding via physics, defense procurement rules or quality requirements.
The anchor idea is Solstice Advanced Materials (SOLS), the October 2025 Honeywell spin-off that owns Metropolis Works — the only US uranium hexafluoride conversion facility, ~15,000 MTU nameplate, roughly 20% of global conversion capacity. Legacy contracts struck at ~$20/kgU during the 2017-2023 idle are rolling off (~25% per year) into a ~$64/kgU spot market with identical production costs (~$13-16/kgU variable plus $150-170M fixed), so repricing flows straight to EBITDA; Citrini bridges the AES segment to ~$673M of 2028 EBITDA (haircut to $500M EBIT), sees 60% segment margins, a $2B backlog, and argues a 12-14x multiple implies $95-105 per share with a bull case near a triple, versus Centrus at 33x. Subsequent sections tour the other 'atom' monopolies: Materion (over 40% of global beryllium, 70%+ of freshly mined supply, defense bookings +40%, a Commonwealth Fusion agreement), the Japanese titanium sponge duopoly Osaka Titanium and Toho Titanium (~80% Western share with the Saudi JV, single-digit EV/EBITDA, a $210M expansion to 50,000 tonnes by 2028, IperionX the US dark horse), aerospace/high-purity aluminum (Constellium the highest conviction, plus Kaiser, Century, AMAG, Alcoa; copper/aluminum cost ratio at 4.2x versus the 3.5x switching threshold; no new US smelter since 1980), tungsten (prices tripled on Chinese export controls; Kennametal at ~8.5x EV/EBITDA is the vertically integrated Western play with Metal Cutting margins up from 6.0% to 9.6%), superalloys (ATI the best US story; Acerinox with Haynes as the cheap European route), and carbon fiber (Hexcel: ~93% aero/defense mix, guided 2026 revenue of $2.0-2.1B with EPS $2.10-2.30, ~$500M of incremental revenue when OEM production rates normalize, plus underappreciated space exposure as launch cadence grows 20-25% a year).
Electrical steel gets its own section: transformer lead times have blown out from 20 to 128 weeks (144 for GSUs), prices are up 4-6x since 2022, GOES cores are 25-30% of transformer cost, and the plays are JFE (monopoly on 6.5% silicon steel, ~5x EV/EBITDA), POSCO and Nippon Steel, with Cleveland-Cliffs (sole US GOES producer, $400M five-year government contract) a contrarian turnaround. Mining capex favors Komatsu at ~15x forward earnings versus Caterpillar's 31x — CAT itself projects mining capex +50% by 2030, and the collapsed Rio-Glencore merger means two giant standalone checkbooks. Finally, the 'AI materials' update: the upstream molecules-and-powders basket from December is catching up as predicted — WSJ confirmed the Nitto Boseki T-glass bottleneck (stock +75% YTD, dividend nearly tripled), Resonac +40% YTD — with new ideas in Asahi Kasei (PIMEL photosensitive polyimide, doubling capacity after a ¥16B investment; Q Glass for M9-grade CCLs), photomask blanks (Hoya/AGC duopoly), Sumitomo Chemical, Entegris (60%+ of revenue now advanced nodes; the tungsten-to-molybdenum NAND transition), and qualification-moat chemicals Arkema, Olin and Orbia. Conclusion: with AI now writing its own successor models, the premium on un-promptable physical chokepoints should keep expanding.
Key metrics
- SOLS Metropolis plant: ~15,000 MTU nameplate, ~20% of global conversion capacity; legacy contracts at $20/kgU vs ~$64/kgU spot; ~25% of legacy book repricing per year; $2B AES backlog; Citrini 2028E AES EBIT ~$500M and fair value $95-105/share
- Materion supplies >40% of global beryllium and >70% of freshly mined production; defense bookings +40%
- Osaka Titanium investing $210M to expand sponge capacity from 40,000 to 50,000 tonnes by 2028; export sponge volumes +26% YoY in H1; US imports >95% of its titanium sponge
- Copper/aluminum cost ratio at 4.2x vs ~3.5x switching threshold; US produced ~670,000 tons of primary aluminum in 2024 (<1% of global); no new US smelter since 1980
- Tungsten prices have tripled; Kennametal at ~$40/share and ~8.5x EV/EBITDA with Metal Cutting margin up from 6.0% to 9.6% YoY
- Power transformer lead times 128 weeks (vs 20 weeks two years ago), GSU lead times 144 weeks; transformer prices up 4-6x since 2022; GSU demand +274% since 2019
- Hexcel 2026 guidance: $2.0-2.1B revenue, EPS $2.10-2.30 (~25% growth); ~$500M incremental revenue at full OEM production rates; $600M buyback; Airbus sources >80% of its carbon fiber from Hexcel
- Komatsu at ~15x forward earnings / 8x EV/EBITDA vs Caterpillar at 31x forward / 27x EV/EBITDA; ~900 FrontRunner AHS trucks across 23 mine sites; CAT projects mining capex +50% by 2030
- Nitto Boseki +75% YTD with >70% share in high-end electronic glass fiber; operating profit +26.4% YoY to ¥14.9B; dividend nearly tripled to ¥114/share
- Gold miners' AISC averaging ~$1,600/oz vs gold above $5,000/oz; central banks bought 755+ tons of gold in 2025; F-35 is ~20% titanium by weight, F-22 ~39%
Key insights
- Solstice (SOLS) is 'the cheapest nuclear play in the US': sole domestic UF6 converter (~20% of global capacity), Q4 revenue +39% YoY on only 15-20% volume growth, legacy $20/kgU contracts repricing toward $64+ spot with identical costs — Citrini sees ~60% AES margins, a $2B backlog, and $95-105/share fair value at 12-14x versus Centrus at 33x EV/EBITDA.
- Materion is a near-monopoly on beryllium (>40% of global supply, >70% of freshly mined), with defense bookings +40% and a Commonwealth Fusion Systems agreement giving a free call option on fusion.
- Western titanium sponge is a Japanese duopoly (Osaka + Toho ~80% share with the Saudi JV) trading at single-digit EV/EBITDA in a Boeing-destocking trough; the US imports over 95% of its sponge and Chinese material is blocked by defense law and 4-6 year qualification cycles.
- Tungsten prices have tripled and Kennametal is the only vertically integrated Western tungsten carbide maker with its own powder and recycling; at ~8.5x EV/EBITDA with Metal Cutting margins up 360bps (6.0% to 9.6%), 'the market hasn't figured this out yet.'
- Grain-oriented electrical steel is the grid's hidden chokepoint: power transformer lead times went from 20 weeks to 128 weeks (144 for GSUs), prices up 4-6x since 2022, GSU demand +274% since 2019, and the GOES core is 25-30% of transformer cost — JFE (6.5% silicon steel monopoly, ~5x EV/EBITDA), POSCO and Nippon Steel are the plays, with CLF's $400M government GOES contract a turnaround signal.
- Hexcel is a coiled spring: right-sized costs, 2026 guidance of $2.0-2.1B revenue and $2.10-2.30 EPS (~25% growth), ~$500M of incremental revenue when OEM rates normalize, sole-source positions (Airbus sources >80% of carbon fiber from Hexcel) and unmodeled space upside as launch cadence grows 20-25%/year.
- Komatsu vs Caterpillar is 'one of the more mispriced discrepancies in global industrials': ~15x forward and 8x EV/EBITDA versus CAT's 31x/27x, nearly 900 autonomous trucks deployed across 23 mines with zero safety incidents in 17 years, and CAT itself projecting mining capex +50% by 2030; room to double in 12-18 months.
- The December 'AI materials' upstream call is being validated in real time: WSJ confirmed Nitto Boseki's T-glass bottleneck (>70% share, stock +75% YTD, capacity booked by Apple/Nvidia vendors into 2027, dividend nearly tripled to ¥114), Asahi Kasei's PIMEL PSPI and Q Glass are the next chokepoints, and the copper/aluminum ratio at 4.2x (above the ~3.5x switching threshold) plus data centers outbidding smelters for power ($115/MWh vs the $30-40/MWh smelters need) favor aluminum incumbents like Constellium.
#115
Semis Memo
Jan 26, 2026
Semis Memo: Muscle Memory
As returns from mainstream AI 'layups' (Nvidia, Micron, SK Hynix, Broadcom) moderate, alpha migrates to less-followed layers of the semiconductor supply chain, and Citrini has hired dedicated semis analysts to hunt there. The memory supercycle structurally lifts demand for memory testing (a 16-name basket spanning testers, probe cards, handlers and sockets) because HBM must be tested at every assembly layer and the HBM4E hybrid-bonding transition raises complexity further, while semicap subsystems ('picks and shovels for the picks and shovels') capture disproportionate growth as process steps per wafer multiply. Silicon photonics re-rates legacy foundries GlobalFoundries and UMC, and a watchlist adds legacy memory squeeze names, oversold cybersecurity, SpaceX's Taiwanese supply chain, and a bullish Nvidia earnings setup now that the king is under-owned.
aimemoryaisemicybersecuritysaas
Positions & performance
+68.8%avg return91% win · 11 tracked · L +68.8%
| Position | Mentions | Entry | Last | Return |
|---|
| LICHR:NASDAQ aisemi Ichor Holdings | PT | 30.59Jan 26 '26 | 94.0 | +207.3% |
| LAEHR:NASDAQ aisemi Aehr Test Systems | S | 26.78Jan 26 '26 | 77.48 ● | +189.3% |
| LUCTT:NASDAQ aisemi Ultra Clean Holdings | T | 44.05Jan 26 '26 | 86.97 ● | +97.4% |
| LCOHU:NASDAQ aisemi Cohu | T | 28.97Jan 26 '26 | 50.7 | +75.0% |
| LUMC:NYSE aisemi United Microelectronics | — | 11.33Jan 26 '26 | 19.08 ● | +68.4% |
| LAMAT:NASDAQ aisemi Applied Materials | ISPT | 319.46Jan 26 '26 | 516.89 ● | +61.8% |
| LTER:NASDAQ aisemi Teradyne | ISPT | 231.75Jan 26 '26 | 349.92 | +51.0% |
| LFORM:NASDAQ aimemory FormFactor | ST | 74.0Jan 26 '26 | 104.04 | +40.6% |
| LONTO:NYSE aisemi Onto Innovation | IS | 206.74Jan 26 '26 | 272.62 | +31.9% |
| LGFS:NASDAQ aisemi GlobalFoundries | S | 44.22Jan 26 '26 | 53.18 ● | +20.3% |
| LKLAC:NASDAQ aisemi KLA Corp | ISPT | 1543.03Jan 26 '26 | 210.52 | -86.4% |
Full summary 574 words
The first 'Semis Memo' introduces Citrini's new semiconductor analysts (Zephyr and Jukan) and argues the easy AI trades are over: generalists must go a layer deeper, as the firm did when underwriting Teradyne via memory testing, Amkor via chiplet/OSAT demand, and the January 2024 call that SK Hynix and Micron could double. The memory supercycle frames everything: HBM content per accelerator is rising fast (Nvidia's GB300 carries ~$4k of HBM3E), and long-context, agentic AI pushes KV cache into DRAM and SSDs, structurally lifting demand across the stack.
The deepest section covers memory testing — 'a $40k GPU isn't worth much if its memory doesn't work.' Existing holdings FormFactor, Onto Innovation and Teradyne have outperformed, and the memo maps the whole obstacle course: wafer sort with Tokyo Electron/Accretech probers and Advantest/Teradyne testers, laser repair, burn-in (Aehr), and final test with Cohu/Advantest handlers and a socket 'knife fight' among WinWay, LEENO, ISC and Enplas. HBM raises the stakes: known-good-die screening before stacking, full package testing (Nvidia has reportedly tightened standards further), and probing thousands of 40µm-pitch microbumps — MEMS probe tech supplied almost exclusively by FormFactor and Micronics Japan. The HBM4E transition (2026/27) to hybrid bonding is the next dislocation: Samsung has effectively confirmed adoption with mature yields, and BESI is a favorite — likely capped near 30% share at Samsung (Semes takes the rest) but potentially 50-60% at SK Hynix and over 80% at Micron. A 16-name Memory Testing basket spans capital equipment and consumables.
Semicap and subsystems come next: TSMC is expected to spend $190-200B of capex over three years and Intel could ramp to 100k wafers/month of 18A-P plus 14A capacity by 2029-30. Within wafer fab equipment, Citrini highlights deposition — especially ASM International's atomic layer deposition exposure as GAAFET makes conformal films critical — alongside existing longs AMAT, ONTO and KLAC. Subsystem vendors (called out in July: ICHR, UCTT) are the 'picks and shovels for the picks and shovels': HBM wafer starts growing ~50% annually mean 100-200% more process steps, 3nm-and-below flows exceed 1,500 steps per wafer, and each node raises fab cost ~30%. In silicon photonics and legacy fabs, GlobalFoundries (GF Fotonix at 200G/lane, the Advanced Micro Foundry Singapore acquisition, Cisco partnership, TSMC GaN license with Navitas and ON Semi as 2026 customers, MIPS and Synopsys ARC IP deals) and UMC (imec iSiPP300 partnership targeting 800G/1.6T PICs with risk production 2026-27, 3Q25 utilization at 78%) are commodity-priced foundries building specialty platforms.
The watchlist covers four trends: a legacy memory squeeze (DDR4 EOL panic buying spilling into DDR3 and NOR — Macronix hiked NOR ~30% in 1Q26; MLC NAND capacity projected down 41.7% in 2026), the 'SaaS-pocalypse' unfairly hitting cybersecurity (CrowdStrike, Cloudflare, Rubrik, Zscaler are AI-security beneficiaries, not victims), SpaceX's Taiwanese supply chain ahead of a potential IPO, and a bullish Nvidia earnings setup — after six months sideways, China sales resuming and Claude Code-driven compute demand set up an underpriced guidance surprise, played via longer-dated options. Single names: Cohu (Neon HBM inspection, ~$10-11M 2025 revenue; Eclipse handler selected for a likely-Intel AI processor at ~3,000W), Powertech (PiFO as a CoWoS-L alternative, NT$40B+ 2026 capex, reported Meta interest), ASMPT (TC bonders to SK Hynix; hybrid bonding threat to Hanmi's ~90% HBM4 TCB share), and PDF Solutions (Exensio analytics tied to Intel 18A). The Dynamic AI basket is up ~16% YTD and +278.6% since inception; adds include ASM NA, Kokusai and GFS, with shorts on consumer electronics as the memory squeeze passes through.
Key metrics
- NVIDIA Blackwell Ultra GB300 carries roughly $4,000 of HBM3E content per accelerator
- HBM microbump probing at 40µm pitch; MEMS probe cards supplied almost exclusively by FormFactor and Micronics Japan
- TSMC expected to spend $190B-$200B in capex over the next 3 years; Intel targeting 100k wafers/month of 18A-P + 14A capacity by 2029-30
- HBM wafer starts growing ~50% annually equal 100-200% more process steps per wafer; 1,500+ steps at 3nm and below; ~30% fab cost increase per node
- BESI hybrid bonding share potential: ~30% at Samsung, 50-60% at SK Hynix, >80% at Micron; Hanmi holds ~90% of HBM4 TCB equipment share
- SK Hynix ordered 30+ TC bonders from ASMPT and is targeting ~100 TC bonders total for HBM4
- MLC NAND global capacity projected to drop ~41.7% YoY in 2026; Macronix raised NOR prices ~30% in 1Q26
- UMC 3Q25: wafer shipments +3.4% QoQ, utilization 78%; Powertech guiding 2026 capex over NT$40B
- Cohu: 2025 Neon HBM inspection revenue raised to ~$10-11M; Eclipse handler tests up to 16 devices in parallel, -55°C to +155°C, ~3,000W power dissipation for a likely-Intel AI processor
- Citrindex Dynamic AI basket +16% YTD, +278.60% since inception; IWM has outperformed SPY by ~10% since Citrini turned constructive on small caps
Key insights
- Memory testing is a structural winner of the HBM cycle: HBM requires known-good-die screening, stack-level and package-level testing, and Nvidia has reportedly forced suppliers to fully test HBM packages before foundry integration; FormFactor and Micronics Japan near-exclusively supply the MEMS probe cards that touch 40µm-pitch microbumps.
- Hybrid bonding arrives with HBM4E (2026/27): Samsung has effectively confirmed adoption with yields comparable to TC-NCF; BESI may get only ~30% of Samsung's tool demand (Semes ~70%) but potentially 50-60% at SK Hynix and >80% at Micron — while large-scale hybrid bonding threatens Hanmi Semiconductor's ~90% share in HBM4 TCB equipment.
- Subsystems scale disproportionately: HBM wafer starts growing ~50% annually translate into 100-200% more process steps per wafer, 3nm-and-below requires 1,500+ steps, and each new node lifts fab cost ~30% — favoring ICHR/UCTT-style vendors over already-consensus WFE OEMs.
- TSMC is expected to spend $190-200B of capex over the next three years and Intel could reach 100k wafers/month of 18A-P + 14A capacity by 2029-30, with Intel's 2026 capex front-loaded toward equipment — the fab buildout is another player's revenue.
- GlobalFoundries and UMC are commodity-multiple foundries quietly assembling silicon photonics and power-semi platforms (GF: Fotonix, Singapore fab, Cisco, TSMC GaN license with Navitas/ON Semi in 2026; UMC: imec iSiPP300, risk production 2026-27), setting up multiple re-ratings.
- The legacy memory squeeze is spreading: DDR4 EOL has produced panic buying (DDR4 briefly traded at a premium to DDR5), tightness is spilling into DDR3 and NOR (Macronix ~30% NOR price hike in 1Q26), and MLC NAND capacity is projected to fall 41.7% YoY in 2026 — but these names are crowded, so buy the unwind.
- Selling cybersecurity on agentic coding fears is 'stupid': AI agents are privileged identities that must be secured — CrowdStrike (Falcon Next-Gen Identity, SGNL and Pangea acquisitions), Rubrik (Agent Rewind), Cloudflare and Zscaler are beneficiaries mistakenly sold with SaaS.
- Nvidia is now the neglected trade: sideways for six months while investors chase second-order winners; China re-entry, model competition and coding-driven compute demand set up an upside guidance surprise best played with longer-dated call options — and Citrini's Dynamic AI basket (+16% YTD, +278.6% since inception) stays long semicap while short consumer electronics on unpriced memory cost pass-through.
#114
Macro Memo
Jan 14, 2026
Macro Memo: Running Hot
The US economy is re-accelerating despite a stagnant labor market because AI-driven productivity gains are increasingly showing up in output, while pro-growth pre-midterm policy (MBS purchases to lower mortgage rates, teased stimulus) and the Fed's pivot from QT to ~$40B/month of balance sheet expansion add fuel. That mix supports risk assets, argues rates are too low (hence a contrarian 2s30s flattener), and favors housing-sensitive longs like Rocket. Abroad, the 'Don-roe Doctrine' — a transactional US retrenchment into its hemisphere after the Venezuela intervention — makes LatAm (especially Chile), Southeast Asia (long Vietnam/Indonesia/Malaysia/Philippines), and a reflating China the places to be, while Iran tension plus structural fleet tightness supports long oil and especially tankers.
airare-earthaisemiconsumerreal-estateconsumershoppingenergygridfinancecryptofinancefintechindexclindexcnindexmy
Positions & performance
-14.6%avg return10% win · 10 tracked · L -14.6%
| Position | Mentions | Entry | Last | Return |
|---|
| LUHAL:NYSE consumerreal-estate U-Haul | T | 56.54Jan 14 '26 | 72.96 ● | +29.0% |
| LEWM:NYSE indexmy iShares MSCI Malaysia ETF | — | 28.2Jan 14 '26 | 27.88 ● | -1.1% |
| LHD:NYSE consumershopping Home Depot | IPT | 375.95Jan 14 '26 | 336.09 ● | -10.6% |
| LECH:NASDAQ indexcl iShares MSCI Chile ETF | — | 44.51Jan 14 '26 | 38.61 | -13.3% |
| LFXI:NYSE indexcn iShares China Large-Cap ETF | — | 40.04Jan 14 '26 | 34.58 | -13.6% |
| LSQM:NYSE airare-earth Sociedad Quimica y Minera | — | 83.18Jan 14 '26 | 68.73 | -17.4% |
| LRH:NYSE consumershopping Restoration Hardware | IAP | 217.24Jan 14 '26 | 174.51 | -19.7% |
| LLOW:NYSE consumershopping Lowe's | PT | 274.95Jan 14 '26 | 207.64 | -24.5% |
| LIBIT:NASDAQ financecrypto iShares Bitcoin Trust | P | 55.44Jan 14 '26 | 36.35 | -34.4% |
| LRKT:NYSE financefintech Rocket Companies | IT | 22.67Jan 14 '26 | 13.49 ● | -40.5% |
Full summary 531 words
This January 2026 macro memo lays out a 'running hot' view of the US economy. The two big 2025 worries — tariffs and job creation — never produced a slowdown: real GDP grew 3.8% annualized in Q2 and 4.3% in Q3, with the Atlanta Fed GDPNow tracking 5.1% for Q4, even as net job creation stalled, hire and quit rates settled below pre-COVID norms and wage growth slowed across the income spectrum. Citrini's contrarian resolution of the labor/GDP divergence is productivity: the hundreds of billions invested in AI for three years is actually enhancing output per hour, visible first in software engineering and spreading with agentic AI. They expect 2026 could pair steady-or-rising unemployment with solid GDP and a rising market — a dynamic seen in 1992, 1975, 1958 and the post-WW2 years — with productivity spillover buoying corporate earnings.
The 'Big MAC' (Midterms Are Coming) section argues the administration is greasing voters: proposed credit card rate caps, 'tariff stimmy' checks, and above all housing. Citrini's September 2025 prediction that the White House would compress mortgage rates is playing out via $200 billion of announced MBS purchases, with removal of the GSE MBS purchase cap still on the table. Favored expressions: Rocket Mortgage (which acquired Redfin and Mr. Cooper), U-Haul (less lock-in), RH (jumbo mortgage availability, higher-end demographic) and Home Depot/Lowe's. On liquidity, late-2025 repo stress — SOFR above policy floors and a record $29.4 billion single-day Standing Repo Facility draw on October 31 — killed QT and birthed 'Reserve Management Purchases' expanding the balance sheet ~$40 billion per month, a directional positive for risk assets. The Powell/Trump feud (DOJ subpoenas over the Fed renovation, Trump calling Powell 'a jerk') underpins a contrarian 2s30s flattener: Powell can stay on as governor two more years, hobbling a loyalist replacement, the steepener is crowded, and with the 2-year at 3.5% Citrini thinks the two cuts priced by end-2026 get removed.
Geopolitically, the memo goes long oil (WTI bought at ~$59.15 on January 12 with a stop at entry) and, more interestingly, tankers: record Iranian crude on the water, an aging fleet, sanctions on the shadow fleet and multi-year-high VLCC rates give independent catalysts beyond a Strait of Hormuz event. The 'Don-roe Doctrine' frames the Venezuela intervention (VENZ 9.25% 9/15/27 bonds +37% after Maduro's capture) as a watershed: the US will 'clean house' in LatAm and push out China. Chile is the favorite (25% of world copper, major lithium, pro-market Kast taking office March 11, 2026); Korea, Japan and Southeast Asia benefit from supply chain redesign, with the earlier long-Indonesia/short-Vietnam idea replaced by long VIMP (Vietnam, Indonesia, Malaysia, Philippines) and Malaysia the favorite. China is seen inching toward corporate-sector recovery via anti-involution and reflation — Moore Threads and MetaX traded up 6x on debut — keeping Citrini bullish FXI and specific names. Trade updates: NGZ5 profits taken near the peak and long re-established in NGF27 at 4.42; the HGZ6 copper roll gained another 20%; QQQ/IBIT worked (~8%) and was flipped to outright long IBIT targeting a move back above 100K; the XLU/SPY pair was stopped out. New trades: long Bitcoin, long oil, long FXI calls, EWM and ECH, the 2s30s flattener, and long tankers.
Key metrics
- Real GDP +3.8% annualized Q2 and +4.3% Q3; Atlanta Fed GDPNow forecasting 5.1% for Q4
- $200 billion in announced MBS purchases as pre-midterm housing stimulus
- Record $29.4 billion single-day Standing Repo Facility draw on Oct 31, 2025
- Fed balance sheet expansion opening at a pace of $40 billion per month
- 2-year Treasury at 3.5% with two cuts priced by end-2026 that Citrini expects removed
- Long WTI crude (CLH6) initiated at $59.15 on January 12, 2026
- VENZ 9.25% 9/15/27 bonds rallied 37% after Maduro's capture; +21% since publication of 26 Trades
- Chile produces 25% of the world's copper; Chilean inflation expected at 3% by end of Q1 2026
- HGZ6 copper up another 20% since the last memo's roll; QQQ outperformed IBIT by ~8% during the pair trade
- Moore Threads and MetaX traded up 6x on their December market debuts; NGF27 natural gas bought at 4.42 after falling from above 5.2
Key insights
- AI productivity is the memo's core macro call: real GDP grew 3.8% (Q2) and 4.3% (Q3) annualized with GDPNow at 5.1% for Q4 despite stalled job creation — Citrini argues output per hour is rising because AI tools are working, and 2026 will make it obvious.
- History supports the 'weak labor, strong GDP, rising market' combination: 1992, 1975, 1958 and the post-WW2 demobilization years all saw it.
- Housing is the administration's midterm lever: $200B of announced MBS purchases are 'just the beginning,' with the GSE MBS purchase-cap removal still possible; plays include RKT, UHAL, RH, HD and LOW.
- The Fed has crossed from base-money destruction to creation: after repo stress including a record $29.4B single-day SRF draw on Oct 31, 2025, balance sheet expansion is running ~$40B/month — directionally positive for risk assets.
- Contrarian 2s30s flattener: Powell can remain a governor after his chair term, the steepener is crowded, and the 2-year at 3.5% prices two 2026 cuts Citrini thinks get removed as nominal growth runs hot; also implies a stronger dollar.
- Tankers offer asymmetric, multi-catalyst exposure: record Iranian crude on tankers, an aging fleet, tightening shadow-fleet sanctions and multi-year-high VLCC rates work even without a Hormuz disruption; long WTI from $59.15 with a stop at entry.
- Don-roe Doctrine: post-Venezuela (VENZ 9.25% 9/15/27 bonds +37% after Maduro's capture), the US retrenches into its hemisphere — Chile (25% of global copper, Kast inaugurated March 11, 2026, inflation reaching 3% by end-Q1) is the favorite; long VIMP replaces long Indonesia/short Vietnam.
- Bitcoin flip: after the long QQQ/short IBIT trade returned ~8%, Citrini went long IBIT on January 5, expecting BTC back above 100K with a possible retest of all-time highs.
#113
State of the Themes
Dec 17, 2025
26 Trades for 2026: A Thematic Watchlist for the New Year
Citrini's annual 'Twenty-Something Trades' exercise drops the pretense of a precise year-ahead outlook and instead publishes 26 thematic trade ideas for 2026 as a watchlist designed to minimize intellectual blind spots. The 2025 edition validated the format — over half the ideas beat the S&P 500 and single-stock picks averaged +26.5% — so the 2026 list continues it, delivered as a long PDF with accompanying thematic basket spreadsheets.
airobothealth
Positions & performance
+33.5%avg return50% win · 2 tracked · L +33.5%
| Position | Mentions | Entry | Last | Return |
|---|
| LALNT:NASDAQ airobot Allient | I | 51.41Dec 17 '25 | 86.78 | +68.8% |
| LARQT:NASDAQ health Arcutis Biotherapeutics | P | 28.34Dec 17 '25 | 27.84 ● | -1.8% |
Full summary 183 words
This is a short wrapper post introducing '26 Trades for 2026,' Citrini's annual thematic watchlist published December 17, 2025. The introduction argues that conventional year-ahead outlooks are a 'ridiculous premise' and that once a year Citrini deliberately drops the pressure of being right at the right time, generating a long list of ideas — some potential winners, some scenario preparation, some just names to keep on screen — to minimize intellectual blind spots. A 2025 scorecard recaps last year's edition: a bit more than half of the ideas outperformed the S&P 500 and more than 80% had positive returns; winners included drone names (most doubled), Ukraine normalization picks, and South Africa over Turkey riding the gold rally, while the remittances idea failed amid ramped deportations. Single-stock picks averaged +26.50% equally weighted, beating the S&P 500 by more than 10 percentage points, with Allient doubling and ARQT's Zoryve success correctly anticipated. The actual 26 trades — each roughly six pages — live in a downloadable PDF, with thematic basket holdings in a linked spreadsheet; this post itself contains no detail on the new ideas.
Key metrics
- 26 trade ideas for 2026, each about 6 pages in the PDF
- More than half of the 25 Trades for 2025 outperformed the S&P 500
- More than 80% of the 2025 ideas had positive returns
- 2025 single-stock picks averaged +26.50% equally weighted
- Single-name average beat the S&P 500 by more than 10 percentage points
- Most 2025 drone basket names roughly doubled
Key insights
- The 26 Trades format is explicitly a thematic watchlist, not a forecast: 26 ideas published without the 'this has to happen or else I'm wrong' constraint, intended to surface differentiated views and minimize blind spots.
- 2025 scorecard: slightly more than half of the prior year's ideas outperformed the S&P 500 and more than 80% posted positive returns.
- 2025 single-stock picks averaged +26.50% equally weighted, beating the S&P 500 by more than 10 percentage points.
- Standout 2025 winners: most drone basket names doubled, Ukraine normalization picks 'crushed it,' South Africa beat Turkey on the gold rally, Allient doubled on Rockwell's return to growth and robotics tailwinds, and Citrini correctly anticipated the success of Arcutis (ARQT) Zoryve.
- Acknowledged 2025 loser: the remittances idea, which conflicted with the Trump administration's deportation ramp.
- The full 2026 content (each trade ~6 pages) is distributed as a PDF with a separate thematic baskets spreadsheet; this post is the paywalled front door.
#112
Thematic Update
Nov 27, 2025
Carving Up the TPU: Leftovers for Jensen or Just Gravy on the AI Trade?
Gemini 3's success and reported TPU adoption by Anthropic and Meta have vindicated Citrini's August 'Long GOOGL' call, but the market's read that this is simply bearish Nvidia is too crude. A TPU scale-up is more bullish for Google and for the shared supply chain than it is bearish for Nvidia, because both giants will compete for the same TSMC CoWoS capacity, HBM, advanced packaging, PCBs and optics, boosting suppliers' pricing power. Citrini believes the market's reaction will effectively force Google to sell TPUs as a merchant vendor, which turns a walled-garden asset into revenue and optionality. The trade is therefore a basket of first-order TPU suppliers (packaging, memory, dense PCBs, optical circuit switch players) plus second-order winners like Apple (as a prospective Google TPU/Gemini customer), SiTime and MACOM riding the 800G-to-1.6T optical transition.
aimemoryaineocloudaiopticalaisemienergygridmag5
Positions & performance
+73.1%avg return91% win · 11 tracked · L +73.1%
Full summary 491 words
The report opens by recapping Citrini's August State of the Themes call — 'Long GOOGL' — grounded in Google's vertical integration, cheap TPU-based training, best-in-class first-party data and low customer acquisition costs, versus a compute-constrained OpenAI. Since then sentiment has flipped violently: Gemini 3 put Google at the frontier on its own silicon, and reports that Anthropic and Meta plan to adopt TPUs (Meta reportedly for training, not just inference) triggered a 'passing of the public torch.' Google remains the largest allocation in Citrini's Dynamic AI basket, but the author warns against recency bias and consensus crowding, citing Oracle's trip from a 40% gap-up to CDS-watching in weeks.
A 'TPUs for Idiots' section explains the architecture: neural nets reduce to matrix multiplication, and TPUs dedicate nearly all silicon to matmuls via systolic arrays of MAC cells that take data rather than instructions, yielding superior performance per watt and per dollar on ML at the cost of flexibility. On Nvidia, Citrini is deliberately non-sensationalist: switching from CUDA/PyTorch to JAX is expensive and disruptive, Google spent ten years optimizing around TPUs, Google itself remains one of Nvidia's largest customers, and Gemini's success should push NVDA-locked labs to buy more next-gen chips. The kneejerk NVDA selloff reflects future margin risk (27/28), not volume risk; supply and infrastructure, not demand, are the bottleneck. Citrini would even consider dipping back into NVDA if bearish sentiment overshoots.
On distribution, the report argues the decision to sell TPUs has effectively been made: chip deals with Anthropic, Meta and Fluidstack contradict a pure walled-garden approach, and the Fluidstack arrangement (TPUs deployed in a Terawulf-leased NYC data center with a $3.2 billion Google backstop and 14% equity) shows a 'franchise' model. Selling TPUs is a pure-margin, variable-production hedge against long-duration data center capex risk, and not selling would invite a new merchant silicon competitor (possibly Chinese) within 4-7 years.
Positioning centers on a 25-name, equally weighted TPU Supply Chain basket — the best performing group in Citrini's AI coverage YTD, yet still cheaper than the broader 125-name Phase 1 AI Infrastructure basket. Favored areas: advanced packaging (TSMC, ASE, Amkor), HBM (SK Hynix, Samsung, Micron), a Mediatek catch-up, dense TPU boards benefiting Isu Petasys, TTM and Unimicron, and Google's MEMS-based Optical Circuit Switches benefiting Lumentum (R300/R64), Silex owner Sai MicroElectronics, and Huber+Suhner. Second-order ideas: Apple as a natural TPU/Gemini cloud-inference customer for a better Siri; SiTime, whose MEMS oscillator content roughly doubles to ~$2 per 1.6T module as 1.6T optical modules jump from ~3 million (2025) to ~20 million (2026) on Google's TPU forecast doubling from ~2 to ~4 million units, plus an exclusive Apple 5G-modem win worth ~$240M of 2027 revenue; and MACOM with >60% share in 200G photodiodes. The report closes cautious — net long cut from +100% to +80% and hedged — flagging shrinking big-tech buybacks, a $200 billion-plus gap between hyperscaler capex and D&A overstating earnings, and Nvidia's oddly defensive public posture as a signal worth watching.
Key metrics
- Google internal TPU forecast for next cycle revised from ~2 million to ~4 million units
- 1.6T optical module demand expected to jump from ~3 million modules in 2025 to ~20 million in 2026, with Google consuming 6-10 million
- SiTime MEMS oscillator content per 1.6T module roughly doubles to ~$2, implying ~$40M of 2026 TAM from 1.6T modules alone
- SiTime guiding to $100-103M Q4 revenue at ~60% gross margin, implying >$400M annualized run-rate; quarterly revenue +45% YoY
- SiTime Apple 5G modem exclusive MEMS oscillator win estimated at ~$240M of 2027 revenue
- MACOM holds >60% share in 200G photodiodes used in 1.6T modules
- Fluidstack/Terawulf TPU deployment backed by a $3.2 billion Google backstop with Google taking 14% equity
- Hyperscaler capex minus D&A gap has exploded to over $200 billion in the past twelve months
- Nvidia B200: 192 SMs totaling 768 tensor cores and 24,576 CUDA cores (architecture comparison)
- Citrini reduced from +100% to +80% net long into year-end, significantly hedged
Key insights
- Citrini views the TPU narrative as more bullish for GOOGL than bearish for NVDA: Google and Nvidia will fight for the same TSMC CoWoS capacity, so the shared supply chain gains pricing power regardless of who wins share.
- Switching costs are the underrated moat: moving from CUDA/PyTorch to JAX is non-trivial and expensive, and Google's 10 years of TPU optimization is not easily replicable by third parties — Google itself is still one of Nvidia's largest customers.
- The market's reaction will reflexively force Google to sell TPUs; deals with Anthropic, Meta and Fluidstack (a Terawulf-hosted deployment with a $3.2B Google backstop and 14% equity) show the merchant/franchise decision is largely made.
- Citrini's 25-name TPU supplier basket has been the best performing AI category YTD and still trades cheaper than the GPU-tilted 125-name Phase 1 AI Infrastructure basket, leaving room for a re-rating in PCBs, substrates and networking.
- Google's OCS architecture (Lumentum-built optical circuit switches using MEMS mirrors fabbed by Silex/Sai MicroElectronics, with Huber+Suhner the other key player) replaces power-hungry electrical switching, a key structural difference from Nvidia clusters.
- SiTime: Google's TPU forecast doubling to ~4M units helps drive 1.6T optical module demand from ~3M (2025) to ~20M (2026); at ~$2 of MEMS timing content per module that is ~$40M of 2026 TAM, of which SiTime may capture 25-50%, on top of a ~$240M 2027 Apple 5G modem revenue opportunity.
- Apple is flagged as a surprising second-order TPU winner: TPU pods' static determinism suits a fast, reliable cloud-inference Siri, and Apple is not locked into Nvidia's ecosystem.
- Macro caution: hyperscaler capex now exceeds D&A by over $200 billion in twelve months, overstating earnings versus cash flow, and buyback capacity is eroding — a narrative Citrini expects to surface in a downturn; positioning cut to +80% net long and hedged.
#111
Macro Memo
Nov 17, 2025
Macro Memo: Mo-vember
With the shutdown ending and a deluge of delayed data incoming, Citrini expects continued labor deterioration on private data, a cautious Fed that skips the December cut, risk-off pressure on speculative assets (crypto, quantum, miners) into mid-December, and then a Santa rally as 2026's fiscal impulse ($380-545B of OBBBA tax savings plus possible tariff dividends) gets priced. The durable structural call is that AI datacenter load exhausts every 'spare grid capacity' workaround — storage, demand response, BYOG microgrids — forcing real generation buildout that transforms utilities' earnings runway; hence a new long XLU/short SPY pair, alongside long QQQ/short IBIT (reflexive Bitcoin to ~75K), profit-taking in natural gas (+15%) and gold puts (+100% on half), rolling copper long on undermodeled datacenter demand, and re-entering the SOFR H6H7 flattener on aggressive cuts under Powell's successor.
airare-earthcommoditiesenergygridenergywarfinancecryptoindexbondsindexjpindexus
Positions & performance
-4.5%avg return40% win · 5 tracked · L -14.0% · S +9.6%
| Position | Mentions | Entry | Last | Return |
|---|
| SIBIT:NASDAQ financecrypto iShares Bitcoin Trust | P | 52.1Nov 17 '25 | 36.35 | +30.2% |
| LQQQ:NASDAQ indexus Invesco QQQ | S | 603.66Nov 17 '25 | 682.12 ● | +13.0% |
| LTLT:NASDAQ indexbonds iShares 20+ Year Treasury Bond ETF | — | 89.09Nov 17 '25 | 83.25 | -6.6% |
| SSPY:NYSEARCA indexus SPDR S&P 500 ETF | IS | 665.67Nov 17 '25 | 739.09 ● | -11.0% |
| LXLU:NYSEARCA energygrid Utilities Select Sector SPDR | SP | 89.56Nov 17 '25 | 46.29 | -48.3% |
Full summary 594 words
This November 17, 2025 Macro Memo scores last month's calls (slowing-without-breaking, deepening K-shape, China tensions peaking then easing, a 5-10% pullback within a continuing bull) and sets four-week expectations: further private-data labor deterioration, volatility from the post-shutdown data deluge, improved funding liquidity as the shutdown and QT end, a December Fed hold (market prices 43% cut odds; Citrini's FOMC tally suggests lower), continued risk-off in speculative corners (crypto, quantum, bitcoin miners) into mid-December, then a Santa rally as 2026 fiscal expansion is priced. The economy section marshals private data — ADP payrolls steadily slowing, Indeed job postings falling, hire/quit rates at lows, construction payroll growth declining, consumer confidence sliding — against a paradoxical Atlanta Fed Q3 GDP nowcast of 3.7%, with earnings from McDonald's, Chipotle, Cava and Tyson confirming low-income strain while auto-loan and student-loan delinquencies climb (mortgages remain historically healthy thanks to household deleveraging).
Three macro subplots get attention. Funding-market stress: SOFR has traded above IORB at spreads last seen in 2019, indicating reserve scarcity from QT and the shutdown's Treasury General Account freeze — a reason the Fed is ending QT and a hidden-leverage warning worth monitoring rather than trading. The fiscal impulse: 2026 OBBBA tax savings of roughly $380-545B (mostly TCJA extension, ~$75B incremental) plus potential 'tariff dividend' checks mean the wall of worry likely resolves bullishly in Q1 2026, while tariffs collect ~$30B/month (~$360B/year, ~20% of the FY2025 deficit) with SCOTUS odds of upholding them priced at just 25% — an overturn would pressure UST yields. Sentiment: AAII bulls at only 39%, VIX ~16 at the recent high versus 25+ at late-90s peaks, breadth at 62% above 200-day averages — consistent with Citrini's 1998 analog of a bull that advances with rising two-way volatility; ES's 50-day EMA (6722) is the tactical line in the sand.
The trade block is extensive. Natural gas: three-quarters of the NGZ5 long (from ~$3.90) is booked for +15%, with intent to re-add further out the curve; the structural equity thesis strengthens as behind-the-meter power-gen demand already shows up as +1 Bcf/d YoY of summer res/comm demand, large caps like EXE buy resource despite higher costs, and LNG FIDs continue. Copper: rolled from HGZ5 to HGZ6 booking +7% — datacenter additions going from 5GW to 25GW/year imply ~500kt of incremental annual copper demand at a conservative 25kt/GW, 'a year of China entering the WTO,' with scrap export restrictions adding a resource-nationalism bid. Gold: the contrarian GLD 350 December puts bought October 15 caught the momentum unwind; half closed for ~+100%. Rates: re-entering the SOFR H6H7 flattener at half size — the curve prices ~50bps between March 2026 and March 2027 versus Citrini's 75bps base case with a fat 100bps tail under Powell's successor; a December hold should push more cuts into the spread.
Two new trades anchor the piece. Long XLU/short SPY is the macro/AI crossover: every substitute for new generation — reserve margins, storage ('fixes shape, not supply'), demand response, sweating assets — is temporary, and BYOG microgrids are prohibitively expensive (SLAs require ~1.5-2x load in firm capacity; Stargate plans 1.2GW of load against only ~360MW of generation), so operators will ultimately partner with utilities, converting massive investment-grade load growth into rate-base and earnings-runway expansion, with defensive beta as the free hedge. Long QQQ/short IBIT exploits Bitcoin's pure reflexivity now that MicroStrategy can no longer be the buyer of last resort: target ~75K on BTC, stop on a close above 100K. A Nikkei short sits on the watchlist (trigger: close below 50K JPY, target -5%, stop 51.5K) on Takaichi's wage-focused rhetoric and Japan's GDP contraction.
Key metrics
- Market prices 43% odds of a December 25bp cut; Citrini expects a hold
- OBBBA 2026 tax savings estimated $380-545B (~$75B incremental new savings)
- Tariff revenue ~$30B/month (~$360B/year), ~20% of the FY2025 deficit; SCOTUS upholding odds priced at 25%
- Natural gas: NGZ5 long from ~$3.9, 3/4 taken off for +15%; BTM demand +1 Bcf/d YoY
- Copper: 5GW → 25GW/year of DC additions ≈ 500kt incremental demand at 25kt/GW; HGZ5→HGZ6 roll booked +7%
- Gold: GLD 350 Dec 31 puts (bought 10/15), half closed for ~+100%
- SOFR H6H7: curve prices ~50bps of cuts Mar26-Mar27; Citrini targets 75bps, fat tail 100bps
- BYOG requires ~1.5-2x load in firm capacity; Stargate 1.2GW load vs ~360MW planned generation
- QQQ/IBIT: BTC target ~75K, stop on close above 100K; Nikkei short watchlist trigger below 50K JPY (stop 51.5K)
- Sentiment: AAII 39% bullish; VIX ~16 at recent high vs >25 at late-90s peaks; 62% of S&P above 200dma; ES 50-day EMA 6722
Key insights
- The Fed likely skips December: market prices a 43% cut probability but Citrini's tally of FOMC member views suggests lower odds, and a hold should push additional cuts into 2026 pricing — fueling the re-entered SOFR H6H7 flattener (curve at ~50bps vs Citrini's 75bps base, 100bps tail).
- The 2026 fiscal impulse is large and underappreciated: $380-545B of OBBBA tax savings (~$75B incremental beyond TCJA extension) plus possible tariff-dividend checks mean the wall of worry likely resolves into a Q1 2026 rally, with a Santa rally expected as this gets priced.
- Grid substitutes are temporary — 'storage fixes shape, not supply' — and BYOG microgrids require ~1.5-2x load in firm capacity (Stargate: 1.2GW load vs ~360MW planned generation), so persistent AI load ultimately forces real generation buildout through utilities: go long XLU/short SPY, with defensive beta as the hedge.
- Datacenter copper demand is massively undermodeled: moving from 5GW to 25GW of annual DC additions implies ~500kt of incremental copper demand at a conservative 25kt/GW — equivalent to a year of China entering the WTO — while US scrap export restrictions add a resource-nationalism bid; rolled HGZ5 to HGZ6 (+7%).
- Behind-the-meter gas demand is already visible but miscategorized: EIA books it as commercial demand, and summer res+comm gas demand ran +1 Bcf/d over 2024 without unusual weather — early confirmation of the structural gas thesis; 3/4 of the NGZ5 long booked at +15%.
- Bitcoin trades on pure reflexivity and MicroStrategy can no longer act as buyer of last resort: long QQQ/short IBIT targets BTC ~75K with a defined stop on a close above 100K.
- The contrarian gold-put trade (GLD 350p bought 10/15 against crowded macro momentum longs) paid ~+100% on the half closed, validating the view that gold's fundamental narratives were exaggerated.
- Sentiment is far from euphoric — AAII bulls at 39%, VIX ~16 at the high versus 25+ at late-90s peaks, 62% breadth — supporting the 1998 analog of a bull that grinds higher with rising volatility; ES's 50-day EMA at 6722 is the key tactical level after holding all of May-October.
#110
Thematic Update
Nov 03, 2025
I Can See Clearly Now... The Rain Is Gone?
Fifteen months into the Healthcare Innovation basket, the feared Trump-era policy damage never materialized — funding cuts were walked back, landmark approvals landed, diagnostics reimbursement improved — yet healthcare positioning sits at 20-year lows with post-COVID-high short interest and depressed multiples, while guidance beats run near record highs and 2025 M&A tracks ahead of any year on record. Citrini argues this is the start of a multi-year upswing led by small-cap medtech crossing into profitability (the IRTC/ATEC re-rating template applies to the STAX names), insurers' medical-cost crisis funneling business to value-based care (TOI, ALHC, new add ASTH), GLP-1 second-order winners (AIRS, WW, NGVC, LLY vs shorts in low-end food), and a diversified life-sciences upcycle sleeve (TKNO, NOTV, AVTR, plus new FTRE and CYRX).
airobotaisemiconsumerhealthconsumershoppinghealthGLPhealthhealthtesting
Positions & performance
-10.0%avg return47% win · 19 tracked · L -8.7% · S -14.6%
| Position | Mentions | Entry | Last | Return |
|---|
| LFTRE:NASDAQ health Fortrea | I | 10.12Nov 03 '25 | 19.2 ● | +89.7% |
| LCYRX:NASDAQ health Cryoport | — | 9.04Nov 03 '25 | 15.15 ● | +67.6% |
| SSHAK:NYSE consumershopping Shake Shack | APT | 93.53Nov 03 '25 | 61.57 ● | +34.2% |
| LLLY:NYSE healthGLP Eli Lilly | IPT | 896.53Nov 03 '25 | 1196.03 | +33.4% |
| LTOI:NASDAQ health The Oncology Institute | A | 4.49Nov 03 '25 | 5.39 | +20.0% |
| LASTH:NASDAQ health Astrana Health | T | 32.99Nov 03 '25 | 38.19 ● | +15.8% |
| LALHC:NASDAQ health Alignment Healthcare | T | 16.84Nov 03 '25 | 19.43 | +15.4% |
| SDPZ:NASDAQ consumershopping Domino's Pizza | IPT | 403.63Nov 03 '25 | 343.53 ● | +14.9% |
| LAVTR:NYSE health Avantor | IAT | 11.68Nov 03 '25 | 11.76 ● | +0.7% |
| LTKNO:NASDAQ health Alpha Teknova | — | 5.08Nov 03 '25 | 4.85 ● | -4.5% |
| LNGVC:NYSE consumerhealth Natural Grocers | — | 32.96Nov 03 '25 | 30.01 | -9.0% |
| SHRL:NYSE consumershopping Hormel | IT | 21.48Nov 03 '25 | 26.05 ● | -21.3% |
| LSTIM:NASDAQ health Neuronetics | A | 2.77Nov 03 '25 | 1.81 ● | -34.7% |
| LCVRX:NASDAQ health CVRx | A | 10.36Nov 03 '25 | 4.74 | -54.2% |
| LAIRS:NASDAQ health AirSculpt | A | 10.39Nov 03 '25 | 4.61 | -55.6% |
| LWW:NASDAQ health WW International | A | 34.06Nov 03 '25 | 13.85 ● | -59.3% |
| LXGN:NASDAQ health Exagen | — | 11.83Nov 03 '25 | 4.4 ● | -62.8% |
| SEAT:NYSE consumershopping Brinker International | IT | 105.05Nov 03 '25 | 195.44 ● | -86.0% |
| LNOTV:NASDAQ healthtesting Inotiv | — | 1.24Nov 03 '25 | 0.08 | -93.6% |
Full summary 598 words
This November 3, 2025 Healthcare Innovation update marks fifteen months since basket inception and declares the policy storm over — for now. The predicted MAGA-era catastrophes largely failed to materialize: funding-cut threats were walked back, pharma struck domestic-manufacturing deals reducing pricing risk, landmark approvals arrived, and diagnostics reimbursement enjoys unprecedented support. Companies guiding above expectations are near record highs — yet healthcare long positioning sits around 20-year lows, short interest tests post-COVID highs, and the Russell 2000 healthcare growth sub-index trades well below historical revenue multiples. That disconnect is attracting strategic buyers: 2025 healthcare M&A deal count is tracking substantially ahead of any prior year on record, and Citrini thinks several basket names are targets.
The core of the report is the 'STAX' medtech quartet (STIM, TOI, AIRS, XGN) and the profitability-inflection playbook: when loss-making medtechs cross into profits, the market re-rates them from peer discounts to premiums — as former basket members iRhythm (IRTC) and Alphatec (ATEC) demonstrated — and all four STAX names are guided to cross that threshold within quarters. TOI anchors the value-based-care (VBC) theme: with insurers reporting elevated medical loss ratios, Cigna, Centene, CVS and Elevance all explicitly named VBC as strategy, and Molina called out oncology drug costs specifically — playing straight into TOI's vertically integrated oncology VBC model. TOI just beat its first-ever active sellside estimates before large new contracts even contribute, guided to sustainable profitability before end-2025, and trades at a 50%+ discount to peers like Privia. The VBC sleeve deepens: CVRx (BAROSTIM saves at least $9,000 per patient versus standard of care; largest shareholder JNJ is hunting high-growth medtech), ALHC (exceeded its entire annual EBITDA guidance in a single quarter in Q2, then tripled Q3 consensus), and new addition Astrana Health (ASTH) — 20+ payers across thirteen markets, ~10% FCF yield, a path to 25%+ revenue growth, and the lowest revenue multiple among VBC players.
XGN and STIM ride industry tailwinds: diagnostics peers re-rated from ~4x to >9x trailing revenue since July while XGN still sits just above 4x despite accelerating growth, AI-enabled data moats and Labcorp naming autoimmune diagnostics a strategic acquisition area; TMS search interest ended Q3 at multi-year highs, and STIM's multiple contracted while inferior peer Brainsway re-rated — a gap Citrini attributes to accounting optics (STIM consolidates its Greenbrook clinics and has invested nearly twice BWAY's R&D over five years) that resolves as STIM reaches profitability. AIRS extends into the GLP-1 'Second Serving' thesis: the cosmetic-surgery headwind is flipping to tailwind (WSJ, NY Post and McKinsey document the GLP-1-driven aesthetics boom; a Needham survey of 250+ patients shows rising procedure intent), and returning to 2024 utilization would produce over $60M of free cash flow in three years. The GLP-1 shorts (SHAK, DPZ, EAT, HRL) keep working, while Natural Grocers (NGVC) is upgraded — its ~$100k-median-income customer is thriving, a third of its SKUs are supplements benefiting from GLP-1 behavior change, and the Sprouts readthrough is misplaced. WW (effectively 'a value-based care provider specializing in GLP-1s') and NGVC weights rise, funded by exiting Danone; LLY's orforglipron oral GLP-1 launches in 2026.
The life-sciences upcycle remains 'waiting for Godot' but the three supports strengthen: improved biotech valuations (XBI rebound, ICON's backlog stabilizing three quarters running), reshoring policy tailwinds (TMO and DHR both guiding above consensus with bullish supply-chain commentary), and AI in drug development (new NVDA partnerships with LLY and Verily). Citrini diversifies this sleeve for beta — trimming overweights, raising Avantor to equal weight after its sell-off, and adding Fortrea (FTRE) and Cryoport (CYRX) alongside TKNO and NOTV — with full basket weights published on Citrindex.
Key metrics
- Healthcare long positioning around 20-year lows; short interest testing post-COVID highs
- 2025 healthcare M&A deal count tracking substantially ahead of any prior year on record
- TOI trades at a 50%+ discount to peers such as Privia (PRVA); guided to sustainable profitability before end of 2025
- CVRX BAROSTIM saves at least $9,000 per patient vs standard of care (US and European studies)
- ALHC exceeded full-year EBITDA guidance in Q2 alone, then tripled analyst consensus in Q3
- ASTH: ~10% free-cash-flow yield, 20+ payers across 13 markets, path to 25%+ revenue growth
- XGN at just over 4x trailing revenue vs diagnostic peer group now above 9x (both ~4x in July)
- STIM has invested nearly 2x Brainsway's R&D over the last five years; TMS search growth at multi-year high
- AIRS: return to 2024 utilization implies over $60M of free cash flow over three years
- NGVC customer median income near $100,000; nearly one-third of SKUs are vitamins/supplements
Key insights
- The feared policy damage never came: funding cuts walked back, pharma-government manufacturing deals struck, landmark approvals granted — yet healthcare long positioning is at ~20-year lows with post-COVID-high short interest, creating the setup for a multi-year upswing.
- 2025 healthcare M&A deal count is tracking substantially ahead of any prior year on record, and depressed small-cap valuations make several basket names (XGN, TOI, CVRX) plausible strategic targets — Labcorp has explicitly named autoimmune diagnostics as an acquisition focus and JNJ is CVRX's largest shareholder.
- The profitability-inflection template drives the STAX thesis: iRhythm and Alphatec re-rated from peer discounts to premiums upon turning profitable, and all four STAX names are guided to cross that threshold in coming quarters.
- Insurers' MLR crisis is the value-based care demand engine: Cigna, Centene, CVS and Elevance all named VBC as core strategy and Molina blamed oncology drug costs specifically — TOI, the vertically integrated oncology VBC leader, trades at a 50%+ discount to Privia despite guiding to profitability by end-2025.
- ALHC validated the VBC bet by exceeding its entire annual EBITDA guidance in one quarter (Q2) then tripling Q3 consensus; new addition ASTH offers ~10% FCF yield, 20+ payer relationships in 13 markets and a path to 25%+ revenue growth at the lowest multiple in VBC.
- XGN's peer group re-rated from ~4x to >9x trailing revenue since July while XGN itself still trades just over 4x — the market is paying up for AI-leverageable diagnostic data moats and XGN owns the autoimmune niche.
- GLP-1 second-order effects are inflecting: aesthetics demand is rebounding (Needham's 250+ patient survey, WSJ/McKinsey coverage) benefiting AIRS (>$60M 3-year FCF potential at 2024 utilization), while low-end food shorts (SHAK, DPZ, EAT, HRL) keep working and NGVC's supplement-heavy, ~$100k-income customer base makes the sell-off a buying opportunity.
- Life sciences recovery is diversified for beta rather than timed: ICON's backlog has stabilized three quarters running, TMO/DHR guide above consensus on reshoring, NVDA signed drug-discovery partnerships with LLY and Verily — sleeve now TKNO, NOTV, AVTR, plus new FTRE and CYRX.
#109
Thematic Primer
Oct 17, 2025
Power Struggle: Natural Gas
The US natural gas market is flipping from fifteen years of price-insensitive supply-push to demand-pull: ~35 Bcf/d of high-confidence demand growth from LNG exports and AI/electrification power generation over the next decade collides with only 15-20 Bcf/d of supply growth at current strip prices, because the Permian's 'free' associated gas is oversubscribed (~7-10 Bcf/d left) and dry-gas producers need $4-5+/MMBtu to dispatch growth from deteriorating rock. With early-2030s NYMEX futures at ~$3.20 in steep backwardation, the curve is mispriced and the repricing gets more violent the longer it waits; Citrini positions in a broadened basket of deep-inventory upstream E&Ps (US and Canadian), midstream, utilities, compression, power-generation equipment and E&C, most trading at 8-12x earnings.
aineocloudenergyaienergygridenergywar
Positions & performance
+29.9%avg return67% win · 9 tracked · L +29.9%
| Position | Mentions | Entry | Last | Return |
|---|
| LAGX:NYSE energygrid Argan | T | 283.94Oct 17 '25 | 568.92 | +100.4% |
| LGEV:NYSE energygrid GE Vernova | IPT | 600.0Oct 17 '25 | 1014.75 | +69.1% |
| LBE:NYSE energygrid Bloom Energy | ISPT | 111.5Oct 17 '25 | 188.18 ● | +68.8% |
| LLNG:NYSE energywar Cheniere Energy | IPT | 218.96Oct 17 '25 | 269.72 | +23.2% |
| LKMI:NYSE energywar Kinder Morgan | IPT | 27.38Oct 17 '25 | 32.86 | +20.0% |
| LWMB:NYSE energywar Williams Companies | IPT | 62.46Oct 17 '25 | 70.79 ● | +13.3% |
| LSRE:NYSE energygrid Sempra | AT | 91.29Oct 17 '25 | 91.25 ● | -0.0% |
| LEQT:NYSE energywar EQT | PT | 54.08Oct 17 '25 | 53.03 | -1.9% |
| LCRK:NYSE energywar Comstock Resources | T | 17.0Oct 17 '25 | 13.0 ● | -23.5% |
Full summary 599 words
Published October 17, 2025 as a part-primer/part-thesis sequel to the Stargate field trip, this report argues 'AI eats electrons, electrons eat gas' — and the natural gas market is at a structural inflection. For fifteen years, shale drillers and Permian associated gas overwhelmed the market with price-insensitive supply, training investors to assume cheap gas forever. Now Appalachia has plateaued, dry-gas producers demand economic returns, and the Permian's associated-gas deluge is in its final innings — just as two demand walls rise: the largest LNG export buildout in history and power generation for data centers, onshoring and electrification. Citrini quantifies ~35 Bcf/d of high-confidence demand growth over the next decade (a fuller view approaches 70 Bcf/d, a 70% increase on current production) versus just 15-20 Bcf/d of supply growth at current NYMEX forwards, with early-2030s futures at ~$3.20/MMBtu in steep backwardation — a curve deemed self-defeating, since cheap-forever strip pricing keeps new gas-demand projects penciling.
The demand section details both engines. Data centers consumed ~17GW of US electricity in 2022 and could need 130GW (~12% of US demand) by 2030; PJM credits gas at ~90% of nameplate versus far less for solar-plus-storage, and Transco Zone 6 hit $97/MMBtu in a January 2025 cold snap. GE Vernova signed 9GW of Q2 2025 turbine orders with a 29GW backlog plus 25GW of slot reservations — ~55GW, enough to burn 6-9 Bcf/d — and reconstructed turbine delivery schedules imply ~1 Bcf/d per year of new gas demand for a decade (Sam Altman's '1GW of compute per week' would mean up to 7 Bcf/d annually). Examples span Stargate's simple-cycle plant, Meta's 5GW Hyperion (sited at the crossroads of four pipelines, with ~0.3 Bcf/d of Entergy generation being permitted), Williams' Project Socrates, EQT's agreement to supply nearly 1.5 Bcf/d to two planned Pennsylvania power plants, and Bloom Energy fuel cells running on gas. On LNG: ~14 Bcf/d of operating export capacity will more than double; the Trump administration approved ~8 Bcf/d of new FIDs this year (with ~3.5 more expected) — more than in Biden's entire term — and large developers aspire to another ~40 Bcf/d (~300 MTPA), implying $260-340B of liquefaction capex.
The supply section attacks the consensus crutch that 'the Permian will take care of it.' Permian gas is a byproduct of oil drilling: with US onshore oil likely peaking (Diamondback's CEO says production has peaked; frac crews down ~15-20%), only ~7-10 Bcf/d of associated growth remains, gas is just ~5-7% of Permian operators' cash flow, and incenting gas-directed Permian drilling would take >$6/MMBtu. Dry-gas plays are the only on-demand growth source, but trigger prices have risen: ~$4.00/MMBtu for maintenance and $5+ for growth, per executive quotes from Aethon ('probably starts with a $5-handle'), Expand Energy ($3.50 marginal breakeven) and Comstock (~3 years from legacy Haynesville inventory exhaustion; can't reach 20 Bcf/d 'even at $6'). Enverus shows the Haynesville with ~6 years and the Marcellus <10 years of 'good' inventory by 2030, full-cycle Appalachian costs exceed $3/MMBtu with Mountain Valley Pipeline transport, and recurring Transco basis blowouts show regional molecule competition already emerging.
Positioning: the January natural gas basket (construction-tilted; top weight AGX doubled YTD) is broadened up the supply chain now that Citrini has conviction on the commodity itself — adding US and Canadian E&Ps with deep inventory, midstream, regulated utilities, compression, power-gen equipment and E&C, most trading at 8-12x earnings versus large-cap tech at 8-12x sales. The invalidator is explicit: if strip prices near $3.35 could really summon the needed supply, the thesis fails — but geology, inventory exhaustion and producer discipline argue the repricing only grows more violent with delay.
Key metrics
- ~35 Bcf/d high-confidence demand growth next decade vs 15-20 Bcf/d supply growth at current strip; expansive demand view ~70 Bcf/d (+70%)
- US data centers: ~17GW consumed in 2022 → ~130GW by 2030 (~12% of US demand)
- GE Vernova Q2 2025: 9GW new gas turbine orders, 29GW backlog, 25GW slot reservations (~55GW ≈ 6-9 Bcf/d of burn)
- Gas turbine prices up ~50% since summer 2024; turbines last 30+ years vs GPUs replaced 10+ times
- LNG: ~14 Bcf/d operating capacity; under-construction projects add ~5.3 Bcf/d by 2027; ~8 Bcf/d FID'd in 2025 (+~3.5 expected); developers seek ~40 Bcf/d more (~$260-340B capex)
- Permian: ~7-10 Bcf/d of associated gas growth remaining; >$6/MMBtu needed for gas-directed drilling; gas only ~10% of revenue, ~5-7% of cash flow for top operators
- Dry gas trigger prices: ~$4.00/MMBtu for maintenance, $5+/MMBtu for meaningful growth (EQT pursuing $5 fixed-price deals)
- Enverus 2030 inventory: Haynesville ~6 years, Marcellus <10 years of 'good' inventory
- Early-2030s NYMEX at ~$3.20/MMBtu; Transco Zone 6 spiked to $97/MMBtu in January 2025
- PJM ATC power prices rose from $0.04/KWh (2024) to ~$0.06/KWh ≈ ~$300/year higher household bill; basket names at 8-12x earnings
Key insights
- The gas market is flipping from supply-push to demand-pull: ~35 Bcf/d of high-confidence decade-ahead demand growth (LNG + power) versus 15-20 Bcf/d of supply growth at current strip — and a fuller demand view approaches 70 Bcf/d, a 70% increase on current production.
- 'The Permian will take care of it' is the consensus cop-out and it's wrong: only ~7-10 Bcf/d of associated-gas growth remains, gas is just ~5-7% of Permian operators' cash flow, and gas-directed Permian drilling needs >$6/MMBtu — associated gas doesn't respond to gas prices at all.
- Dry-gas producers are openly naming their price: Aethon says meaningful development 'starts with a $5-handle,' Expand pegs marginal Haynesville breakeven at $3.50 with materially higher needed for growth, and Comstock is ~3 years from legacy inventory exhaustion — these firms represent ~30% of US dry gas.
- The early-2030s NYMEX strip at ~$3.20/MMBtu in steep backwardation is self-defeating: cheap-forever pricing keeps demand projects penciling, so the longer the back of the curve stays low, the more violent the eventual repricing.
- Turbine orderbooks lock in demand: GE Vernova's 9GW of new Q2 2025 orders, 29GW backlog and 25GW of reservations (~55GW total) imply 6-9 Bcf/d of future burn, and reconstructed delivery schedules point to ~1 Bcf/d of new gas demand per year for a decade.
- LNG stacks on top: operating capacity of ~14 Bcf/d will more than double, the Trump administration FID'd ~8 Bcf/d in one year (more than Biden's whole term), and developers want another ~40 Bcf/d (~$260-340B of liquefaction capex) — while tolling contracts push price risk onto buyers.
- Geology is the quiet second engine of the thesis: cores of the Haynesville and Marcellus are drilled up (~6 and <10 years of good inventory by 2030 per Enverus), F&D costs are rising after 15 years of declines, and full-cycle Appalachian costs exceed $3/MMBtu with MVP transport.
- The basket shifts up the supply chain from construction winners (AGX doubled YTD) to commodity-levered upstream with deep inventory (e.g., EQT, Comstock, Canadian E&Ps) plus midstream, utilities, compression and E&C — most trading at 8-12x earnings.
#108
Macro Memo
Oct 12, 2025
Macro Memo: Red October
October's tariff flare-up (China's rare-earth export controls, Trump's 100% tariff threat) is escalation-to-negotiate, not the end of the bull market: both sides will repeatedly go to the brink and seek off-ramps, constrained by debt, demographics, recession risk, midterms and defense. Meanwhile the K-shaped economy keeps 'slowing without breaking' — private data show deteriorating jobs during the shutdown data blackout — which supports continued Fed cuts, while the AI bull market at 77% above its 10-year moving average is still well short of the 100-120%+ extremes that marked 1929, 1987, 2000 and Japan 1989. Citrini holds course: rare earths as a fiscal-subsidy watchlist trade (+193% in 5 months), tactical index puts as October insurance, and vigilance on emerging credit cracks (Tricolor, First Brands, subprime auto).
airare-earthaisemiindexbondsindexus
Positions & performance
-36.6%avg return0% win · 2 tracked · L -8.1% · S -65.2%
| Position | Mentions | Entry | Last | Return |
|---|
| LTLT:NASDAQ indexbonds iShares 20+ Year Treasury Bond ETF | — | 90.57Oct 13 '25 | 83.25 | -8.1% |
| SSMH:NASDAQ aisemi VanEck Semiconductor ETF | — | 339.75Oct 13 '25 | 561.19 | -65.2% |
Full summary 567 words
This October 12, 2025 Macro Memo, published into the sell-off triggered by China's October 9 rare-earth export controls and Trump's retaliatory threat of 100% tariffs, opens by restating Citrini's macro priors: a K-shaped economy where the lower-income cohort struggles, a secular AI capex cycle roughly halfway done driving index returns (the 'Macroeconomic Ouroboros' of wealth-effect-driven spending), Fiscal Primacy/Dominance meaning the administration will do whatever it takes to support asset prices into the midterms (tariff-refund checks, lifting GSE MBS caps), and a tariff view distinct from 'TACO': Trump will repeatedly bring markets to the brink, and each episode carries real risk weighed against constraints of Debt, Demographics, Recession-Risk, Midterms and Defense.
With the government shutdown blacking out official data, private sources still show 'slowing without breaking': ADP job growth has printed two negative months (the latest the biggest in two years), the Dallas Fed estimates breakeven job growth has fallen to ~30k/month (others say ~10k) due to a smaller labor force, hire/quit rates are at decade lows, Indeed job postings keep falling below Waller's 4.5% threshold, and wage growth for job switchers and new hires has turned negative in real terms. Inflation-wise, the 'integer problem' of rent (wages, not wealth, pay most rents) anchors services inflation while goods prices rebound; 1-year and 5-year inflation swaps have declined and the bond market prices at least two more 25bp cuts. On China, Citrini rejects theories that Beijing timed controls to 'pop the AI bubble,' seeing instead formalized tit-for-tat strangleholds ahead of the expected Trump–Xi APEC meeting, with resolution likely after China's October 20-23 plenum.
The rare-earths section is both victory lap and warning. The May watchlist is up +193% in roughly five months; highlighted names include Neo Performance Materials (2k tonnes scaling to 5k, plans for 20k; 2k tonnes ≈ $20M EBITDA), Solvay (claims the only ex-China capacity to distill all 17 REEs from any ore, potentially 30% of European demand) and Ucore (Rapid5X tech claiming 3-10x processing speed in a third of the space). But Citrini stresses these are macro/fiscal-subsidy trades, not fundamental ones — rare earths are abundant, low-margin and polluting; the US imported only $170M of REEs last year; the defense angle is overstated (110 F-35s consume ~50 tonnes versus 10,000 tonnes of annual US demand, mostly EVs); Japan already cut China reliance from 90% to 60%. The basket becomes a broader watchlist since government picking of winners means many projects never materialize (MP's limited heavy-REE refining is flagged).
On the 'AI bubble' question, Citrini's yardstick — % above the 10-year moving average — shows the four great tops (1929, 1987, 2000, Japan 1989) all occurred >100% above trend with 120% the lowest common threshold; the S&P 500 sits at 77% (8150 would mark 120%), so mania comparisons are premature. New risks get flagged: the Tricolor (Sept 10) and First Brands (Sept 29, ~$2B vanished) collapses, subprime auto ABS spreads +30bps, repossessions at 2009 levels, Carvana's 2023-vintage ABS losing at twice rating-agency expectations, opaque private credit, and a crypto liquidation cascade with an estimated $20-40B of mostly-retail losses. Trades barely change: sized-up SMH January 2026 puts and new SPX November puts as insurance ('October is a minefield... would rather burn put premiums'), the SOFR H6H7 flattener, remaining long TLT December 95 calls (half sold in September), and abandoning the USDJPY short given Takaichi's pro-growth agenda — while reiterating this is a correction within a continuing bull market.
Key metrics
- Rare earths watchlist +193% in roughly 5 months
- S&P 500 currently 77% above its 10-year moving average; historic tops occurred at 100-120%+ (8150 = 120%)
- Trump threatened 100% tariffs on Chinese goods after China's Oct 9 REE export controls
- Dallas Fed breakeven job growth estimate ~30,000/month (others ~10,000)
- US imported only $170M of rare earth elements last year; F-35 uses ~450kg REE, 110 jets ≈ 50 tonnes vs 10,000 tonnes US annual demand
- Neo Performance: 2K tonnes scaling to 5K (plans 20K); 2K tonnes ≈ $20M EBITDA; Solvay could serve ~30% of European demand
- Japan's rare-earth reliance on China cut from 90% to 60%, heading to 50%
- First Brands: at least $2B owed to factoring financiers unaccounted for; auto ABS spreads +30bps since early September
- Crypto liquidation cascade losses estimated at $20-40B, mostly retail
- Positions: SMH January 2026 puts sized up, SPX November puts added, long TLT Dec 95 calls (half sold)
Key insights
- China's rare-earth export controls are a negotiating card played before it expires, not a bubble-popping strike: Citrini expects tit-for-tat escalation into China's Oct 20-23 plenum, then deal-making before/at the Trump-Xi APEC meeting — a view distinct from the complacent 'TACO' narrative.
- The rare-earth basket is up +193% in ~5 months, but it is purely a fiscal-subsidy macro trade: the US imported just $170M of REEs last year, the defense angle is overstated (110 F-35s ≈ 50 tonnes vs 10,000 tonnes of US annual demand), and many watchlist names will never produce revenue.
- Bubble check: the four great tops (1929, 1987, 2000, Japan 1989) all peaked >100% above the 10-year moving average with 120% the lowest threshold; the S&P 500 is at 77% (8150 = 120%), so significant upside can remain before a true mania top.
- Private data during the shutdown blackout show continued labor deterioration — two negative ADP months (biggest in two years), decade-low hire/quit rates — but breakeven job growth may have fallen to ~10-30k/month, muting the unemployment impact.
- Rent's 'integer problem' anchors services inflation: no matter how rich the top decile is, they occupy one apartment, so softening wages contain rent CPI; bond markets price at least two more 25bp cuts despite the data blackout.
- Credit cracks are the canary: Tricolor and First Brands collapsed weeks apart with ~$2B missing at First Brands, subprime auto ABS spreads widened 30bps, repossessions are at 2009 levels, and Carvana's mid-2023 ABS vintages are losing at twice rating-agency expectations.
- An estimated $20-40B of mostly-retail crypto losses in Friday's liquidation cascade could have negative wealth-effect implications given how levered speculative spending has been.
- Positioning is insurance, not capitulation: sized-up SMH Jan 2026 puts plus SPX Nov puts, still long TLT Dec 95 calls and the H6H7 flattener, and the USDJPY short is abandoned on Takaichi's pro-growth agenda; 5-10% pullbacks are 'natural' wall-of-worry rebuilding.
#107
Field Trip
Sep 28, 2025
Stargate: A Citrini Field Trip
Citrini sent a drone (with Hunterbrook Media) to OpenAI's Stargate site in Abilene, Texas to physically verify the AI datacenter buildout, and concluded the scale — eight 'ludicrous buildings' totaling ~4M sq ft and 1.2GW, a footprint the size of lower Manhattan, one of tens-to-hundreds of similar megaprojects — makes the industrial supply chain around the data hall the next leg of the trade. Because reliability trumps everything, these sites run on natural gas (simple-cycle turbines available in 12-18 months vs 5+ years for combined cycle and 10+ for nuclear), and with >30 Bcf/d of demand chasing ~10 Bcf/d of 'free' Permian gas growth, gas prices must move structurally higher. The actionable takeaway is 'more power, more natural gas, more thermal management and more construction': a 50-name high-confidence (plus 200 low-medium) beneficiary list across power, cooling, MEP, building envelope, fiber and construction services, with EQT added to the portfolio.
aiopticalairobotaisemiconsumertrainingenergyaienergygridenergywar
Positions & performance
-2.6%avg return0% win · 1 tracked · L -2.6%
| Position | Mentions | Entry | Last | Return |
|---|
| LEQT:NYSE energywar EQT | PT | 54.46Sep 29 '25 | 53.03 | -2.6% |
Full summary 570 words
Published September 28, 2025, this 'field trip' report is Citrini's ground-truth verification of the AI datacenter thesis it first laid out in May 2023. Partnering with investigative outlet Hunterbrook Media, the firm flew drones over the Stargate site in Abilene, Texas, documenting how bare dirt a year earlier had become eight buildings under construction — ~4 million square feet and 1.2GW of capacity by mid-2026, '600 football fields' of cables, transformers, chillers, switchgear and 200,000 tons of equipment consuming Seattle-scale electricity, with waste-heat plumes visible on weather radar. The complex's footprint approximates lower Manhattan, and Meta's Louisiana Hyperion is even larger; five more Stargate sites are already permitted or under construction, alongside xAI's Colossus 2, Microsoft's Fairwater, Amazon's Pennsylvania project and Google/Anthropic's Project Rainier. The framing: 'tech' has become capital-intensive again for the first time in a quarter century — the largest US industrial investment cycle since World War Two.
The biggest insight is energy. Stargate's behind-the-meter plant uses ten simple-cycle gas turbines (5x 38MW Solar Titan 350 from Caterpillar, 5x 34MW GE LM2500) licensed for 361MW of continuous 24/7 output — because combined-cycle turbines have 5+ year lead times, nuclear is 10+ years away, and simple-cycle units ship in 12-18 months; efficiency doesn't matter when you take what you can get. xAI's Memphis site runs 30+ turbines. Citrini builds a gas-demand forecast from turbine delivery schedules and FERC filings showing >30 Bcf/d of committed demand lined up against only ~10 Bcf/d of 'free' Permian associated-gas growth — the consensus 'the Permian will take care of it' is wrong, and captured flared gas would power only ~5% of the full ~5GW Stargate complex. EQT is reportedly negotiating fixed-price supply deals at ~$5/MMBtu, ~70% above Henry Hub spot — hyperscalers paying up for flow surety, the first time in shale history producers are compensated for dispatching growth. Meta's moves corroborate: legendary gas trader John Arnold joined its board, it is funding >2GW of Louisiana gas generation, and it formed power-trading arm Atem Energy ('Meta' backwards).
The report then walks each physical layer with named suppliers: transmission (a 200MW/138kV substation expanding to 1.2GW with a 345kV yard; ABB, Siemens, GE, Schneider as Tier 1, with Powell Industries' custom power control rooms and Prysmian's $118M medium-voltage cable contract; UPS lead times stretched to 18-24 months, pulling Tier 2 names like Mitsubishi Electric and Saft into orders); thermal management (39 cooling towers flanking each side of each building — 624 across eight buildings; Vertiv the clear leader, Schneider second, with Modine, Munters, Trane, Carrier, SPX, Daikin and water-treatment names Xylem/Evoqua, Pentair, Veolia); MEP systems; civil/structural (5-10 million sq ft of specialized insulated metal panels per major project); fiber/networking (Arista fabric, Ciena 400G/800G with Lumentum and Coherent lasers, Prysmian/CommScope/Corning/Belden cable, Dycom installation) for the moonshot of operating six campuses as a single logical data center; and construction services (CAT, Komatsu, Deere, United Rentals, Ashtead, Herc, WillScot, Primoris, Quanta, EMCOR, AECOM — plus commissioning by Acuren (TIC), Citrini's latest single-stock long, and Mistras).
Positioning: Citrini added EQT and will add more natural gas and gas-infrastructure exposure, publishing a spreadsheet of 50 high-confidence and 200 low-to-medium-confidence public beneficiaries, organized into six trackable Citrindex baskets (Power & Energy, Thermal, MEP, Civil/Structural, Fiber, Construction Services). The conviction: whether or not capacity is being overbuilt, 'it's going to get built' — and the power/infrastructure leg of the AI trade persists as long as these monuments to compute keep being funded.
Key metrics
- Stargate Abilene: 8 buildings, ~4 million sq ft, 1.2GW total power capacity by mid-2026; targeted full size ~5GW
- Behind-the-meter plant: 10 turbines (5x 38MW Titan 350 + 5x 34MW GE LM2500) = 361MW continuous
- Lead times: simple-cycle turbines 12-18 months; combined-cycle 5+ years; nuclear 10+ years; UPS systems 18-24 months
- >30 Bcf/d of gas demand lined up vs ~10 Bcf/d of 'free' Permian growth
- EQT fixed-price supply negotiations at ~$5/MMBtu, ~70% above Henry Hub spot
- Captured Permian flared gas would power only ~5% of the ~5GW complex
- Prysmian $118M medium-voltage cable contract; substation expanding from 200MW/138kV to 1.2GW with 345kV
- 624 cooling towers across eight buildings (39 per side per building)
- Each major project uses 5-10 million sq ft of insulated metal panels
- Beneficiary list: 50 high-confidence and 200 low-medium-confidence public companies across six baskets
Key insights
- Seeing is believing: Stargate Abilene alone will be eight buildings, ~4M sq ft and 1.2GW by mid-2026 — a footprint the size of lower Manhattan — and it is one of tens-to-hundreds of similar megaprojects (Hyperion, Colossus 2, Fairwater, Project Rainier), making this the largest US industrial investment cycle since WWII.
- Natural gas is the only dispatchable answer: simple-cycle turbines ship in 12-18 months versus 5+ years for combined-cycle and 10+ for nuclear, so Stargate runs 10 GE/Caterpillar simple-cycle units (361MW continuous) and xAI Memphis runs 30+ — reliability beats both efficiency and net-zero pledges.
- US gas demand is 'backed by committed infrastructure,' not estimates: >30 Bcf/d of demand from LNG exports plus data centers is chasing only ~10 Bcf/d of remaining 'free' Permian associated-gas growth — the consensus 'Permian will take care of it' is wrong.
- EQT is negotiating fixed-price gas supply at ~$5/MMBtu — ~70% above Henry Hub spot — signaling hyperscalers will pay up for flow surety and producers finally get compensated for dispatching growth, a radical change in supply dynamics.
- Meta is telegraphing a volatile gas/power future: it added legendary gas trader John Arnold to its board, is funding >2GW of new Louisiana gas generation, formed power-trading arm Atem Energy, and sited Hyperion at the crossroads of four major gas pipelines.
- Supply-chain scarcity cascades down tiers: UPS lead times have hit 18-24 months, Powell Industries' 3-year backlog should lengthen further, Prysmian signed a $118M cable contract for Abilene alone, and Tier 2/3 vendors will catch orders as Tier 1 lead times blow out.
- The thermal layer is enormous and quantifiable: 39 cooling towers per side of each building means 624 school-bus-dwarfing HVAC racks across the eight Abilene buildings, with Vertiv the clear leader and Schneider a distant second.
- Captured Permian flared gas would cover only ~5% of the full ~5GW Stargate complex, and data centers siphoning associated gas is detrimental to LNG exporters — the gas market is a closed loop that pulls forward a natural gas bull market.
#106
Single Stock
Sep 18, 2025
Single Stock Long Thesis: Acuren (TIC)
Acuren (TIC US) is a mispriced, multi-thematic toll road on the AI/infrastructure buildout: its core non-destructive testing business converts stressed, can't-go-offline infrastructure (data centers, grids, pipelines, aging power plants) into >90% recurring, mandated inspection revenue, and its opportunistic $1.7B acquisition of NV5 adds hyperscaler data-center MEP design, grid engineering, geospatial data and digital twins just as those businesses inflect. Because of SPAC stigma, misperceived cyclicality and merger complexity, the combined entity trades under 8x EBITDA versus peers at 11-30x; with Sir Martin Franklin running the proven APG playbook (guidance update, investor day, re-rating), Citrini sees 100-200% base-case upside and a path for shares to double or triple in 18-36 months.
aisemienergygridhealthtestingsaas
Positions & performance
-47.0%avg return0% win · 1 tracked · L -47.0%
| Position | Mentions | Entry | Last | Return |
|---|
| LTIC:NYSE energygrid Acuren | — | 13.45Sep 18 '25 | 7.13 | -47.0% |
Full summary 563 words
Citrini's first Single Stock Long Thesis in nearly a year (September 18, 2025) emerges from its AI-power research: as the buildout moves to greenfield data centers, the firm asks who benefits from the maintenance, testing and design layer, and lands on Acuren Corporation (TIC US) — an obscure name that came public via a UK-listed SPAC transferred to the NYSE, backed by Sir Martin Franklin, which in August completed a transformational 'merger of equals' with NV5 Global that doubled EBITDA. The report (with a companion slide deck) argues obscurity plus 'weirdness' — the same overhangs that once hid Vertiv, Celestica and AMSC — is masking an exceptionally high-quality, multi-thematic business.
Core Acuren is North America's second-largest non-destructive testing (NDT) provider: mandated, mission-critical inspection of pipelines, refineries, power plants and transport infrastructure using radiography, ultrasonics and phased array, performed without taking assets offline. Over 90% of revenue is recurring, the service costs customers under 2% of opex, the safety record shows 75% fewer incidents than industry average, and organic growth runs high-single-digit versus ~5% for the industry and low-single-digits for subscale peers Mistras and Team Inc, at high-teens margins versus their 6-12%. The demand kicker is the ASCE's estimate that the US needs $9.1 trillion of infrastructure maintenance against $5.4 trillion of funding — a $3.7 trillion gap — while AI load forces utilities to run aging plants harder and defer retirements, converting one-time decommissioning into years of premium recurring inspection. Yet TIC has traded at 4-8x consensus EBITDA versus peers SGS, Intertek and UL Solutions at 11-18x, held back by SPAC stigma and a misread of cyclicality (revenue barely declined in 2008, 2015-16 and 2020; the recent softness was deliberate exits of low-margin contracts while EBITDA margins expanded 100bps+ to 17%).
NV5, acquired for just $1.7B (<10x EBITDA) while peers Willdan, Stantec, AECOM and Trimble trade at 15-30x, brings three engines: infrastructure engineering for electric/water utilities (~50% of revenue), geospatial data (~30%), and mission-critical building consulting (~20%). NV5 works with every major hyperscaler on liquid cooling and power distribution, has surpassed 1GW of global data-center design/commissioning, unlocked ~300MW of additional computing capacity for clients in 2024, and management targets growing the sub-$50M data-center unit to $400M+ annually. Its geospatial moat (100,000+ miles of transmission scanned yearly) underpins digital twins and future industrial robotics — maps and predictive maintenance that convert TIC's model from selling 'testing' to selling 'outcomes.' Notably, MEP peer Legence, with roughly NV5's 2024 EBITDA, just IPO'd near $5B — versus the entire combined TIC at just over $3B and under 8x EBITDA.
The combination math: if NV5 hits its pre-deal $1.6B 2028 revenue target and legacy TIC grows 8% annually with 20% margins (co-chairman Robert Franklin: 'no reason' combined margins can't exceed 20%), TIC generates $600M+ of 2028 EBITDA — ~30% annualized growth and 20%+ above consensus, which implausibly embeds legacy TIC revenue declining 20%+ through 2028. The APG analog (another Franklin SPAC that returned 250% in three years post its Chubb acquisition and popped 40%+ after its investor day; TIC's CFO came from APG) frames the catalyst path: November guidance update, an investor day, new analyst coverage and deleveraging. Base case is a re-rate to peers' mid-to-high-teens multiples for 100-200% upside; the bull case with revenue synergies makes shares worth multiples of current levels. TIC joins the Citrindex as a standalone long with a projected double-to-triple over 18-36 months.
Key metrics
- TIC combined entity valued just over $3B, under 8x consensus NTM EBITDA
- NV5 acquired for $1.7B, <10x EBITDA; NV5 peers valued 15-30x EBITDA
- TIC peers SGS/Intertek/UL Solutions trade 11-18x EBITDA; TIC has traded 4-8x
- ASCE: $9.1T US maintenance need vs $5.4T funding = $3.7T shortfall
- >90% of core Acuren revenue recurring; service <2% of customer operating expenses; 75% fewer safety incidents than industry average
- NV5 data-center unit: <$50M 2024 revenue, management target $400M+ annually; >1GW designed/commissioned; ~300MW client capacity unlocked in 2024
- NV5 standalone 2028 revenue target $1.6B; $20M identified cost synergies (~90bps margin)
- Scenario: $600M+ combined EBITDA in 2028, ~30% annualized 4-year growth, 20%+ above consensus
- APG analog: 250% 3-year return post-merger; 30%+ annualized over 5 years; 40%+ move in weeks after investor day
- Base case 100-200% upside; shares seen doubling or tripling over 18-36 months
Key insights
- Acuren is a 'toll road' on infrastructure stress: >90% recurring revenue, mandated by insurers/codes/uptime guarantees, costing customers under 2% of opex — small, predictable inspection dollars protecting very large uptime dollars.
- The valuation gap is stark: combined TIC trades below 8x consensus EBITDA versus TIC peers at 11-18x (SGS, Intertek, ULS) and NV5 peers at 15-30x (Willdan, Stantec, AECOM, Trimble) — and MEP peer Legence just IPO'd near $5B on roughly NV5's standalone EBITDA versus $3B for all of TIC.
- The ASCE's $3.7 trillion US infrastructure maintenance shortfall ($9.1T need vs $5.4T funding) plus AI-driven deferral of power-plant retirements structurally accelerates demand for life-extending NDT work.
- NV5 was bought at an inflection: >1GW of data-center design/commissioning completed, ~300MW of client computing capacity unlocked in 2024, and management targets 10x growth in the data-center unit from <$50M to $400M+ annual revenue.
- Cyclicality fears are misplaced — revenue fell only marginally in 2008, 2015-16 and 2020 because exposure is downstream (pipelines, refiners, power) and non-discretionary; 2024 softness was deliberate low-margin contract exits while margins expanded 100bps+ to 17%.
- Consensus implicitly assumes legacy TIC revenue shrinks >20% by 2028 if NV5 hits its $1.6B target inside ~$2.5B combined estimates — a sharp contrast to consistent historical growth, making estimates look badly mis-set.
- The Martin Franklin/APG playbook is the catalyst map: APG returned 250% in three years after its transformational Chubb deal and gained 40%+ in weeks after its investor day; TIC's CFO came from APG and an investor day plus November guidance are imminent.
- Scenario math: NV5 at target + legacy TIC at 8% growth + 20% combined margin yields $600M+ 2028 EBITDA (~30% 4-year CAGR, 20%+ above consensus); a peer-multiple re-rate alone implies 100-200% equity upside.
#105
Macro Memo
Sep 03, 2025
Macro Memo: Summer is Over
The US economy is slowing without breaking — labor demand is sagging (more unemployed than job openings for the first time since August 2021) while tariff revenue (~$360B annualized) is quietly halving the primary deficit and supporting bonds. Citrini's key insight is that the Trump administration cares less about Treasury yields than mortgage rates ahead of the 2026 midterms, and will likely lift post-GFC caps on GSE MBS holdings — unleashing up to $1 trillion of quasi-QE MBS demand that compresses mortgage spreads without touching the Treasury market. That favors mortgage originators like RKT and long-duration bonds, while seasonal September/October fragility argues for a tactical equity short and long natural gas on electricity-price inflation.
financefintechindexbonds
Positions & performance
-14.2%avg return0% win · 2 tracked · L -14.2%
| Position | Mentions | Entry | Last | Return |
|---|
| LTLT:NASDAQ indexbonds iShares 20+ Year Treasury Bond ETF | — | 86.57Sep 03 '25 | 83.25 | -3.8% |
| LRKT:NYSE financefintech Rocket Companies | IT | 17.88Sep 03 '25 | 13.49 ● | -24.6% |
Full summary 486 words
This September 3, 2025 Macro Memo opens by scoring the prior memo's predictions (slowing-not-breaking economy: yes; flat inflation: half right; Fed openness to cuts: yes) and sets expectations for a cyclical slowdown, a September Fed cut, seasonal equity turbulence, and a Trump administration push to lower mortgage rates via GSE privatization and deregulation. The labor-market check-in shows big downward BLS payroll revisions converging on the ADP series (which Citrini now treats as the more reliable gauge), a job-opening rate back under the 4.5% threshold that historically precedes rising unemployment, more unemployed people than job openings for the first time since August 2021, and Fed Governor Waller — Citrini's and the betting markets' favorite to succeed Powell — publicly emphasizing labor weakness ahead of September 8 benchmark revisions. Continued claims running well above prior years signal 'nobody fired, nobody hired' turning into longer joblessness spells.
On fiscal and bonds, the memo argues tariffs function as a de facto consumption/VAT tax bringing in ~$360B annualized against a likely ~$1.7T FY2025 deficit; the primary deficit is roughly 2% of GDP (not the '8% recession-level deficit' doomers cite) and tariffs cut that underlying gap in half — so a Supreme Court overturn of IEEPA tariffs would ultimately be bond-negative. Secularly, the 'four Ds' (Demographics, De-globalization, Defense, Debt) put a floor under inflation and long rates, explaining blowing-out ultra-long global yields even as the 10Y stays anchored near 4.2%.
The centerpiece is the 'housing unlock' thesis: with affordability the administration's midterm cornerstone and Bessent floating a national housing emergency, Citrini believes Treasury/FHFA plan to remove post-GFC caps on GSE MBS purchases — at the extreme freeing up to $1 trillion of incremental MBS demand, compressing mortgage spreads with 5x GSE balance-sheet leverage while boosting GSE ROEs, all within existing Treasury/FHFA authority. This is 'quasi-QE' delivered through housing credit that bypasses the Treasury market entirely, timed to stimulate exactly one year before the midterms. Housing data support the need: new single-family sales contracting YoY, permits at post-lockdown lows, inventory back at pre-pandemic levels, and Case-Shiller ticking down — hence a preference for mortgage originators (RKT) over homebuilders.
The memo closes with trades built on this backdrop plus an extended riff on March/September/October seasonality (September is the only month with a negative long-run average US equity return; a 'market paranoia index' of top-20 SPX declines and scored crises clusters in those months, driven by fiscal-year-end policy brinkmanship and thin post-summer liquidity). Positions: long natural gas NGZ5 at 3.945 (stop 3.545, target 5) on electricity-price inflation from LNG exports and AI compute; replace the U5H6H7 STIR fly with an H6H7 flattener (short at -55bps, target -90bps) betting Powell's successor cuts more; stay long TLT December 95 calls (cost 0.40) since compressed bond vol resolves violently when yields fall; and short ES at 6450 (stop 6525, target 6240, ~3:1) for a tactical September–October correction — explicitly not a call that the bull market is over.
Key metrics
- Tariffs on track for ~$360B annualized revenue; FY2025 deficit ~$1.7 trillion
- Primary deficit ~2% of GDP; tariffs cut it roughly in half
- Job-opening rate back below 4.5%; more unemployed than openings for first time since Aug 2021
- 10Y Treasury anchored ~4.2%; 30Y range-bound 4.75%-5.00% all summer
- Lifting GSE caps could free up to $1 trillion of incremental MBS demand with 5x leverage
- Trade: Long NGZ5 @ 3.945, stop 3.545, target 5
- Trade: Short H6H7 @ -55bps, stop -45bps, target -90bps
- Trade: Short ES @ 6450, stop 6525, target 6240 (~3:1 reward/risk)
- Long TLT December 2025 95 calls, cost basis 0.40
Key insights
- For the first time since August 2021 there are more unemployed Americans than job openings, and the job-opening rate is back below the 4.5% threshold that historically precedes further rises in unemployment.
- ADP has proven more reliable than the BLS: post-revision NFP growth converged onto the private ADP series, and Waller flagged that September 8 annual benchmark revisions will likely push official job creation down further.
- Tariffs are quietly fixing the fiscal picture: ~$360B annualized revenue against a ~$1.7T FY2025 deficit, cutting the ~2%-of-GDP primary deficit roughly in half — so a Supreme Court tariff overturn would be net negative for bonds.
- The administration's real target is mortgage rates, not Treasury yields: lifting GSE MBS caps could unlock up to $1T of incremental MBS demand — quasi-QE via housing credit that sits entirely within Treasury/FHFA authority, timed one year before the midterms.
- Prefer mortgage originators (RKT) over homebuilders: existing-home inventory returning to pre-pandemic levels erodes builders' 'only game in town' advantage while lower rates plus tighter spreads revive origination volumes.
- The secular 'four Ds' — Demographics, De-globalization, Defense, Debt — are mutually reinforcing and floor inflation and long rates, which is why ultra-long global yields are blowing out while the 10Y stays anchored near 4.2%.
- September is the only month with a negative long-run average US equity return, and crash risk clusters in March/September/October around fiscal deadlines and thin liquidity — justifying a tactical short ES at 6450 targeting 6240 with a 6525 stop.
- Compressed bond volatility (30Y stuck in a 25bps range all summer) tends to resolve violently to lower yields; stay long TLT December 95 calls at a 0.40 cost basis.
#104
State of the Themes
Aug 18, 2025
State of the Themes: Long GOOGL, Asian Outperformance and the Age of Virality
Citrini's quarterly State of the Themes argues that 2025's thematically dispersed market rewards selectivity: GPT-5's incremental improvement confirms AI is shifting from infrastructure builders to implementers, which favors Google (research depth, TPUs, ad monetization at 20x forward P/E) and data-and-distribution owners like fintech super-apps, while the remaining infrastructure upside sits in specific bottlenecks (interconnects, memory, AMD) and cheap Taiwanese suppliers. Simultaneously, fiscal policy is the other dominant driver — the AI Action Plan and OBBB tax provisions subsidize the US buildout, Korea's 'KOSPI 5000' governance push warrants broad long exposure, and beaten-down solar offers asymmetric recovery. With rate cuts imminent and SMID caps deeply underowned, Citrini re-launches its Small Themes basket around rate-sensitive names and 'virality'-driven retail winners, while pressing high-conviction healthcare (STAX) and GLP-1 second-order positions.
aimemoryaiopticalairobotaisemiconsumerautoconsumerhealthconsumershoppingdefensedroneenergygridenergynuclearfinancefintechhealthGLPhealthhealthsenior-homemag5saasspace
Positions & performance
+33.9%avg return59% win · 41 tracked · L +34.5% · S +21.1%
| Position | Mentions | Entry | Last | Return |
|---|
| LMU:NASDAQ aimemory Micron | ISAPT | 123.55Aug 18 '25 | 920.95 | +645.4% |
| LTER:NASDAQ aisemi Teradyne | ISPT | 110.41Aug 18 '25 | 349.92 | +216.9% |
| LAMD:NASDAQ aisemi AMD | ISPT | 176.14Aug 18 '25 | 521.95 | +196.3% |
| LEWY:NYSEARCA aimemory iShares MSCI South Korea ETF | IS | 72.8Aug 18 '25 | 162.96 | +123.8% |
| LALNT:NASDAQ airobot Allient | I | 44.56Aug 18 '25 | 86.78 | +94.7% |
| LCRDO:NASDAQ aisemi Credo | ISPT | 118.74Aug 18 '25 | 213.15 | +79.5% |
| LLLY:NYSE healthGLP Eli Lilly | IPT | 698.05Aug 18 '25 | 1196.03 | +71.3% |
| LBVS:NASDAQ health Bioventus | — | 7.18Aug 18 '25 | 11.8 | +64.3% |
| LGOOGL:NASDAQ mag5 Alphabet | SPT | 203.5Aug 18 '25 | 319.74 | +57.1% |
| LALAB:NASDAQ aisemi Astera Labs | IST | 186.43Aug 18 '25 | 291.58 | +56.4% |
| LNXT:NASDAQ energygrid Nextracker | T | 67.7Aug 18 '25 | 103.73 ● | +53.2% |
| LCGNX:NASDAQ airobot Cognex | I | 43.01Aug 18 '25 | 62.05 | +44.3% |
| LRRX:NYSE airobot Regal Rexnord | — | 146.66Aug 18 '25 | 210.87 ● | +43.8% |
| LAPH:NYSE aisemi Amphenol | ISAPT | 111.06Aug 18 '25 | 149.28 ● | +34.4% |
| LTOI:NASDAQ health The Oncology Institute | A | 4.04Aug 18 '25 | 5.39 | +33.4% |
| SHIMS:NYSE health Hims & Hers | ISA | 45.1Aug 18 '25 | 30.24 ● | +32.9% |
| LMOB:NASDAQ defensedrone Mobilicom | — | 4.12Aug 18 '25 | 4.89 | +18.7% |
| LINSG:NASDAQ aisemi Inseego | — | 8.81Aug 18 '25 | 9.79 | +11.1% |
| SNVO:NYSE healthGLP Novo Nordisk | ISP | 53.75Aug 18 '25 | 48.77 | +9.3% |
| LNU:NYSE financefintech Nu Holdings | I | 13.33Aug 18 '25 | 14.53 ● | +9.0% |
| LZETA:NYSE saas Zeta Global | — | 19.71Aug 18 '25 | 20.74 ● | +5.2% |
| LPAGS:NYSE financefintech PagSeguro | A | 9.06Aug 18 '25 | 9.38 ● | +3.5% |
| LURA:NYSE energynuclear Global X Uranium ETF | — | 39.2Aug 18 '25 | 40.32 ● | +2.9% |
| LENPH:NASDAQ energygrid Enphase | IAT | 35.77Aug 18 '25 | 36.7 | +2.6% |
| LAPP:NASDAQ saas AppLovin | IPT | 438.54Aug 18 '25 | 412.73 ● | -5.9% |
| LFSLR:NASDAQ energygrid First Solar | IPT | 219.33Aug 18 '25 | 202.82 | -7.5% |
| LEOLS:NASDAQ health Evolus | — | 6.69Aug 18 '25 | 6.18 ● | -7.6% |
| LKSPI:NASDAQ financefintech Kaspi | I | 93.67Aug 18 '25 | 85.79 | -8.4% |
| LDLO:NASDAQ financefintech DLocal | — | 15.25Aug 18 '25 | 12.69 | -16.8% |
| LMETA:NASDAQ mag5 Meta | ISPT | 767.37Aug 18 '25 | 593.87 ● | -22.6% |
| LMELI:NASDAQ airobot MercadoLibre | ISAP | 2364.01Aug 18 '25 | 1819.74 ● | -23.0% |
| LRKT:NYSE financefintech Rocket Companies | IT | 17.83Aug 18 '25 | 13.49 ● | -24.3% |
| LAIRS:NASDAQ health AirSculpt | A | 6.32Aug 18 '25 | 4.61 | -27.1% |
| LXPOF:NYSE consumerhealth Xponential Fitness | A | 9.07Aug 18 '25 | 6.32 | -30.3% |
| LCVRX:NASDAQ health CVRx | A | 6.87Aug 18 '25 | 4.74 | -31.0% |
| LARRY:NASDAQ energygrid Array Technologies | I | 8.42Aug 18 '25 | 5.32 | -36.8% |
| LAMSC:NASDAQ energygrid American Superconductor | S | 53.46Aug 18 '25 | 30.52 | -42.9% |
| LSTIM:NASDAQ health Neuronetics | A | 3.54Aug 18 '25 | 1.81 ● | -48.9% |
| LXGN:NASDAQ health Exagen | — | 9.75Aug 18 '25 | 4.4 ● | -54.9% |
| LWW:NASDAQ health WW International | A | 30.77Aug 18 '25 | 13.85 ● | -55.0% |
| LSNWV:NASDAQ health SANUWAVE Health | — | 38.36Aug 18 '25 | 8.61 | -77.6% |
Full summary 566 words
This August 2025 quarterly review sweeps across the entire CitriniResearch coverage universe, framing 2025 as one of the most thematically dispersed years in memory — unlike 2024's single AI theme — spanning drones/electronic warfare, EU defense, robotics, and Trump-policy trades, while warning that rapid-fire thematic markets produce misfires like 5G, IoT and the Digital Asset Treasury / quantum computing fads. The core AI judgment: GPT-5's release was 'much more incremental than promised,' confirming the transition from Phase 1 infrastructure to Phase 2 implementers — 'we are less focused now on companies building AI and more focused on companies using it' — with hyperscaler capex effectively committed through 2028 and inference the real bottleneck.
Within AI, Citrini makes the case for Google: AGI needs another research S-curve breakthrough (Google spends ~half of GBDM resources on pure research), Gemini went 2.0 to 2.5 in six months vs OpenAI's 24+ months for GPT-4 to GPT-5, TPUs are the only mass-produced Nvidia-competitive chip, and Google earned $200B in search/video ad revenue versus OpenAI's under $4B consumer revenue — yet GOOGL trades at just ~20x forward P/E; a $5-10T AGI call option at 50% probability implies $1T+ of unpriced value. Selectivity in the datacenter has worked: AMD returned 127% since 4/8/25 versus 87% for NVDA and 64% for SMH, driven by memory-bound inference and MI300X's HBM advantage; optical (LITE, CIEN, COHR), memory (MU) and interconnects (CRDO, ALAB, APH) held through drawdowns. Deepseek's R2 is delayed by failed Huawei training chips. Taiwan offers the biggest valuation gap — JPC Connectivity at 13.6x EV/LTM EBITDA vs Amphenol's 28x with identical ~21.7% 3-year sales growth; Lite-On at 10.7x EV/EBITDA vs MPWR at 40x — and small-cap Inseego could hit $200M 2026 revenue at under 0.8x sales.
In Payments, the AI-implementation lens leads to EM super-apps: Kaspi (KSPI, 'Central Asia's Tencent') at 8.3x forward earnings with 61% YoY revenue growth is added along with NU and MELI, while COIN and TBBK exit. In Fiscal Primacy, the July AI Action Plan earmarks ~$50B for fabs, grid and datacenter fast-tracking (with history suggesting each public dollar crowds in 3-7 private), OBBB's expensing rules create a ~$210M year-one federal tax shield per $1B of qualifying equipment and raise the semiconductor manufacturing credit from 25% to 35%, and tariffs generate ~$360B annualized revenue funding the fiscal winners. Citrini swaps nuclear (URA) for solar asymmetry — adding FSLR, ARRY, NXT and ENPH after Treasury Notice 2025-42 — and goes long EWY on Korea's export strength plus the 'KOSPI 5000' governance re-rating.
Robotics tightens around the 'muscle, nerves and power' of embodied AI (adding CGNX, exiting SYM, AMZN, BSY, JUN3), highlighting the Regal Rexnord–ABB 7th-axis cobot partnership and Teradyne's confirmed Vulcan contract. Electronic warfare profits are trimmed in small-cap drones (UMAC, RCAT) while Mobilicom (MOB) is kept. Healthcare presses the 'STAX' quartet to maximum weights: XGN at 3x revenue (35% discount to VCYT), STIM under 2x revenue (75%+ discount to Brainsway), TOI set to grow 25%+ in 2026 versus 16% consensus with M&A comps implying $20-25+/share, and AIRS worth $14+ at peer 15x EBITDA. GLP-1 second-order adds go to WW (under 5x EBITDA, 60%+ EBITDA growth), LLY, XPOF and EOLS. Finally, the Small Themes basket returns — mortgage originators (RKT), elder care REITs, home-furnishing housing plays, and a new 'Virality' retail basket (American Eagle-style social-marketing winners, ZETA, APP) — plus the first community-picks results: longs +11.4%, shorts -7.8% in one month.
Key metrics
- AMD +127% since 4/8/25 close vs NVDA +87% and SMH +64%
- Google ~20x forward P/E; $200B ad revenue vs OpenAI <$4B consumer revenue
- JPC Connectivity 13.6x EV/LTM EBITDA vs Amphenol 28.0x; Lite-On 10.7x EV/EBITDA vs MPWR 40x
- Tariffs annualizing ~$360B of federal revenue vs ~$1T 2024 primary deficit
- AI Action Plan earmarks ~US$50B; each public dollar historically crowds in 3-7 private dollars
- OBBB: ~$210M year-one tax shield per $1B of qualifying kit; chip manufacturing credit raised 25% to 35%
- Kaspi (KSPI) at 8.3x forward earnings with 61% YoY revenue growth
- Inseego expected ~$200M 2026 revenue, valuation <0.8x sales
- WW International trades at <5x EBITDA with EBITDA growth over 60% YoY
- Community picks after one month: long basket +11.4%, short basket -7.8% (ABVX +600%)
Key insights
- GPT-5's incremental improvement confirms the shift to AI 'Phase 2': gains from pure LLM scaling will moderate while LLM + reinforcement learning + data compound, so positioning should favor implementers over infrastructure builders.
- Google is the mispriced AGI call option: $200B of search/video ad revenue vs OpenAI's <$4B consumer revenue, 6-month Gemini iteration cycles, TPU vertical integration, and only ~20x forward P/E; Citrini's math implies $1T+ of unpriced AGI optionality.
- Selectivity beats broad AI beta: AMD +127% since 4/8/25 vs NVDA +87% and SMH +64%, because inference is memory-bound and MI300X is the only at-scale second source (Azure and Meta already deploying).
- The Taiwan/US discount gap is extreme — JPC Connectivity trades at 13.6x EV/LTM EBITDA vs Amphenol at 28x despite nearly identical 3-year sales growth (21.724% vs 21.673%); Citrini sees no good reason for the 2x spread.
- Fiscal and AI now intersect: the AI Action Plan earmarks ~$50B, OBBB gives ~$210M year-one tax shield per $1B of datacenter equipment and lifts the section 48D chip-manufacturing credit from 25% to 35%, quietly underwriting hyperscaler capex.
- Citrini swaps nuclear for solar (FSLR, ARRY, NXT, ENPH added) on three-part asymmetry: political pressure from rising electricity bills, solar projects in Republican districts, and solar+storage maturity — plus the favorable IRS Notice 2025-42 safe-harbor clarity.
- Korea long via EWY: export pillars (semis, autos/EVs, batteries, shipbuilding, defense) plus the Lee administration's 'KOSPI 5000' governance campaign should re-rate a market discounted for chaebol capital inefficiency.
- Healthcare STAX positions get maxed out: XGN at 3x revenue (35% discount to VCYT), STIM at <2x revenue (75%+ discount to Brainsway), TOI implied at $20-25+/share by McKesson/TPG private-market comps, AIRS at $14+ on peer 15x EBITDA.
#103
Macro Memo
Jul 27, 2025
Macro Memo: The Powell Struggle
The US economy will keep slowing without breaking while disinflation persists and tariff inflation stays modest and transitory, so the path is toward lower rates. The key dynamic is 'The Powell Struggle': Trump's failed public pressure on Powell is morphing into a strategic fiscal-monetary convergence (tariff truces, back-loaded spending, disinflationary regulatory nudges) that manufactures conditions justifying cuts, opening the door to easing and gradually lower long-term yields, which would eventually unlock housing. Trade tensions continue taking off-ramps (EU/Japan 'deals' as strategic acquiescence; US-China a stabilized strategic divorce). Markets risk either a seasonal late-summer correction or a 1998-style melt-up into a dotcom-like bubble phase. Positioning leans into the obvious rather than fading extremes: SOFR curve spreads betting the next Fed chair cuts more aggressively, long TLT calls as a hedge, and watchlist interest in agency mREITs.
airare-earthfinancefintechindexarindexbondsindexbrindexclindexmx
Positions & performance
+5.1%avg return67% win · 3 tracked · L +5.1%
| Position | Mentions | Entry | Last | Return |
|---|
| LAGNC:NASDAQ financefintech AGNC Investment | — | 9.68Jul 28 '25 | 10.59 | +9.4% |
| LNLY:NYSE financefintech Annaly Capital Management | IT | 20.68Jul 28 '25 | 22.57 ● | +9.1% |
| LTLT:NASDAQ indexbonds iShares 20+ Year Treasury Bond ETF | — | 85.87Jul 28 '25 | 83.25 | -3.1% |
Full summary 701 words
Published July 27, 2025, 'Macro Memo: The Powell Struggle' opens with a scorecard: most prior calls played out (tariff inflation overstated, services disinflation overwhelming goods inflation, resilient economy with a softening labor market, US-China taking off-ramps, rare earths as strategic leverage), though 'good news' Fed cuts haven't come yet and European FX/equity outperformance hasn't tapered. The upshot: the US economy keeps slowing without breaking, inflation stays flat-to-lower despite tariffs, and 'The Powell Struggle' leads to fiscal-monetary convergence as tariff uncertainty resolves, the Fed signals openness to cuts, and falling long yields eventually unlock housing.
The labor and economy check-in shows resilience masking softening: a 'nobody fired, nobody hired' dynamic with unemployment near cycle lows, but the recent-college-grad jobless rate at a ten-year high, job openings around the 4.5% threshold below which unemployment historically rises, and declining wage growth supporting Citrini's view that rent inflation stays contained. Bloomberg growth and inflation surprise indices turned negative in 2025, and the Atlanta Fed GDPNow points to trend-like Q2 growth, neither recessionary nor reaccelerating.
On trade, Citrini's constraint-based framework (analyzing incentives, especially Trump's) correctly forecast off-ramps. EU and Japan 'deals' (a 15% blanket EU framework except autos) are framed as strategic acquiescence given their reliance on the US defense umbrella and inability to coordinate as a bloc, the product of Trump's 'apply maximum pressure, create chaos, relieve pressure' tactic. US-China is an irreversible strategic divorce stabilized by mutual supply-chain leverage, with the tariff deadline extended 90 days and talks moving to Stockholm; Citrini cautions against mistaking detente for rapprochement. It notes its prior MP Materials (MP) and Metals Company (TMC) picks worked (MP re-rated sharply after the DoD became a large shareholder and Apple signed on as a customer) and recommends taking profit, expecting the truce period to be used to fortify vulnerabilities and any rare-earth sell-off to offer new entries. On inflation, tariffs are a regressive, one-time price-level adjustment, phased in gradually via higher prices or margin compression, not net inflationary given the service-based US economy.
The centerpiece is the Powell Struggle: the trajectory of rates is now shaped by the political economy around the Fed. Trump's public campaign (blaming Powell for 6%+ mortgages, firing rumors, name-checking the 1951 Treasury-Fed Accord) failed to move markets, so confrontation is morphing into coordination via a tariff truce, quieter/back-loaded fiscal spend (OBBB), and disinflationary regulatory nudges (environmental waivers, biofuel credits). Two-year breakevens fell 30bp and the ten-year term premium fell ~20bp from May highs, giving the Fed cover. Dovish members like Waller argue for preemptive cuts (tariffs are one-off), though Citrini suggests Waller's dissent may also be the Fed 'circling the wagons' to give Trump a viable dovish successor option. The call: barring an inflation surprise, Powell opens the door to a September cut at the July FOMC or Jackson Hole; markets price ~1.75 cuts by year-end. Long yields should trend gradually lower regardless of who cuts, as long as inflation stays controlled. On markets, Citrini flags rich pricing and complacency (VIX under 15) plus seasonal August/September weakness, drawing striking parallels to the 1998 correction and recovery, and warns weak market breadth (weakest since late 1998) could mark the start of a dotcom-style 'bubble phase,' while noting margin debt build-up remains benign relative to 2000 and 2007.
Positioning leans into the obvious rather than fading extremes: a new SOFR U5H6H7 fly (selling H6) betting more cuts get priced into March 2026-27 than the nearer window, plus long TLT December 2025 95 calls as fairly-priced upside optionality and a hedge to the STIR play, expecting long yields to fall as cuts are anticipated. Watchlist items: agency MBS REITs (NLY, AGNC) which broke out on spread dynamics (Annaly GAAP NIM 1.04%, economic NIM ex-PAA 1.71%, prepay speeds low), best played on a mild bull steepener; and mortgage originators (RKT, UWMC) which need a 75-100bp rate rally or looser credit (MCAI above 110 or mortgage rates below 6%) before working. Existing positions: short EURUSD was stopped out (still sees a dollar rebound but timing hard); long palladium performed well, sold half above $1,300 with a $1,250 stop; and it exited the Long LatAm (EWW+EWZ+ECH) vs short Argentina (ARGT) trade after ~10% outperformance, flipping tactically bullish Argentina ahead of Milei's mid-terms.
Key metrics
- Markets price ~1.75 rate cuts by year-end 2025
- 2-year breakeven inflation fell 30bp; 10-year term premium fell ~20bp from May highs
- Official job openings rate ~4.5% (threshold below which unemployment historically rises)
- EU trade framework: 15% blanket tariff except autos; US-China deadline extended 90 days (talks in Stockholm)
- 1 Year Yield 1 Year forward roughly 82bps lower; March 2026 policy rate ~3.25% priced
- Annaly Q2 GAAP NIM 1.04% (+17bps YoY), economic NIM ex-PAA 1.71%; prepay 6.8% vs 4.1% effective mortgage rate
- AGNC shock table: 50bp parallel decline trims tangible book ~3.8%, 75bp move ~7%
- At March 2000 top only 35% of S&P 500 above 200-day MA; margin debt grew >75% early 1999-early 2000 vs S&P <25%
- Mortgage originator triggers: 75-100bp rate rally, MCAI above 110, or mortgage rates below 6%; VIX under 15
- Palladium: sold half above $1,300, stop at $1,250; LatAm vs Argentina trade ~10% outperformance before flipping long Argentina
Key insights
- The core thesis is 'The Powell Struggle': Trump's failed public pressure on Powell is morphing into strategic fiscal-monetary coordination (tariff truce, back-loaded OBBB spend, disinflationary regulatory nudges) that manufactures conditions justifying rate cuts.
- Citrini expects Powell to open the door to a September cut at the July FOMC or Jackson Hole; markets price ~1.75 cuts by year-end, and long yields should trend lower regardless of who ultimately cuts.
- The labor market shows resilience masking softening: recent-college-grad joblessness at a ten-year high, job openings near the 4.5% threshold that historically precedes rising unemployment, and decelerating wage growth keeping rent inflation contained.
- EU and Japan trade 'deals' (15% blanket EU framework except autos) are strategic acquiescence, not negotiated settlements; US-China is a stabilized strategic divorce with the tariff deadline extended 90 days and talks moving to Stockholm.
- Prior rare-earth picks worked: MP Materials re-rated sharply after the DoD became a large shareholder and Apple signed on as a customer, prompting Citrini to recommend taking profit.
- Markets face a fork: a seasonal late-summer correction or a 1998-style melt-up; breadth (weakest since late 1998) on new highs could signal the start of a dotcom-like 'bubble phase,' though margin debt remains benign versus 2000 and 2007.
- New positioning leans into the obvious: a SOFR U5H6H7 fly (sell H6) betting more cuts price into March 2026-27, plus long TLT December 2025 95 calls as a hedge and fairly-priced upside optionality.
- Watchlist: agency mREITs (NLY, AGNC) broke out on spread dynamics (Annaly economic NIM ex-PAA at 1.71%), best on a mild bull steepener; mortgage originators (RKT, UWMC) need mortgage rates below 6% or MCAI above 110 to work.
#102
Thematic Update
Jul 24, 2025
GLP-1s: The Second Serving - Revisiting our GLP-1 Basket
GLP-1 obesity drugs have reached a tipping point of adoption, so the second-order effects Citrini predicted two years ago (which the market has now grown complacent about) are about to show up clearly on income statements. As a critical mass of patients has been on the drugs long enough, lagged effects create investable dislocations: aesthetic/cosmetic surgery demand is inflecting up (loose skin, 'Ozempic Face'), food/beverage consumption is shifting toward protein and away from junk/alcohol, and access/sustainability services and fitness benefit, while sleep-apnea, dialysis and diabetic-complication names face lagged headwinds. Among manufacturers, Eli Lilly is favored over Novo Nordisk on a superior, more durable pipeline. Citrini re-establishes its GLP-1 basket (9% of Citrindex) with longs on beneficiaries, shorts on losers, and selective manufacturer/supply-chain exposure, backed by detailed clinical-trial analysis.
airobotconsumerhealthconsumershoppinghealthGLPhealth
Positions & performance
+6.5%avg return55% win · 31 tracked · L +3.5% · S +10.2%
| Position | Mentions | Entry | Last | Return |
|---|
| LESTA:NASDAQ health Establishment Labs | — | 43.15Jul 24 '25 | 88.38 | +104.8% |
| LAPYX:NASDAQ health Apyx Medical | — | 2.37Jul 24 '25 | 4.5 | +89.9% |
| LUNFI:NYSE consumerhealth United Natural Foods | A | 27.52Jul 24 '25 | 49.05 ● | +78.2% |
| SWING:NASDAQ consumershopping Wingstop | IT | 299.63Jul 24 '25 | 135.2 | +54.9% |
| SSHAK:NYSE consumershopping Shake Shack | APT | 133.72Jul 24 '25 | 61.57 ● | +54.0% |
| LLLY:NYSE healthGLP Eli Lilly | IPT | 805.43Jul 24 '25 | 1196.03 | +48.5% |
| LLTH:NYSE consumerhealth Life Time Group | AT | 29.09Jul 24 '25 | 42.33 | +45.5% |
| SMDXG:NASDAQ health MiMedx Group | — | 6.85Jul 24 '25 | 4.26 ● | +37.8% |
| LABBV:NYSE health AbbVie | IPT | 190.83Jul 24 '25 | 256.91 ● | +34.6% |
| SNVO:NYSE healthGLP Novo Nordisk | ISP | 70.73Jul 24 '25 | 48.77 | +31.0% |
| SDPZ:NASDAQ consumershopping Domino's Pizza | IPT | 476.34Jul 24 '25 | 343.53 ● | +27.9% |
| SRMD:NYSE health ResMed | IPT | 273.5Jul 24 '25 | 203.08 ● | +25.7% |
| SINGR:NYSE consumershopping Ingredion | IT | 132.74Jul 24 '25 | 101.45 ● | +23.6% |
| LLWAY:NASDAQ consumerhealth Lifeway Foods | A | 25.92Jul 24 '25 | 30.44 | +17.4% |
| SHRL:NYSE consumershopping Hormel | IT | 29.3Jul 24 '25 | 26.05 ● | +11.1% |
| SFMS:NYSE health Fresenius Medical Care | — | 26.76Jul 24 '25 | 24.59 | +8.1% |
| LIFF:NYSE consumershopping International Flavors & Fragrances | IAT | 75.88Jul 24 '25 | 76.4 ● | +0.7% |
| SYUM:NYSE consumershopping Yum! Brands | IPT | 145.83Jul 24 '25 | 147.8 ● | -1.4% |
| SQSR:NYSE consumershopping Restaurant Brands International | IA | 70.02Jul 24 '25 | 72.47 | -3.5% |
| LATS:NYSE airobot ATS Corporation | — | 31.65Jul 24 '25 | 26.42 | -16.5% |
| LATR:NYSE healthGLP AptarGroup | IT | 161.82Jul 24 '25 | 132.36 | -18.2% |
| LNGVC:NYSE consumerhealth Natural Grocers | — | 39.79Jul 24 '25 | 30.01 | -24.6% |
| LAIRS:NASDAQ health AirSculpt | A | 6.29Jul 24 '25 | 4.61 | -26.7% |
| SEAT:NYSE consumershopping Brinker International | IT | 152.32Jul 24 '25 | 195.44 ● | -28.3% |
| SPBPB:NASDAQ consumershopping Potbelly | — | 12.64Jul 24 '25 | 17.12 | -35.4% |
| LEOLS:NASDAQ health Evolus | — | 9.65Jul 24 '25 | 6.18 ● | -36.0% |
| LXPOF:NYSE consumerhealth Xponential Fitness | A | 10.62Jul 24 '25 | 6.32 | -40.5% |
| LSG:NYSE consumershopping Sweetgreen | SA | 14.29Jul 24 '25 | 6.0 | -58.0% |
| SDVA:NYSE health DaVita | IPT | 144.77Jul 24 '25 | 235.44 | -62.6% |
| LWW:NASDAQ health WW International | A | 38.01Jul 24 '25 | 13.85 ● | -63.6% |
| LBRBR:NYSE consumerhealth BellRing Brands | I | 53.95Jul 24 '25 | 13.07 ● | -75.8% |
Full summary 585 words
Published July 24, 2025, 'GLP-1s: The Second Serving' revisits Citrini's third-ever thematic primer ('Upgrading from Overweight,' 2023), which argued GLP-1s would become ubiquitous like Lipitor or Viagra and drive the first downtick in US obesity in four decades, and that the biggest trade would be the second-order effects. Citrini exited the basket in November 2024 for a 75% gain over 14 months, fearing the market was front-running effects amid patent-cliff and compounding risks. Now it re-establishes the basket because adoption has hit critical mass (nearly 4% of US adults had a GLP-1 prescription at end-2024, likely 2-3x higher counting grey-market peptides and compounders), just as the market has become complacent that slower-moving second-order changes won't arrive.
On manufacturers, Citrini brings back Eli Lilly (LLY) as its favorite: tirzepatide has a longer runway before generics than Novo's semaglutide and fewer side effects, and at ~26x a conservative 2026 EPS the valuation is justified by tirzepatide alone at 15% share of a $125B market, with orforglipron, retatrutide and tablet economics 'for free.' The pipeline is detailed: orforglipron (oral) hit -7.9% weight at week 40 in ACHIEVE-1, retatrutide's 'triple-G' showed -24% weight (the category high-score), and bimagrumab+tirzepatide targets lean-mass preservation. Novo trades cheap 'for a reason,' partly due to worrying cagrilintide fatigue/depression signals on trial subreddits. The supply chain (autoinjectors/pens) benefits AptarGroup (ATR), Lonza, Polypeptide, Peptidream and ATS (backlog up ~40% YoY) as capacity constraints ease and orals emerge.
The heart of the report is second-order effects. Aesthetics: after an 18-month cyclical bust (a COVID-era boom-to-bust, misread as GLP-1 demand destruction), demand is inflecting; Google Trends turned positive YoY in January 2025 for the first time since 2022, and McKinsey found nearly two-thirds of post-GLP-1 aesthetic patients are new to the market. Airsculpt (AIRS) is the favorite (network can do $750M+ revenue at full utilization, path to 30% EBITDA margins, under 2x EBITDA), with Apyx (APYX), Establishment Labs (ESTA), and for injectables Galderma (GALD), Evolus (EOLS) and AbbVie (ABBV). Food & beverage: shorts on fast food (Brinker/EAT, Domino's/DPZ, Potbelly, QSR, Shake Shack, Yum, Wingstop) as 'funding shorts' against healthy-food longs (Natural Grocers/NGVC with 5.3% same-store traffic versus Sprouts' ~4%, plus UNFI, Lifeway/LWAY, BellRing/BRBR, Sweetgreen/SG), with additional pair shorts (Hormel, Ingredion) versus Danone and IFF. Access/sustainability: WW International (WW), post-bankruptcy with net debt cut to ~$300M (<3x EBITDA) and a GLP-1 telehealth platform now ~20% of revenue, trading under 4x 2024 EBITDA versus Hims at 6x revenue; plus fitness names Life Time (LTH, MIORA platform) and Xponential (XPOF, ~7x EBITDA versus peers north of 20x). Losers from lagged effects: adding shorts on ResMed (RMD, ~half the sleep-apnea device market), DaVita (DVA), Fresenius (FMS) and MiMedx (MDXG), as sleep apnea, kidney disease and diabetic-ulcer demand faces eventual GLP-1-driven decline plus reimbursement pressure.
The final, extensive section is a clinical/scientific review across 20+ companies and three innovation vectors (oral formulations, novel mechanisms like dual/triple agonists and amylin, and convenience/monthly dosing), including deep dives on Lilly's retatrutide (-24% weight, MASLD data, dose-dependent arrhythmia at 12mg), orforglipron, bimagrumab and eloralintide; Metsera (MTSR, MINT/HALO/MOMENTUM platforms, ~16-19 day half-lives for monthly dosing); Amgen's maridebart cafraglutide; and a raft of Chinese players (BrightGene's BGM0504 at 19.78% placebo-adjusted weight loss at 24 weeks, Innovent's Mazdutide as the first China-approved obesity GLP-1, United Labs' UBT251, Hengrui's HRS9531 at ~18% at 32 weeks). Citrini concludes weight-loss efficacy keeps climbing (early GLP-1s 5-10%, dual agonists 15-20%, next-gen 20%+) and that it will be discerning, favoring LLY and Innovent. Positioning: 9% of the Citrindex is put into the updated GLP-1 basket.
Key metrics
- ~4% of US adults had a GLP-1 prescription at end-2024; likely 2-3x higher counting grey-market/compounded; over 30% of US adults obese
- Prior basket: 75% gain over 14 months (exited Nov 2024); new basket = 9% of Citrindex
- LLY ~26x conservative 2026 EPS; tirzepatide at 15% share of a $125B global market; orforglipron -7.9% weight at week 40; retatrutide -24% weight
- Retatrutide visceral fat reduction 29.4% (8mg) / 31.4% (12mg); arrhythmia 12% at 8mg, 7% at 12mg, 6% overall
- AIRS: $750M+ revenue at full utilization, path to 30% EBITDA margins, under 2x EBITDA; fat grafting ~50% annual growth
- WW: net debt ~$300M (<3x EBITDA), telehealth ~20% of revenue (from <5%), <4x 2024 EBITDA vs Hims 6x revenue
- NGVC same-store traffic +5.3% vs Sprouts ~4% vs grocery <1%; supplements >20% of revenue
- XPOF ~7x 2025 EBITDA vs fitness franchisors >20x; GLP-1 drugs cost $900-1,200/month uninsured, up to $200 insured
- Chinese data: BGM0504 19.78% placebo-adjusted at 24 weeks; Hengrui HRS9531 ~18% at 32 weeks; UBT251 16.6% at 12 weeks
- Efficacy progression: early GLP-1s 5-10%, dual agonists 15-20%, next-gen compounds 20%+
Key insights
- GLP-1 adoption has hit critical mass (nearly 4% of US adults prescribed at end-2024, likely 2-3x higher counting grey-market peptides), so predicted second-order effects will now show up clearly on income statements just as the market has grown complacent.
- Eli Lilly is favored over Novo Nordisk: at ~26x conservative 2026 EPS, tirzepatide alone at 15% share of a $125B market justifies the valuation, with orforglipron, retatrutide and tablet economics as free upside.
- Aesthetic surgery demand is inflecting after an 18-month bust misread as GLP-1 demand destruction; Google Trends turned positive YoY in January 2025 and McKinsey found ~two-thirds of post-GLP-1 aesthetic patients are new to the market.
- Airsculpt (AIRS) is the top aesthetics pick: its network can generate $750M+ revenue at full utilization with a path to 30% EBITDA margins, valuing it under 2x EBITDA at full utilization.
- Citrini adds a diversified 'funding short' basket of fast-food names (EAT, DPZ, QSR, SHAK, YUM, WING) against healthy-food longs like Natural Grocers (NGVC), whose 5.3% same-store traffic beat Sprouts' ~4%.
- WW International (post-bankruptcy) is a favored access/sustainability play: net debt cut to ~$300M (<3x EBITDA), GLP-1 telehealth now ~20% of revenue, trading under 4x 2024 EBITDA versus Hims at 6x revenue.
- New shorts on lagged losers: ResMed (RMD, ~half the sleep-apnea device market), DaVita (DVA), Fresenius (FMS) and MiMedx (MDXG), facing eventual GLP-1-driven demand decline plus reimbursement pressure.
- Weight-loss efficacy keeps climbing (early GLP-1s 5-10%, dual agonists 15-20%, next-gen 20%+); Chinese players are competitive (BrightGene's BGM0504 at 19.78% placebo-adjusted at 24 weeks; Innovent's Mazdutide first China-approved obesity GLP-1).
#101
Robotics
Jul 10, 2025
Robotics Update: Teradyne's Vulcan Win, China Supply-Chain Tour, and Basket Winners
The robotics supply chain is a secular growth story hidden inside cyclically depressed, auto-exposed suppliers, and Citrini's May primer thesis is playing out via three converging forces: a collapsing robot cost curve, VLA models finally giving robots a usable brain, and key suppliers trading at trough valuations. The report's headline reveal (with Hunterbrook) is that Teradyne (TER) supplies the Universal Robots arms behind Amazon's breakthrough Vulcan robot, a potentially catalytic contract on top of a cyclical rebound in TER's semiconductor-test business, implying large upside. A China supply-chain tour confirms rapid Chinese progress and a declining cost curve but a leading edge of autonomy still in the US, so Citrini favors non-China, IP-rich Western/Japanese suppliers with design-win proof. The basket is narrowed toward names converting real orders into booked revenue (sensors/LiDAR, power semis, warehouse bots, actuators) over prototype-stage OEMs.
aimemoryaiopticalairobotaisemidefensecomponentsenergyaienergygridsaas
Positions & performance
+76.2%avg return74% win · 19 tracked · L +76.2%
| Position | Mentions | Entry | Last | Return |
|---|
| LICHR:NASDAQ aisemi Ichor Holdings | PT | 23.71Jul 10 '25 | 94.0 | +296.5% |
| LTER:NASDAQ aisemi Teradyne | ISPT | 98.62Jul 10 '25 | 349.92 | +254.8% |
| LUCTT:NASDAQ aisemi Ultra Clean Holdings | T | 25.02Jul 10 '25 | 86.97 ● | +247.6% |
| LTTMI:NASDAQ aioptical TTM Technologies | ST | 43.88Jul 10 '25 | 123.71 ● | +181.9% |
| LALNT:NASDAQ airobot Allient | I | 39.03Jul 10 '25 | 86.78 | +122.3% |
| LDCO:NYSE defensecomponents Ducommun | AP | 83.93Jul 10 '25 | 177.44 | +111.4% |
| LCLS:NYSE aisemi Celestica | IS | 158.83Jul 10 '25 | 318.24 ● | +100.4% |
| LNVTS:NASDAQ energyai Navitas Semiconductor | SA | 6.26Jul 10 '25 | 10.92 | +74.4% |
| LSTM:NYSE aisemi STMicroelectronics | SP | 33.14Jul 10 '25 | 53.45 ● | +61.3% |
| LCW:NYSE defensecomponents Curtiss-Wright | IT | 474.49Jul 10 '25 | 743.83 ● | +56.8% |
| LON:NASDAQ aisemi ONSemi | IT | 59.52Jul 10 '25 | 89.04 ● | +49.6% |
| LJBL:NYSE aioptical Jabil | IST | 220.96Jul 10 '25 | 312.59 | +41.5% |
| LOUST:NASDAQ airobot Ouster | IS | 24.46Jul 10 '25 | 34.04 | +39.2% |
| LALGM:NASDAQ aisemi Allegro MicroSystems | — | 37.51Jul 10 '25 | 46.03 | +22.7% |
| LSYM:NASDAQ airobot Symbotic | A | 47.81Jul 10 '25 | 40.15 | -16.0% |
| LBSY:NASDAQ saas Bentley Systems | T | 56.68Jul 10 '25 | 33.71 ● | -40.5% |
| LPONY:NASDAQ airobot Pony.ai | I | 12.89Jul 10 '25 | 7.13 | -44.7% |
| LAEVA:NASDAQ airobot Aeva | SA | 29.21Jul 10 '25 | 14.85 | -49.2% |
| LINVZ:NASDAQ airobot Innoviz | — | 1.69Jul 10 '25 | 0.63 ● | -62.6% |
Full summary 640 words
Published July 10, 2025, 'Robotics Update' follows Citrini's May humanoid primer with three parts: a Hunterbrook Media investigation into Teradyne's (TER) hidden robotics upside, takeaways from a China supply-chain tour, and a review of robotics-basket winners. The framing reaffirms the primer's thesis that robotics is a secular growth story sitting inside cyclically depressed, auto-exposed suppliers, with three converging factors: a collapsing robot cost curve, VLA models giving robots a usable brain, and key suppliers at cyclical-trough valuations.
The Teradyne reveal is the centerpiece. Amazon's new Vulcan warehouse robot, billed as the first with a 'sense of touch' able to pick and stow at near-human speeds, uses arms made by Universal Robots, the Danish cobot maker Teradyne bought for $285M in 2015. Hunterbrook corroborated this via UR/Robotiq labels on Amazon materials and the physical proximity of Teradyne HQ and Amazon Robotics, and noted this was the first quarter since 2018 with no Teradyne insider selling. Napkin math: Amazon stows 14 billion items/year by hand and wants Vulcan to handle 80% (11.2 billion) at 300 items/hour, 20 hours/day, implying ~5,114 robots; at $150K-$250K each, ~5,000 units would be roughly $600M of hardware, and Citrini conservatively estimates $300-400M revenue for TER, adding roughly $1.00 to EPS as deployments scale. On the core business, Citrini argues TER's semiconductor-test segment (which saw peak-to-trough EPS decline over 50%) is inflecting up on auto-test reordering and HBM ramps, with secular tailwinds from edge AI, custom ASIC test (Marvell, Broadcom) and 2nm. Management guides $7.00-$9.50 EPS by 2028; Citrini thinks that's conservative, and using $11.00 EPS at a 20x average multiple implies a price target over $200 (a double), with a bull case near $400 (30x on ~$13 EPS).
The China tour (June 22-July 1, eleven companies) yields four takeaways. First, 'robot fever': dozens of Chinese firms (UBTech, Unitree, Agibot/Zhiyuan, plus Xpeng, Xiaomi) are building humanoid prototypes, driving A-share supplier run-ups. Second, on OEMs (body vs. brains): US leaders Tesla and Figure AI were repeatedly cited as global leaders in AI-integrated autonomy; UBTech pursues a full-stack solution but demos looked slow and it has revealed only one commercial purchase of 20 robots; Unitree offers impressive hardware (G1 humanoid as low as $16,000) but is remote-controlled with pre-wired motions and open-sources its AI rather than developing autonomy in-house. Citrini concludes 'humanoids are hard' and the leading edge of autonomy remains in the US (noting Tesla removed its Optimus head in June amid a production pause/redesign). Third, the supply chain: most components are still small-batch/samples for prototyping, with the most concrete scale-production signals from roller-screw and linear-actuator makers (Ningbo Shuanglin, Zhejiang XCC) building capacity for Tesla Optimus (each Optimus needs 14 linear actuators; Ningbo targeting 300,000 units/year). Fourth, final observations: despite weak domestic consumption, China's advanced-manufacturing pace and falling cost curve are impressive (a Pony.ai/PONY robotaxi ride cost under RMB20).
The performance review shows the market rewarding real orders over prototypes: sensors (especially LiDAR), power semis (SiC/GaN), and warehouse bots led. Sub-basket leaders include sensing/perception (Ouster/OUST shipping 4,700 sensors in Q1 25 with Q2 guidance $32-35M, Aeva, Innoviz, Allegro/ALGM sizing a >$10B humanoid sensor SAM for 2030-2035, Sensirion), contract manufacturing (Celestica, Jabil, Spectris which took a £5.6B KKR bid, TTMI), actuators favoring Western/IP names (Schaeffler/SHA0 selling full joint modules at ~€1,500/bot with only 18% China revenue, Duocommun, Curtiss-Wright, plus Japanese Nabtesco/Nippon-Thompson), motion control (Allient/ALNT up 72% since the Q1 call on its 'Simplify to Accelerate' restructuring, Delta, Syntec), warehouse automation (Jungheinrich, Symbotic/SYM with revenue up 40% to $550M and ~$22B backlog, Bentley/BSY), and wide-bandgap power (Navitas, Onsemi, Rohm, STM, plus subsystem suppliers Ichor/ICHR and Ultra Clean/UCTT, newly added July 1). Basket changes: closing BYD, Harmonic Drive, Ace Pillar, Deere, Zhejiang Rongtai, Metallus, CATL, Aurotek and China Leadshine; adding Japanese actuator names, Sensirion and Teradyne in sensing, Bentley and Jungheinrich in autonomy software, and adding to ALNT, SHA0, SYM and INVZ.
Key metrics
- Teradyne bought Universal Robots for $285M (2015); UR revenue ~$40M at acquisition, $311M in 2021, $326M in 2022; robotics segment ~$404M in 2022, $375M in 2023
- Vulcan: 14B items stowed/year, 80% target, 300 items/hour x 20 hours/day = ~5,114 robots; ~$600M hardware; Citrini est. $300-400M TER revenue, ~$1.00 EPS add
- TER guidance: $7.00-$9.50 EPS by 2028; Citrini $11 EPS x 20x => >$200 target; bull ~$400 (30x on ~$13 EPS)
- Amazon has 750,000+ active robots across 20 model types; warehouses nearing more robots than humans
- Unitree G1 humanoid as low as $16,000; each Tesla Optimus needs 14 linear actuators; Ningbo Shuanglin targeting 300,000 units/year
- Ouster shipped 4,700 sensors in Q1 25; Q2 guidance $32-35M vs Street ~$30M; Allegro humanoid sensor SAM >$10B for 2030-2035
- Symbotic Q: revenue +40% to $550M, software sales +162%, backlog ~$22B; Allient +72% since Q1 25 call
- Schaeffler joint module ~17kg content at ~€1,500/bot (3x industrial-arm attach rate), 18% China revenue
- Spectris accepted £5.6B KKR bid; order book £526M; China tour June 22-July 1 visited 11 companies; ICHR +~20% and UCTT +~10% since July 1 initiation
Key insights
- The headline reveal: Amazon's breakthrough Vulcan warehouse robot uses Universal Robots arms owned by Teradyne (TER), which bought UR for $285M in 2015; it was also the first quarter since 2018 with no TER insider selling.
- Vulcan napkin math implies ~5,114 robots needed (14B items stowed/year x 80% at 300 items/hour, 20 hours/day), roughly $600M of hardware, and Citrini estimates $300-400M revenue for Teradyne, adding ~$1.00 to EPS.
- Teradyne's core semiconductor-test business is inflecting off a >50% peak-to-trough EPS decline; management guides $7.00-$9.50 EPS by 2028, and Citrini's $11 EPS at 20x implies >$200/share (a double), bull case ~$400.
- China's supply-chain tour confirmed rapid progress and a falling cost curve, but the leading edge of autonomy remains in the US (Tesla and Figure AI cited as leaders); Unitree's G1 hardware is impressive but remote-controlled with open-sourced AI.
- The market is paying for real orders and non-China IP: Schaeffler (SHA0) rallied selling full joint modules (~17kg content at ~€1,500/bot, 3x industrial-arm attach rate) with only 18% China revenue.
- Each Tesla Optimus requires 14 linear actuators; roller-screw/actuator makers Ningbo Shuanglin (targeting 300,000 units/year) and Zhejiang XCC gave the most concrete scale-production signals.
- Symbotic (SYM) posted revenue up 40% to $550M with software sales up 162% and ~$22B backlog after buying Walmart's Advanced Systems group; Allient (ALNT) rose 72% since its Q1 call on restructuring.
- Citrini narrowed the basket, closing BYD, Harmonic Drive, Deere, CATL and others while adding Teradyne, Sensirion, Bentley, Jungheinrich, Japanese actuator names, and newly-initiated power-semi subsystem suppliers Ichor (ICHR) and Ultra Clean (UCTT).
#100
Thematic Primer
Jun 23, 2025
The New WFH (War From Home): Missile Defense, Counter-UAS, Electronic Warfare, and Surveillance
Modern warfare has hit an inflection point ('War From Home'): cheap drones and long-range strikes let under-resourced actors inflict asymmetric damage on great powers, forcing a massive fiscal realignment toward defense in the US and NATO. The FY2026 US defense budget blueprint broke $1 trillion for the first time, and within it spending is shifting disproportionately toward procurement and technology, specifically the emerging vectors: missile intercept (including a space-based 'Golden Dome'), counter-unmanned aerial systems, electronic warfare, and ISR/surveillance. Because this technology-focused defense spending has bipartisan support and hard geopolitical catalysts (Russia, Israel/US-Iran, China), the beneficiaries are the contractors and specialized suppliers levered to these four pillars. Citrini positions via a Warfare basket and watchlist across these categories, scaling exposure as the legislative bill clears.
airobotdefensecomponentsdefensedefensedronedefenseprimespace
Positions & performance
+51.4%avg return83% win · 18 tracked · L +51.4%
| Position | Mentions | Entry | Last | Return |
|---|
| LONDS:NASDAQ defensedrone Ondas Holdings | S | 1.43Jun 23 '25 | 7.8 | +445.5% |
| LUMAC:NYSE defensedrone Unusual Machines | — | 8.16Jun 23 '25 | 19.36 | +137.3% |
| LMPTI:NYSE defensecomponents M-tron Industries | A | 40.16Jun 23 '25 | 85.33 ● | +112.5% |
| LMRCY:NASDAQ defensecomponents Mercury Systems | IA | 51.83Jun 23 '25 | 103.27 | +99.2% |
| LRTX:NYSE defenseprime RTX | ISPT | 145.81Jun 23 '25 | 212.79 | +45.9% |
| LBKSY:NYSE space BlackSky | S | 16.47Jun 23 '25 | 22.07 ● | +34.0% |
| LLMT:NYSE defenseprime Lockheed Martin | ISPT | 472.46Jun 23 '25 | 580.0 ● | +22.8% |
| LLHX:NYSE defense L3Harris | IPT | 251.11Jun 23 '25 | 303.48 ● | +20.9% |
| LSAIC:NASDAQ defense Science Applications International | I | 104.21Jun 23 '25 | 118.48 ● | +13.7% |
| LKTOS:NASDAQ defensedrone Kratos Defense | IS | 43.63Jun 23 '25 | 49.45 ● | +13.3% |
| LNOC:NYSE defenseprime Northrop Grumman | ISPT | 499.67Jun 23 '25 | 547.58 ● | +9.6% |
| LCACI:NYSE defense CACI International | — | 457.61Jun 23 '25 | 495.89 ● | +8.4% |
| LDRS:NASDAQ defense Leonardo DRS | IAP | 44.73Jun 23 '25 | 48.1 | +7.5% |
| LRCAT:NASDAQ defensedrone Red Cat Holdings | S | 7.18Jun 23 '25 | 7.64 | +6.4% |
| LBA:NYSE defense Boeing | ISAPT | 201.31Jun 23 '25 | 211.5 ● | +5.1% |
| LPSN:NYSE defense Parsons | IA | 66.37Jun 23 '25 | 58.73 | -11.5% |
| LAVAV:NASDAQ defensedrone AeroVironment | ISP | 191.23Jun 23 '25 | 154.24 ● | -19.3% |
| LLDOS:NYSE defense Leidos | IPT | 150.67Jun 23 '25 | 112.14 | -25.6% |
Non-US / no priceDRO:ASX defensedrone
Full summary 599 words
Published June 23, 2025, 'The New WFH (War From Home)' argues warfare has structurally changed: cheap drones torch billion-dollar assets and countries wage war from thousands of miles away. Citrini cites Houthi drones blocking Red Sea commerce despite US carriers, Ukraine's 104-drone strike 800km into Russia hitting the Kirishi refinery, and Israel's smuggled-drone attack on Iran, with Iran responding via hundreds of Shahed drones and missiles. Israel's defenses blocked most, but at roughly $45,000 per Tamir interceptor shot, defense is neither free nor unlimited. The thesis: for under-resourced countries this is new leverage; for resource-rich ones a wake-up call, driving a fiscal realignment toward defense.
Why investors should care: a massive fiscal realignment toward defense (US and NATO), military superiority being redefined by technology, and hard catalysts from armed adversaries (Russia into eastern Europe, Israel/US-Iran, China's reunification aim). For the first time the FY2026 US defense budget blueprint broke the $1 trillion ceiling. Citrini frames this as re-industrialization via militarization, noting Trump's 'skinny budget' boosted DoD and DHS while cutting other agencies, and that within the DoD budget procurement, technology development and hard-asset contracts should rise disproportionately (today half the DoD budget is personnel). SecDef Hegseth is culling four-star generals by 20% and redirecting savings to procurement. The OBBBA adds $13 billion for missile defense, authorizes a 'Golden Dome' space layer, and singles out a $693 million C-UAS fund; the Senate markup keeps the $150 billion discretionary defense allocation unchanged. Fiscal asymmetry is the core problem: Shahed drones cost as little as $20,000 with 2,500km range, while SHORADS interceptors (AMRAAM/AIM-120, IRIS-T) cost 20-50x per drone, and FPV drones cost under $1,000. Electronic warfare (lasers with 'unlimited' ammunition, jamming, spoofing, high-power microwaves) levels the field.
The report details the 'four pillars of the modern shield.' Missile intercept spans boost (AEGIS, prime Lockheed/LMT), midcourse (GMD, prime Boeing/BA, 40 interceptors at Fort Greely plus 4 at Vandenberg), and terminal (THAAD, PAC by Lockheed with interceptors from RTX/L3Harris), all reliant on a space sensor layer at the center of budget priorities (HBTSS, PWSA slated for nearly $9B over four years, Resilient MW/MT slated for $5B), with hypersonic defense prime Northrop (NOC) and subcontractor Kratos (KTOS), plus space-focused Leidos (LDOS) and Parsons (PSN). The IRON DOME Act allocated $12B to expand GMD, $1.4B to THAAD, $1.5B to PAC-2/PAC-3, and $1B for Aegis Ashore. Counter-UAS spans finders (RF, radar, EO/IR) and finishers: kinetic guns/interceptors, directed-energy (Leonardo/LDO DE M-SHORAD), and jamming (DroneShield/DRO AU DroneGun Mk4), with Replicator 2.0 opening the door to smaller players Ondas (ONDS), Unusual Machines (UMAC), Redcat (RCAT), and offensive loitering munitions from AeroVironment (AVAV). Electronic warfare leaders include L3Harris (LHX), CACI, Leonardo DRS (DRS), Mercury Systems (MRCY), Northrop, BAE Systems, and niche RF supplier Mtron (MPTI). Surveillance/ISR beneficiaries include BlackSky (BKSY) for high-refresh satellite imagery and SAIC for ground systems and AI analytics.
Positioning: Citrini originally published Electronic Defense and C-UAS in its '25 Trades for 2025' watchlist and now sees Trump's fiscal realignment plus geopolitics creating a durable next leg. It maintains a Warfare thematic basket (added to Citrindex May 13 at 6% weight) plus a 'War From Home' watchlist across the four categories, approaching with modest caution given uncertainty on final bill timing/allocations and allowing more aggressive exposure as the legislative hurdle clears. A key risk flagged: after the US bombed Iranian nuclear facilities, some Republican senators wary of interventionism could threaten the Big Beautiful Bill, though Citrini believes Medicaid/entitlements are likelier Democratic targets than defense. It also notes robotics names like Ouster (OUST) have upside to the trend but are excluded from this watchlist as they are allocated elsewhere.
Key metrics
- FY2026 US defense budget blueprint exceeds $1 trillion (first ever)
- OBBBA: +$13B missile defense, $693M C-UAS fund; Senate keeps $150B discretionary defense allocation unchanged
- IRON DOME Act: $12B GMD expansion, $1.4B THAAD, $1.5B PAC-2/PAC-3, $1B Aegis Ashore
- Space layer funding: PWSA ~$9B over 4 years; Resilient MW/MT $5B over several years
- Shahed drone cost as low as $20,000, range up to 2,500km; FPV drones under $1,000
- Interceptor cost asymmetry 20-50x per drone; Tamir ~$45,000/shot; AIM-9/AIM-120 $500K-$1M; SM-2 $2M
- GMD interceptors: 40 at Fort Greely, Alaska + 4 at Vandenberg; Aegis BMD ships 56 (FY2025) growing to 69 by FY2030
- SecDef ordered 20% cut to four-star generals/admirals, 20% to National Guard generals, 10% overall
- Ukraine strike: 104 drones 800km into Russia; Warfare basket added to Citrindex May 13 at 6% weight
Key insights
- The FY2026 US defense budget blueprint broke the $1 trillion ceiling for the first time, and within it spending shifts disproportionately toward procurement, technology and hard assets rather than personnel (currently half the DoD budget).
- Cost asymmetry is the central problem: Shahed drones cost as little as $20,000 with 2,500km range while interceptors cost 20-50x per drone; FPV drones cost under $1,000 and Israel's Tamir shots run ~$45,000 each.
- The 'Golden Dome' is not one system but a catchall for budget across missile-defense layers, with the space sensor layer central: PWSA slated for nearly $9B over four years and Resilient MW/MT for $5B.
- The OBBBA adds $13B for missile defense and a $693M C-UAS fund; the IRON DOME Act allocated $12B to expand GMD, $1.4B THAAD, $1.5B PAC-2/PAC-3, and $1B for Aegis Ashore.
- Prime contractors map to layers: Lockheed (AEGIS, THAAD, PAC), Boeing (GMD), Northrop (hypersonic Glide Phase Interceptor, sea-based EW), with RTX and L3Harris supplying interceptors.
- Counter-UAS opens the door to smaller/speculative names via the Pentagon's Replicator 2.0 program: Ondas (ONDS), Unusual Machines (UMAC), Redcat (RCAT), plus DroneShield (DRO AU) and AeroVironment (AVAV).
- Electronic warfare and ISR beneficiaries include L3Harris (LHX), CACI, Leonardo DRS (DRS), Mercury (MRCY), niche RF supplier Mtron (MPTI), plus BlackSky (BKSY) and SAIC for surveillance/analytics.
- The Warfare basket was added to Citrindex on May 13 at a 6% weight, with exposure to scale up as the spending bill clears; the key risk is Republican senators wavering on the Big Beautiful Bill after the Iran strikes.
#099
In Conversation
Jun 19, 2025
In Conversation: Ouster (OUST)
The US economy is resilient with a slowly cooling but not breaking labor market, and disinflation continues while tariff-driven inflation is transitory, so the Fed should be able to resume 'good-news' rate cuts (Citrini expects Powell to open the window in July). Trade policy should be read through Trump's constraints (bond yields, tax-bill passage, recession risk, and now rare earths) rather than his preferences; those constraints push both the US and China toward off-ramps, though the US-China relationship is a long, drawn-out strategic divorce. Geopolitical shocks (Israel-Iran) are analyzed via the same constraint lens: Trump is highly reluctant to enter a war because higher oil, higher yields and delayed cuts all hurt him. The positioning rotates from an EU-fiscal/rest-of-world tilt back toward select US and commodity exposure (biofuels, grains, palladium), takes profits where trades worked, and adds rate-cut and short-EURUSD plays.
airobot
Positions & performance
+58.1%avg return100% win · 1 tracked · L +58.1%
| Position | Mentions | Entry | Last | Return |
|---|
| LOUST:NASDAQ airobot Ouster | IS | 21.53Jun 20 '25 | 34.04 | +58.1% |
Full summary 554 words
Published June 17, 2025, 'Macro Memo: Summer Blues' is a monthly macro update in which Citrini says, unlike the prior memo, it has no contrarian view because its prior calls largely played out: recession risk was overstated and receded, the US-China trade war de-escalated, disinflation continued with muted tariff inflation, a SOFR spread trade hit its target (0bps), and WTI crude rose from $57.80 to $75. The overarching message: the US economy remains resilient despite earlier tariff-driven recession fears, and the trend is one of gradual labor-market cooling capping wage growth, with transitory tariff goods inflation offset by services (especially shelter/rent) disinflation.
The labor section paints a 'nobody is quitting and nobody is hiring' picture: continuing jobless claims at multi-year highs while initial claims move sideways, attrition way down, employers reluctant to hire after COVID overhiring, and job seekers unemployed longer. The job openings rate is under 4.5%, a threshold Fed governor Chris Waller has flagged as historically preceding a rising unemployment rate; Citrini expects unemployment to drift higher and is skeptical that reduced immigration/deportations will prevent it.
On US-China, Citrini frames trade through Trump's constraints (debt financing/10yr yield, tax-bill passage, recession risk, and newly added rare earth minerals). It recounts constructive Geneva talks and a Trump-Xi call, but notes the London round yielded only a 'positive framework,' concluding this is a long, drawn-out negotiated divorce underpinned by mutual leverage (US in advanced semis/aircraft parts and its consumer market; China in rare-earth refining). It highlights the negative correlation between Trump's approval and MP Materials' stock as a proxy for trade tensions, and stays bullish on a stable outcome and on China (a 'vibes-boom, real-cession' economy where the stock market bottoms before fundamentals; Xi is under domestic pressure to get to 'yes'). On Israel-Iran, Citrini avoids military analysis and again uses constraints: Trump campaigned on not starting wars, and escalation would raise oil, yields and inflation while delaying cuts, so he is reluctant and seeking an Iranian nuclear deal (and perhaps a Nobel).
On the Fed, Citrini argues inflation ex-tariffs is essentially a solved problem and the Fed should cut on 'good-news' logic, but tariff-driven inflation uncertainty (fear of being 'Arthur Burns') and Trump's hectoring of Powell have stalled it. It compares tariff inflation to Japan's 2014 sales-tax hike (a temporary spike; CPI +3.2% YoY, but 1.5% ex-tax) and expects services disinflation to more than offset goods inflation. The call: Powell opens the window to resuming cuts in July, with some dots moving lower without the median moving much. Positioning changes: hit the target on the SFRM5Z5M6 fly (entry -33bps to +2.5bps) and exit it; new long December 2025 Fed Funds futures (FFZ5) for more year-end cuts; turned more bullish US versus rest-of-world (taking profits on the EU-fiscal-primacy rotation that outperformed by ~16% YTD) and rotating into commodities (biofuels, grains, uranium) and US fiscal winners from the proposed BBB; new short EURUSD (highlighting August 1.13/1.15 Euro put spreads at ~5:1); new long palladium (initiated June 9, replacing an HGZ5 copper long, on auto-cycle/scrap thesis, SBSW as equity play); new long soybeans (X5, on biofuel/crush-spread reflation, ADM and BG in equities); pared the crude long by half at ~$75 (from $57.80, stop up to $68, added CVX and XOM, watching tanker TNK); and took profits on Long South Africa (EZA)/Short Turkey (TUR), which worked ~36% YTD.
Key metrics
- WTI crude rose from $57.80 (May entry) to ~$75; crude long pared by half, stop raised from $55 to $68
- SFRM5Z5M6 fly: entry -33bps to +2.5bps (target 0bps) hit and exited
- Job openings rate under 4.5% (Waller threshold for rising unemployment)
- Japan 2014 sales-tax analogy: CPI +3.2% YoY, 1.5% ex-tax
- EU/RoW fiscal basket outperformed US fiscal universe by ~16% YTD; EU defense (Rheinmetall) weighted up to 30%
- FFZ5 pricing year-end EFFR just under 4%
- EURUSD August 1.13/1.15 put spread ~5:1 payout below 1.15
- Long South Africa (EZA)/Short Turkey (TUR) worked ~36% YTD
- Palladium long initiated June 9; oil/soybean ratio above 5 (mean-reversion level)
Key insights
- Citrini says its prior macro calls mostly played out: recession risk receded, US-China de-escalated, disinflation continued, and its crude long rose from $57.80 to $75.
- The labor market is a 'nobody quitting, nobody hiring' regime: continuing claims at multi-year highs while initial claims move sideways, with the job openings rate under 4.5%, a level Waller flags as preceding rising unemployment.
- Trade policy should be read through Trump's constraints (10yr yield, tax bill, recession risk, and now rare earths), which push both sides toward off-ramps; US-China is a long strategic divorce, not a rapprochement.
- The Israel-Iran conflict is analyzed via constraints: escalation raises oil, yields and inflation and delays Fed cuts, all bad for Trump, so he is reluctant to enter and seeks an Iran nuclear deal.
- Citrini expects Powell to open the window to resuming rate cuts in July, comparing transitory tariff inflation to Japan's 2014 sales-tax hike (CPI +3.2% YoY, 1.5% ex-tax).
- The EU-fiscal-primacy/rest-of-world rotation outperformed the US fiscal universe by ~16% YTD, but Citrini took profits and rotated toward select US and commodity exposure.
- New commodity plays: long palladium (initiated June 9, replacing a copper long, auto-cycle/scrap thesis, SBSW equity) and long soybeans (X5, biofuel/reflation, ADM and BG equities).
- New rates/FX plays: long December 2025 Fed Funds futures (FFZ5, pricing ~4% year-end EFFR) and short EURUSD via August 1.13/1.15 put spreads at ~5:1 payout.
#098
Macro Memo
Jun 17, 2025
Macro Memo: Summer Blues
Ouster (OUST) is a pure-play way to own the robotics/physical-AI megatrend at a cyclical inflection: it is the largest Western LiDAR provider and the inventor of digital LiDAR (LiDAR on CMOS silicon), which rides Moore's law for cost and performance. Because Ouster diversified early across automotive, industrial, robotics and smart infrastructure rather than betting only on consumer autos, it has posted nine straight quarters of revenue growth while peers bleed. As autonomous machines proliferate (from robotaxis to forklifts to humanoids), LiDAR demand grows for decades; non-automotive LiDAR is a larger market than automotive. Ouster's diversification, strong balance sheet, ~40% gross margins and software attach (Blue City, Gemini) position it to reach profitability while capturing a $70B opportunity. This is an 'In Conversation' interview, so it presents management's view rather than an explicit price target.
airare-earthcommoditiesconsumershoppingenergywarindextrindexza
Positions & performance
+28.4%avg return88% win · 8 tracked · L +36.7% · S -29.8%
| Position | Mentions | Entry | Last | Return |
|---|
| LADM:NYSE consumershopping Archer-Daniels-Midland | IAPT | 54.1Jun 17 '25 | 85.92 | +58.8% |
| LTNK:NYSE energywar Teekay Tankers | — | 47.22Jun 17 '25 | 67.99 | +44.0% |
| LBG:NYSE consumershopping Bunge | IPT | 85.69Jun 17 '25 | 121.53 | +41.8% |
| LXOM:NYSE energywar ExxonMobil | IPT | 114.0Jun 17 '25 | 154.77 ● | +35.8% |
| LCVX:NYSE energywar Chevron | ISPT | 148.85Jun 17 '25 | 194.79 | +30.9% |
| LSBSW:NYSE commodities Sibanye Stillwater | A | 6.82Jun 17 '25 | 8.55 ● | +25.4% |
| LEZA:NYSE indexza iShares MSCI South Africa ETF | — | 51.56Jun 17 '25 | 61.94 ● | +20.1% |
| STUR:NASDAQ indextr iShares MSCI Turkey ETF | — | 30.21Jun 17 '25 | 39.2 | -29.8% |
Full summary 573 words
Published June 19, 2025, this is a Citrini 'In Conversation' interview with Ouster (OUST) CEO/co-founder Angus Pacala and SVP Chen Geng, framing the company as a pure-play on the robotics and automation megatrend included in Citrini's May Humanoid Robots primer. Citrini's setup is its standard one: hunt for megatrends but enter at cyclical inflections, when a rebound is underway but sentiment stays depressed. Ouster is the largest Western LiDAR provider and inventor of 'digital LiDAR' (integrating the LiDAR system onto a custom CMOS silicon chip, first commercialized in 2018), which lets its products improve exponentially like other semiconductor products while being cheaper, smaller, more power-efficient and more robust.
The interview lays out the business and thesis. LiDAR is described as 'the eyes of robots,' superior to cameras in reliability and precision, and Pacala argues advances in AI benefit LiDAR as much as cameras. Ouster founded in 2015 on two theses: put LiDAR on low-cost CMOS, and diversify across industries because 'everything that moves will be robotic.' It serves four verticals (automotive, industrial, robotics, smart infrastructure) with roughly even 2024 revenue split. Management set a long-term framework two years ago of 30-50% annual revenue growth, 35-40% gross margins and flat operating costs, and has hit those targets for nine consecutive quarters (grew over 30% in 2024, Q1 25 gross margin ~41%). Ouster went public via SPAC in 2021 and merged with Velodyne in 2023, achieving operational synergies, a cost structure roughly half of the two standalone companies, and one of the industry's strongest balance sheets: $171M cash at end of Q1, ~$37M burn, with sell-side analysts modeling break-even in late 2026/early 2027.
Detail spans product and competitive dynamics. Ouster shipped over 17,000 sensors on $111M revenue in 2024, has 1,000+ end customers and 100+ use cases, with named clients John Deere, Komatsu, Motional, May Mobility, Forterra and Serve Robotics. Robotaxis use ~5 Ouster LiDARs (May Mobility), mining machines up to seven, while smaller robots (Serve, humanoids) use one spinning LiDAR, potentially moving to four solid-state DF sensors. Differentiation versus Luminar, Innoviz and Aeva rests on three points: digital/CMOS technology (SPAD detectors that ride Moore's law), AI software (Gemini and Blue City), and a diversified, commercially validated business at ~$140M annualized run-rate versus peers Pacala says generate 'de minimis revenue with significantly negative gross margin.' Chinese rivals Hesai and Robosense have more revenue but depend on the Chinese auto market; Ouster benefits from geopolitical preference for a US/Western supplier (it works with DoD, divested its Chinese supply chain, manufactures in Thailand at a 10% tariff it calls immaterial). The interview details in-sensor 3D zone-monitoring safety firmware (free on REV7 sensors), the Blue City smart-traffic product (two LiDARs plus an NVIDIA GPU, trained on 4M+ annotated objects, deploying at 100+ Chattanooga intersections), and a deep NVIDIA partnership across Drive, Omniverse and Jetson.
Positioning is implicit given the interview format: Citrini owns Ouster in its Robotics basket as a sensing/perception play. Management sizes the total LiDAR opportunity at $70 billion, expects non-automotive LiDAR adoption to surpass automotive, guided Q2 25 revenue of $32-35M, and stresses margin tailwinds from software attach (Blue City/Gemini are margin-accretive) against the headwind of customers moving to production at lower ASPs/higher volumes. Pacala is candid that humanoids are 'in an iffy spot' like robotaxis circa 2015 and will take longer than hoped, so Ouster hedges its humanoid exposure while planting many bets, consistent with Citrini's view that industrial and warehouse automation come first.
Key metrics
- Total LiDAR opportunity sized at $70 billion
- Q2 2025 revenue guidance: $32-35 million (Street midpoint ~$30M)
- 2024 revenue: $111M; over 17,000 sensors shipped; ~$140M annualized run-rate
- Cash: $171M at 3/31; ~$37M burn in 2025
- Long-term framework: 30-50% annual revenue growth, 35-40% gross margins; Q1 25 gross margin ~41%
- Nine consecutive quarters of revenue growth and margin-target achievement
- 1,000+ end customers, 100+ use cases across four verticals
- Blue City trained on 4M+ annotated LiDAR objects; deploying at 100+ Chattanooga intersections
- Thailand manufacturing at 10% tariff, called immaterial; break-even modeled late 2026/early 2027
Key insights
- Ouster is the largest Western LiDAR provider and inventor of digital LiDAR (LiDAR on custom CMOS silicon since 2018), letting its products ride Moore's law for cost and performance unlike non-CMOS peers.
- Diversification is the durable edge: revenue is split roughly evenly across automotive, industrial, robotics and smart infrastructure, so Ouster grew while auto-only LiDAR peers struggled.
- The company has hit its long-term framework (30-50% revenue growth, 35-40% gross margin, flat opex) for nine consecutive quarters, with Q1 25 gross margin ~41% and 2024 growth over 30%.
- Balance sheet strength: $171M cash at end of Q1 against ~$37M annual burn, with break-even modeled by sell-side for late 2026/early 2027; the Velodyne merger cut the cost structure to roughly half of the two standalone companies.
- Management sizes the LiDAR opportunity at $70 billion and expects non-automotive LiDAR adoption to exceed automotive, calling itself 'still in the locker room' on adoption.
- Sensor content scales with platform: robotaxis use ~5 Ouster LiDARs, mining machines up to 7, and small robots/humanoids one spinning LiDAR (or four solid-state DF sensors).
- Geopolitics is a tailwind: Ouster works with DoD, divested its Chinese supply chain, manufactures in Thailand at an immaterial 10% tariff, giving it preference over Chinese rivals Hesai and Robosense with US/Western and defense customers.
- Software (Blue City smart-traffic, Gemini) is margin-accretive and a differentiator; Blue City runs two LiDARs plus an NVIDIA GPU trained on 4M+ annotated objects and is deploying at 100+ Chattanooga intersections.
#097
Thematic Update
May 28, 2025
Rough Seas Make Strong Sailors: Navigating the Healthcare Policy Tsunami
Healthcare, especially small-cap medtech, life sciences supply chain and small biotech, has been sold off on policy fear (RFK/MAHA, Vinay Prasad at FDA, a Most Favored Nation drug-pricing executive order) that is far more benign than the market prices. Citrini argues these headline negatives are overstated relative to expectations, and that the real Trump/administration agenda actually strengthens the biopharma industry (domestic reshoring, decoupling from China). This creates dislocations to exploit through domestically-focused, share-gaining smaller companies and catalyst-rich, idiosyncratic medtech names rebounding from their own cyclical busts. As policy clarity arrives in 2H 2025 and rates eventually mean-revert, sentiment turns and M&A accelerates, re-rating these names. The report adds a new derisked-science small-biotech basket to position for the turn.
healthGLPhealthhealthtesting
Positions & performance
+65.2%avg return62% win · 26 tracked · L +65.2%
| Position | Mentions | Entry | Last | Return |
|---|
| LARWR:NASDAQ health Arrowhead Pharmaceuticals | T | 15.56May 28 '25 | 85.6 | +450.1% |
| LBTSG:NASDAQ health BrightSpring Health | T | 23.2May 28 '25 | 72.91 | +214.3% |
| LNUVB:NYSE health Nuvation Bio | I | 2.2May 28 '25 | 6.66 ● | +202.7% |
| LPTGX:NASDAQ health Protagonist Therapeutics | IT | 45.75May 28 '25 | 135.56 ● | +196.3% |
| LCYTK:NASDAQ health Cytokinetics | P | 30.28May 28 '25 | 80.62 ● | +166.2% |
| LAPLS:NASDAQ health Apellis Pharmaceuticals | T | 16.8May 28 '25 | 41.03 | +144.2% |
| LCGEM:NASDAQ health Cullinan Therapeutics | — | 7.84May 28 '25 | 17.1 | +118.1% |
| LSLN:NASDAQ health Silence Therapeutics | — | 5.19May 28 '25 | 11.02 | +112.3% |
| LDYN:NASDAQ health Dyne Therapeutics | — | 11.76May 28 '25 | 24.44 | +107.8% |
| LARQT:NASDAQ health Arcutis Biotherapeutics | P | 13.58May 28 '25 | 27.84 ● | +105.0% |
| LLRMR:NASDAQ health Larimar Therapeutics | A | 1.99May 28 '25 | 4.0 | +101.0% |
| LACLX:NASDAQ health Arcellx | — | 61.15May 28 '25 | 115.07 | +88.2% |
| LTOI:NASDAQ health The Oncology Institute | A | 3.12May 28 '25 | 5.39 | +72.8% |
| LHALO:NASDAQ health Halozyme | P | 54.43May 28 '25 | 81.48 ● | +49.7% |
| LRGEN:NASDAQ health Repligen | IT | 121.18May 28 '25 | 131.96 | +8.9% |
| LAIRS:NASDAQ health AirSculpt | A | 4.35May 28 '25 | 4.61 | +6.0% |
| LACOG:NASDAQ health Alpha Cognition | A | 8.43May 28 '25 | 7.9 | -6.3% |
| LTKNO:NASDAQ health Alpha Teknova | — | 5.8May 28 '25 | 4.85 ● | -16.4% |
| LQTRX:NASDAQ health Quanterix | — | 5.28May 28 '25 | 4.32 | -18.2% |
| LXGN:NASDAQ health Exagen | — | 6.7May 28 '25 | 4.4 ● | -34.3% |
| LJANX:NASDAQ health Janux Therapeutics | — | 23.7May 28 '25 | 15.33 | -35.3% |
| LOPRX:NASDAQ health OptimizeRx | — | 12.19May 28 '25 | 6.38 ● | -47.7% |
| LSTIM:NASDAQ health Neuronetics | A | 3.85May 28 '25 | 1.81 ● | -53.0% |
| LSPRY:NASDAQ health ARS Pharmaceuticals | — | 14.85May 28 '25 | 5.94 | -60.0% |
| LOM:NASDAQ health Outset Medical | — | 19.5May 28 '25 | 4.04 | -79.3% |
| LNOTV:NASDAQ healthtesting Inotiv | — | 2.43May 28 '25 | 0.08 | -96.7% |
Full summary 542 words
Published May 28, 2025, 'Rough Seas Make Strong Sailors' revisits Citrini's Medtech & Healthcare basket (first published August 2024) amid a barrage of policy-driven 'tape bombs.' Citrini's thesis is that the market has been trading healthcare as if macro (rates, recession) and policy dominate micro, when in fact the sector, especially the smaller companies they favor, is fundamentally insulated. They recount actively managing the basket through dislocations: upsizing during the RFK-induced panic (Markets Gone RF-Krazy), covering shorts in January Musings, doubling down on longs in Insuring Against Insanity, and adding in Talk to Me, Goose, claiming significant outperformance versus healthcare benchmarks.
The original three-pillar thesis was: the market is overly pessimistic on healthcare (especially small cap); this created opportunity in innovative medtech at depressed valuations exiting idiosyncratic downcycles; and a similar setup exists in the life sciences supply chain, where a cyclical bust obscured secular growth. They argue the first two pillars have borne out, citing Neuronetics (STIM, TMS therapy) rebounding from a COVID-era slowdown and Airsculpt (AIRS) rolling out standalone skin-tightening for GLP-1 patients. The life sciences call was early but shows green shoots: Lonza cited 'robust commercial demand,' Repligen (RGEN) returned to double-digit growth for the first time in three years with its 50%+ opportunity funnel up 30% YoY, corroborated by Danaher and Sartorius. KKR paid a 60% premium for Biotage, and healthcare M&A hit a record share of announced deals.
The core of the report dismantles four 'misperceptions.' (1) Trump is anti-biopharma: Citrini argues actions (a domestic-manufacturing EO that drew ~$300B in announced US biopharma capex/R&D from companies that spent under $170B globally the prior five years) and quotes from Trump and Merck's CEO suggest a pro-industry, anti-China reshoring agenda. Trades: Alpha Teknova (TKNO, custom reagents, path to $250M revenue/$75M+ EBITDA versus RGEN at 10x revenue/70x EBITDA), preclinical CRO Inotiv (NOTV, 1x revenue versus peers 2-2.5x, implying $16-17/share versus $2.12), and OptimizeRX (OPRX, 2M+ providers, NRR up from 105% to 121%). (2) New health officials are anti-science: they argue it's reprioritization toward chronic disease, backing STIM (2.1x revenue versus peers 5-8x, North Carolina TMS coverage catalyst) and diagnostics Exagen (XGN, 2.3x revenue versus 4-7x). (3) Cutting costs will kill industry: they cite 10X Genomics and Bio-Techne stabilization, flag Quanterix (QTRX, negative $30M EV, $100M+ revenue) and site-of-care shift names Surgery Partners, Outset Medical (OM), BrightSpring (BTSG), plus Oncology Institute (TOI) for value-based cancer care and AI. (4) Biotech is dead: with four recent large-premium takeouts (BioMarin/Inozyme +266%, Sanofi/Vigil +247%, Novartis/Regulus +108%, Merck KGaA/SpringWorks), they introduce a new 17-name Biotech 2025 basket built on derisked assets (primary endpoint hit in past 18 months), large underserved markets, 2H 2025 catalysts, and acquirability, spanning oncology (Nuvation/NUVB, Arcellx/ACLX, Cullinan/CGEM, Janux/JANX), metabolic/cardiovascular (Arrowhead/ARWR, Cytokinetics/CYTK, Silence/SLN) and specialty/rare disease (Larimar/LRMR, Protagonist/PTGX, Dyne/DYN), plus later-stage/commercial names (Apellis/APLS, Alpha Cognition/ACOG, ARS/SPRY, Halozyme/HALO, Arcutis/ARQT).
Citrindex portfolio changes as of May 28: take profit on 50% of the IBIT long, exit the Insurance Long/Short basket, exit Brazil ETFs (EWZ, EWZS), initiate the 17-name Biotech 2025 basket at 5% weight, leave 1% cash for hedging, and allocate remaining cash to the Robotics basket. The basket is built with breadth across indications so one clinical flop won't sink it, with beta to bonds plus an idiosyncratic kicker from data and M&A.
Key metrics
- ~$300B announced US biopharma manufacturing/R&D over 5 years vs under $170B global capex prior 5 years
- TKNO at full utilization: $250M revenue, $75M+ EBITDA; RGEN comp at 10x revenue, 70x+ EBITDA
- NOTV: 1x revenue vs peers 2-2.5x; implied $16-17/share vs current $2.12
- STIM valuation: 2.1x revenue vs neuro-medtech peers 5-8x
- XGN valuation: 2.3x revenue vs peers 4-7x
- OPRX net revenue retention improved from 105% (2023) to 121% (2024); 2M+ providers; ~11% portfolio penetration; $2-3B opportunity
- QTRX: $100M+ revenue, negative $30M enterprise value; equity down >50% YTD
- Biotech takeout premiums: Inozyme +266%, Vigil +247%, Regulus +108% upfront, SpringWorks +26%
- Nasdaq biotech index fell over 6% on Prasad's appointment day; MFN EO promised 30-80% US drug price cuts
- New 17-name Biotech 2025 basket initiated at 5% Citrindex weight; 50% of IBIT long taken as profit
Key insights
- The report's central claim is that healthcare policy fears (RFK/MAHA, Vinay Prasad at FDA CBER, the MFN drug-pricing EO) are vastly overstated versus what's priced in; the biotech index fell over 6% on Prasad's appointment yet biopharma ETFs XBI and PPH rose the Monday after the pricing EO.
- Trump's real agenda looks pro-industry and anti-China: a domestic-manufacturing EO drew ~$300B in announced US biopharma capex/R&D versus under $170B spent globally the prior five years.
- Alpha Teknova (TKNO) is the key reshoring beneficiary: at full utilization it should generate $250M revenue and $75M+ EBITDA versus comparable Repligen (RGEN) trading at 10x revenue and over 70x EBITDA.
- Inotiv (NOTV) preclinical CRO trades at just 1x revenue versus peers at 2-2.5x; a re-rate to the low end implies $16-17/share versus the then-current $2.12.
- Neuronetics (STIM), a top basket contributor, trades at 2.1x revenue versus neuro-medtech peers at 5-8x, with a North Carolina primary-care TMS coverage vote as a near-term catalyst.
- Quanterix (QTRX) has $100M+ revenue but a negative $30M enterprise value; its equity is down over 50% YTD on displeasure over the Akoya (AKYA) deal, setting up a relief rally if the deal falls apart.
- Recent large-premium biotech takeouts validate the M&A thesis: BioMarin/Inozyme +266%, Sanofi/Vigil +247%, Novartis/Regulus +108% upfront, plus Merck KGaA/SpringWorks.
- The new Biotech 2025 basket screens for derisked science (primary endpoint hit within 18 months), underserved markets, 2H 2025 catalysts and acquirability, deliberately spread across oncology, metabolic/CV and rare disease to reduce binary-event correlation.
#096
Thematic Primer
May 16, 2025
Thematic Primer: Humanoid Robots (Optimus, Unitree and More)
Humanoid and other advanced robots are moving from science fiction to commercial deployment because AI (specifically Vision-Language-Action models) has finally given robots a usable 'brain' and the hardware cost curve has collapsed (Unitree's G1 at $16k versus $500k industrial units in 2023). Most of the companies exposed to the robotics supply chain are advanced-machinery, auto and defense names currently trading at cyclical-trough valuations because analysts extrapolate a brutal auto/analog-semi downcycle forever. Citrini argues you can buy a secular growth story at a cyclical price today, before the consumer robot 'ChatGPT moment' re-rates the group. The bridge to mass adoption does not require full autonomy or AGI: teleoperation (one overseas operator coaching 4-5 robots) plus improving AI can make robots economic now. The trade is a basket of picks-and-shovels suppliers of sensors, actuators, inverters and compute that have upside to robot proliferation as it climbs the industrial to service to domestic ladder.
airobotaisemiconsumertravel
Positions & performance
+55.1%avg return100% win · 5 tracked · L +55.1%
| Position | Mentions | Entry | Last | Return |
|---|
| LON:NASDAQ aisemi ONSemi | IT | 44.92May 16 '25 | 89.04 ● | +98.2% |
| LNVDA:NASDAQ aisemi Nvidia | ISPT | 135.4May 16 '25 | 206.84 | +52.8% |
| LRRX:NYSE airobot Regal Rexnord | — | 141.43May 16 '25 | 210.87 ● | +49.1% |
| LTXN:NASDAQ aisemi Texas Instruments | ISPT | 188.5May 16 '25 | 279.41 ● | +48.2% |
| LMCHP:NASDAQ aisemi Microchip Technology | IPT | 61.21May 16 '25 | 77.9 ● | +27.3% |
Full summary 529 words
This is Citrini Research's thematic primer on humanoid robots, published May 16, 2025, framed as 'a future secular story at a current cyclical price.' The motivation is timing: embodied AI has always been the end goal of AI (the purest form of using AI to do physical things and raise productivity), but for years it was only investable via the compute layer. Citrini argues the reason to act 'now' rather than wait is that the most-exposed suppliers are trading on a depressed auto and analog-semiconductor cycle, with estimates that don't price in even a return to growth, let alone a 'robot-shaped right tail.' They note Texas Instruments felt compelled to remind analysts that analog cycles do bottom.
The report answers 'why humanoid' and 'why now.' Humanoids matter because the world is already ergonomically built for two arms, ten fingers and human reach, so a humanoid slots into existing workflows (a BMW body cell, a warehouse) without retrofitting. Early deployment already rhymes with the 2010 Kiva-to-Amazon warehouse pivot: Amazon is deploying Agility's Digit, GXO and Apptronik have piloted pick-and-place humanoids for about a year, and Unitree ships humanoids at $16k/unit. Crucially, Citrini stresses robots don't need to be fully autonomous; teleoperation is the bridge. One tele-operator in India could coach four to five US robots, echoing 2000-era call-center offshoring 'only this time the headset controls a spine,' cutting per-task labor costs before autonomy matures. They foresee brownfield retail and light-industrial sites wanting robot workers under $25/hour, with consumer crossover once costs dip below a used Honda Civic or a robotics-as-a-service subscription runs ~$500/month, a 3-4 year rather than next-decade event.
The 'why now' rests on three legs. The macro/cyclical: robotics suppliers sit in automotive and defense, both beaten down (auto cycle poor, defense sold on DOGE fears), with commentary from RRX, MCHP, ON and IFX suggesting the downtrend has bottomed and inventory purges are over, so incremental demand drops straight to the P&L. The cost curve: Unitree's G1 at $16k is a 97% drop from $500k industrial mannequins of 2023, signaling robots are joining a Moore-style curve. AI innovation: VLA models (multimodal models that turn pixels and plain-language commands into joint torque targets) are advancing with only a slight lag to LLMs. Figure AI's Helix uses one weight file for every task on BMW pilot lines; NVIDIA dominates compute (Jetson Orin NX at 275 TOPS, next-gen Thor tripling that) and released GR00T N1, the first open humanoid-scale VLA, bundled with Isaac Sim synthetic-data pipelines, and trained a 1X robot to do dishes in a week. The moat, in Citrini's 'AI Phase 2' framing, shifts from hard-coded motion to proprietary motion data: whoever owns the fleet logs owns the flywheel.
Positioning follows as a basket of names with upside to robot proliferation as it climbs the industrial-to-service-to-domestic ladder, most of which currently trade as if the down-cycle lasts forever. The piece names Unitree (private), NEO, Agility, Figure, plus supply-chain and compute beneficiaries (NVIDIA, TXN, and the analog/industrial names cited as bottoming). The report is explicitly a scaling-in exercise ('doing the work now') so they are ready before the consumer robot ChatGPT moment; the full basket and universe are behind a paywall/PDF.
Key metrics
- Unitree G1 humanoid sticker price: $16,000 per unit
- Robot cost curve: 97% decline from ~$500k industrial units (2023) to $16k
- Consumer robot labor threshold cited: under $25/hour; RaaS subscription ~$500/month
- NVIDIA Jetson Orin NX: 275 TOPS; next-gen Thor triples this
- OpenVLA-OFT toolkits shave 25-50x off inference latency
- NVIDIA/1X pilot: trained a humanoid to do dishes in one week
- Estimated consumer-crossover timeline: 3-4 years, not next decade
Key insights
- Citrini's core edge is timing, not prediction: robotics suppliers sit in beaten-down auto and defense sectors, letting investors buy a secular growth story at cyclical-trough valuations before any robot re-rating.
- The bridge to mass robot adoption is teleoperation, not full autonomy: one overseas tele-operator can 'coach' 4-5 US robots, cutting per-task labor cost now, echoing 2000-era call-center offshoring.
- Cost curve collapse is the key catalyst: Unitree's G1 humanoid at $16k is a 97% drop from ~$500k industrial units in 2023, signaling robots are joining a Moore-style cost curve.
- Humanoid form factor wins because the world is already tooled for two arms and human reach, so robots slot into existing warehouses and body cells without retrofitting.
- VLA (Vision-Language-Action) models gave robots a usable brain; Figure AI's Helix runs every task from one weight file on BMW pilot lines, and NVIDIA's GR00T N1 is the first open humanoid-scale VLA.
- NVIDIA dominates robotics compute the way it does AI: Jetson Orin NX runs 275 TOPS palm-sized, and Isaac Sim generates billions of synthetic training frames.
- Early deployment is already underway (Amazon's Digit humanoids, GXO/Apptronik pilots), mirroring the 2010 Kiva-to-Amazon warehouse automation pivot.
- The durable moat has moved from hard-coded motion trees to proprietary motion data: whoever owns the robot fleet logs owns the data flywheel.
#095
Macro Memo
May 06, 2025
Who Holds the Cards?
Recession risk from the trade war is real but overstated, because every major actor — Trump, Xi, and the Fed — faces binding constraints pushing them toward an off-ramp. Trump is constrained by $6-9 trillion of debt refinancing and the bond market's 'moron risk premium', the need to pass his tax bill through a Congress that requires visible trade-deal progress, and his stated horror of being Herbert Hoover; China's export engine is under unemployment pressure; and the Fed, with core inflation at 2.8%/2.65% and falling, has room to cut once it finds a politically graceful exit. Meanwhile hard data (labor market cooling but not breaking, resilient card spending, ~2 months of front-run inventory) buys time until early June before real damage sets in. The stance is constructively contrarian: stay net long equities with cheap index-put hedges, expect the Fed to cut sooner than the 27% June probability implies, trade the import-data dislocations (long tankers/ro-ro, short parcel networks), and watch Taiwan's 19-sigma FX move as the key systemic risk to Treasuries.
consumerautoconsumertravelenergywar
Positions & performance
+7.1%avg return43% win · 7 tracked · L +92.8% · S -57.2%
| Position | Mentions | Entry | Last | Return |
|---|
| LINSW:NYSE energywar International Seaways | AT | 36.54May 06 '25 | 90.69 ● | +148.2% |
| LSTNG:NYSE energywar Scorpio Tankers | — | 40.68May 06 '25 | 78.4 ● | +92.7% |
| LF:NYSE consumerauto Ford | IAPT | 10.44May 06 '25 | 14.37 | +37.6% |
| SUPS:NYSE consumertravel United Parcel Service | IPT | 93.81May 06 '25 | 114.79 | -22.4% |
| SFDX:NYSE consumertravel FedEx | ISPT | 213.41May 06 '25 | 314.96 | -47.6% |
| SEXPD:NYSE consumertravel Expeditors | IPT | 106.18May 06 '25 | 171.34 ● | -61.4% |
| SCHRW:NASDAQ consumertravel C.H. Robinson | IPT | 88.32May 06 '25 | 174.46 ● | -97.5% |
Full summary 598 words
Published May 6, 2025, this macro memo asks who actually holds the cards in Trade War II and answers with Marko Papic's constraints-over-preferences framework. Citrini leans against consensus: recession risks are presently overstated, though bonds (front end) and oil price far more recession than equities, and indices should chop sideways with violent overreactions and extreme dispersion. The labor market has unmistakably cooled — job openings falling (Indeed data leading), the 4.5% openings rate sitting at Chris Waller's warning threshold, claims and unemployment ticking up slightly — but the softening predates tariffs, and hire/quit rates have actually gone sideways or up. Sentiment is dire (consumer confidence at 2020 or even GFC lows), but Citrini prefers 'watch what they do': Visa shows spending growth flat-to-up after Liberation Day, Fiserv SpendTrend moderated from 3.67% to 2.76% y/y, and Bloomberg Second Measure data on lower-middle-income Midwest households agrees on resiliency, with cutbacks concentrated in discretionary services and big-ticket durables.
March import data reveals who front-ran tariffs: pharmaceutical products jumped 71% month-over-month (+$13 billion, the largest dollar move), organic chemicals and lead articles rose triple digits, luxury/seasonal goods (cut flowers, pearls, furs) fell 25-40% with no front-running, and everyday textiles/footwear barely moved because retailers remain inventory-heavy. The implication: roughly a two-month inventory buffer, meaning genuinely negative economic impact starts appearing by early June — a timeline both the administration and big-box CEOs understand. Trade ideas fall directly out of the data: long long-haul, tariff-agnostic shipping (HAUTO, HAFNI, STNG, INSW — tankers and car carriers price off voyage distance and scarcity) against short time-definite parcel networks hit by the China/HK de-minimis repeal (UPS, FDX, EXPD, CHRW; DHL excluded as better prepared). A Ford earnings-call read-through ($1.5 billion net EBIT tariff impact but guidance otherwise pulled, strong van demand, telematics at 40% of pro unit revenue, new SUVs pricing 18-23% higher with nine days on lots) shows a company under uncertainty but not in COVID-style panic.
Trump's three constraints: (1) the 'moron risk premium' — 10-year yields surged and the dollar plunged after Liberation Day, breaking the flight-to-safety correlation, revealing that the Trump put lives in credit and rates, with $6-9 trillion of federal debt maturing April-June just as price-insensitive East Asian buyers pull back; (2) the tax bill — Bessent's 'three-legged stool' (tariffs, tax cuts, deregulation) and his promised second-half re-acceleration require congressional Republicans, who now have leverage to demand visible trade-deal progress; (3) recession — Trump is quoted saying he doesn't want to be Herbert Hoover. China faces its own export-sector unemployment pressure and wants an off-ramp too. On the Fed: core CPI at 2.8% and core PCE at 2.65% with services disinflation continuing make inflation 'practically a solved problem'; Powell's stagflation talk is read as the only politically safe justification for inaction, and Citrini thinks a June cut is likelier than the 27% market-implied odds.
Positioning: exit the natural gas long for long crude and copper; exit the SFRM6 long above target at 96.825 and the SOFR/EURIBOR spread; new STIR play selling Z5 on the M5Z5M6 fly at -0.33; longer-term bearish USD but waiting to re-short on rallies; net long equities ('bad news, good action') hedged with 2% of NAV in SPX June 5200 and August 4800 puts, with the flip-short signal being the market treating bad news as bad news and the 200-day (~5750) the paranoia line. A bonus section flags Taiwan: USDTWD's 19-standard-deviation, 10%-in-two-sessions move (sharpest since 1992) threatens Taiwanese life insurers' $1.7 trillion, ~70%-USD offshore book — an SVB-like unhedged-assumption blowup whose forced Treasury selling or proxy-hedge unwinds (short KRW/INR) could spill into US rates; watch TWD cross-currency basis.
Key metrics
- Job openings rate at 4.5% — Waller's warning threshold for accelerating unemployment
- Fiserv SpendTrend consumer spending growth: 3.67% y/y (March) → 2.76% (April)
- March imports: pharmaceuticals +71% MoM (+$13bn); luxury/seasonal goods -25-40%
- ~2-month US inventory buffer; truly negative impact expected from early June
- Ford: $1.5B net tariff EBIT impact; telematics = 40% of pro-segment unit revenue; new SUVs priced 18-23% higher with 9 days on dealer lots
- Core CPI 2.8%, core PCE 2.65%; market-implied June cut odds 27% (Citrini sees higher)
- $6-9 trillion of US federal debt maturing April-June 2025
- Hedges: 2% of NAV in SPX June 5200 and August 4800 puts; SPX 200dma ~5750; new STIR play sells Z5 on M5Z5M6 fly at -0.33 (SFRM6 exited at 96.825)
- Taiwan: USDTWD 19-standard-deviation move, -10% in two sessions (sharpest since 1992); life insurers' $1.7T offshore book ~70% USD; ~$300B in USTs; FX reserves >$560B; current account surplus ~8% of GDP
- USTR deadline July 9 for 'reciprocity' MOUs; 75+ simultaneous negotiations called a logistical fantasy
Key insights
- Papic's constraints framework says watch what Trump CAN'T do: $6-9 trillion of federal debt matures April-June amid a buyers' strike from East Asian institutions, the 'moron risk premium' (10Y yields up, dollar down post-Liberation Day) revealed the Trump put lives in rates and credit, the tax bill needs congressional goodwill, and Trump explicitly fears being Herbert Hoover — all pushing toward trade-war off-ramps.
- Hard data beats vibes: consumer confidence sits at 2020/GFC-era lows, but Visa card spending picked up after Liberation Day, Fiserv SpendTrend only moderated (3.67% → 2.76% y/y March to April), and labor softening (openings at Waller's 4.5% threshold) predates tariffs while hire/quit rates went sideways.
- March import data maps the front-running: pharmaceuticals +71% MoM (+$13bn, the biggest dollar jump), organic chemicals and lead articles up triple digits, while luxury/seasonal goods fell 25-40% and textiles/footwear barely moved — implying a ~2-month inventory buffer, so real economic damage shows up from early June if no de-escalation.
- Direct trade from the data: long tariff-agnostic long-haul shipping (HAUTO, HAFNI, STNG, INSW) versus short parcel networks losing the China/HK de-minimis shield (UPS, FDX, EXPD, CHRW), with DHL excluded as better positioned.
- The Fed is 'frozen but won't stay that way': core CPI 2.8% and core PCE 2.65% with services disinflation make inflation practically solved; stagflation rhetoric is the politically safe cover for inaction, and Citrini puts June cut odds above the market's 27%.
- Equity stance: net long with 'bad news, good action' as the tell, hedged with 2% of NAV in SPX June 5200 and August 4800 puts; the signal to flip meaningfully short is the market treating bad news as bad news, with paranoia maintained below the ~5750 200-day moving average.
- Macro book changes: exited natural gas long for long crude oil and copper; took profits on SFRM6 at 96.825 (above the 96.60 target); new play sells Z5 on the M5Z5M6 SOFR fly at -0.33, betting cut pricing shifts from H2 2025 toward H1 2026.
- Systemic risk watch — Taiwan: USDTWD's 19-standard-deviation move (10% in two sessions, sharpest since 1992) threatens life insurers' $1.7 trillion offshore book (~70% USD, including ~$300B of Treasuries) that is the least hedged in seven years; an SVB-style unwind or blowout in KRW/INR proxy hedges could transmit into US bond markets — watch TWD cross-currency basis.
#094
Thematic Primer
Apr 23, 2025
Thematic Primer: Artificial Intelligence, Phase 2
AI investing is transitioning from Phase 1 (scaling infrastructure — a trade whose basket more than doubled and which Citrini exited/shorted around the DeepSeek moment) to Phase 2: implementation, where cheap inference and commoditizing models mean the winners are not those building agents but those with the preconditions to make agents useful. The framework is the 4 D's — Data (proprietary, domain-specific datasets generic models can't match), Design (embedding agents into existing workflows), Distribution (owning the channel where the model meets the user), and Deployment (hybrid cloud/on-prem economics as inference volumes spike). Value therefore migrates from GPU suppliers to data-rich incumbents and application-layer operators — healthcare data owners, data/analytics franchises, and 'AI sleeper' industrials — because agentic AI is the only kind that drives real ROI, and margins accrue to whoever owns the interface, not the cluster.
airobotaisemiconsumerautoconsumermediaconsumerreal-estatedefenseenergyaifinancefintechhealthsaas
Positions & performance
+42.4%avg return42% win · 24 tracked · L +42.4%
Full summary 569 words
This April 23, 2025 primer formally rewrites Citrini's AI thesis for 'Phase 2: From Infrastructure to Implementation.' It opens with a track-record recap: the original May 2023 initiation framed Phase 1 as a simple bet that AI datacenter capex estimates were too low, focusing on picks-and-shovels (Nvidia, SuperMicro, Dell, Broadcom, SK Hynix), bottleneck-wideners (Credo, Monolithic Power, Coherent, Ciena, Constellation Energy) and enablers (Meta, Amazon, Microsoft, Alphabet, Oracle); the Phase 1 basket more than doubled in 18 months. Citrini exited NVDA entirely on December 8, 2024 at $140, went short SMH and NVDA on January 24, 2025 into the DeepSeek episode, avoided a 20%+ Q1 drawdown, and has now covered the shorts — but isn't long again, preferring select infrastructure (AMD, CLS, VRT, CSCO).
The Phase 2 thesis: all shortages lead to gluts, and the AI revolution now unfolds amid cheap inference and commoditizing models — 'if Phase 1 was about who could get a GPU, Phase 2 is about who knows what to do with one.' Open-source models approaching frontier capability erode model-layer moats (Palo Alto CEO Nikesh Arora is quoted: for efficiency tasks 'I don't want to pay a dollar for that. I'd rather pay five cents'). The winning layer is the one closest to the user — the Apple analogy of charging $100 for $20 of NAND by owning the interface. The defining Phase 2 capability is agency: autonomous systems that decide and act, which Citrini argues is 'the only kind of AI that can drive significant ROI.'
The 4-D framework organizes stock selection. Data is deemed most important: proprietary domain datasets (TOI's oncology outcomes database is the exemplar) create defensible verticals; named data-moat beneficiaries include ELV, UNH, COR and TOI in healthcare, plus FICO, EFX, SPGI, MSCI, CSGP and SRAD; hard-to-replicate UX flywheels favor DUOL, CVNA, FIS, NFLX, MELI; and 'AI sleepers' with unpriced data moats include RELX, RRX, PH and LDOS. Design means agents embedded inside existing workflows, with a five-question 'design-ready' test (interaction data capture, three-clicks surfacing, kill-switch dashboards, API/low-code exposure, scoped memory) — incumbents slapping agents into industry-standard platforms beat disruptors in slow/regulated industries. Distribution is the compounding edge as technical differentiation compresses (Microsoft force-feeding Copilot shows reach alone isn't enough). Deployment covers unit economics: inference costs falling 30-40% annually, on-prem GPUs at roughly one-third the cost of cloud over three years driving a 'train in the cloud, run in the rack' hybrid norm, fragmenting pricing (seats giving way to outcome-based fees), and gross margins clustering at 60-75% for infrastructure, 70-85% for foundation models (drifting lower), and 65-90% for applications — with observability (DDOG cited) becoming mandatory as agentic workloads scatter costs.
On recent developments: Manus and Devin — both built on Claude — suggest foundation layers are evolving into something like an operating system, reinforced by Anthropic's Model Context Protocol; MCP has real developer uptake (Block and Apollo integrations; Zed, Replit, Codeium, Sourcegraph) but won't matter in boardrooms until agents demonstrably save money. A roadmap sketches the progression: augmentation (Nov 2022-end 2024), independent reasoning and autonomous tasks (Q4 2024-present, with DeepSeek R1's RL-taught reasoning the breakthrough), workflow management (perhaps end-2026), with people and processes — not technology — the adoption bottleneck, and a possible 'mini-trough of disillusionment' ahead. The conclusion: NVDA is probably not the whipsaw rebound trade; the alpha now lies with 'actual companies, with actual AI use cases, seeing actual margin improvement,' collected in the new Phase 2 AI basket.
Key metrics
- Phase 1 AI basket more than doubled over ~18 months from May 2023 initiation
- Exited NVDA at $140 on December 8, 2024; short SMH/NVDA initiated January 24, 2025; avoided a 20%+ Q1 drawdown
- Inference costs declining 30-40% annually
- On-prem GPUs amortized over three years cost ~one-third of equivalent cloud capacity
- Gross margins: infrastructure 60-75%, foundation models 70-85% (drifting lower), applications 65-90%
- Framework: 4 D's — Data, Design, Distribution, Deployment; 5-point 'design-ready' test
- Agentic AI roadmap: augmentation Nov 2022-2024; autonomous tasks Q4 2024-present; workflow management ~end-2026
- MCP adopters cited: Block (XYZ), Apollo (APO), plus dev tools Zed, Replit, Codeium, Sourcegraph
Key insights
- Track record anchors the pivot: the Phase 1 AI basket more than doubled in 18 months; Citrini exited NVDA at $140 on December 8, 2024, shorted SMH/NVDA on January 24, 2025 around DeepSeek, and thereby avoided a 20%+ Q1 2025 drawdown — the shorts are now covered but they are not re-longing NVDA.
- Core Phase 2 thesis: winners won't be those building agents but those with the preconditions to make agents useful — summarized as Data + Design → Distribution + Deployment (the 4 D's).
- Model-layer moats are eroding: open-source models like DeepSeek approach frontier capability, and PANW CEO Nikesh Arora captures buyer economics — for efficiency tasks he'd 'rather pay five cents' than a dollar — so margins accrue to whoever owns the user interface (the Apple/NAND analogy).
- Proprietary domain data is the most durable moat: TOI's oncology outcomes database exemplifies data generic models can't access; named beneficiaries span healthcare (ELV, UNH, COR, TOI), data franchises (FICO, EFX, SPGI, MSCI, CSGP, SRAD), UX flywheels (DUOL, CVNA, FIS, NFLX, MELI) and unpriced 'AI sleepers' (RELX, RRX, PH, LDOS).
- Incumbents beat disruptors in Phase 2: it is much easier for an incumbent to bolt an off-the-shelf MCP agent onto an archaic but industry-standard platform than for a startup to take share in slow, regulated industries.
- Deployment economics favor hybrid: inference costs are falling 30-40% annually, and on-prem GPUs amortized over three years cost roughly one-third of equivalent cloud capacity — the norm becomes 'train in the cloud, run in the rack,' making orchestration and observability (e.g. DDOG) mission-critical.
- Agentic tooling is real but early: Manus and Devin are both built on Claude, suggesting foundation layers become OS-like; Anthropic's MCP has developer traction (Block, Apollo, Zed, Replit, Codeium, Sourcegraph) but enterprise adoption awaits undeniable ROI proof, with people and processes the true bottleneck.
- Roadmap and market call: independent-reasoning agents arrived Q4 2024 (DeepSeek R1 proving RL can teach reasoning), workflow-managing 'virtual employees' perhaps by end-2026, a mini-trough of disillusionment is possible — and NVDA is 'probably not' the best rebound vehicle; preferred infrastructure exposure is AMD, CLS, VRT, CSCO.
#093
Deep Dive
Apr 18, 2025
A Tale of Two Tariffs
A rare non-actionable history essay arguing that Trump's tariff regime is not a Smoot-Hawley rerun but something novel: the deliberate conversion of US hegemony into a fee-for-service business. Using Douglas Irwin's 'three R's' of tariff history — Revenue, Restriction, Reciprocity — Citrini shows all three have returned at once and adds a fourth, 'Rent': tariffs as a toll charged for access to the system the US built ('Globalization-as-a-Service'). The historical lesson (Fordney-McCumber 1922 vs Smoot-Hawley 1930) is that tariffs are recession accelerants whose damage depends on starting conditions and retaliation dynamics; today's difference is that the world has never tried de-integrating a genuinely globalized economy, the US is both debtor and restrictor, and the resulting unpredictability is itself a tax on capital formation. Practical takeaways: this won't be over in three months, 2-3 months of inventory masks the real impact, and the dollar has entered a secular bear market as reserve managers diversify.
Positions & performance
No single-stock positions tracked in this report.
Full summary 592 words
Published April 18, 2025 after the author spent one of the two post-Liberation-Day weeks in the US and one in China talking to tariff-affected businesses, this is Citrini's first history piece in over two years. The ground truth is stark: a top-100-by-volume Shanghai trading company reports receiving zero holiday-season orders that would normally be ramping now (ordering starts eight months ahead), and while Chinese factories believe they can cut prices enough to preserve their post-tariff cost advantage, 'that doesn't matter much when nobody is transacting.'
The essay's framework comes from Douglas Irwin's 'Clashing over Commerce': US tariff history moves through Revenue (tariffs were >90% of federal revenue in the 1800s, the 'original stealth tax' before the 1913 income tax), Restriction (post-WWI protection of domestic industry), and Reciprocity (post-1934 bargaining toward liberalization). Two case studies carry the argument. Fordney-McCumber (1922) raised tariffs into a booming economy: manufacturing output rose nearly 50% from 1922-29 and unemployment fell from 6.7% to 3.2%, but farm income collapsed from $22 billion (1919) to $13 billion (1922) as Europe retaliated — concentrated benefit, diffuse harm. Smoot-Hawley (1930) raised duties on over 20,000 goods to a 59.1% average dutiable rate into a collapsing economy, over the written protest of 1,028 economists and pleas from Thomas Lamont and Henry Ford; 25+ countries retaliated (Canada alone hit 16 products covering ~30% of US exports to it), US imports fell from $4.4B to $1.3B and exports from $5.4B to $1.6B by 1932, and world trade fell roughly two-thirds. The lesson: tariffs are recession accelerants — the same policy is survivable in a boom and catastrophic into fragility, with retaliation and signaling effects doing the worst damage. The essay then traces the repair: the 1934 RTAA (executive negotiating authority, bilateral cuts up to 50%, MFN), Bretton Woods 1944 (Keynes' bancor vs Harry Dexter White's dollar-gold plan; $35/oz), GATT 1947 (tariffs treated 'like nuclear weapons'; global average tariffs fell from 22% to under 4% by the WTO's 1994 creation), and Nixon's 1971 gold-window closure, which counterintuitively cemented dollar reserve dominance and locked the US into structural trade deficits (Triffin dilemma), with the 'exorbitant privilege' as compensation.
Applying the framework to 2025: all three R's have returned simultaneously — revenue (billions of new federal intake), restriction (a blanket 'wall at the port' populist aesthetic), and reciprocity (a scoreboard grudge match tallied in deficits) — but none capture the novelty. Citrini proposes a fourth R, Rent: the administration views reserve-currency status and system maintenance (shipping lanes, deep markets, the reserve asset) as an unpaid service and is billing the world for it — 'Globalization-as-a-Service.' The 125-145% China tariff makes sense only as a fee-framing opening bid; ideas like a coerced century-bond swap (floated around a 'Mar-a-Lago accord,' which the author still deems very unlikely and Stephen Miran has disavowed) illustrate how rent could be extracted, at the cost of undermining Treasury creditworthiness. Consequences already visible: declining foreign official Treasury holdings, expected diversification into gold, euros, francs and yen, and a secular dollar bear market.
The conclusion is a warning about unpredictability itself: the 90-day pause is tactical, not resolution; 2-3 months of US warehouse inventory will blunt then reveal the real impact; and unlike 1930, the world has never attempted to de-integrate genuinely globalized just-in-time supply chains. US market resilience rests on trade centrality, political stability, rule of law, the dollar, and luck — an equilibrium that regime-level 'plumbing' changes (1971 the precedent) historically convert into protracted volatility rather than buy-the-dip moments. Trade policy, and above all US-China talks, will drive cross-asset returns for the year.
Key metrics
- Tariffs provided >90% of US federal revenue in the 1800s; income tax introduced 1913
- 1922-29 under Fordney-McCumber: manufacturing output +~50%, unemployment 6.7% → 3.2%; farm income $22B (1919) → $13B (1922)
- Smoot-Hawley: tariff increases on 20,000+ goods; average dutiable rate 59.1%; 1,028 economists petitioned Hoover to veto
- Post-Smoot-Hawley: US imports $4.4B (1929) → $1.3B (1932); exports $5.4B → $1.6B; world trade fell ~two-thirds 1929-34; 25+ countries retaliated
- Canada's Sept 1930 retaliation hit 16 US products = ~30% of US exports to Canada
- RTAA (1934) allowed presidential tariff cuts up to 50%; Bretton Woods (1944): 730 delegates, 44 nations, gold at $35/oz
- GATT-to-WTO era: global average tariffs 22% → under 4% by 1994
- US-China tariffs escalated to 125-145% in the current spiral
- ~2-3 months of inventory in US warehouses buffers the initial trade shock
Key insights
- Ground-level China check: a top-100-by-trade-volume Shanghai company reports zero holiday-season orders (normally placed ~8 months ahead) — at >100% tariffs, factories can't discount their way through, and trade simply stops.
- Irwin's three R's frame tariff history — Revenue (>90% of federal revenue in the 1800s), Restriction (post-WWI industrial protection), Reciprocity (post-1934 liberalization) — and Trump has revived all three at once, plus a novel fourth: Rent, tariffs as a fee for access to the US-run global system.
- The 1922 vs 1930 comparison shows tariffs are recession accelerants, not causes: Fordney-McCumber into a boom coincided with manufacturing output +50% and unemployment falling 6.7%→3.2% (while farm income collapsed $22B→$13B); Smoot-Hawley into fragility drew retaliation from 25+ countries and helped shrink world trade by two-thirds.
- Smoot-Hawley's true catastrophe was retaliation and signaling, not the 59.1% average dutiable rate itself: Canada alone raised tariffs on 16 products covering ~30% of US exports to it, and the act was read globally as isolationist 'policy insanity' at a critical moment — a warning about backing counterparties into corners.
- The post-war repair arc (RTAA 1934 → Bretton Woods 1944 → GATT 1947) cut global average tariffs from 22% to under 4% by 1994; GATT worked by treating tariffs 'like nuclear weapons — dangerous if used, contagious if retaliated against'.
- The 'Rent' regime reframes the 125-145% China tariffs as an opening invoice, with the coerced century-bond swap idea (however unlikely, and disavowed by Miran) illustrating the logic: extract financial rent from reserve-currency status even at the cost of Treasury credibility.
- Practical market read: this isn't over in three months; 2-3 months of domestic inventory will mask then reveal the real trade shock; foreign official Treasury holdings are already declining; and the dollar has entered a secular bear market as reserves diversify into gold, euros, francs and yen.
- Regime changes to the system's 'plumbing' (1971 the precedent) are the one class of geopolitical event that historically produces protracted volatility rather than a buy-the-dip moment — and unpredictability itself becomes a capital-formation problem: no company can underwrite 30-year investments when rules change by tweet.
#092
Market Memo
Apr 13, 2025
Market Memo: Talk to Me, Goose
While the market obsesses over tariffs, a series of healthcare policy developments — the FDA shake-up, the animal-testing/organoid initiative, and CMS's surprisingly large Medicare Advantage rate increase — are being misread by a 'shoot first, ask questions later' market, creating asymmetric opportunities in small-cap life sciences and medtech. Citrini's thesis is that the new health administration is biased toward lowering barriers to innovation (even if not every policy works), NIH/FDA cuts have been far smaller than feared, and panic selling has left names like QTRX at negative enterprise value and NOTV/CRL priced as if animal testing ends tomorrow when the organoid transition is realistically 5-10+ years away. The MA rate increase is a direct tailwind for brokers (EHTH, SLQT), value-based care (TOI, PRVA), and above all Talkspace, whose Medicare expansion and payer-model economics make it the basket's most compelling risk/reward.
financefintechhealthGLPhealthhealthtestinginsurance
Positions & performance
-26.1%avg return37% win · 19 tracked · L -1.2% · S -119.5%
| Position | Mentions | Entry | Last | Return |
|---|
| LTOI:NASDAQ health The Oncology Institute | A | 1.95Apr 14 '25 | 5.39 | +176.4% |
| LCRL:NYSE healthtesting Charles River Laboratories | IT | 106.6Apr 14 '25 | 226.58 | +112.6% |
| LTALK:NASDAQ health Talkspace | I | 2.79Apr 14 '25 | 5.22 ● | +87.1% |
| SNVO:NYSE healthGLP Novo Nordisk | ISP | 66.06Apr 14 '25 | 48.77 | +26.2% |
| LRDNT:NASDAQ health RadNet | T | 53.36Apr 14 '25 | 61.57 | +15.4% |
| LPRVA:NASDAQ health Privia Health | IT | 24.05Apr 14 '25 | 25.5 | +6.0% |
| LPACB:NASDAQ health Pacific Biosciences | — | 1.32Apr 14 '25 | 1.36 | +3.0% |
| LVRTX:NASDAQ health Vertex Pharmaceuticals | IPT | 495.83Apr 14 '25 | 477.36 | -3.7% |
| LTKNO:NASDAQ health Alpha Teknova | — | 5.67Apr 14 '25 | 4.85 ● | -14.5% |
| SGILD:NASDAQ health Gilead | IPT | 106.5Apr 14 '25 | 129.31 | -21.4% |
| LQTRX:NASDAQ health Quanterix | — | 5.6Apr 14 '25 | 4.32 | -22.9% |
| LCVRX:NASDAQ health CVRx | A | 6.53Apr 14 '25 | 4.74 | -27.4% |
| SAMGN:NASDAQ healthGLP Amgen | IPT | 293.92Apr 14 '25 | 376.04 | -27.9% |
| LCERT:NASDAQ health Certara | T | 14.4Apr 14 '25 | 7.51 | -47.8% |
| LSTIM:NASDAQ health Neuronetics | A | 3.81Apr 14 '25 | 1.81 ● | -52.5% |
| LSLQT:NYSE insurance SelectQuote | — | 3.16Apr 14 '25 | 0.72 ● | -77.1% |
| LEHTH:NASDAQ insurance eHealth | A | 6.14Apr 14 '25 | 1.34 | -78.2% |
| LNOTV:NASDAQ healthtesting Inotiv | — | 1.55Apr 14 '25 | 0.08 | -94.8% |
| STXG:NASDAQ health 10x Genomics | I | 8.28Apr 14 '25 | 45.92 ● | -454.9% |
Full summary 591 words
Published April 13, 2025 after two weeks of historic tariff-driven volatility, this memo explains why Citrini increased exposure to its Healthcare Innovation basket — its largest allocation — despite (and because of) the turmoil. Valuation sets the scene: the Russell 2000 healthcare sub-index and NASDAQ biotech index both hit levels that marked bottoms repeatedly in recent years, and small caps are the only part of the market pricing in bad news, while healthcare demand is inelastic and relatively trade-insulated. The drawdown is attributed to technicals — five bad years for sector specialists, long exposure at January lows and short exposure at new highs — an 'explosive cocktail' if sentiment turns.
On life sciences policy, the memo works through the controversy: Peter Marks' forced FDA resignation is weighed against a Jefferies analyst noting drugs are still being approved on schedule and Commissioner Makary supports conditional rare-disease approvals; RFK adviser Calley Means is quoted arguing the FDA 'boxes out' small innovators with billion-dollar approval costs. Data from FDA/Oppenheimer shows biopharma R&D spend doubled over ten years while approvals stagnated. Cuts have been smaller than feared: NIH reductions landed at 1,200 (mostly administrative) versus 3,500-5,000 initially estimated, and funding has begun flowing again — PACB (newly added long) beat Q1 estimates despite funding pressure, with TXG shorted against it to neutralize academic-funding exposure. QTRX is the standout asymmetry: a NEGATIVE $50 million enterprise value despite an industry-leading ultra-sensitive diagnostics platform with recurring revenue and a path to profitability.
The FDA's initiative to reduce animal testing via AI models and organoids cratered NOTV and CRL, but Citrini holds NOTV and adds CRL, arguing the announcement is more flash than substance: the FDA already waived animal-testing requirements in 2022, the new program is merely a public workshop toward a toxicology pilot for monoclonal antibodies (~one-third of the pipeline), and industry contacts expect 5-10 years before protocols are clear enough to switch. Both companies' proprietary datasets and incumbent advantages could make them long-run AI beneficiaries (the Walmart-to-eCommerce analogy), while CRL's CDMO segment alone, at peer multiples, covers its entire market cap. TKNO gets another catalyst — it supplies the foundational reagents for producing organoids and just signed its first partnership with a stem-cell company — while CERT (biosimulation, expanded into discovery via the Chemaxon acquisition) and VRTX (proprietary cystic fibrosis data moat, added long against AMGN/NVO/GILD shorts) round out the AI-in-trials theme.
In medtech, STIM and CVRX have domestically-insulated supply chains (Southern California equipment; Minnesota manufacturing); CVRX's post-guidance selloff is seen as an overreaction given BAROSTIM's ~$3 billion opportunity, 80%+ gross margins, JNJ as largest shareholder, and an Inari-style acquisition multiple implying ~$20/share. The biggest industry development is Trump's CMS dramatically raising Medicare Advantage payments — well above expectations and counter to the 'slash and burn' narrative. Beneficiaries: MA brokers EHTH and SLQT (added at combined equal weight; SLQT's Senior segment is ~80% of EBITDA), RDNT (~25% Medicare revenue, estimates should revise up), and value-based care (TOI overweight — PRVA's trailing multiple on TOI revenue implies $5+/share — with PRVA added). The capstone is an 'In Conversation' interview with Talkspace CEO Jon Cohen: TALK is the largest in-network telehealth mental-health provider (nearly two-thirds of Americans covered, versus $175-$400/month out-of-pocket elsewhere), its payer business has more than doubled in two years, guidance calls for 20-25% annual revenue growth and 12-15% EBITDA margins by 2026 — before a transformational Medicare deal adding tens of millions of covered lives — and it trades under 9x 2026 guided EBITDA with a quarter of its market cap in cash and no debt.
Key metrics
- NIH staff cuts: 1,200 actual vs 3,500-5,000 initially estimated
- Biopharma R&D spending doubled over ten years while FDA approvals stagnated (FDA/Oppenheimer data)
- QTRX enterprise value: negative $50 million
- FDA organoid pilot targets toxicology for monoclonal antibodies, ~one-third of the drug development pipeline; industry expects 5-10 years before protocols are adopted
- CVRX: ~$3B annual BAROSTIM opportunity, 80%+ gross margins, Inari takeout multiple implies ~$20/share
- SLQT Senior segment = ~80% of company EBITDA; RDNT derives ~25% of revenue from Medicare
- TOI at PRVA's trailing revenue multiple implies a share price over $5
- TALK: ~2/3 of Americans covered in-network; out-of-pocket alternatives cost $175-$400/month; payer business doubled in two years
- TALK guidance: 20-25% annual revenue growth and 12-15% EBITDA margins by 2026; valued at <9x midpoint of 2026 EBITDA guidance
- Mental health issue incidence at least 20% higher among seniors than the general population
Key insights
- Small-cap healthcare valuations (Russell 2000 healthcare and NASDAQ biotech indices) hit levels that repeatedly marked bottoms in recent years, while sector short exposure hit new highs against long exposure at January lows — a potentially explosive positioning setup.
- The administration's health-agency cuts landed far smaller than feared: NIH reductions of 1,200 (mostly administrative) versus initial estimates of 3,500-5,000, with funding resuming — evidenced by newly-added PACB beating Q1 estimates despite the headwind.
- QTRX traded at a NEGATIVE $50 million enterprise value despite an industry-leading ultra-sensitive biomarker diagnostics platform with recurring revenue and a path to profitability — called 'exceptionally asymmetric'.
- The FDA animal-testing/organoid announcement is more flash than substance: it merely proposes a workshop toward a toxicology pilot for monoclonal antibodies (~one-third of the pipeline), industry expects a 5-10 year transition, and the FDA already waived animal-testing requirements in 2022 — so the market assigning near-zero value to NOTV's and CRL's testing businesses is an overreaction; CRL's CDMO segment alone at peer multiples covers its whole market cap.
- TKNO gains yet another catalyst: it provides the foundational production and transport services for organoids and just announced its first partnership with a stem-cell company positioned to lead organoid proliferation.
- CVRX's selloff is an opportunity: BAROSTIM addresses a ~$3 billion annual heart-failure opportunity essentially alone, carries 80%+ gross margins, counts JNJ (an active cardiovascular acquirer) as largest shareholder, and applying Inari's takeout multiple implies ~$20/share.
- Trump's CMS raised Medicare Advantage payments by the most in recent years — well above industry expectations — a tailwind for MA brokers EHTH and SLQT (Senior segment ~80% of SLQT EBITDA), RDNT (~25% Medicare revenue), and value-based care names TOI (overweight; PRVA's multiple implies $5+/share) and newly-added PRVA.
- TALK is the memo's highest-conviction idea: largest in-network telehealth mental-health provider with ~2/3 of Americans covered, payer revenue doubled in two years, guidance of 20-25% revenue growth and 12-15% EBITDA margins by 2026 set before a Medicare deal adding tens of millions of covered lives, trading under 9x guided 2026 EBITDA with 25% of market cap in cash and zero debt.
#091
Market Memo
Apr 03, 2025
Market Memo: Seeing the Stag
Trump's Liberation Day tariffs — a universal 10% levy plus 'reciprocal' rates set by trade-deficit math rather than actual foreign tariffs — function like the 1970s oil shocks: a supply-side cost shock that raises prices while destroying productivity and growth, and one the Fed cannot fix with rates. Because the tariffs are formula-driven and deficit-targeting, they are stickier than a bargaining chip, and their costs cascade non-linearly through global supply chains (the 2018 washing-machine episode saw 12% price hikes from metals that were only ~5% of costs). Citrini's base case remains that tariffs are ultimately deflationary/recessionary and the 'Reciprocity Paradox' may cause the policy to collapse under its own contradictions, but stagflation is a distinct enough risk to build a dedicated basket: long domestic-revenue, pricing-power, inelastic-demand names; short globally-supply-chained, thin-margin, discretionary hardware and logistics names.
aineocloudaiopticalconsumermediaconsumershoppingconsumertravelcybersecurityhealthmag5quantumsaas
Positions & performance
-85.8%avg return9% win · 23 tracked · S -85.8%
| Position | Mentions | Entry | Last | Return |
|---|
| SPODD:NASDAQ health Insulet | IAPT | 256.8Apr 03 '25 | 163.26 | +36.4% |
| SZS:NASDAQ cybersecurity Zscaler | T | 192.21Apr 03 '25 | 142.32 | +26.0% |
| SIOT:NYSE saas Samsara | IT | 34.11Apr 03 '25 | 35.34 ● | -3.6% |
| SHPQ:NYSE consumershopping HP | IPT | 23.78Apr 03 '25 | 25.75 | -8.3% |
| SPTON:NASDAQ consumershopping Peloton | IP | 5.4Apr 03 '25 | 6.08 | -12.6% |
| SDXCM:NASDAQ health DexCom | IPT | 61.8Apr 03 '25 | 71.54 | -15.8% |
| SMASI:NASDAQ health Masimo | A | 152.37Apr 03 '25 | 179.95 | -18.1% |
| SGRMN:NYSE consumershopping Garmin | T | 185.34Apr 03 '25 | 242.47 ● | -30.8% |
| SSAIA:NASDAQ consumertravel Saia | — | 319.97Apr 03 '25 | 423.68 | -32.4% |
| SIONQ:NYSE quantum IonQ | S | 23.25Apr 03 '25 | 35.92 ● | -54.5% |
| SWERN:NASDAQ consumertravel Werner Enterprises | T | 27.34Apr 03 '25 | 42.42 | -55.2% |
| SAAPL:NASDAQ mag5 Apple | ISPT | 203.19Apr 03 '25 | 333.02 | -63.9% |
| SSONO:NASDAQ consumershopping Sonos | IA | 8.9Apr 03 '25 | 14.69 | -65.1% |
| SKNX:NYSE consumertravel Knight-Swift | I | 39.57Apr 03 '25 | 72.5 | -83.2% |
| SRGTI:NASDAQ quantum Rigetti | S | 8.15Apr 03 '25 | 15.64 ● | -91.9% |
| SPANW:NASDAQ cybersecurity Palo Alto Networks | IAPT | 165.17Apr 03 '25 | 323.79 | -96.0% |
| SNTAP:NASDAQ aineocloud NetApp | PT | 81.61Apr 03 '25 | 169.8 ● | -108.1% |
| SQBTS:NYSE quantum D-Wave Quantum | S | 7.16Apr 03 '25 | 16.21 | -126.4% |
| SARCB:NASDAQ consumertravel ArcBest | — | 64.25Apr 03 '25 | 148.87 ● | -131.7% |
| SROKU:NASDAQ consumermedia Roku | IT | 60.26Apr 03 '25 | 141.97 | -135.6% |
| SJBL:NYSE aioptical Jabil | IST | 123.49Apr 03 '25 | 312.59 | -153.1% |
| SFLEX:NASDAQ aineocloud Flex | T | 29.32Apr 03 '25 | 116.07 ● | -295.9% |
| SDELL:NYSE aineocloud Dell | ISAPT | 77.23Apr 03 '25 | 426.91 ● | -452.8% |
Full summary 574 words
Written April 3, 2025, immediately after Liberation Day, this memo quantifies stagflation risk from the most comprehensive restructuring of US trade policy in centuries — levies beyond Smoot-Hawley: a universal 10% tariff effective April 5, reciprocal tariffs on largest-deficit partners effective April 9, carve-outs for copper, pharma, semis, lumber and energy, USMCA provisions, and escalation authority. Critically, the reciprocal rates are computed as trade deficit divided by imports — not actual foreign tariff levels — implying the policy targets deficit reduction and may persist far longer than markets hope. It builds on the earlier 'Tariff-ied' memo's warning not to expect Trump to retreat before significant impact.
A 1970s history section frames tariffs as the new oil shock: OPEC quadrupled oil from $3 to $12 in six months in 1973-74, then doubled it again to $39.50 in 1979; Burns treated inflation as transitory until wage-price spirals entrenched, and Volcker's cure required 20% rates and a near-depression. Tariffs recreate supply-shock economics through a different channel — but with broader reach, since modern supply chains mean costs compound at each production stage (a 10% steel tariff becomes 12% in parts, 15% in vehicles). The 2018 washing-machine case is the empirical anchor: 12% price increases despite tariffed metals being only ~5% of costs. Differences from the 1970s cut both ways: today's shock is an intentional policy choice hitting all sectors simultaneously, but labor has less wage-bargaining power.
The 'market's blind spots' section attacks three consensus assumptions. First, easy supply-chain adjustment: Citrini's analysis of capacity utilization shows the domestic capacity to replace even 25% of imports simply doesn't exist, a multi-year build during which consumers eat inflation without growth; losers include outsourced manufacturers FLEX and JBL and truckers (ARCB, WERN, SAIA, KNX) facing a demand air-pocket after inventory front-running. Second, tech's supposed insulation: hardware-dependent names (AAPL, GRMN, PTON, SONO, DELL, HPQ, ROKU) face cost inflation into weak demand; nominally 'software' companies like NTAP, PANW (13x revenue, 58x earnings, Asia-concentrated component supply) and ZS depend on hardware; IOT trades at 17x revenue with Taiwan-sourced hardware; medtech names PODD and DXCM just moved production to tariff-hit Malaysia; MASI's consumer wearables/audio mix is 'worst of all'; and speculative quantum names RGTI, QBTS, IONQ still carry $2B+ market caps. The WTO e-commerce tariff moratorium (since 1998) is also effectively dead, exposing US big tech to retaliation. Third, productivity destruction: every 10-point increase in domestic sourcing drops sector productivity ~3.7%, and pervasive uncertainty is itself a tax. Monetary policy is frozen: 1-year inflation swaps repriced to the highest since Q1 2022, with the year moving from ~2.5% expected inflation and 2-3 cuts to 3.5% and 4-5 cuts — Citrini expects continued dollar weakness and curve flattening.
The trade: a 2025 Stagflation Risk basket — ideal longs have domestic revenue dominance, proven pricing power, supply-chain resilience and inelastic demand; ideal shorts have global supply-chain dependency, thin margins, limited pricing power, discretionary exposure and high fixed costs. Intellectual honesty gets a full section: the 'Reciprocity Paradox' (defining unfairness by deficits while demanding reciprocity implies zero tariffs globally, contradicting the protectionist intent) suggests the regime may end in superficial wins and a vanilla slowdown rather than stagflation — which is why the portfolio keeps a significant long-bond position betting the Fed and investors look through inflation to the slowdown. Catalysts: initial implementation April 5-9 (rapid reductions would signal negotiation), first retaliation April-May (would force the bluff), and Q2 earnings in July-August as the first hard corporate evidence.
Key metrics
- Universal 10% tariff on all imports effective April 5, 2025; reciprocal tariffs effective April 9, 2025
- Reciprocal rate formula: Trade Deficit ÷ Total Imports × 100
- 1973-74 OPEC embargo: oil $3 → $12/bbl in six months; 1979 shock doubled prices to $39.50
- Volcker required ~20% interest rates to break 1970s inflation
- 2018 washing machine tariffs: prices +12% despite metals being ~5% of costs
- Every 10pp increase in domestic sourcing → ~3.7% average sector productivity decline
- 1-year inflation swaps at highest level since Q1 2022; expectations moved from ~2.5% inflation/2-3 cuts to 3.5%/4-5 cuts YTD
- PANW at 13x revenue and 58x earnings; IOT at 17x revenue; RGTI, QBTS, IONQ each still $2B+ market cap
- WTO e-commerce tariff moratorium in place since 1998, previously set to expire 2026, now effectively dead
Key insights
- The reciprocal tariff formula is trade deficit ÷ total imports × 100 — not a function of foreign tariff rates — meaning the policy targets deficit reduction itself and is likely stickier and more prolonged than a negotiating-chip interpretation implies.
- Tariffs are the new oil shock: like OPEC's $3→$12 quadrupling in 1973-74, they are supply-side inflation the Fed cannot cure — hiking crushes demand without fixing supply, while easing risks unanchoring expectations, leaving policy frozen.
- Tariff costs cascade non-linearly: in 2018, washing machine prices rose 12% even though tariffed steel and aluminum were only ~5% of costs; a 10% steel tariff compounds into ~15% vehicle cost increases through multi-stage supply chains.
- Domestic capacity to replace even 25% of imports doesn't exist per Citrini's capacity-utilization analysis — building it is a multi-year process during which the US gets inflation without growth; each 10pp of re-shored sourcing costs ~3.7% of sector productivity.
- Tech is not insulated: PANW (13x revenue, 58x earnings) discloses Asia-concentrated component supply; IOT trades at 17x revenue with Taiwan-sourced hardware; PODD and DXCM just moved production to tariff-hit Malaysia; MASI combines consumer wearables, high-end audio, and Malaysia sourcing.
- Markets have repriced inflation but not the Fed: 1-year inflation swaps hit the highest level since Q1 2022, and YTD expectations moved from ~2.5% inflation with 2-3 cuts to 3.5% with 4-5 cuts priced by December 2025 — Citrini expects continued dollar weakness and a flattening curve.
- The 'Reciprocity Paradox' is the best counterargument: defining unfair trade by bilateral deficits while demanding reciprocal tariff cuts logically ends at zero tariffs globally, contradicting protectionist intent — so the regime may collapse into superficial 'wins' and a vanilla slowdown before stagflation entrenches.
- Positioning hedges both outcomes: a stagflation equity basket (long domestic pricing-power/inelastic names, short global-supply-chain thin-margin names like FLEX, JBL and truckers ARCB/WERN/SAIA/KNX) sits alongside a significant long-bond position betting the Fed ultimately looks through tariff inflation to the slowdown.
#090
Market Memo
Mar 31, 2025
Market Memo: Insuring Against Insanity
Published the day before 'Liberation Day', this Q2 memo argues investors must play offense and defense simultaneously: offense by concentrating into unfairly-punished high-conviction healthcare and natural-gas infrastructure names after a record drawdown in high-volatility stocks, and defense via new long/short baskets that profit from consumer normalization and boring-beats-flashy insurance regardless of whether the high-income consumer cracks. The through-line is that recent sector carnage is technical (high-vol positioning) rather than fundamental, creating dislocations to buy, while post-COVID consumer distortions — housing frozen by rate lock-in and top-20% services spending 45% above pre-pandemic — will mean-revert toward essentials and lower-income categories either way.
airobotconsumerautoconsumerhealthconsumermediaconsumerreal-estateconsumershoppingconsumertraveldefenseenergygridenergynuclearenergywarfinancefintechhealthGLPhealthhealthtestinginsurancesaas
Positions & performance
+5.7%avg return48% win · 83 tracked · L +23.7% · S -18.9%
| Position | Mentions | Entry | Last | Return |
|---|
| LTOI:NASDAQ health The Oncology Institute | A | 1.14Mar 31 '25 | 5.39 | +372.8% |
| LAGX:NYSE energygrid Argan | T | 131.17Mar 31 '25 | 568.92 | +333.7% |
| LECG:NYSE energygrid Everus Construction | — | 37.09Mar 31 '25 | 127.56 ● | +243.9% |
| LFIVE:NASDAQ consumershopping Five Below | I | 74.92Mar 31 '25 | 207.14 ● | +176.5% |
| LWBD:NASDAQ consumermedia Warner Bros Discovery | IPT | 10.73Mar 31 '25 | 25.28 ● | +135.6% |
| LTALK:NASDAQ health Talkspace | I | 2.56Mar 31 '25 | 5.22 ● | +103.9% |
| LESOA:NASDAQ energygrid Energy Services of America | — | 9.45Mar 31 '25 | 18.94 | +100.4% |
| LROST:NASDAQ consumershopping Ross Stores | IT | 127.79Mar 31 '25 | 238.89 | +86.9% |
| SSG:NYSE consumershopping Sweetgreen | SA | 25.02Mar 31 '25 | 6.0 | +76.0% |
| LGM:NYSE airobot General Motors | ISPT | 47.03Mar 31 '25 | 82.64 | +75.7% |
| LDLTR:NASDAQ consumershopping Dollar Tree | IPT | 75.07Mar 31 '25 | 125.54 ● | +67.2% |
| SDOCS:NYSE health Doximity | IT | 58.03Mar 31 '25 | 20.99 ● | +63.8% |
| SLULU:NASDAQ consumershopping Lululemon | ISAPT | 283.06Mar 31 '25 | 114.28 | +59.6% |
| SROOT:NASDAQ insurance Root | A | 133.44Mar 31 '25 | 57.95 | +56.6% |
| LFLR:NYSE energygrid Fluor | IP | 35.82Mar 31 '25 | 51.7 ● | +44.3% |
| LF:NYSE consumerauto Ford | IAPT | 10.03Mar 31 '25 | 14.37 | +43.3% |
| SUPST:NASDAQ financefintech Upstart | IAT | 46.03Mar 31 '25 | 27.49 ● | +40.3% |
| SSMR:NYSE energynuclear NuScale Power | SA | 14.16Mar 31 '25 | 8.54 ● | +39.7% |
| LRNR:NYSE insurance RenaissanceRe | I | 240.0Mar 31 '25 | 329.1 | +37.1% |
| STRUP:NASDAQ insurance Trupanion | T | 37.27Mar 31 '25 | 24.87 ● | +33.3% |
| SOXM:NYSE consumershopping Oxford Industries | — | 58.67Mar 31 '25 | 40.29 ● | +31.3% |
| SSHAK:NYSE consumershopping Shake Shack | APT | 88.17Mar 31 '25 | 61.57 ● | +30.2% |
| LPVH:NYSE consumershopping PVH | IT | 64.64Mar 31 '25 | 83.93 ● | +29.8% |
| LULTA:NASDAQ consumershopping Ulta Beauty | IPT | 366.54Mar 31 '25 | 475.36 | +29.7% |
| LRDNT:NASDAQ health RadNet | T | 49.72Mar 31 '25 | 61.57 | +23.8% |
| LXGN:NASDAQ health Exagen | — | 3.59Mar 31 '25 | 4.4 ● | +22.6% |
| SCPRI:NYSE consumershopping Capri Holdings | A | 19.73Mar 31 '25 | 15.44 | +21.7% |
| LCB:NYSE insurance Chubb | PT | 301.99Mar 31 '25 | 358.91 ● | +18.8% |
| SONON:NYSE consumershopping On Holding | AP | 43.92Mar 31 '25 | 37.07 | +15.6% |
| SDECK:NYSE consumershopping Deckers | IT | 111.81Mar 31 '25 | 96.04 | +14.1% |
| STOST:NYSE financefintech Toast | IT | 33.17Mar 31 '25 | 29.04 | +12.5% |
| SSPOT:NYSE consumermedia Spotify | ISP | 550.03Mar 31 '25 | 482.66 | +12.2% |
| LRKT:NYSE financefintech Rocket Companies | IT | 12.07Mar 31 '25 | 13.49 ● | +11.8% |
| LEPD:NYSE energywar Enterprise Products Partners | P | 34.14Mar 31 '25 | 38.12 ● | +11.7% |
| LSKX:NASDAQ consumershopping Skechers | — | 56.78Mar 31 '25 | 63.13 | +11.2% |
| LSYY:NYSE consumershopping Sysco | IAT | 75.04Mar 31 '25 | 83.11 | +10.8% |
| LET:NYSE energywar Energy Transfer | IP | 18.59Mar 31 '25 | 20.36 | +9.5% |
| LQSR:NYSE consumershopping Restaurant Brands International | IA | 66.64Mar 31 '25 | 72.47 | +8.7% |
| LWRB:NYSE insurance W.R. Berkley | APT | 71.16Mar 31 '25 | 75.46 | +6.0% |
| LACGL:NASDAQ insurance Arch Capital | APT | 96.18Mar 31 '25 | 97.54 | +1.4% |
| SLPLA:NASDAQ financefintech LPL Financial | IPT | 327.14Mar 31 '25 | 328.7 | -0.5% |
| SDASH:NASDAQ consumershopping DoorDash | ISPT | 182.77Mar 31 '25 | 184.37 ● | -0.9% |
| SBMY:NYSE health Bristol Myers Squibb | IPT | 60.99Mar 31 '25 | 62.56 ● | -2.6% |
| LFOX:NASDAQ consumermedia Fox Corp | AP | 52.71Mar 31 '25 | 50.81 ● | -3.6% |
| LCQP:NYSE energywar Cheniere Energy Partners | — | 66.04Mar 31 '25 | 62.94 ● | -4.7% |
| LTKNO:NASDAQ health Alpha Teknova | — | 5.19Mar 31 '25 | 4.85 ● | -6.6% |
| LPARA:NASDAQ consumermedia Paramount | — | 11.96Mar 31 '25 | 11.04 | -7.7% |
| LHD:NYSE consumershopping Home Depot | IPT | 366.49Mar 31 '25 | 336.09 ● | -8.3% |
| LLOW:NYSE consumershopping Lowe's | PT | 233.23Mar 31 '25 | 207.64 | -11.0% |
| SHIPO:NYSE insurance Hippo | — | 25.56Mar 31 '25 | 29.15 ● | -14.0% |
| SGIL:NYSE consumershopping Gildan Activewear | IP | 44.22Mar 31 '25 | 50.68 ● | -14.6% |
| SABNB:NASDAQ consumertravel Airbnb | IPT | 119.46Mar 31 '25 | 141.1 | -18.1% |
| LTREE:NASDAQ insurance LendingTree | — | 50.27Mar 31 '25 | 40.4 ● | -19.6% |
| LFOXF:NASDAQ consumerauto Fox Factory | — | 23.34Mar 31 '25 | 18.51 | -20.7% |
| SAMGN:NASDAQ healthGLP Amgen | IPT | 311.55Mar 31 '25 | 376.04 | -20.7% |
| SRJF:NYSE financefintech Raymond James | IT | 138.91Mar 31 '25 | 169.3 | -21.9% |
| SABBV:NYSE health AbbVie | IPT | 209.52Mar 31 '25 | 256.91 ● | -22.6% |
| LKBR:NYSE defense KBR Inc | IA | 49.81Mar 31 '25 | 36.93 | -25.9% |
| LEFX:NYSE financefintech Equifax | IAT | 243.56Mar 31 '25 | 177.31 ● | -27.2% |
| SJLL:NYSE consumerreal-estate Jones Lang LaSalle | PT | 247.91Mar 31 '25 | 325.45 | -31.3% |
| LQTRX:NASDAQ health Quanterix | — | 6.51Mar 31 '25 | 4.32 | -33.6% |
| SWRBY:NYSE consumershopping Warby Parker | I | 18.23Mar 31 '25 | 24.56 | -34.7% |
| SCOMP:NYSE consumerreal-estate Compass | I | 8.73Mar 31 '25 | 11.8 ● | -35.2% |
| SCEG:NASDAQ energygrid Constellation Energy | ISPT | 201.63Mar 31 '25 | 274.35 | -36.1% |
| SLYV:NYSE consumertravel Live Nation | IPT | 130.58Mar 31 '25 | 179.4 ● | -37.4% |
| SVST:NYSE energygrid Vistra | IST | 117.44Mar 31 '25 | 163.38 | -39.1% |
| LTSCO:NASDAQ consumershopping Tractor Supply | IPT | 55.1Mar 31 '25 | 31.8 ● | -42.3% |
| LOLLI:NASDAQ consumershopping Ollie's Bargain Outlet | IT | 116.36Mar 31 '25 | 66.31 | -43.0% |
| SNRG:NYSE energygrid NRG Energy | IT | 95.46Mar 31 '25 | 136.5 ● | -43.0% |
| LBLND:NYSE financefintech Blend Labs | A | 3.35Mar 31 '25 | 1.69 | -49.6% |
| LSTIM:NASDAQ health Neuronetics | A | 3.68Mar 31 '25 | 1.81 ● | -50.8% |
| LHCAT:NASDAQ health Health Catalyst | A | 4.53Mar 31 '25 | 2.15 ● | -52.5% |
| LZ:NASDAQ consumerreal-estate Zillow | ISAT | 68.56Mar 31 '25 | 32.0 ● | -53.3% |
| LUWMC:NYSE financefintech UWM Holdings | A | 5.46Mar 31 '25 | 1.84 ● | -66.3% |
| SUBS:NYSE financefintech UBS | P | 30.63Mar 31 '25 | 52.54 ● | -71.5% |
| LPAR:NYSE saas PAR Technology | APT | 61.34Mar 31 '25 | 15.44 | -74.8% |
| LHAIN:NASDAQ consumerhealth Hain Celestial | S | 4.15Mar 31 '25 | 0.53 | -87.2% |
| LNFLX:NASDAQ consumermedia Netflix | IPT | 932.53Mar 31 '25 | 70.09 | -92.5% |
| SOKLO:NYSE energynuclear Oklo | ISA | 21.63Mar 31 '25 | 41.81 ● | -93.3% |
| LNOTV:NASDAQ healthtesting Inotiv | — | 2.21Mar 31 '25 | 0.08 | -96.4% |
| SLMND:NYSE insurance Lemonade | A | 31.43Mar 31 '25 | 61.99 ● | -97.2% |
| SYOU:NYSE consumertravel Clear Secure | T | 25.91Mar 31 '25 | 53.23 ● | -105.4% |
| SHOUS:NASDAQ consumerreal-estate Anywhere Real Estate | — | 3.33Mar 31 '25 | 17.64 | -429.7% |
Full summary 555 words
This March 31, 2025 memo operationalizes the previous day's 'Haves vs. Have Nots' collaboration into tradeable baskets, published deliberately before Trump's tariff reveal. Citrini notes the drawdown in high-volatility stocks was the most significant in a decade — exceeding the COVID panic — with Russell 3000 healthcare and energy down toward 50% from highs, which they attribute to technical positioning (those sectors have the most high-vol small caps) rather than deteriorating fundamentals. The response: concentrate into best ideas, take losses on marginal positions, and add defensive long/short exposure that has positive expected value even in a recovery.
The new Consumer Normalization basket bets on essentials over optional spending. In housing, low-income households are rate-locked (only 12% relocated vs 22% of high-income), so falling rates should release pent-up transactions benefiting the financing supply chain: longs RKT, TREE, UWMC, EFX, Z, and BLND (whose non-mortgage banking products are projected at a 40% CAGR and which inflects to profitability this year), against shorts in high-end real estate and wealth management (COMP, HOUS, JLL, UPST, RJF, UBS, LPLA). In services — where top-20% spending is +45% vs pre-pandemic while bottom-20% is -6% — they short YOU, SPOT, LYV, and ABNB against accessible-entertainment longs WBD, FOX, PARA, NFLX. Retail longs are bombed-out low-income names (OLLI, ULTA, FIVE, DLTR, TSCO, ROST, FOXF, LOW, PVH, HD, SKX) against premium apparel shorts (LULU, CPRI, ONON, DECK, OXM, WOSG, BRBY, ATZ, GIL, WRBY); restaurants pair QSR/PAR/HAIN/SYY long against DASH/TOST/SG/SHAK short, plus long F/GM vs short BMW/Mercedes on auto tariffs. A revived 'Insurance Redux' basket goes long proven underwriters at discounted valuations (ACGL, CB, RNR, WRB) against unprofitable insurtechs at nosebleed multiples (LMND, ROOT, HIPO, TRUP).
In healthcare, the memo high-grades into highest conviction: mental-health names STIM (Google Trends interest exploding, new payer coverage of millions of lives, trading at a 25-80% discount to peers on trailing revenue) and TALK (nearly 200 million Americans can access therapy for ~$15 average out-of-pocket, 50% y/y core growth, a quarter of market cap in cash, no debt), funded by exiting MNMD and TDOC — with Dr. Oz's expected CMS confirmation seen as a policy tailwind for both. In life sciences, NIH cut fears are called overblown (1,200 confirmed job cuts, 6% of staff, versus 3,000-5,000 initially reported); TKNO (path to ~30% EBITDA margins, backed by ~$85 billion of announced domestic biopharma manufacturing investment), NOTV, and QTRX (negative-value operations implied by the market) are added to, funded by exiting seven other names. A new health-data-plus-AI subtheme adds TOI, RDNT, HCAT, and XGN (1x revenue, insider buying, path to profitability this year). Insurer and vaccine shorts (CNC, ELV, UNH, DVA, UHS, PCVX, MRNA) are covered; new shorts target tariff/tax-exposed legacy pharma (ABBV, AMGN, BMY) and DOCS.
The NatGas basket pivots from LNG exporters and tariff-exposed component makers (exiting PSIX) toward infrastructure builders: AGX's blowout quarter is cited as proof of a multi-year gas power plant buildout, and ESOA (single-digit P/E, insider buying) and spinoff ECG (halved since spin despite cost-plus contracts) go overweight, alongside FLR, KBR, EPD, CQP, and ET. Nuclear 'AI power' highfliers (SMR, OKLO, VST, CEG, NRG) are suggested as an optional short pairing — VST added $30B of market cap without a single data-center deal. Finally, the AI basket's SMH and NVDA shorts are covered and, for the first time since December 2024, the portfolio goes unhedged.
Key metrics
- Russell 3000 healthcare and energy declines approaching 50% from recent highs
- BLND: projected 40% CAGR in non-mortgage consumer banking products
- Top-20% service spending +45% vs pre-pandemic; bottom-20% -6%
- 22% of high-income vs 12% of low-income households relocated post-COVID
- STIM trades at a 25-80% discount to peers on trailing revenue
- TALK: ~200M Americans can access therapy at ~$15 average out-of-pocket; 50% y/y core revenue growth; ~25% of market cap in cash
- NIH cuts confirmed at 1,200 jobs (6% of staff) vs 3,000-5,000 initially reported; QTRX worst-case NIH headwind ~250bps of revenue growth
- TKNO targeting ~30% EBITDA margins within two years; ~$85B of announced domestic biopharma manufacturing investment (LLY, JNJ, MRK, AMGN)
- VST added $30B+ market cap with zero announced data-center agreements
- XGN valued at ~1x revenue with positive earnings/FCF expected by year-end
Key insights
- The drawdown in high-volatility stocks was the most severe in a decade — worse than during COVID — and concentrated in Russell 3000 healthcare and energy (declines approaching 50%), which Citrini reads as technical positioning damage, not fundamental deterioration, hence an opportunity to concentrate.
- Housing normalization long: rate lock-in has frozen low-income mobility (12% moved vs 22% of high-income households), so falling rates should unleash pent-up lower-end transactions benefiting RKT, TREE, UWMC, EFX, Z and BLND — BLND has a projected 40% CAGR in non-mortgage consumer banking and inflects to positive FCF this year.
- Services mean-reversion short: top-20% service spending is 45% above pre-pandemic while bottom-20% remains 6% below, so premium-experience names (YOU, SPOT, LYV, ABNB) are shorted against accessible entertainment longs (WBD, FOX, PARA, NFLX).
- Insurance Redux pairs long boring compounders at historical discounts (ACGL, CB, RNR, WRB) against unprofitable insurtechs (LMND, ROOT, HIPO, TRUP) that are 'dangerously short on unencumbered cash' — a gap expected to close regardless of market direction, faster in risk-off.
- NIH funding fears are overblown: confirmed cuts were 1,200 jobs (6% of staff) versus 3,000-5,000 initially reported; NOTV's NIH exposure (~10% of revenue) has offsets from closed NIH facilities, and QTRX quantified a worst-case headwind of only ~250bps to revenue growth while the market values its operations at zero.
- STIM's consumer TMS interest has inflected (Google Trends correlates with reported treatment sessions) just as coverage expanded by millions of lives, yet it trades at a 25-80% discount to peers on trailing revenue; TALK offers ~200 million Americans therapy at ~$15 average out-of-pocket with 50% y/y core growth, a quarter of its market cap in cash and zero debt.
- The nuclear 'AI power' trade is called out as narrative-heavy: VST added over $30B of market cap after buying four nuclear plants yet has announced zero data-center commercial agreements, while gas players (ET, DEC) sign real deals — so the basket pivots to gas infrastructure builders AGX, ESOA, ECG, FLR, KBR plus midstream EPD, CQP, ET.
- Portfolio actions: covered SMH and NVDA shorts, monetized all hedges, and went unhedged for the first time since December 2024 — recycling that capital into the new baskets.
#089
Thematic Primer
Mar 30, 2025
Haves vs. Have Nots (with The Last Bear Standing)
The US economy has bifurcated so severely that the top 10% of earners — who now drive roughly 50% of all consumer spending and hold record equity exposure — are the economy's single point of failure. Because the bottom 90% have already been in a 'rolling recession' since 2021 (depleted savings, multiple jobs, cut discretionary spending), the next downturn would be a wealth-effect recession: a sustained stock market decline cuts high-income spending through direct wealth, psychological, income (bonuses/options), and housing channels, transmitting market stress into real contraction. Trump 2.0's populist policy mix (tariffs, immigration reversal, no-tax-on-tips) further tilts the pain toward the affluent. The trade is therefore not classic staples-vs-discretionary but long companies serving already-recessed lower-income consumers (favorable base effects, bombed-out valuations) against short premium/'premiumization' names most sensitive to affluent spending.
financefintech
Positions & performance
+11.8%avg return100% win · 1 tracked · L +11.8%
| Position | Mentions | Entry | Last | Return |
|---|
| LRKT:NYSE financefintech Rocket Companies | IT | 12.07Mar 31 '25 | 13.49 ● | +11.8% |
Full summary 533 words
Published March 30, 2025 as Citrini's first newsletter collaboration since 2023 (with fellow Substack author The Last Bear Standing), the piece extends the wealth-effect recession concept introduced in Citrini's 'After the Trump Bump' macro memo. With the fiscal impulse fading and recession chatter rising, the authors argue that guessing recession probabilities is useless; what matters is what KIND of recession, and this one would be driven by the top of the income distribution. TLBS draws the parallel to China's policy-driven $50 trillion property deflation; today a $60 trillion asset class — the US stock market — plays the same role as the primary store of American wealth, with an administration that may be serious about 'Main Street vs. Wall Street'.
The macro setup: the top 10% of earners (households above ~$250,000) account for roughly 50% of US consumer spending, a concentration compared to the 1920s. Total COVID stimulus of $4.6 trillion pales against $35 trillion of household financial wealth accumulation since 2019, more than half of which accrued to the top 1% (net worth +$17 trillion). Stocks are a larger share of household financial assets than at any time since the 1940s data begins. Fed research is cited showing lower interest expenses and corporate tax rates mechanically explain over 40% of real corporate profit growth from 1989-2019, while tech margins expanded from 10% (2004) to 27% (2024). Meanwhile the bottom 90% face an 'invisible recession': 15% of bottom-quintile workers hold multiple jobs (+87.5% since 2019), low-income debt service ratios are up 5 points since 2019, and the bottom 20% now spend 94% of their budget on necessities versus 85% pre-pandemic. A 'Bank of Mom and Dad' argument holds that official income data is distorted by boomer-to-millennial wealth transfer, which itself would slow if stocks fall.
The report also layers in an AI angle: white-collar work faces an LLM 'Sword of Damocles' — large law firms have cut entry-level hiring ~25%, Grammarly laid off 20% of staff citing AI, and Vanguard reports hiring for $96,000+ jobs at a decade low — while hands-on lower-wage work is harder to automate, potentially inverting the usual recession-resilience hierarchy. A key sentiment inversion is flagged: high-income consumers now expect unemployment more than low-income ones, historically rare and underpriced because aggregate confidence indices average across brackets. The transmission math: a 20% sustained drawdown could cut high-income spending 5-8%, a 2.5-4% hit to total consumption — enough for contraction. Second-order effects hit aspirational luxury, premium subscriptions (high-income households hold 8x more), trading-down cascades, and high-fixed-cost premium services; traditional defensives may not protect because staples have premiumized and trade at peak multiples.
Positioning: a systematic five-factor scoring framework (customer demographics, price elasticity, geographic concentration, trading-down vulnerability, operating leverage) builds a long basket of value-positioned, necessity-focused, lower-income-serving names already priced for recession (mortgage originator RKT is given as an example beneficiary of improved low-income mobility) against a short basket of premium-priced, wealth-effect-sensitive companies. A backtest shows the long/short tracking the spread between bottom-third and top-third consumer sentiment, accelerating when high-income confidence falls below middle-income confidence. Crucially, the trade doesn't require a recession — it also wins if low-income spending recovers and inequality narrows; the authors even invite skeptics to invert the baskets.
Key metrics
- Top 10% of earners = ~50% of US consumer spending
- $35T household financial wealth gain since 2019 vs $4.6T total COVID stimulus
- Top 1% net worth +$17 trillion since 2019
- Fed research: lower interest expense and tax rates explain >40% of real corporate profit growth 1989-2019
- Tech margins expanded from 10% (2004) to 27% (2024)
- 15% of bottom-quintile workers hold multiple jobs, +87.5% vs 2019
- Bottom 20% spend 94% of budget on necessities vs 85% pre-pandemic
- 20% market drawdown → estimated 5-8% cut in high-income spending → 2.5-4% hit to total consumption
- High-income households hold 8x more subscription services; top quintile spends 12x more on online shopping
- Top-20% service spending +45% vs pre-pandemic; bottom-20% still -6%; S&P 500 +160% since Trump's first inauguration
Key insights
- The top 10% of earners (households making >$250,000) account for ~50% of all US consumer spending — a concentration not seen since the 1920s — making the economy structurally hostage to affluent sentiment and asset prices.
- Since 2019, US households gained $35 trillion in financial wealth versus $4.6 trillion of COVID stimulus; over half the gains went to the top 1%, whose net worth grew $17 trillion, and stocks are now the largest share of financial assets in data back to the 1940s.
- The bottom 90% have been in a 'rolling recession' since 2021: 15% of bottom-quintile workers hold multiple jobs (up 87.5% since 2019), low-income debt-service ratios are +5pp since 2019, and the bottom 20% spend 94% of their budget on necessities vs 85% pre-pandemic.
- A 20% sustained market drawdown could cut high-income consumer spending 5-8%, translating to a 2.5-4% decline in total consumption — enough to trigger broad contraction via wealth-effect, psychological, income, and housing channels.
- AI adds a white-collar dimension: big law entry-level hiring is down ~25%, Grammarly cut 20% of staff citing AI capability, and hiring for jobs paying over $96,000 is at a decade low per Vanguard — while manual/physical jobs remain hard to automate.
- A rare sentiment inversion is underway: high-income earners increasingly expect unemployment in 2025 while low-income expectations have improved, an underpriced signal because aggregate confidence indices average across income brackets.
- Traditional defensives may fail this cycle: staples have 'premiumized' their mix, healthcare has grown discretionary components, defensive sectors carry high fixed costs, and they start from historically premium valuations.
- The long have-nots/short haves basket's backtest tracks the bottom-third-minus-top-third consumer sentiment spread and works without a recession — it also pays off if low-income spending recovers, giving the trade asymmetry in both scenarios.
#088
State of the Themes
Mar 18, 2025
State of the Themes: Q1 2025
This is Citrini's quarterly 'State of the Themes' review for Q1 2025, released deliberately right before the March FOMC during the first real market drawdown since the prior summer. The core message is portfolio attribution: active management across 30+ thematic baskets kept the Core Thematic Portfolio positive (+4.17% YTD) even in a drawdown, because gains in Chinese equities, hedges, and European fiscal beneficiaries offset losses in connectivity, natural gas, and medtech. The actionable content — a thematic chartbook and suggested basket adjustments — sits below the paywall, so the public text is primarily a performance scoreboard for the Citrindex.
Positions & performance
No single-stock positions tracked in this report.
Full summary 166 words
This is a short quarterly-review wrapper, with most of the substance (the Q1 2025 Thematic Chartbook covering the 30+ themes in Citrini's coverage, plus commentary and suggested basket adjustments) behind the paywall. Released March 18, 2025 — intentionally timed right before the March FOMC and during the first real market drawdown since the previous summer, continuing Citrini's habit of publishing these reviews when attention is elsewhere.
The visible content is attribution for the Citrindex Core Thematic Portfolio, which had returned +4.17% year-to-date as of March 14, 2025. Top contributors: the Chinese Equity Barbell (+21.15% total return YTD, 10.96% average weight, +2.32% contribution), Hedges (+38.41% return, 3.32% weight, +1.83% contribution), and Fiscal Primacy (+13.07% return, 11.23% weight, +1.46% contribution). Top detractors: Connectivity (-8.17%, 5.61% weight, -0.55% contribution), NatGas (-9.56%, 7.38% weight, -0.74%), and Medtech & Healthcare Innovation (-15.43%, 14.00% weight, -1.06%). The chartbook's stated goal is a quick visual overview of the thematic landscape, and readers are pointed to the live Citrindex sheet for current basket allocations.
Key metrics
- Core Thematic Portfolio +4.17% YTD (as of March 14, 2025)
- Chinese Equity Barbell: +21.15% YTD, 10.96% average weight, +2.32% contribution
- Hedges: +38.41% return, 3.32% average weight, +1.83% contribution
- Fiscal Primacy: +13.07% return, 11.23% average weight, +1.46% contribution
- Connectivity: -8.17% QTD, 5.61% weight, -0.55% contribution
- NatGas: -9.56% QTD, 7.38% weight, -0.74% contribution
- Medtech & Healthcare Innovation: -15.43% QTD, 14.00% weight, -1.06% contribution
- 30+ themes covered in the quarterly chartbook
Key insights
- The Core Thematic Portfolio was +4.17% YTD as of March 14, 2025, staying positive through the first real market drawdown since summer 2024 thanks to diversification across 30+ thematic baskets.
- The Chinese Equity Barbell was the biggest winner: +21.15% YTD on a 10.96% average weight, contributing +2.32% to portfolio return — vindicating Citrini's contrarian China exposure.
- The Hedges sleeve returned +38.41% on only a 3.32% average weight, adding +1.83% — the second-largest contributor despite the smallest allocation, showing the drawdown-protection working as designed.
- Fiscal Primacy (the European fiscal-expansion theme) returned +13.07% and contributed +1.46%, making all three top contributors non-US-tech exposures.
- The healthcare/medtech basket was the largest detractor (-15.43% return, -1.06% contribution) and also the largest average weight at 14.00% — Citrini's highest-conviction theme was its worst Q1 performer.
- NatGas (-9.56%) and Connectivity (-8.17%) also detracted, foreshadowing the basket-repair work done in subsequent memos.
- Citrini deliberately times these quarterly reviews for moments when 'everyone is focused on anything but thematic equity' — the prior edition landed the day before the US election.
#087
Thematic Primer
Mar 06, 2025
European Fiscal Primacy: A Cure for the Sick Man?
Trump's America First turn — ending military support for Ukraine and threatening trade war — has forced Europe to abandon fifteen years of austerity: Germany's €500bn infrastructure fund and debt-brake reform, the EU's €800bn ReArm Europe plan, and Draghi-report industrial policy amount to 'fiscal primacy crossing the pond.' Just as US fiscal spending drove US equity winners from 2022-2024, European deficit spending along Draghi's sectoral lines should re-rate European industrials, chemicals and construction — where Citrini sees better risk/reward than the already-run defense trade — and the same logic supports a stronger euro (EURUSD target 1.15), lower relative US rates, and a potential durable break in rest-of-world versus US equity performance. Citrini launches an EU Fiscal Primacy basket and pairs it with long EUR/JPY vs short USD/CHF and a long SOFR/short EURIBOR STIR spread.
defense
Positions & performance
Full summary 507 words
Published March 6, 2025, this report ports Citrini's September 2023 'US Fiscal Primacy' megatrend framework to Europe. The setup: Europe is the friend who peaked in high school — fifteen years of post-GFC austerity, underinvestment, deindustrialization and regulatory burden left it trailing the US and China. But Trump's rapid upending of the security and trade order (ending military support for Ukraine, tariff threats) has triggered a genuine vibe shift: what was once unthinkable — large deficits, joint debt issuance, expansive state aid — is now official policy direction. The report catalogs the announcements: the European Commission's €800bn 'ReArm Europe' plan with €150bn in loans for defense investment and €150bn of proposed new joint EU borrowing; invocation of the Stability and Growth Pact's national escape clause, potentially creating ~€650bn of fiscal space over four years; and Germany's watershed under incoming Chancellor Merz — a €500bn infrastructure fund, debt-brake reform, and defense spending potentially reaching 3.5% of GDP by 2027. Citrini frames the analytical touchstone as Mario Draghi's September 2024 competitiveness report, whose €750-800bn annual investment program and sector-specific industrial policy provide the sectoral map for where money will flow — the same way IRA/IIJA/CHIPS mapped US fiscal winners. Three policy pillars structure the basket: military defense; reindustrialization and reversing headwinds (about 6% of European chemical capacity has been announced for closure or review, and the German stimulus is comparable in scale, relative to €4.5 trillion GDP, to America's $891bn IRA plus $1.2tn IIJA combined); and rebuilding Ukraine, whose World Bank/UN/EC-assessed cost has risen 7% to $524bn — 2.8x Ukraine's 2024 GDP, with 13% of housing stock damaged affecting 2.5 million households. Citrini's positioning history matters here: it recommended long EU Defense/short US Defense in its March 2024 election basket (the year's best-performing policy basket), and while it doesn't doubt Rheinmetall, Thales and Safran can go higher (5%-of-GDP German defense spending 'probably makes RHM a €3,000 stock'), it sees better risk/reward in the broadening trade — industrials, diversified chemicals and construction — echoing the profitability boost US infrastructure names enjoyed. The new EU Fiscal Primacy basket is explicitly an incremental-improvement play, not a bet that Europe fully escapes its slumber, and doubles as a hedge to US momentum longs the way the Chinese equity basket has been. The macro section ('Marshall Plan 2.0 — MEGA') argues the ECB will backstop the fiscal push: conditional QE/OMT eligibility for defense-linked national issuance is easy to imagine, the Maastricht 3%/60% limits were always arbitrary, Eurozone inflation is anchored (5y5y swaps near target) and German capacity utilization is at recessionary levels, so real resources exist. FX views: EURUSD target 1.15 supported by German-vs-US yield direction, five-year-extreme negative speculative EUR positioning as a contrarian signal, and falling natural gas prices; current exposure is 50% long JPY, 50% long EUR, 100% short USD, with the Hungarian forint flagged as a sleeper Ukraine-rebuild play. In rates, Citrini keeps the long SFRZ5/short ERZ5 spread rather than trading BTP-Bund, and notes rest-of-world versus US equities may finally break a 15-year downtrend since fiscal deficits drive aggregate corporate profits.
Key metrics
- ReArm Europe plan: €800bn total, including €150bn loans and €150bn proposed joint EU borrowing
- SGP national escape clause could create ~€650bn of fiscal space over four years
- Germany: €500bn infrastructure fund; defense spending potentially 3.5% of GDP by 2027
- Draghi report: €750-800bn annual investment program; EU investment-to-GDP must rise ~5% of GDP per year
- Ukraine rebuild cost: $524bn (up 7% from $486bn), 2.8x Ukraine's 2024 GDP; 13% of housing stock damaged, 2.5M households affected
- German stimulus scale vs €4.5tn GDP comparable to combined US IRA ($891bn) + IIJA ($1.2tn)
- ~6% of European chemical capacity announced for closure or review
- Over 60% of EU companies cite regulation as an obstacle to investment; 55% of SMEs cite administrative burden
- EURUSD near-term target: 1.15; net speculative EUR positioning most negative in five years
- FX exposure: 50% long JPY, 50% long EUR, 100% short USD; STIR: long SFRZ5 / short ERZ5
Key insights
- The core transplant: fiscal primacy — government spending as the dominant driver of corporate profits and equity returns — has crossed the pond, with Trump's America First policies as the forcing function that broke Europe's austerity consensus.
- The numbers are historic: €800bn ReArm Europe (including €150bn loans and €150bn joint borrowing), ~€650bn of fiscal space from SGP escape-clause invocation over four years, Germany's €500bn infrastructure fund and defense potentially at 3.5% of GDP by 2027 under Merz.
- The Draghi report is the investment map: a €750-800bn annual investment program with sector-specific industrial policy gives investors the same sectoral lens that IRA/IIJA/CHIPS provided for picking US fiscal winners.
- Citrini prefers the broadening trade over crowded defense: industrials, diversified chemicals and construction offer better risk/reward than Rheinmetall/Thales/Safran after the run — though it quips 5%-of-GDP German defense spending 'probably makes RHM a €3,000 stock.'
- Ukraine reconstruction is a quantified third pillar: $524bn estimated rebuild cost (up 7% YoY), equal to 2.8x Ukraine's 2024 GDP, with 13% of housing stock damaged across 2.5M households — necessarily funded by international allies.
- The ECB provides the backstop ('bazooka to finance bazookas'): conditional QE/OMT support for defense-linked national bond issuance is plausible, spread blowouts would be dealt with swiftly, and anchored 5y5y inflation swaps plus recessionary German capacity utilization mean the real-resource constraint isn't binding.
- FX call: EURUSD to 1.15, supported by diverging German (higher) vs US (lower) 10-year yields, the most negative speculative EUR positioning in five years as a contrarian signal, and falling natural gas prices; book is 50% long JPY, 50% long EUR, 100% short USD, with HUF a sleeper Ukraine-rebuild play.
- Track record cited as validation: the long EU Defense/short US Defense basket from the March 2024 election primer is the best-performing Citrini policy basket YTD, while IRA-heavy US fiscal baskets peaked precisely at Trump's victory.
#086
Macro Memo
Feb 25, 2025
Macro Memo: After the Trump Bump
Fiscal primacy — Citrini's September 2023 thesis that government spending drives the US cycle — now cuts the other way: DOGE cuts, federal buyouts, rollback of Biden industrial programs like BEAD, tariff chaos and housing weakness are tightening fiscal impulse and freezing business investment, so risk shifts from inflation back to growth and bad news is now bad news for stocks. The January macro trades all worked (10y from 4.8% to 4.3%, SOFR M5M6 hit target, CHFJPY at 2024 lows), and the firm doubles down: stay long duration (TLT lifted from 6.5% to 24.5% of the Citrindex), short USD, short homebuilders, with the twist that the biggest risk to the economy is the stock market itself — a wealth-effect ouroboros where a sustained drawdown among top-10% households becomes self-fulfilling.
aisemiconsumerreal-estateindexbonds
Positions & performance
+15.4%avg return71% win · 7 tracked · L -0.9% · S +22.0%
| Position | Mentions | Entry | Last | Return |
|---|
| SBLDR:NYSE consumerreal-estate Builders FirstSource | IAT | 140.78Feb 25 '25 | 72.86 | +48.2% |
| SDFH:NYSE consumerreal-estate Dream Finders Homes | T | 24.76Feb 25 '25 | 15.63 ● | +36.9% |
| SLEN:NYSE consumerreal-estate Lennar | IPT | 124.32Feb 25 '25 | 84.64 | +31.9% |
| LXLRE:NYSE consumerreal-estate Real Estate Select Sector SPDR | — | 42.87Feb 25 '25 | 45.95 | +7.2% |
| SITB:NASDAQ consumerreal-estate iShares U.S. Home Construction ETF | — | 101.0Feb 25 '25 | 97.09 | +3.9% |
| LTLT:NASDAQ indexbonds iShares 20+ Year Treasury Bond ETF | — | 91.42Feb 25 '25 | 83.25 | -8.9% |
| SDHI:NYSE consumerreal-estate D.R. Horton | PT | 132.11Feb 25 '25 | 146.76 | -11.1% |
Full summary 466 words
This February 25, 2025 Macro Memo, subtitled 'Fiscal Primacy Cuts Both Ways,' takes a victory lap and then extends the thesis. Since January's memo, all three macro positions worked: bonds rallied violently with the 10-year falling from 4.8% to 4.3% (near the 4.2% target), the SOFR M5M6 flattener went from pricing zero cuts to the -34.5bps target, and CHFJPY returned to its 2024 lows. The core argument: the September 2023 'Fiscal Primacy' framework — that aggressive fiscal spending (CHIPS, IIJA, IRA) drives the US cycle — now operates in reverse under Trump. DOGE contract freezes, roughly 50-75K federal worker buyouts (DC unemployment claims up 150K this year), a DoD 8% savings target, only ~6% of federal employees full-time under RTO, and the likely rollback of programs like BEAD (fully awarded but barely disbursed, vulnerable to Musk's Starlink preference) all constitute fiscal retrenchment whose mere threat slows the economy. The memo marshals soft data — services and composite PMIs turning sharply lower post-inauguration, NFIB optimism retreating and uncertainty rising, the Citi economic surprise index going negative, Conference Board job plentifulness and consumer confidence round-tripping to pre-election levels — and hard data: hiring and quit rates at multiyear lows below pre-COVID levels, slowing wage growth, and anchored real-time rents that should keep feeding CPI disinflation. Housing gets special attention: new-home supply has risen to historically recessionary levels, the gap between home inventory and construction employment is unsustainable, and the 25 Trades for 2025 homebuilder short (DHI, LEN, BLDR, DFH, targeting 20-30% downside) has drastically outperformed; new macro expressions are long XLRE/short ITB and long lumber/short ITB, since lower rates help real estate more than builders and deportation threatens builder labor costs. Forecasts: slower real growth, modestly higher unemployment, lower inflation (favorable PCE base effects could put headline at 1.9% YoY by the April report), lower 10-year yields, and a Fed that skips (possibly again in March) but could deliver a make-up 50bps cut in May. The most original section is the 'macroeconomic ouroboros': with the wealth effect the strongest in decades and the economy increasingly sensitive to top-10% households earning over $250K, a stock drawdown lasting more than a month could become a self-fulfilling growth shock — making the market's reaction to Nvidia earnings a better six-month economic indicator than any data release. Trades: FX shifts to long 70% JPY, 20% EUR, 10% BRL versus short 50% CHF, 50% USD (CNH short eliminated, EUR added); the SOFR flattener is half-monetized with the M5 short covered, leaving long SFRM6 targeting 96.60; bonds retain asymmetry (30bps against you if wrong, 100bps+ if right — 'Elon Musk is on the same side of this trade'); and the Citrindex moves most of its ~18% cash into TLT, lifting the position from 6.5% to 24.5% as 'cash+' duration to hedge the equity book.
Key metrics
- 10-year yield fell from 4.8% to 4.3% vs original 4.2% target
- SOFR M5M6 flattener hit -34.5bps target; remaining long SFRM6 targets 96.60
- Roughly 50-75K government workers took buyouts; DC unemployment claims up 150K this year
- Only ~6% of federal employees working full time under the RTO mandate; DoD targeting 8% savings
- Homebuilder short thesis: 20-30% downside to inflated estimates for DHI, LEN, BLDR, DFH
- If PCE runs at target MoM, headline PCE hits 1.9% YoY in the April report (out May 31)
- Bond asymmetry: ~30bps against if wrong vs 100bps+ if right
- TLT position raised from 6.5% to 24.5% of the Citrindex (from ~18% cash)
- FX: long 70% JPY / 20% EUR / 10% BRL vs short 50% CHF / 50% USD
- Top-10% households (income >$250K) drive the wealth-effect sensitivity of consumption
Key insights
- All three January macro trades hit: 10-year yield fell from 4.8% to 4.3% (target 4.2%), SOFR M5M6 reached the -34.5bps target, and CHFJPY returned to 2024 lows — the memo extends rather than exits the theme.
- Fiscal primacy in reverse: DOGE freezes, 50-75K federal buyouts, a DoD 8% savings target and BEAD rollback risk mean the fiscal impulse that carried the economy since 2022 is turning contractionary — and the threat alone slows activity even if deficits don't actually fall.
- Regime shift declared: after two years when slower growth meant Fed relief ('bad news is good news'), bad news is now simply bad news for stocks, with risk shifting from inflation back to growth.
- The wealth-effect ouroboros is the key novel risk: the economy is unusually sensitive to top-10% households (>$250K income), so a stock drawdown lasting over a month becomes self-fulfilling — Nvidia's earnings reaction is a better 6-month macro indicator than any data print.
- Homebuilder short pressed: new-home supply at historically recessionary levels, weak spring pricing power, and deportation-driven labor cost risk; macro expressions are long XLRE/short ITB and long lumber/short ITB (ITB preferred over XHB).
- Hard labor data confirms softness: hiring and quit rates at multiyear lows below pre-COVID levels and slowing wage growth — the Fed risks a policy mistake if it misreads employment; a March skip could be followed by a make-up 50bps cut in May.
- Bond asymmetry quantified: if the market's DOGE worry is wrong, yields back up maybe 30bps; if right, 100bps or more of rally — so the Citrindex moves cash into TLT, lifting the position from 6.5% to 24.5% as 'cash+'.
- FX book restructured: long 70% JPY, 20% EUR, 10% BRL against short 50% CHF, 50% USD — the CNH short is eliminated and EUR added, foreshadowing the European fiscal pivot.
#085
In Conversation
Feb 16, 2025
In Conversation: Neuronetics (STIM)
An interview-driven deep dive arguing Neuronetics (STIM) is at a GLP-1-style adoption inflection: its TMS depression therapy has proven efficacy (62% remission odds after multiple drug failures versus 6.9% on a fourth antidepressant) but has been held back by awareness, restrictive labels and psychiatrist-only reimbursement — barriers CEO Keith Sullivan's team is now dismantling via the Better Me provider program, the Greenbrook acquisition, improving payer coverage, and a favorable policy environment (Dr. Oz at CMS, a North Carolina access bill). With $22.6M of merger synergies essentially actioned, cash-flow breakeven targeted for Q3 2025, and the stock at ~2x revenue versus peer BWAY at 4x and comps like CLPT above 12x, Citrini sees significant near-term upside even after a 700%+ run, plus a path to $500M+ revenue by 2030.
health
Positions & performance
-63.8%avg return0% win · 1 tracked · L -63.8%
| Position | Mentions | Entry | Last | Return |
|---|
| LSTIM:NASDAQ health Neuronetics | A | 5.0Feb 18 '25 | 1.81 ● | -63.8% |
Full summary 460 words
This February 16, 2025 installment of Citrini's 'In Conversation' series pairs a bull-case update on Neuronetics (STIM) with a transcript of the firm's sit-down with CEO Keith Sullivan. STIM, first covered in the August 2024 Healthcare & Medtech primer and repeatedly bought on dips, has soared more than 700% from its mid-November low, yet Citrini argues the company is at the start of its adoption curve, not the end. The framing analogy is GLP-1s: drugs whose obesity efficacy was long known but which only exploded once labels, coverage, awareness and adoption were deliberately built — TMS (transcranial magnetic stimulation) for depression sits at the same inflection, addressing a huge underserved market where SSRIs deliver only ~27% remission on first use, falling to 6.9% by the fourth drug, while TMS lifts remission odds to 62% with over 80% of patients responding and only 36 reported seizures across 200,000+ treated patients. The interview covers the company's history (FDA clearance 2008, major-payer reimbursement 2016, IPO 2018, Sullivan's 2020 arrival motivated by personal losses to depression), the mechanics of the 19-minute, 36-session treatment course, and the awareness problem: patient awareness was under 9% twelve years post-clearance, and an early TV campaign generated 43,000 inquiries but only 123 treatments because providers never answered the phone. Sullivan's fix is the Better Me program — five standards including a staffed phone line, 24-hour lead response, full 36-session treatment, co-op-funded web presence and Neurostar University training — which now has 350 providers with 120+ waiting, has cut patient lead time from 87 to 17 days, and tripled patients treated per practice from 3 to 10 per quarter. The Greenbrook acquisition adds a 188-clinic national network being rationalized (site closures raised from 60 to 88, leaving 550+ points of access including Better Me practices), new revenue streams (Spravato buy-and-bill, potentially psilocybin), and synergies that grew from $10M initially identified to $22.6M, all but $1.3M already actioned. A recent $18M equity raise strengthens the balance sheet — partly to win trade credit for Spravato inventory — alongside a Perceptive debt facility of $50M expandable to $90M. Management targets cash-flow breakeven by Q3 2025 (with executive stock bonuses tied to hitting it as early as Q2), and policy tailwinds abound: payer drug-failure requirements have fallen from four to two (sometimes one), a North Carolina bill would open reimbursement beyond psychiatrists — critical since primary care writes 70% of antidepressant prescriptions — and incoming CMS head Dr. Mehmet Oz has repeatedly featured Neurostar on television. Citrini's valuation case: STIM should meet or beat its $145-155M 2025 revenue guidance, trades at roughly 2x revenue versus inferior TMS peer BWAY at 4x and comp Clearpoint Neuro above 12x sales, and can compound 20%+ organic revenue growth with expanding margins toward $500M+ revenue by 2030.
Key metrics
- STIM up more than 700% from mid-November 2024 local low
- 2025 guidance: $145-155M revenue with sustainable positive cash flow from H2; cash-flow breakeven targeted Q3
- TMS remission odds 62% vs 6.9% on a fourth antidepressant; first SSRI remission ~27%; >80% respond to first TMS course
- 200,000+ patients treated; 36 reported seizures total
- Treatment: 19-minute sessions, 5 days/week for 7 weeks (36 sessions); ~25% need a touch-up after 12+ months
- Better Me program: 350 providers, 120+ waitlisted; lead time cut from 87 to 17 days; patients per practice up from 3 to 10 per quarter
- Greenbrook synergies: $22.6M identified (up from $10M), all but $1.3M actioned; site closures increased from 60 to 88, leaving 550+ locations
- $18M equity raise; Perceptive debt facility of $50M expandable to $90M
- Valuation: STIM ~2x revenue vs BWAY 4x and Clearpoint Neuro >12x sales
- Prior standalone plan: $70M to $200M revenue = 166,240 patients treated = 3,325 lives saved annually; $500M+ revenue possible by 2030
Key insights
- The GLP-1 analogy anchors the thesis: like GLP-1s pre-2014, TMS has long-proven efficacy but was throttled by labels, coverage and awareness — and those barriers are now falling simultaneously, marking an adoption inflection rather than a topped-out trade after the 700%+ rally.
- Efficacy data is stark: SSRI remission is ~27% on the first drug, falling to 6.9% by the fourth, while TMS lifts remission odds to 62%; over 80% of patients respond, and safety is strong with 36 reported seizures across 200,000+ treated patients.
- Awareness, not competition, was the bottleneck: patient awareness was under 9% twelve years after FDA clearance, and an early TV campaign produced 43,000 inquiries but only 123 treatments because provider practices failed at basic follow-up.
- The Better Me program (350 providers, 120+ waiting) operationalizes the fix — staffed phone lines, 24-hour response, full 36-session treatment, Neurostar University — cutting lead-to-treatment time from 87 to 17 days and tripling per-practice volume from 3 to 10 patients per quarter.
- Greenbrook gives vertical integration and national access: 188 clinics rationalized (closures raised from 60 to 88, leaving 550+ sites), plus Spravato buy-and-bill and potential psilocybin optionality; synergies grew from $10M to $22.6M identified, all but $1.3M already actioned.
- Policy is a pure tailwind: payer requirements have dropped from four failed drugs to two (sometimes one), a North Carolina bill would extend reimbursement to all licensed providers, primary care writes 70% of antidepressant scripts, and Dr. Oz — who has featured Neurostar on TV — will run CMS.
- Valuation gap: at 2025 guidance of $145-155M revenue and cash-flow breakeven by Q3, STIM trades at ~2x revenue versus smaller TMS peer BWAY at 4x and razor-and-blade comp Clearpoint Neuro at over 12x sales.
- Long-term case: 20%+ sustained organic revenue growth with margin expansion and potential $500M+ revenue by 2030; management incentives are stock bonuses explicitly tied to reaching and maintaining positive cash flow starting as early as Q2 2025.
#084
Market Memo
Feb 09, 2025
Market Memo: Healthcare's AI-Powered Trump Card
With the January healthcare catch-up call working and earnings season winding down, policy narratives from Trump 2.0 and RFK's HHS will drive healthcare returns next — so the basket is repositioned around the administration's agenda. RFK's focus on mental health, alternative therapies, telemedicine and chronic disease creates tailwinds for STIM, TALK, TDOC, healthcare-IT and diagnostics names, while biopharma-supply-chain onshoring favors domestic providers like TKNO, NOTV and FTRE. The cost-cutting side cuts the other way: international reference pricing threatens Novo Nordisk, PBM reform overhangs CVS/CI/UNH, and DOGE's fraud and discretionary-payment crusade endangers dialysis operators, behavioral health, hospital DPP recipients, and Gilead via USAID/PEPFAR. AI enablers in healthcare are layered on top using Citrini's data-design-distribution Phase 2 framework.
consumerhealthconsumershoppinghealthGLPhealthhealthtesting
Positions & performance
+9.8%avg return51% win · 39 tracked · L +21.5% · S -3.8%
| Position | Mentions | Entry | Last | Return |
|---|
| LTOI:NASDAQ health The Oncology Institute | A | 1.0Feb 10 '25 | 5.39 | +439.0% |
| LGH:NASDAQ health Guardant Health | — | 44.4Feb 10 '25 | 147.33 | +231.8% |
| LEXAS:NASDAQ health Exact Sciences | PT | 52.38Feb 10 '25 | 104.91 | +100.3% |
| LGRAL:NASDAQ health Grail | — | 33.37Feb 10 '25 | 66.77 ● | +100.1% |
| SNVO:NYSE healthGLP Novo Nordisk | ISP | 83.91Feb 10 '25 | 48.77 | +41.9% |
| LLLY:NYSE healthGLP Eli Lilly | IPT | 868.88Feb 10 '25 | 1196.03 | +37.7% |
| SPCVX:NASDAQ health Vaxcyte | I | 85.94Feb 10 '25 | 54.66 | +36.4% |
| SMOH:NYSE health Molina Healthcare | IT | 286.42Feb 10 '25 | 197.55 | +31.0% |
| SARDT:NYSE health Ardent Health Partners | — | 14.72Feb 10 '25 | 10.64 | +27.7% |
| LFTRE:NASDAQ health Fortrea | I | 15.07Feb 10 '25 | 19.2 ● | +27.4% |
| LTALK:NASDAQ health Talkspace | I | 4.1Feb 10 '25 | 5.22 ● | +27.3% |
| SACHC:NASDAQ health Acadia Healthcare | IA | 42.85Feb 10 '25 | 32.5 ● | +24.2% |
| SUNH:NYSE health UnitedHealth | ISPT | 533.37Feb 10 '25 | 417.64 ● | +21.7% |
| SUHS:NYSE health Universal Health Services | IPT | 185.35Feb 10 '25 | 159.31 ● | +14.0% |
| LICAD:NASDAQ health iCAD | — | 3.6Feb 10 '25 | 3.87 | +7.5% |
| LPRVA:NASDAQ health Privia Health | IT | 23.83Feb 10 '25 | 25.5 | +7.0% |
| SELV:NYSE health Elevance Health | IAPT | 396.14Feb 10 '25 | 377.68 | +4.7% |
| SPEP:NASDAQ consumershopping PepsiCo | IPT | 144.35Feb 10 '25 | 139.79 ● | +3.2% |
| LTBRG:NASDAQ health TruBridge | A | 25.52Feb 10 '25 | 26.2 | +2.7% |
| SCI:NYSE health Cigna | IPT | 292.82Feb 10 '25 | 291.02 ● | +0.6% |
| LPCRX:NASDAQ health Pacira Biosciences | AT | 26.1Feb 10 '25 | 25.88 | -0.8% |
| SFMS:NYSE health Fresenius Medical Care | — | 24.17Feb 10 '25 | 24.59 | -1.7% |
| SMDLZ:NASDAQ consumershopping Mondelez | IPT | 58.53Feb 10 '25 | 60.52 | -3.4% |
| SCNC:NYSE health Centene | IPT | 58.91Feb 10 '25 | 64.08 ● | -8.8% |
| LHQY:NASDAQ health HealthEquity | P | 112.15Feb 10 '25 | 94.64 | -15.6% |
| LDXCM:NASDAQ health DexCom | IPT | 88.27Feb 10 '25 | 71.54 | -19.0% |
| SHCA:NYSE health HCA Healthcare | IAPT | 318.26Feb 10 '25 | 382.19 | -20.1% |
| SGILD:NASDAQ health Gilead | IPT | 95.48Feb 10 '25 | 129.31 | -35.4% |
| LTDOC:NYSE health Teladoc | I | 13.86Feb 10 '25 | 8.91 ● | -35.7% |
| SDVA:NYSE health DaVita | IPT | 173.52Feb 10 '25 | 235.44 | -35.7% |
| LNGVC:NYSE consumerhealth Natural Grocers | — | 46.76Feb 10 '25 | 30.01 | -35.8% |
| LCERT:NASDAQ health Certara | T | 14.0Feb 10 '25 | 7.51 | -46.4% |
| LTKNO:NASDAQ health Alpha Teknova | — | 9.17Feb 10 '25 | 4.85 ● | -47.1% |
| LSTIM:NASDAQ health Neuronetics | A | 3.86Feb 10 '25 | 1.81 ● | -53.1% |
| SMRNA:NASDAQ health Moderna | IT | 31.87Feb 10 '25 | 54.07 | -69.7% |
| LDH:NASDAQ health Definitive Healthcare | — | 5.35Feb 10 '25 | 0.68 | -87.2% |
| LARAY:NASDAQ health Accuray | A | 2.45Feb 10 '25 | 0.23 ● | -90.8% |
| LNOTV:NASDAQ healthtesting Inotiv | — | 4.1Feb 10 '25 | 0.08 | -98.1% |
| SCVS:NYSE health CVS Health | IPT | 54.29Feb 10 '25 | 107.74 | -98.5% |
Full summary 476 words
Published February 9, 2025, this memo updates the Medtech & Healthcare Innovation basket for the Trump 2.0 policy era and the post-DeepSeek AI landscape. It opens by noting the January Musings sector catch-up call has been rewarded — the basket outperformed healthcare indices through the JP Morgan conference and earnings season — and argues that with the catalyst calendar now empty, DC policy narratives will dominate returns. Citrini explicitly disclaims policy opinions: 'we are investors, not policy wonks.' The first theme is mental health and alternative therapies. RFK's advocacy — including 'wellness farms' for getting people off both illegal and psychiatric drugs — puts Neuronetics (STIM) squarely in the sweet spot: its non-invasive TMS therapy for major depressive disorder has been held back by requirements to fail multiple drugs and psychiatrist-only reimbursement, and a North Carolina bill expanding TMS to primary care could migrate to the national stage. Pacira (PCRX, non-opioid pain) and Talkspace (TALK, B2B telehealth with partners like Amazon) also benefit. Second, technology and AI: Trump has appointed healthcare investors to CMS roles and RFK champions telemedicine and AI; Citrini recently added healthcare IT names DH, PRVA and TBRG plus CERT, an AI-enabled CRO that touches over 90% of FDA-approved novel drugs. Teladoc (TDOC) is a featured turnaround — profitable, unlike 2021-era peers — whose Catapult Health acquisition fits Citrini's Phase 2 'data, design, distribution' AI framework: longitudinal data on 3M+ covered lives (nearly 50% with chronic conditions), an 81+ NPS experience with a 77% reduction in crisis-level hypertension and 56% medication-compliance improvement, distribution across 93.9 million US integrated-care members, and $1,400 verified savings per member over three years. Third, onshoring biopharma supply chains: China weakness still bites (DHR and AVTR comments), decoupling is just beginning, and Brad Setser's observation that the US trade deficit with Ireland roughly equals its EU pharma deficit signals EU exposure too — all favoring domestic providers TKNO, NOTV (bookings accelerating) and FTRE. Relatedly, Citrini expects Trump 1.0's international reference pricing to re-emerge (estimated $10B+ annual savings); Novo Nordisk is the standout loser since US semaglutide list prices run 3-5x Europe, while LLY June 1000 calls are kept for pipeline optionality. Fourth, cost-cutting: PBM reform has bipartisan support (RFK cited 60+ senators; the FTC found the Big 3 PBMs booked $7.3B above acquisition cost on specialty generics in 2017-2022), an overhang for CVS, Cigna and UnitedHealth. DOGE's fraud hunt threatens dialysis (DVA, FMS), behavioral health (ACHC, UHS), and Directed Payments Program hospital recipients (UHS, ARDT, HCA, ACHC — THC excluded for its Conifer AI asset); Gilead is flagged as USAID/PEPFAR collateral damage; and Medicaid work-requirement risk makes Citrini cautious on CNC, MOH and ELV. Finally, RFK's chronic-over-infectious-disease pivot supports DXCM, oncology diagnostics EXAS/GRAL/GH, oncology turnarounds ARAY, ICAD and TOI, and wellness longs NGVC and HQY — against losers MRNA and PCVX (vaccine funding) and packaged-food shorts PEP and MDLZ.
Key metrics
- CERT touches over 90% of all novel drugs approved by the FDA
- Teladoc/Catapult: 3M+ covered lives, ~50% with identifiable chronic conditions, 81+ NPS
- Catapult clinical outcomes: 77% reduction in crisis-level hypertension, 56% improvement in medication compliance
- Teladoc: 93.9 million US integrated care members; $1,400 verified cost savings per member over three years; pre-diabetes newly identified in 28% of members
- International reference pricing estimated to save more than $10B per year
- NVO's US semaglutide list prices 3-5x the same products in Europe
- FTC: Big 3 PBMs generated over $7.3B above estimated drug acquisition costs, 2017-2022
- Over 60 senators consider PBM reform 'top-of-mind' per RFK's hearing
- Primary care physicians write over 70% of US antidepressant prescriptions (STIM access thesis)
Key insights
- With the earnings/conference calendar empty, DC policy becomes the dominant healthcare return driver — the basket is explicitly repositioned around RFK's HHS agenda and Trump 2.0 cost-cutting, without debating the policies' merits.
- STIM is the purest RFK beneficiary: TMS adoption has been throttled by fail-five-drugs requirements and psychiatrist-only reimbursement; a pending North Carolina bill opening TMS to primary care could go national under RFK's mental-health focus.
- CERT (AI-enabled CRO) touches over 90% of all novel FDA-approved drugs; Teladoc's Catapult acquisition brings data on 3M+ covered lives, 77% reduction in crisis-level hypertension, 56% medication-compliance improvement, 93.9M members, and $1,400 verified per-member savings over three years — a model Phase 2 'data, design, distribution' play.
- International reference pricing is expected to return (Trump 1.0 estimated $10B+/year savings); Novo Nordisk is the marquee loser because US semaglutide list prices are 3-5x European levels and NVO is a high-profile European champion.
- PBM reform has rare bipartisan momentum — RFK said 60+ senators consider it top-of-mind, and the FTC found Big 3 PBMs (CVS Caremark, Express Scripts, OptumRx) generated over $7.3B above drug acquisition costs in 2017-2022 — a durable overhang for CVS, CI and UNH.
- DOGE scrutiny creates a short map: dialysis operators DVA and FMS (past fraud cases), behavioral health ACHC and UHS, and Directed Payments Program hospital recipients UHS, ARDT, HCA and ACHC; THC is excluded from shorts because of its Conifer Health AI asset.
- Gilead flagged as non-obvious collateral damage: USAID's PEPFAR funds global HIV treatment, and losing high-margin revenue while trading at a peer premium is a serious risk after the stock's 12-month run.
- The chronic-disease pivot cuts both ways: long diagnostics/oncology (DXCM, EXAS, GRAL, GH, ARAY, ICAD, TOI) and wellness (NGVC, HQY); short infectious-disease-funded MRNA and PCVX and unhealthy packaged food PEP and MDLZ.
#083
Market Memo
Feb 03, 2025
Market Memo: Tariff-ied
Trump's weekend announcement of 25% tariffs on Mexico and Canada (10% on Canadian energy) plus 10% incremental duties on China proves the trade war is not a bluff: it is an intentionally manufactured pain trade designed to demonstrate credibility, with the fentanyl/IEEPA pretext offering no clear path to appeasement. Because the market priced tariffs as negotiating bluster, tightly-correlated long/short pairs — domestic substitutes versus import-dependent and Mexico/Canada-exposed names — can now diverge violently, creating asymmetric basket trades across autos, consumer goods, steel, energy, and lumber/homebuilders. On macro, Citrini treats tariffs as a tax increase rather than an inflation shock — net deflationary via the hit to discretionary spending — so unlike consensus it stays bullish bonds, adds to its 2s10s flattener, goes long lumber against homebuilders, and expects near-term USD strength.
airobotcommoditiesconsumerautoconsumerreal-estateconsumershoppingdefenseenergygridenergywarindexbonds
Positions & performance
-2.3%avg return43% win · 61 tracked · L +36.8% · S -21.4%
| Position | Mentions | Entry | Last | Return |
|---|
| LDK:NYSE energywar Delek US | — | 18.06Feb 03 '25 | 63.2 | +249.9% |
| LPBF:NYSE energywar PBF Energy | IA | 27.72Feb 03 '25 | 61.63 | +122.3% |
| LSTLD:NASDAQ commodities Steel Dynamics | IPT | 127.92Feb 03 '25 | 250.27 ● | +95.6% |
| SORLY:NASDAQ consumerauto O'Reilly Automotive | IPT | 1316.06Feb 03 '25 | 87.4 | +93.4% |
| LCMI:NYSE energygrid Cummins | IT | 348.21Feb 03 '25 | 661.84 ● | +90.1% |
| LNUE:NYSE commodities Nucor | IPT | 131.3Feb 03 '25 | 247.56 | +88.5% |
| LDAN:NYSE consumerauto Dana | — | 15.73Feb 03 '25 | 28.13 | +78.8% |
| SWHR:NYSE consumershopping Whirlpool | IPT | 99.21Feb 03 '25 | 37.27 | +62.4% |
| SSTLA:NYSE consumerauto Stellantis | IPT | 12.62Feb 03 '25 | 5.69 | +54.9% |
| LX:NASDAQ commodities US Steel | — | 36.44Feb 03 '25 | 54.84 | +50.5% |
| SNKE:NYSE consumershopping Nike | ISAPT | 76.59Feb 03 '25 | 41.7 | +45.6% |
| LYETI:NYSE consumershopping Yeti Holdings | I | 36.03Feb 03 '25 | 50.38 | +39.8% |
| SBCC:NYSE commodities Boise Cascade | T | 125.14Feb 03 '25 | 77.84 | +37.8% |
| LDVN:NYSE energywar Devon Energy | IPT | 33.75Feb 03 '25 | 45.04 | +33.5% |
| SLEN:NYSE consumerreal-estate Lennar | IPT | 126.19Feb 03 '25 | 84.64 | +32.9% |
| SVFC:NYSE consumershopping VF Corp | I | 24.62Feb 03 '25 | 17.03 | +30.8% |
| SSTZ:NYSE consumershopping Constellation Brands | IPT | 174.41Feb 03 '25 | 130.16 | +25.4% |
| LFANG:NASDAQ energywar Diamondback Energy | APT | 164.48Feb 03 '25 | 204.68 | +24.4% |
| SLOW:NYSE consumershopping Lowe's | PT | 256.5Feb 03 '25 | 207.64 | +19.0% |
| SHD:NYSE consumershopping Home Depot | IPT | 408.76Feb 03 '25 | 336.09 ● | +17.8% |
| LEOG:NYSE energywar EOG Resources | PT | 126.4Feb 03 '25 | 146.39 | +15.8% |
| SUAA:NYSE consumershopping Under Armour | A | 8.25Feb 03 '25 | 7.08 ● | +14.2% |
| SITB:NASDAQ consumerreal-estate iShares U.S. Home Construction ETF | — | 104.44Feb 03 '25 | 97.09 | +7.0% |
| SFDP:NYSE consumershopping Fresh Del Monte | T | 30.91Feb 03 '25 | 29.22 | +5.5% |
| STM consumerauto Toyota | PT | 183.65Feb 03 '25 | 177.42 | +3.4% |
| STSN:NYSE consumershopping Tyson Foods | IAT | 57.74Feb 03 '25 | 57.45 | +0.5% |
| SDOLE:NYSE consumershopping Dole | A | 13.34Feb 03 '25 | 14.05 | -5.3% |
| LTLT:NASDAQ indexbonds iShares 20+ Year Treasury Bond ETF | — | 88.16Feb 03 '25 | 83.25 | -5.6% |
| SBBY:NYSE consumershopping Best Buy | IPT | 83.78Feb 03 '25 | 88.45 ● | -5.6% |
| LPCH:NASDAQ consumerreal-estate PotlatchDeltic | I | 44.5Feb 03 '25 | 41.73 | -6.2% |
| SDHI:NYSE consumerreal-estate D.R. Horton | PT | 137.46Feb 03 '25 | 146.76 | -6.8% |
| SGPC:NYSE consumerauto Genuine Parts | IPT | 115.92Feb 03 '25 | 124.21 | -7.2% |
| SHMC:NYSE consumerauto Honda | P | 26.9Feb 03 '25 | 29.13 ● | -8.3% |
| SWMT:NASDAQ consumershopping Walmart | ISAPT | 99.54Feb 03 '25 | 109.47 | -10.0% |
| LBF:NASDAQ consumershopping Brown-Forman | — | 31.91Feb 03 '25 | 27.96 | -12.4% |
| STHRM:NASDAQ consumerauto Gentherm | T | 36.2Feb 03 '25 | 42.07 ● | -16.2% |
| LRYN:NYSE consumerreal-estate Rayonier | I | 25.94Feb 03 '25 | 21.58 | -16.8% |
| LTSLA:NASDAQ airobot Tesla | ISPT | 383.68Feb 03 '25 | 313.03 | -18.4% |
| SPHM:NYSE consumerreal-estate PulteGroup | IT | 109.15Feb 03 '25 | 130.59 ● | -19.6% |
| SBA:NYSE defense Boeing | ISAPT | 175.87Feb 03 '25 | 211.5 ● | -20.3% |
| LAOUT:NASDAQ consumershopping American Outdoor Brands | I | 16.52Feb 03 '25 | 12.95 | -21.6% |
| LWY:NYSE consumerreal-estate Weyerhaeuser | IAT | 30.75Feb 03 '25 | 23.94 | -22.1% |
| LUFPI:NASDAQ consumerreal-estate UFP Industries | PT | 115.32Feb 03 '25 | 87.94 | -23.7% |
| STJX:NYSE consumershopping TJX Companies | IPT | 124.31Feb 03 '25 | 154.22 | -24.1% |
| LSAM:NYSE consumershopping Boston Beer | I | 246.63Feb 03 '25 | 183.6 ● | -25.6% |
| SCNQ:NYSE energywar Canadian Natural Resources | — | 30.02Feb 03 '25 | 39.49 | -31.5% |
| SDE:NYSE airobot Deere | IPT | 467.05Feb 03 '25 | 628.16 | -34.5% |
| SF:NYSE consumerauto Ford | IAPT | 9.89Feb 03 '25 | 14.37 | -45.3% |
| SBZH:NYSE consumerreal-estate Beazer Homes | — | 21.33Feb 03 '25 | 33.05 ● | -54.9% |
| SLEA:NYSE consumerauto Lear | I | 90.99Feb 03 '25 | 143.6 | -57.8% |
| SDG:NYSE consumershopping Dollar General | IPT | 71.47Feb 03 '25 | 117.23 | -64.0% |
| SADM:NYSE consumershopping Archer-Daniels-Midland | IAPT | 50.02Feb 03 '25 | 85.92 | -71.8% |
| SGM:NYSE airobot General Motors | ISPT | 47.9Feb 03 '25 | 82.64 | -72.5% |
| SSU:NYSE energywar Suncor Energy | I | 37.56Feb 03 '25 | 65.81 | -75.2% |
| SDLTR:NASDAQ consumershopping Dollar Tree | IPT | 71.63Feb 03 '25 | 125.54 ● | -75.3% |
| SPSX:NYSE energywar Phillips 66 | IAPT | 117.86Feb 03 '25 | 206.77 | -75.4% |
| SMGA:NYSE consumerauto Magna International | IP | 37.15Feb 03 '25 | 65.66 | -76.7% |
| SCVE:NYSE energywar Cenovus Energy | — | 14.11Feb 03 '25 | 28.04 ● | -98.7% |
| SBWA:NYSE consumerauto BorgWarner | IS | 31.16Feb 03 '25 | 64.39 | -106.6% |
| SVLO:NYSE energywar Valero Energy | IPT | 136.18Feb 03 '25 | 304.93 ● | -123.9% |
| SCAT:NYSE energygrid Caterpillar | IPT | 361.55Feb 03 '25 | 873.28 ● | -141.5% |
Full summary 480 words
Published February 3, 2025, hours after Trump's Saturday announcement of 25% tariffs on Mexican and Canadian goods (10% on Canadian energy) and an incremental 10% duty on Chinese goods, this unpaywalled memo argues the market fundamentally misread tariffs as campaign bluster or a Bessent/Miran-style gradual approach. Citrini frames the move — ostensibly tied to fentanyl and triggered via IEEPA — as an intentionally manufactured pain trade: Trump believes the asymmetry favors the US (trade is 67% of Canada's GDP, 73% of Mexico's, 37% of China's, but only 24% of America's, even with the world's largest goods deficit at over $1 trillion in 2023), and the ambiguous pretext lets him grant 'reprieve' at his discretion while training partners to believe his threats for the rest of his term. The numbers: the three countries are ~40% of US international trade; 2024 imports from them totaled $1,358 billion (42% of total) and exports $832 billion (40%); the new tariffs amount to over $250 billion in annualized duty, with announced retaliation adding over $150 billion on exports. The trading logic is that tightly-correlated pairs can now diverge violently, so Citrini builds a Tariff Long/Short basket around four buckets: long domestic substitutes gaining pricing power (US lumber, steel, agriculture), long relative pricing power with the US consumer, short import-dependent cost-takers, and short Mexico/Canada-exposed exporters facing demand destruction. Sector by sector: in autos, the Big Three's border-crossing supply chains are exposed — short GM, Ford, Lear, Magna, Toyota, Honda, Stellantis, BorgWarner, ORLY, GPC, Gentherm; long insulated TSLA, Cummins, Dana. In consumer, short importers WMT, HD, LOW, STZ (Corona/Modelo brewed in Mexico), Dole, Fresh Del Monte, BBY, NKE and others; long domestic producers SAM, Brown-Forman, AOUT, YETI. On retaliation, short high-profile targets CAT, Deere, Boeing, Whirlpool, ADM, Tyson; long domestic steel NUE, STLD, X. In energy, the 10% Canadian duty (~$6/bbl) tightens the WCS-WTI differential, benefiting US producers and light-crude refiners (long FANG, EOG, DVN, PBF, DK) at the expense of Canadian producers and heavy-crude refiners (short CVE, SU, CNQ, VLO, PSX). In housing, tariffed Canadian softwood squeezes homebuilder margins already pressured by mortgage rates — long RYN, PCH, UFPI, WY; short builders DHI, LEN, PHM, BZH and Canadian lumber names. The macro section is deliberately contrarian: tariffs function more like a tax hike than a price shock, so the net effect is deflationary via the hit to discretionary spending and growth — the immediate bond reaction agreed. Citrini increases the DV01 of its 2s10s flattener (entered January 10 at +38.6bps, target +20bps) by 50% and cites the Fed's 2018 'look through tariffs' staff analysis, noting the labor market is looser now than in September 2018. It expects a Tariff Tantrum in equities, flight to safety, short-term USD strength resolving to longer-term strength, and flags the risk that China devalues the renminbi rather than retaliating conventionally — likely part of why China's opening tariff was only 10%.
Key metrics
- Tariffs announced: 25% on Mexican and Canadian goods, 10% on Canadian energy, incremental 10% on Chinese goods
- Trade as share of GDP: Canada 67%, Mexico 73%, China 37%, US 24%
- US 2023 goods trade deficit over $1 trillion — world's largest
- 2024 US imports from Canada/Mexico/China: $1,358B (42% of total); exports $832B (40%)
- New tariffs equal over $250B in annualized duty; retaliation adds over $150B on exports
- 10% Canadian energy tariff equals roughly $6/bbl on heavy crude
- 2s10s flattener: entered 1/10/25 at +38.6bps, target +20bps, stop moved from +45.6 to +40bps, DV01 increased 50%
- FX book: long 80% JPY + 20% BRL vs short 80% CHF + 20% CNH
- New commodity position: long lumber (front month) or WY/PCH vs short ITB homebuilders
Key insights
- The tariff announcement is read as an intentionally manufactured pain trade, not a negotiating bluff that fizzles: the fentanyl/IEEPA pretext offers no concrete appeasement path, letting Trump grant reprieve at his discretion while establishing credibility for the rest of his term.
- The asymmetry argument is quantified: trade is 67% of Canada's GDP, 73% of Mexico's, and 37% of China's, versus 24% for the US — Trump is willing to absorb domestic pain because the pain is disproportionately foreign.
- The trade construct exploits correlation breakdown: long/short pairs that historically traded tightly (domestic substitutes vs importers/exposed exporters) can diverge violently, making a basket approach asymmetric across autos, consumer, steel, energy, and lumber/homebuilders.
- Autos are the cleanest short: Big Three supply chains cross the borders multiple times, so GM, Ford, Lear and Magna face margin compression, while US-assembled Tesla plus Cummins and Dana benefit from reshoring of supplier relationships.
- The 10% Canadian energy tariff (~$6/bbl) tightens the WCS-WTI differential — long US producers and domestic-feedstock refiners (FANG, EOG, DVN, PBF, DK), short Canadian producers and heavy-crude-configured refiners (CVE, SU, CNQ, VLO, PSX).
- Contrarian macro call: tariffs act like a tax increase and are net deflationary via the discretionary-spending hit, so the threat of tariffs is bullish for bonds — 2s10s flattener DV01 increased 50% (entered 1/10/25 at +38.6bps, target +20bps, stop moved to +40bps).
- The Fed's own 2018 analysis argued for looking through tariffs since hiking would cause recession, and the labor market was tighter then than now — so no Fed-driven reason to short bonds.
- FX risk flag: China may respond by devaluing the renminbi rather than matching tariffs, which Citrini believes is partly why the opening China tariff was set at 10% rather than 25%.
#082
Market Memo
Jan 26, 2025
DeepSeeking Answers: Beyond "How Does This Impact NVDA?"
DeepSeek's open-source V3 and R1 models prove that top-tier AI can be trained and run far more cheaply — via FP8 precision, mixture-of-experts, and pure reinforcement learning without human feedback — which Citrini had anticipated as China's hardware handicap forcing architectural breakthroughs. Cheaper, commoditized LLMs are bearish for companies whose value rests on ever-escalating capex (a key reason Citrini already sold NVDA) but strongly bullish for AI commercialization, because training/inference cost was the biggest barrier to profitable AI software. This marks the starting gun for 'Phase 2' of the AI trade: rotate from picks-and-shovels infrastructure toward software, agents, and application-layer winners, stay long Chinese semis and Chinese AI names, and tactically short SMH to fund the additions.
aisemi
Positions & performance
-138.0%avg return0% win · 1 tracked · S -138.0%
| Position | Mentions | Entry | Last | Return |
|---|
| SSMH:NASDAQ aisemi VanEck Semiconductor ETF | — | 235.81Jan 27 '25 | 561.19 | -138.0% |
Full summary 443 words
Written January 26, 2025 as markets convulsed over Chinese lab DeepSeek's release of the open-source V3 and R1 models, this memo pushes past the reflexive 'what does this mean for NVDA?' question. Citrini notes it had explicitly predicted this in its June 2024 Citrindex anniversary piece: China's restricted access to NVIDIA-class hardware would force architectural breakthroughs that could leapfrog the current paradigm. The memo explains the technology in lay terms: DeepSeek used pure reinforcement learning — a simple right-answer-gets-a-reward scheme starting from the math-savvy Qwen2.5-Math-7B, using only 8,000 math problems where others use millions — plus FP8 8-bit precision training, multi-token prediction, KV-index compression, and a mixture-of-experts design whereby the 671B-parameter V3 activates only about 37B parameters per inference task, allowing consumer-grade GPUs to run it. R1 Zero showed test-time-compute reasoning can emerge from RL alone, without human-supervised fine-tuning, and distilled versions (a 1.5B-parameter Qwen distillation outperforming GPT-4o and Claude on some reasoning tasks) can run locally on a pair of Mac Minis. Citrini addresses the psyop question directly: the final training-run numbers are replicable, even if total resource claims may be misleading — the famous $6M figure covers only pretraining, and the firm employs a couple hundred engineers. Its PCIe architecture also suggests NVLink is not required, a slight crack in NVDA's chokehold. The investment read: this is the starting gun for LLM commoditization Citrini had been waiting for — the transition from Phase 1 (picks and shovels, where the firm cast a wide net of ~120 potential data-center winners then narrowed 60-70%) to Phase 2 (products, software, agents). Cheaper models are bearish for names whose value derives from ever-escalating capex estimates — the memo restates the 25 Trades for 2025 rationale for selling NVDA, that risk/reward was no longer asymmetric — but bullish for AI commercialization, since training and inference cost has been the biggest barrier to profitable AI software. The Jevons paradox bull case (Dylan Patel: 'Now we can have even more AI') is acknowledged: efficiency gains may simply expand demand and keep capex intact, but Citrini is less enthused, noting the market's muted reaction to half a trillion dollars of announced investment shows little room for incremental capex to surprise. Positioning: tactically short SMH to fund Phase 2 additions in software and agent-enablers; stay long the Chinese semiconductor industry and the Chinese AI basket first added in May 2024 and doubled in October's 'Another Brick in the Wall (of Worry)'; and explore companies building a new application layer designed for AI-agent interaction rather than humans. The conclusion is enthusiastic: open-source, commoditized LLMs mean more nerds in basements, more AI products, and the real test of what AI can do.
Key metrics
- DeepSeek-V3: 671B total parameters with only ~37B active per inference task (MoE)
- RL training used only 8,000 math problems vs millions typically required
- Qwen 1.5B R1-distilled model outperforms GPT-4o and Claude on some reasoning tasks
- $6M figure covers only the final pretraining run, not total development resources
- DeepSeek employs a couple hundred engineers
- FP8 (8-bit floating point) precision training slashed GPU requirements
- Phase 1 playbook: ~120 potential winners bought, then narrowed by 60-70%
- Chinese AI names first added May 2024, doubled down October 2024
- Market shrugged at a half-trillion-dollar AI investment announcement — capex upside already priced
Key insights
- Citrini claims validation of its June 2024 call that US chip sanctions would force Chinese labs into architectural breakthroughs — DeepSeek's V3/R1 arriving from a lab with a couple hundred engineers is exactly that dynamic.
- The technical unlock: pure reinforcement learning with no human-supervised fine-tuning, only 8,000 math problems (vs millions typically), FP8 precision, and mixture-of-experts letting a 671B-parameter model run with only ~37B active parameters — distilled versions run locally on two Mac Minis.
- The $6M cost figure is only the final pretraining run, not total resources — but the efficiency leap is real and replicable, so 'psyop' dismissals miss the point; DeepSeek's PCIe-based architecture also shows NVLink and 8 NICs per node aren't required, a crack in NVDA's moat.
- Cheap commoditized LLMs are bearish for escalating-capex stories but bullish for AI commercialization — cost of training and inference was the largest barrier to profitable AI software; this is the starting gun for Phase 2 (products and agents) after Phase 1 (infrastructure).
- Citrini had already sold NVDA (explained in 25 Trades for 2025) on the view that commoditization of training/inference workloads would enter the narrative in 2025 and destroy the risk/reward asymmetry.
- Positioning: tactically short SMH to fund Phase 2 additions, applying the same wide-net-then-narrow approach used in Phase 1 (~120 names cut by 60-70%); stay long Chinese semis and the Chinese AI basket added May 2024 and doubled in October.
- The Jevons paradox bull case (efficiency expands demand, capex holds) is acknowledged but discounted: the market's reaction to a half-trillion-dollar investment announcement suggests incremental capex is already priced in.
- Speculative kicker: human readability may be suboptimal for LLM reasoning (R1 Zero 'thinks' in nonsensical text), implying a future application layer built solely for agentic AI interaction — a new area Citrini is scouting for Phase 2 winners.
#081
Macro Memo
Jan 16, 2025
Macro Memo: January 2025
The market has swung to peak perceived Fed hawkishness after hot jobs and inflation prints drove the 10-year yield to 2023 highs, but the underlying disinflation drivers — shelter disinflation anchored by slowing wage growth — remain intact, as the latest CPI confirmed. The Fed will skip, not pause, at the January meeting and likely resume cutting in March, so being early on the 10-year call is not the same as wrong: Citrini expects the 10-year to retrace from 4.8% toward the multi-decade mode of 4.2%. Positioning follows via TLT call options, a long SFRM6/short SFRM5 flattener, and a short CHF/long JPY FX trade, with the LA fires flagged as the main new upside risk to measured shelter and services inflation.
indexbonds
Positions & performance
-4.4%avg return0% win · 1 tracked · L -4.4%
| Position | Mentions | Entry | Last | Return |
|---|
| LTLT:NASDAQ indexbonds iShares 20+ Year Treasury Bond ETF | — | 87.04Jan 16 '25 | 83.25 | -4.4% |
Full summary 489 words
This January 16, 2025 Macro Memo updates Citrini's 'Schrödinger's soft landing' framework after a rough stretch: the firm admits its 10-year yield forecast was wrong as yields surged post-Fed-cuts on hot jobs and inflation prints, wobbling stocks through Christmas. Yet it argues the disinflation thesis is intact — the January CPI validated continued shelter disinflation anchored by slowing wage growth — and notes that while broad indices erased post-election gains, Citrini's thematic baskets (AI, Trump trade) held theirs and made new highs, evidence that themes can dominate traditional macro forces. The core call: the market has hit peak perceived monetary policy hawkishness and peak US growth optimism while under-discounting Trump-policy risks to growth. The Fed will skip, not pause, in January — it wants to 'protect a good thing' and still sees policy above neutral — and likely resumes cutting in March once disinflation re-emerges. The memo walks through the data: core PCE has drifted the wrong way since easing began, but CPI core services ex-shelter printed 0.21% MoM (effectively at target) and shelter 0.26%, the second-lowest in six months; hire and quit rates keep declining and Atlanta Fed wage growth trends lower, anchoring rents. Goods inflation is seen anchored by China's weak economy and excess capacity, tariff threats notwithstanding. A dedicated section builds a preliminary framework for the LA fires' inflationary impact: LA County is roughly 8-9% of national CPI, so a spike in temporary lodging, then gradually-captured rent increases over one to two years, vehicle and furnishings inflation from simultaneous supply destruction and replacement demand, and multi-year construction labor cost pressure (worsened if immigration is restricted) could all distort CPI upward even as the shock is initially deflationary through employment. On rates, Citrini says it was early, not wrong: the 10-year should retrace from the over-extended 4.8% toward 4.2%, the multi-decade mode, which it deems more relevant than the oft-cited 5.8% mean. It recalls that the macro narrative has flipped every quarter since the start of 2024 and remains skeptical of extrapolating 'no cuts in 2025 / hikes are back.' Trades: rather than shorting bonds (poor asymmetry), burn premium on wingy TLT upside calls — hedges pared from equity puts to TLT calls on January 8 — since bonds hedge the book's cyclical equity risk; a long SFRM6/short SFRM5 STIR flattener (entry -0.04, stop 0.015, target -0.345) that wins if the hawkish repricing unwinds violently as in late 2023; and in FX, reiterate short CHF/JPY, as the BoJ will likely have higher overnight rates than the SNB before Q1 ends and the franc is extremely overvalued to the yen on PPP. The memo closes with a historical rhyme: in 1998-99 the Greenspan Fed cut four times then paused while inflation and the 10-year rose — and stocks melted up into the Dotcom bubble. Citrini isn't predicting a repeat but notes secularly higher rates don't mean imminent collapse, and 5-15% drawdowns were routine in the late-90s bull market.
Key metrics
- 10-year yield target: retrace from 4.8% to 4.2% (multi-decade mode) vs 5.8% mean
- CPI core services ex-shelter +0.21% MoM, effectively at Fed target
- Shelter CPI +0.26% MoM, second-lowest reading in six months; OER +0.3%
- LA County weight in national CPI approximately 8-9%
- Fed path in 2024: 50bps cut followed by two 25bp cuts (100bps total)
- SFRM5/M6 flattener: entry -0.04, stop 0.015, target -0.345
- Q3 2024 growth scare took the 10-year down to 3.6%
- 1998/1999 analogy: Greenspan Fed cut 4 times then paused as inflation and 10y rose
Key insights
- Citrini concedes the 10-year yield call was early but not wrong: it expects a retrace from the over-extended 4.8% toward 4.2%, the multi-decade mode, which it considers far more relevant than the 5.8% historical mean.
- The Fed will skip, not pause, at the January FOMC and likely resume cutting in March — perceived hawkishness is overdone, and between the latest CPI and PPI the next PCE print should come in cooler.
- The January CPI supported the disinflation thesis: CPI core services ex-shelter printed 0.21% MoM (effectively at the Fed's target) and shelter 0.26%, the second-lowest reading in six months; declining hire/quit rates and slowing wage growth keep rents anchored.
- The LA fires are the key new inflation risk: LA County carries roughly 8-9% weight in national CPI, and the fires should push up lodging, rents (over 1-2 years via BLS methodology), vehicles and furnishings, and multi-year construction labor costs — even though the shock is initially deflationary through employment.
- Rather than shorting bonds, Citrini prefers wingy TLT upside calls — on January 8 it pared equity hedges and added TLT calls — because Treasuries hedge the book's cyclical equity exposure and 'the cure for high rates is high rates.'
- New STIR trade: long SFRM6/short SFRM5 flattener at -0.04 entry, 0.015 stop, -0.345 target, positioned for a violent unwind of hawkish bets like late 2023.
- FX: reiterates short CHF/JPY — the BoJ should have higher overnight rates than the SNB before Q1 ends, and the franc is extremely overvalued versus the yen on relative PPP.
- Historical rhyme flagged: 1998-99, when the Fed cut four times then paused as inflation and the 10-year rose, saw the Dotcom melt-up — secularly higher rates need not mean imminent stock market collapse.
#080
Market Memo
Jan 09, 2025
Market Memo: January Musings
Two threads for January 2025: healthcare and natural gas power generation. Healthcare has been crushed by tax-loss selling and record-low sentiment even as bioprocessing and medtech fundamentals inflect, so year-end de-grossing ends, the JP Morgan conference brings catalysts, and record M&A dry powder meets depressed valuations — the whole sector should re-rate, favoring small innovative life-science and medtech names. Separately, AI data centers, LNG exports, and gas-fueled transportation are creating structural natural gas demand that supply and infrastructure cannot easily meet, so Citrini launches a NatGas/Power Generation basket focused on companies that relieve bottlenecks (turbines, compression, LNG, transport) rather than betting on the gas price itself. The memo also rotates the AI basket toward beaten-down semicap, analog and electrical-component names, dips a toe into solar, and hedges cyclical risk with bond calls.
aimemoryaiopticalaisemienergyaienergygridenergywarhealthhealthtesting
Positions & performance
+59.8%avg return58% win · 33 tracked · L +65.7% · S -127.0%
| Position | Mentions | Entry | Last | Return |
|---|
| LMU:NASDAQ aimemory Micron | ISAPT | 99.34Jan 10 '25 | 920.95 | +827.1% |
| LGRAL:NASDAQ health Grail | — | 17.73Jan 10 '25 | 66.77 ● | +276.6% |
| LAGX:NYSE energygrid Argan | T | 159.42Jan 10 '25 | 568.92 | +256.9% |
| LMXL:NASDAQ aioptical MaxLinear | ST | 20.63Jan 10 '25 | 71.59 | +247.0% |
| LMASS:NASDAQ health 908 Devices | — | 2.26Jan 10 '25 | 7.13 ● | +215.5% |
| LGEV:NYSE energygrid GE Vernova | IPT | 367.1Jan 10 '25 | 1014.75 | +176.4% |
| LNXT:NASDAQ energygrid Nextracker | T | 41.1Jan 10 '25 | 103.73 ● | +152.4% |
| LPSNL:NASDAQ health Personalis | A | 5.59Jan 10 '25 | 11.78 | +110.7% |
| LOSCR:NYSE health Oscar Health | ISA | 14.18Jan 10 '25 | 28.19 | +98.8% |
| LSEI:NYSE energyai Solaris Energy | SAP | 28.64Jan 10 '25 | 54.03 | +88.7% |
| LEXAS:NASDAQ health Exact Sciences | PT | 56.5Jan 10 '25 | 104.91 | +85.7% |
| LESOA:NASDAQ energygrid Energy Services of America | — | 11.61Jan 10 '25 | 18.94 | +63.1% |
| LNPCE:NASDAQ health NeuroPace | — | 11.94Jan 10 '25 | 15.3 ● | +28.1% |
| LPUMP:NYSE energywar ProPetro | — | 10.19Jan 10 '25 | 11.8 | +15.8% |
| LIRTC:NASDAQ health iRhythm | — | 97.7Jan 10 '25 | 109.2 | +11.8% |
| LGTLS:NYSE energygrid Chart Industries | I | 195.11Jan 10 '25 | 209.91 | +7.6% |
| LFSLR:NASDAQ energygrid First Solar | IPT | 189.24Jan 10 '25 | 202.82 | +7.2% |
| LSTIM:NASDAQ health Neuronetics | A | 1.71Jan 10 '25 | 1.81 ● | +5.8% |
| LFTRE:NASDAQ health Fortrea | I | 18.19Jan 10 '25 | 19.2 ● | +5.6% |
| LEXE:NASDAQ energywar Expand Energy | IPT | 102.15Jan 10 '25 | 90.51 ● | -11.4% |
| LMDWD:NASDAQ health MediWound | — | 16.72Jan 10 '25 | 14.23 | -14.9% |
| LLBRT:NYSE energywar Liberty Energy | A | 21.4Jan 10 '25 | 17.36 | -18.9% |
| LDEC:NYSE energywar Diversified Energy | A | 16.47Jan 10 '25 | 12.71 ● | -22.8% |
| LOBIO:NASDAQ health Orchestra BioMed | A | 5.47Jan 10 '25 | 3.82 ● | -30.2% |
| LGDRX:NASDAQ health GoodRx | I | 4.55Jan 10 '25 | 3.05 ● | -33.0% |
| LTKNO:NASDAQ health Alpha Teknova | — | 8.06Jan 10 '25 | 4.85 ● | -39.8% |
| LENPH:NASDAQ energygrid Enphase | IAT | 66.74Jan 10 '25 | 36.7 | -45.0% |
| LWVE:NASDAQ health Wave Life Sciences | A | 11.54Jan 10 '25 | 5.92 ● | -48.7% |
| LQDEL:NASDAQ health QuidelOrtho | T | 45.75Jan 10 '25 | 16.05 | -64.9% |
| LCVRX:NASDAQ health CVRx | A | 14.17Jan 10 '25 | 4.74 | -66.5% |
| LRXST:NASDAQ health RxSight | — | 33.43Jan 10 '25 | 5.19 | -84.5% |
| LNOTV:NASDAQ healthtesting Inotiv | — | 4.37Jan 10 '25 | 0.08 | -98.2% |
| SSMH:NASDAQ aisemi VanEck Semiconductor ETF | — | 247.18Jan 10 '25 | 561.19 | -127.0% |
Full summary 505 words
Published January 9, 2025, this Market Memo lays out Citrini's two highest-conviction January ideas: a healthcare re-positioning and a new natural gas / power generation basket, plus AI basket and solar changes. The healthcare setup builds on the firm's earlier Healthcare Cyclical Inflection primer and the Markets Gone RF-Krazy update. The sector's S&P weighting is the lowest this century, Bank of America's Fund Manager Survey shows the worst sentiment in nearly a decade, less than 7% of healthcare stocks have recently outperformed the index (worst in 25 years), and medtech trades at a 20% discount to the S&P versus a long-term 15-25% premium. Citrini argues much of this is technical — heavy tax-loss harvesting and de-grossing into year-end after healthcare finished 2024 as the second-worst sector — and that the calendar flip removes that pressure just as the J.P. Morgan healthcare conference opens the busiest catalyst and M&A window of the year, with record dry powder. Having delivered alpha in 2024 via catalysts, the basket now leans into beta: shorts are covered to raise net exposure. Adds include QDEL (turnaround diagnostics at a low valuation), tax-loss-victim small caps MASS, PSNL and WVE, and in medtech NPCE (responsive neurostimulation for drug-resistant epilepsy nearing profitability), RXST (adjustable IOL) and OBIO. Stryker's premium bid for NARI signals more cardiology M&A, so IRTC and CVRX go back to overweight; MDWD and STIM are doubled. In managed care, longs in CVS and HUM are exited in favor of OSCR plus new add GDRX. The natural gas section argues demand keeps stacking: Mitsubishi Power expects a 50% increase in gas-turbine orders over two years, EQT sees data centers driving load growth, the Data-Center Power Gap is estimated at 15GW by 2026, and new LNG export terminals plus gas-fueled trucking and shipping add more. Supply is constrained by producer capital discipline and concentrated acreage, but Citrini explicitly takes no view on the gas price — the trade is anything that relieves bottlenecks in turbines, compression, processing, LNG export/hub balancing and gas marketing. Existing holdings (GEV, Siemens Energy, GTLS, AGX, ESOA, DEC, EXE) are combined with SEI, LBRT and PUMP from 25 Trades for 2025 into a new basket, funded by exiting the H2O basket. In the AI basket, after Broadcom's 43% December and Ciena's 21.6% gain versus Micron -14% and WDC -18%, Citrini rotates toward cyclically-depressed names with AI tails — semicap, analog and passive/active electrical components — highlighting MaxLinear's power-conversion and optical DSP optionality and turning incrementally bullish on Micron again, while trimming Connectivity by 10% after CIEN/AVGO/COHR re-rated. In the Fiscal basket, solar gets a toe-hold: TAN fell roughly 70% over Biden's term and leading names dropped 15-20% on Trump's win, yet solar capacity grows over 20% annually and FSLR trades at 16x and NXT at 11x trailing earnings, with ENPH a coiled spring. The macro coda expects a volatile Q1 of Trump Tantrums, notes tariffs were deflationary in the 1920s-30s, and swaps some March equity index puts into bond calls as a cheap hedge with 30-year yields near 5%.
Key metrics
- Medtech trading at 20% discount to S&P vs long-term 15-25% premium
- Less than 7% of healthcare stocks outperforming the index — worst in 25 years
- Mitsubishi Power expects 50% increase in natural gas turbine orders over next two years
- Data-Center Power Gap estimated at 15GW by 2026
- Broadcom +43% and Ciena +21.6% in December 2024; Micron -14%, Western Digital -18%
- TAN solar ETF down ~70% over Biden's term; leading US solar shares fell 15-20% after Trump's win
- US solar capacity consistently growing over 20% annually
- FSLR at 16x trailing earnings; NXT at 11x trailing earnings
- Connectivity allocation reduced by 10%, reallocated to AI basket
- 30-year yields near 5% viewed as a cheap bond-call hedge entry
Key insights
- Healthcare's S&P 500 weighting is the lowest this century and BofA Fund Manager Survey sentiment toward the sector is the worst in nearly a decade; under 7% of healthcare stocks recently beat the index, the worst reading in 25 years — Citrini reads this as capitulation, not fundamentals.
- Medtech trades at a 20% discount to the S&P versus a historical 15-25% premium, right as the JP Morgan healthcare conference and record M&A dry powder create a January catalyst window; Stryker's premium bid for NARI suggests multiple bidders in cardiology.
- The basket shifts from alpha to beta: shorts covered, QDEL, MASS, PSNL, WVE, NPCE, RXST and OBIO added, MDWD and STIM doubled, IRTC and CVRX moved to overweight; CVS and HUM longs exited in favor of OSCR and GDRX.
- A new NatGas/Power Generation basket (replacing the H2O basket) targets bottleneck relievers — turbines, compression, LNG, gas marketing — explicitly without taking a view on the natural gas price; Mitsubishi Power expects gas-turbine orders up 50% in two years and the Data-Center Power Gap is estimated at 15GW by 2026.
- AI basket rotates toward cyclically-hurt names with AI tails (semicap, analog, electrical components), the same playbook that worked with CIEN/COHR/LITE; MXL highlighted for data-center power conversion plus optical DSP optionality, and Micron turned incrementally bullish again.
- Solar gets a tentative long: TAN fell ~70% during Biden's term despite IRA support, but capacity grows 20%+ annually, FSLR trades at 16x and NXT at 11x trailing earnings, and Citrini won't argue with recent relative strength given the power-demand thesis.
- Macro hedge shifted from March equity index puts to bond calls: tariffs are not universally inflationary (deflationary in the 1920s-30s), and with nearly 5% on 30-year yields, bonds are a cheap hedge against the book's heavy cyclical risk.
No reports match your filters.